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Abstract 
This study describes “proof of concept” experiments for development of a novel therapy 
to target B cells in pathological settings such as cancer and inflammation. Targeted 
biological therapies including monoclonal antibodies (mAbs) have revolutionised 
medicine, thus biological therapies are increasingly used in the treatment of patients 
with a range of diseases including cancer. However, despite significant progress in the 
treatment modalities, haematological malignancies remain a leading cause of cancer 
related mortality. Though RNA interference (RNAi) is a promising strategy for cancer 
gene therapy, targeted delivery of siRNAs into cells is a key challenge to their 
therapeutic application. One approach to target intracellular delivery could be to harness 
cell surface receptors that are internalised upon ligation by mAb. Thus, single-chain 
fragment of variable regions (scFv) mediated siRNA delivery into diseased B cells via 
cell surface receptors is a promising strategy. The approach involves generating an 
engineered scFv-protamine fusion protein to deliver siRNA specifically to B cells via 
CD22. For this purpose, gene constructs that combine the VH and VL of mAb (Cy34.1.2) 
targeting mouse CD22 and HA22, a scFv that targets human CD22, were fused to a 
truncated protamine peptide. Gene constructs have been produced for the expression of 
fusion proteins using a range of expression systems. HA22 fusion protein was 
expressed as secretable protein in serum-free cultures of mammalian cells. The protein 
was shown to retain specificity of binding to CD22 on B cells with subsequent 
internalisation and was also able to deliver fluorescently-labelled siRNA into B cells. The 
feasibility of harnessing protamine peptide for siRNA delivery was verified in tumour 
cells expressing αvβ6 integrin using the A20FMDV2-protamine peptide. Furthermore, 
siRNAs to MCL1 and PLK1 genes delivered with HA22 fusion protein to malignant B 
cells induced apoptosis. This study demonstrates the potential for systemic, cell-type 
specific, antibody-mediated siRNA delivery. 
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1.1. Introduction: 
Targeted therapies, which include monoclonal antibodies (mAbs) and small molecule 
inhibitors, have significantly changed treatment of diseases including many types of 
cancer and chronic inflammatory diseases. These therapies act on specific targets that 
are selected to maximise efficacy of treatment while minimising side effects and damage 
to normal cells and tissues. In contrast, standard pharmaceutical therapies affect all cells 
and are usually associated with adverse effects including damage to normal healthy 
cells (1). One example of such benefits can be seen with gene therapy. Thus, using this 
mode of therapy, high and long-term concentrations of therapeutic molecules can be 
achieved locally by targeted delivery to the desired tissue or organ while systemic levels 
are minimised with minimal adverse effects (2). 
 
 The study described in this thesis was conceived to develop a novel approach for 
targeting aberrant B lymphocytes in diseases with a focus on how to change the fate of 
cells especially malignant B cells. Whilst the approach would be highly beneficial in the 
treatment of a wide range of diseases including chronic inflammatory diseases and 
cancer, an immediate outcome of such treatment could best be seen in cancer.   
  
Cancer is a complex and potentially fatal disease that is considered a major 
world-wide public health problem. It starts because of out-of-control growth of abnormal 
cells due to genetic aberrations and environmental factors. Today, millions of people are 
living with cancer or have had cancer. Unfortunately, there is no curative treatment once 
a cancer had spread and some interventions might even be more harmful. Despite 
improved understanding of cancer biology and ability to devise more specific 
therapeutics, cancer treatment has gone through a slow process of development (3, 4). 
  
 Treatment of early-stage cancers can mostly be successful. Unfortunately, 
however, most solid tumours and haematological malignancies remain asymptomatic 
until they advance to invade surrounding tissues and/or metastasize to distant tissues. 
Thus at this advanced stage of the disease, cancers frequently become fatal (5). 
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   Systemic cytotoxic chemotherapies and radiotherapies which mostly provide 
minimal survival benefits in most advance stage cancers are non-specific therapies that 
may destroy normal healthy tissues in addition to the cancer cells. In addition, several 
factors such as resistance to therapy, severe side effects and toxicities limit the benefits 
of these generalised therapies (6-8). Therefore, there is an unmet need to develop novel 
therapeutics particularly targeted therapies with low toxicities, or personalised cancer 
therapies for individual patients with unique “cancer signatures” (9, 10). Analyses of the 
whole-genome sequences of cancers allow the identification of signatures of different 
mutational processes, “cancer signatures”. Therefore, each signature is defined as the 
imprint left on the cancer genome by one or more mutational process (9). 
 
 The rapid progression seen in the treatment of cancer, in particular 
haematological malignancies, demonstrates the great success in development of 
targeted therapies (11, 12). Haematological malignancies are a complex group of 
neoplastic diseases of bone marrow derived cells. Patients with haematological 
malignancies have high rates of morbidity and mortality and are at high risk of 
thrombotic or haemorrhagic complications in spite of the adverse effects associated with 
current therapies. The main groups of these cancers are acute and chronic leukaemias, 
Hodgkin and non-Hodgkin lymphomas and myeloma (13).  
 
 The range of therapeutic options including single and combination 
chemotherapy, radiotherapy and bone marrow transplantation each have a role in the 
management of individual patients with haematological malignancy. Nevertheless, in 
spite of progress in these treatment modalities there are still unmet needs for further 
innovative therapies. This is especially true for patients with more aggressive forms of 
such diseases, for those who relapse or are resistant to treatment and those who 
develop serious side effects (13). 
 
 Targeted therapies using mAbs represent a viable therapeutic approach for 
many diseases including cancer. Furthermore, targeted therapies using mAbs have the 
potential for decreased toxicity, suggesting these agents could lead to improved cancer 
therapy (14).  
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The concept of targeted therapy was first described by Paul Ehrlich, the founder 
of chemotherapy. His postulation of creating “magic bullets” to treat human diseases has 
led to development of molecularly-targeted cancer therapeutics. Hence, targeted 
therapy is defined as using a drug with a focused mechanism that specifically acts on a 
well-defined target or biologic pathway that, when inactivated, causes regression or 
destruction of the disease process (15). 
 
Despite the progress made towards treatment modalities, cancer remains an 
incurable disease and the introduction of new therapeutic strategies is needed. There is 
a need, therefore, for research to focus on the development of new therapeutic 
strategies to target molecular pathologic mechanisms. In this respect, the study 
described in this thesis was conceived to benefit from internalising membrane receptors, 
in this case CD22, for the delivery of therapy. This aim was to develop conjugated 
antibody fragments for anti-CD22 mAb for the delivery of therapeutic agents.     
 
1.2. Strategies for targeted delivery:  
1.2.1. Monoclonal antibodies (mAbs) as targeting therapeutics: 
Antibodies, or immunoglobulins (Igs), are glycoproteins of molecular weight of 150-900 
kDa that are generated in all mammals. Ig synthesis is the defining property of B 
lymphocytes and plasma cells. Resting B lymphocytes produce only small amounts of 
Igs that are mainly inserted in the cell membrane. These membrane-bound Abs capture 
antigens for which they are specific for further processing. However, end-stage 
differentiated B lymphocytes, plasma cells, which show very limited mitotic activity, are 
specialised to produce and secrete copious amounts of Igs. Free Igs that exist in body 
fluids have functions such as agglutination, opsonisation, neutralisation, immobilisation 
of bacteria and their toxins, complement activation, mucosal protection, antibody-
dependent cell-mediated cytotoxicity (ADCC) and conferring immunity to the foetus (16). 
A schematic cartoon representing antibody structure is shown in Figure 1. 
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Figure 1: A cartoon depicting the basic structure of an antibody molecule. Ig molecules 
consist of two light chains, each of molecular weight of ~25 kDa and two heavy chains, each of 
molecular weight ~50 kDa, for IgG and IgD isotypes. These are linked by both disulphide 
covalent bonds and also non-covalent forces. There are five distinctive classes, or isotypes of 
Igs which are IgM, IgG, IgA, IgD, and IgE which differ in size as well as amino acid sequences 
and carbohydrate composition. Light chains exist in two classes, lambda and kappa. Each 
antibody molecule has either lambda or kappa light chains, not both. Regions concerned with 
antigen binding are extremely variable between Ab produced by different clones for B cells, 
whereas in other regions of the molecule, they are relatively constant. Thus, each heavy and 
each light chain possesses a variable (Fab) and a constant region (Fc). Light chains are 
attached to heavy chains by disulphide bonds. Smaller antibody fragments such as single-chain 
fragment of variable regions (scFv) can be engineered by recombinant DNA technology to 
generate a single VH-VL polypeptide antibody fragment. The Figure is adapted and redrawn from 
reference number 16. 
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   Monoclonal antibodies (mAbs) are molecules of great interest for diagnosis and 
treatment of diseases. For example, the use of mAbs for therapy is now one of the most 
successful and important strategies for treating patients, for example patients with solid 
tumours and haematological malignancies which has achieved considerable success 
(17-19). The development of therapeutic antibodies for cancer requires understanding of 
cancer biology, protein engineering techniques and mechanisms of action of the 
targeting Abs. Observation of antigen expression by tumour cells is the fundamental 
basis of antibody-based therapy. The characterisation of cell surface antigens that are 
expressed by human disease-causing cells, including cancer cells, has revealed a broad 
array of targets that are overexpressed, mutated or selectively expressed compared with 
normal tissues. Identifying a suitable tumour antigen for treating cancer is a key 
challenge for antibody-based therapeutics (20). MAbs with increased half-life and 
reduced immunogenicity were generated through the introduction of genetically 
engineered Igs and better identification of targets for antibody therapy. Full length mAbs 
or their recombinant derivatives such as single-chain fragment of variable regions (scFv) 
now account for the single largest group of biotechnology-derived molecules. Their 
successful therapeutic applications include prophylaxis, treatment and control of allergic 
and autoimmune diseases, complications of angioplasty, sepsis, a variety of 
inflammatory diseases, many viral and bacterial infections, organ transplantation 
rejections and solid tumours and haematological malignancies (21, 22). 
 
 MAb-based therapies bring the promise of increased response rates without 
excessive toxicity. For instance, engineered antibody fragments such as scFvs have 
some advantages compared to intact antibodies due to their smaller size, unique and 
highly specific antigen-binding ability, stability and possibly reduced immunogenicity (20-
22). Besides, it is possible to be designed as a bifunctional antibody fragment to work as 
a cargo/carrier fusion protein such as anti-CD22 scFv that will be the subject of this 
thesis. It, thus, makes scFv potentially the best candidate for medical, diagnostic and 
research applications. 
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1.2.2. Engineering therapeutic antibodies to generate scFv: 
The use of single-chain fragment of variable regions (scFv) is a new approach in which 
an engineered recombinant monovalent portion of a monoclonal antibody of molecular 
weight 26-28 kDa is used for targeting, or to deliver a therapeutic cargo. Recombinant 
scFv consists of the Ig variable region binding domains of the heavy (VH) and light (VL) 
chains that are joined together between the C-terminus and the N-terminus with a 
flexible linker usually 10–25 amino acids in length into a single heterodimer polypeptide 
chain (23, 24). Therefore, a scFv contains the entire antigen-binding region and hence 
retains specificity of the parent antibody (25). The most common linker used is the 15-
mer peptide glycine-serine (Gly4Ser)3 and the length of this linker plays a vital role for 
the state of the soluble scFv. Shorter and longer linkers have been shown to favour the 
formation of dimers and multimers, respectively (26, 27). The (Gly4Ser)3 linker should 
provide adequate flexibility to both VH and VL domains, which is the underlying principle 
followed in the most commonly used linker sequences (28).  
 
 scFvs are thought to bind their cognate antigens with affinity similar to that of the 
parent antibodies (26, 29) if the effect of the bivalency of the parent Ig is taken into 
consideration. Retaining specificity of the parent antibody combined with their small size 
has made scFvs attractive candidates for a wide range of applications, including in 
therapeutics, imaging and diagnostics (30). scFvs are currently in pre-clinical and clinical 
trials to treat human diseases ranging from heart disease to cancer and also for use in 
medical imaging (25). In addition, scFvs have shown promise in drug delivery systems 
and for the targeting of vectors for gene therapy (31, 32). 
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Various expression systems for scFvs have also been described, including 
bacteria, fungi, plants, insect and mammalian cells (33-37). Engineering of therapeutic 
antibodies to create scFvs have a number of advantages. For example, scFvs are less 
likely to generate an immune response and the smaller size of the fragments enables 
faster and deeper penetration into tissues impenetrable by full-size mAbs for tumour 
targeting or therapy (38, 39). In addition, antibody engineering allows for increasing 
affinity by mutagenesis. However, monovalency and rapid elimination through the 
kidneys results in lower tumour accumulation of scFvs compared with their parent Abs 
(40, 41). This makes scFv more suited, perhaps, for imaging purposes than for 
therapeutic applications for some antibodies. This problem can be solved by forming 
multivalent scFv variants, which in addition to a larger size have the benefit of higher 
functional affinity (avidity). This could also prolong retention of the recombinant 
antibodies within the tumour tissue (42-44). 
 
Today, the generation of scFv has become an established technique for 
producing functional antigen-binding fragments. Further, bifunctional scFvs can be 
generated to direct therapeutics to desired cells or tissues. For this purpose, the studies 
reported in this thesis have examined the potential of linking anti-CD22 scFv to a 
positively-charged peptide from human protamine (RSQSRSRYYRQRQRSRRRRRR) 
which has a strong ability to bind small interfering RNA (siRNA) (45) and target these to 
B cells. The siRNA to be used would be intended to target key signaling molecules, or 
proteins that are uniquely upregulated in disease settings, for example in malignant B 
cells.  
 
Protamines are a group of small highly basic arginine-rich proteins that replace 
histones and non-histone chromosomal proteins in spermatids during vertebrate 
spermatogenesis. DNA in mature sperm cells is packaged by protamines at a high 
density which makes them transcriptionally inactive (46, 47). Each protamine/DNA 
particle is estimated to contain in the order of 50 kb of DNA (48). Therefore, it has been 
established that the positively-charged guanidinium groups of arginine bind the 
negatively-charged phosphate groups of siRNA (45). 
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1.3. B cells and their role in diseases: 
B cells, the principal mediators of humoral immunity, arise from haematopoietic stem 
cells (HSCs) in the bone marrow. Their development proceeds through a series of 
organised gene expression and selection events in the bone marrow followed by 
migration to secondary lymphoid organs to become follicular, germinal centre or memory 
cells (49-52). 
 
The available repertoire of B cells emanates from the generation of an 
extraordinarily diverse range of clones that differ by the specific structure of their B cell 
receptor (BCR). The BCR, or membrane Ig, is composed of two identical heavy chains 
and two identical light chains covalently linked by disulphide bridges. This membrane Ig 
is associated with two polypeptide chains, the CD79A and CD79B, which contain 
cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) that help transmit 
intracellular signaling upon BCR engagement by antigens. The intracellular signaling 
pathways activated following BCR cross-linking involves a range of tyrosine kinases and 
phosphatases. Depending on the differentiation and activation status, the B cell might be 
induced to proliferate, differentiate or undergo apoptosis upon BCR engagement (53). 
 
Production of antibodies by B cells is the key effector function of these cells. 
However, B cells also carry out various other effector and regulatory functions during the 
course of an immune response. For example, B cells present antigens to and interact 
with T cells to modulate cellular and humoral immune responses to pathogens and to 
autoantigens (54). B lymphocytes can also modulate immune response through the 
production of cytokines. B lymphocyte responses are normally well-regulated and 
disruption of these regulatory events due to mutations, oncogenic chromosomal 
translocations, evasion from apoptosis or uncontrolled proliferation can lead to the 
aberrant responses and diseases (55). These defective responses can lead to 
malignancies or autoimmune diseases. Therefore, therapeutic targeting of B cell 
depletion could be desirable in patients with haematological malignancies or patients 
with autoimmune inflammatory diseases. In this respect, the last 15 years have seen a 
substantial increase in the generation and use of B cell depleting, or modulating mAbs 
that have been used to treat human diseases. Some of the mAbs target membrane 
proteins including CD20, CD52, CD22 and CD40 receptors (56). 
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1.4. CD22 receptor: 
Development, activation and differentiation of B lymphocytes are complex processes 
regulated in part by cell surface co-receptors, soluble mediators and by intracellular 
signaling pathways. An array of cell surface and cytoplasmic proteins also modify 
intracellular signal transduction through BCR following engagement by antigens. One 
such B cell-specific surface molecule is CD22, also known as sialic acid binding Ig-like 
lectin 2 (Siglec-2), that functions as an adhesion molecule, a transducer and modulator 
of intracellular signaling mediated through the BCR complex (57). 
 
1.4.1. CD22 expression: 
Expression of human CD22 (hCD22) is found in the cytoplasm of pro-B and pre-B cells 
but is expressed on the membrane of IgM+ B cells at about the same time as IgD is 
expressed. In lymphoid tissues, hCD22 is expressed by follicular mantle and marginal 
zone B cells, but only weakly by germinal centre B cells (58). Indeed, the vast majority of 
IgM+IgD+ B cells express CD22 (59, 60). Expression of hCD22 in malignant cells was 
first reported to be restricted to the cytoplasm in pre-B acute lymphoblastic leukaemia 
(ALL), with surface expression found only on malignancies corresponding to more 
mature B cells (61-63). Expression of mouse CD22 (mCD22) was found on all mature B 
cells including follicular and marginal zone B cells of the spleen, peritoneal B-1 cells and 
isotype-switched IgA-expressing B cells in Peyer’s patches. However, mCD22 
expression is lost during B cell differentiation to plasma cells and the molecule is not 
present on the membrane during the early stages of B cell development and is not 
expressed on stem cells (64). 
 
 
 
 
 
 
 
 
 
 
Chapter One 
 
29 
 
1.4.2. CD22 structure and function: 
CD22 is a type I membrane protein with molecular weight of ~140 kDa. The extracellular 
portion of CD22 comprises seven immunoglobulin-like domains (65-69). CD22 is a B 
cell-restricted glycoprotein involved in cell adhesion and signaling and plays an 
important role in interactions with other cells by recognising N-linked oligosaccharides 
possessing α2-6-linked sialic acid residues and consequently regulating signaling 
thresholds (70, 71). CD22 ligands include structurally-diverse sialic acid-bearing 
glycoproteins, glycolipids and gangliosides expressed by lymphocytes, neutrophils, 
monocytes and erythrocytes as well as non-haematopoietic cells. Ligands composed of 
α2,6-linked N-glycolylneuraminic acid recognise mCD22 specifically, whereas ligands in 
the form of N-acetylneuraminic acid recognise hCD22 (72-75). Known ligands of CD22 
include CD22 itself, all isoforms of CD45, soluble IgM pentamers, haptoglobin, Ly-6 
proteins and a variety of other proteins present on leukocyte cell surfaces (76, 77). 
CD22 is known to modulate B cell activation upon BCR cross-linking with an antigen (78, 
79). Furthermore, strong cross-linking of CD22 is known to trigger programmed cell 
death in B cells (80). The mouse anti-CD22.2 mAb produced by Cy34.1.2 hybridoma 
(page 55, section 2.2 and page 120, section 3.1) and the anti-human scFv BL22 and 
HA22 (page 84, section 2.26) were both used in this study to generate recombinant 
proteins to target mouse and human CD22 receptor respectively. A schematic diagram 
illustrating the structure and signaling components of CD22 is shown in Figure 2. 
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Figure 2: Schematic diagram of domain structure of CD22 in humans and mice. CD22 is a 
140 kDa type I transmembrane protein that associates with the BCR both physically and 
functionally and negatively regulates BCR signaling. Phosphorylation of CD22 occurs rapidly 
following CD22 or BCR ligation. The cytoplasmic tail of CD22 has six tyrosines that are potential 
targets for phosphorylation, of which three are found within conventional ITIM motifs (Y783, 
Y843, Y863) (green boxes), one is part of an ITIM-like motif (Y817) and one is needed for the 
recruitment of Grb2 (Y828). SHP-1 binds to two phosphorylated ITIMs. SHP-1 interferes with 
signaling pathways leading to the depletion of calcium stores from the endoplasmic reticulum 
(ER) and promotes calcium efflux. Shc and Grb2 bind to the indicated tyrosines and form a 
complex with SHIP. Abbreviations: Grb2: growth factor receptor-bound protein 2; ITIM: 
immunoreceptor tyrosine inhibitory motif; SHIP-1: SH2-domain containing inositol 5-
phosphatase-1. The Figure is adapted and redrawn from reference number 69. 
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1.4.3. The kinetics of CD22 endocytosis: 
Cytoplasmic CD22 represents an internal reservoir for CD22 expression, with 
cytoplasm-to-surface transport occurring in response to activation or differentiation 
signals (81). CD22 is also constitutively endocytosed with kinetics of internalisation (t1/2) 
of less than 1 hour by a clathrin-mediated mechanism and degraded with a relatively 
short half-life after endocytosis from the cell surface (82). The internalisation is then 
followed by routing of CD22 molecules to an acidic intracellular compartment where 
degradation (t1/2 is ~8 hours) occurs without detectable recycling of the molecule back to 
the surface (83-92). However, another study has shown that intracellular CD22 rapidly 
moves to the surface of B cells in a tyrosine kinase-dependent manner following antigen 
receptor stimulation. Therefore, CD22 can carry cargo between the cell surface and 
endosomal compartments of B cells (93).  
 
1.4.4. Therapeutic targeting of CD22: 
Because most B cells in patients with non-Hodgkin’s lymphoma express CD22 that 
becomes internalised upon ligation, CD22 has been considered a promising target for 
toxin or radioisotope-mediated immunotherapy (91). A recent study showed that the 
rapid internalisation of large amounts of anti-CD22 mAb immunotoxin, BL22, bound to 
CD22 makes CD22 a better therapeutic target than CD19 for immunotoxins to act inside 
cells (90). Furthermore, restricted expression of CD22 to the surface of B cells is an 
attractive target in certain haematopoietic malignancies (89).  Recently, CD22 was also 
shown to be expressed on a variety of lung cancer cell lines and a panel of primary 
patient lung cancer specimens. Interestingly, anti-CD22 mAb HB22.7 displayed 
cytotoxicity against CD22+ human lung cancer cells and tumour xenograft models. 
Therefore, aberrant expression of CD22 on various human lung cancer cells is also a 
potential target for anti-CD22 based therapy of lung cancer that has few tumour specific 
targets (94). Furthermore, because B cells play an important role in the pathogenesis of 
many chronic inflammatory diseases, specific B cell directed antibodies are now used in 
the management of these diseases. Epratuzumab, a humanised anti-CD22 mAb, 
originally developed for treatment of non-Hodgkin’s lymphoma, has been reported to be 
effective in treatment of systemic lupus erythematosus (SLE) and primary Sjögren's 
syndrome (95). 
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1.5. Targeting αvβ6 integrin for therapy: 
αvβ6 integrin is a member of a large family of heterodimeric transmembrane receptors 
that consists of α and β subunits and functions as cell-substratum adhesion and 
signaling molecules. The integrin family which comprises of at least 24 distinct integrin 
heterodimers with different functions and ligand binding properties are formed by the 
combination of 18 α and 8 β subunits (96). A generalised structure of an integrin and its 
component domains is shown in Figure 3.  
 
Figure 3: Cartoon representation of integrin structure. The α and β subunits consist of 
several domains with flexible linkers between them. Each subunit has a single membrane-
spanning helix and usually a short unstructured cytoplasmic tail. The α subunit ectodomain 
consists of α –I domain, a seven-bladed β-propeller, a thigh and two calf domains. The β subunit 
has seven domains with flexible interconnections. The β-I is inserted in a hybrid (Hyb) domain. 
The hybrid domain, in turn, is inserted in a plexin-semaphorin-integrin (Psi) domain. These are 
followed by four cysteines-rich epidermal growth factor (EGF) molecules (E) and a β-tail (β-T) 
domain. The Figure is adapted and redrawn from reference number 96. 
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 Integrins serve as anchoring molecules that function as bidirectional signaling 
molecules controlling various cell functions like adhesion, polarity, differentiation, 
migration, cell division and apoptosis during embryogenesis and in the maintenance of 
tissue homeostasis under physiological conditions (97, 98). However, in pathology, 
defective integrin signaling can disrupt these functions resulting in abnormal cell 
division, migration and adhesion, which are hallmarks of cancer, invasion and 
metastasis (99, 100). 
 
 αvβ6 integrin is an exclusive epithelial cell-specific surface molecule that is a 
receptor for the extracellular matrix (ECM) proteins fibronectin, vitronectin, tenascin and 
the latency associated peptide (LAP) of transforming growth factor β (TGFβ). The 
integrin αvβ6 functions as an adhesion molecule, a signal transduction molecule and as 
a modulator of intracellular signaling. During embryogenesis, αvβ6 is expressed at high 
levels in the developing lung, skin and kidney epithelial tissues but its expression is 
downregulated in healthy adult epithelial tissues (101, 102). 
  
 Expression of αvβ6 integrin is low or undetectable in normal adult epithelial 
tissue while during reorganisation of epithelial tissue in development, tissue repair and in 
neoplasia αvβ6 expression is upregulated to support cell spreading, migration and 
growth (102). Furthermore, there are circumstances in which αvβ6 integrin expression is 
upregulated which include wound healing, development and inflammation (103, 104). 
Previous studies have shown that ligands such as fibronectin, tenascin, LAP of TGFβ1 
and TGFβ3 and the viral coat protein-1 (VP1) of the foot-and-mouth-disease (FMD) virus 
that contain arginine-glycine-aspartate (RGD) motif can bind to αvβ6 integrin (105-107).  
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1.5.1. αvβ6 integrin as a therapeutic target for cancer therapy: 
The expression of integrins in various cell types that are involved in tumour progression 
and their ability to crosstalk with growth factor receptors has made them appealing 
therapeutic targets. Since αvβ6 is not expressed in normal epithelia except under 
conditions such as wound healing, αvβ6 lends itself to be a very good molecular target 
for therapy of cancer. Integrin αvβ6 is highly expressed in >95% of oral squamous cell 
carcinomas (OSCCs) and, hence, has been exploited as an efficient means for imaging, 
diagnosis and treatment (108). 
 
For therapeutic targeting of αvβ6, panels of mAbs with specificity for human and 
mouse αvβ6 integrin with high affinity have been generated and studied (109). For 
example, mAb 10D5 was used for blocking αvβ6 integrin in colon cancer cells and 
resulted in reducing metastasis through disrupting extracellular signal-regulated kinase 
(ERK) binding to αvβ6 (110). In another study, blocking αvβ6 with 10D5, resulted in 
tumour cell apoptosis (111). Furthermore, blocking αvβ6 with mAb 6.3G9 led to growth 
inhibition of human pharyngeal carcinoma cells both in vitro and in vivo (112). 
 
A study using peptide A20FMDV2 derived from a protein of FMD virus that 
mimics the ligand for αvβ6 was successfully used for diagnosis by imaging of αvβ6-
expressing tumours and also to deliver chemotherapeutics to the tumour (113). Based 
on this finding, targeted delivery of therapeutics via integrins can be beneficial for 
targeting tumour cells. This observation was exploited in the current study by using 
A20FMDV2-protamine peptide to deliver siRNA to verify specificity and that the 
protamine peptide did not undermine specificity of the targeted delivery.  
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1.6. Targeting gene therapy in cancer: 
Gene-based therapeutics are defined as the introduction, using a vector or delivery 
vehicle, of nucleic acids into cells with the intention of altering gene expression to 
prevent, halt or reverse a pathological process. Somatic cell gene therapy can be 
carried out through four routes: gene replacement/correction, gene 
silencing/knockdown, gene addition/augmentation and suicide gene therapy (114). 
Therefore, gene therapy is a promising treatment option for a number of diseases 
including inherited single gene disorders, cancer and viral infections. In cancer, for 
example, targeting of cancer cells with gene therapy has the potential to treat cancer on 
the basis of its molecular characteristics. Although results from preclinical and clinical 
trials have been encouraging, many practical obstacles need to be overcome before 
gene therapy can fulfill its goals in the clinic. One major challenge is directed delivery of 
the therapeutic gene to target cancer cells (114, 115).  
 
For gene therapy to achieve cell-specific targeted delivery, therapeutic genes can 
be transferred into target cells by integrating ligands such as mAbs that recognise 
specific cellular receptors (116-119). Such a delivery strategy also improves the 
efficiency of gene transfer by enhancing the entry of therapeutic genes into desired cells 
and reducing uptake by non-target cells. Characteristically, receptor-mediated gene 
delivery capitalises on the presence of specific cell surface molecules for uptake of the 
therapeutic genes into cells and represents a particularly appealing approach for 
targeting to specific cell types in vitro and in vivo. Such a method utilises a natural 
mechanism which is receptor-mediated endocytosis (120). 
 
In cancer gene therapy, selective delivery via targeting cell surface receptors is a 
promising method since many receptors are expressed in a cell type-specific manner, 
such as mannose receptor (CD206) on tumour-associated macrophages (121), or are 
highly expressed in malignant cells such as transferrin receptor (122-124). Hence, this 
study intends to employ anti-CD22 scFv-protamine fusion protein for receptor-mediated 
gene transfer via CD22 in B cells derived from leukaemias, lymphomas and other 
diseases in which B cells play a key role. Circulating malignant B cells are readily 
accessible via blood in most leukaemias whereas in lymphomas, tissue penetration is 
more challenging. Therefore, an advantage of using scFv over full-size mAbs is their 
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small size which allows them to extravasate rapidly from blood and penetrate faster and 
deeper into tissues. Since they lack the constant region of the antibody molecule, they 
do not bind Fc receptors and, thus, are not retained in tissues such as the liver and the 
kidneys. Thus, potential side effects are also reduced (38). New anti-cancer targeted 
therapies that make use of siRNA therapeutics have made treatments more specific and 
less toxic (125, 126). Recent data from human clinical trials have shown safe and 
tolerable intravenous administration of siRNA therapeutics in patients with liver 
metastases secondary to endometrial cancer with significant regression of the tumours 
(125). Therefore, therapeutic gene silencing is a promising approach for treatment of 
cancer.  
 
1.7. Cancer therapy using siRNA: 
RNA interference (RNAi) is a natural cellular process for post-transcriptional regulation 
of gene expression. This involves forming double stranded RNA (dsRNA) that suppress 
the expression of specific genes with complementary nucleotide sequences either by 
degrading specific mRNA or by blocking mRNA translation. RNAi can be activated 
exogenously by expressing short hairpin RNA (shRNA) and microRNA (miRNA) 
duplexes with viral vectors, or by incorporating synthetic siRNAs, double stranded 
miRNA mimetics and anti-miRNA oligonucleotides (antagomirs) directly into the cell 
cytoplasm (127-129). Since the discovery of RNAi, its potential application in 
therapeutics received much attention (130). Targeted post-transcriptional gene silencing 
by RNAi represents a promising new approach for the inhibition of gene expression in 
vitro and in vivo. RNAi has also emerged as a promising new strategy for drug target 
validation and the study of functional genomics and it is currently being evaluated in 
clinical trials as a potential therapy for diseases (131-140). RNAi technology can be 
directed against many cancers using a variety of strategies including the suppression of 
overexpressed oncogenes, promotion of apoptosis, regulation of the cell cycle, anti-
angiogenesis and enhanced efficacy of traditional chemotherapy and radiotherapy. For 
example, through the use of an RNAi retroviral system targeting Kirsten rat sarcoma 
virus oncogene homolog (K-RAS) in human pancreatic carcinoma cells, loss of 
anchorage-independent growth and tumourigenicity were induced (141). Furthermore, 
RNAi was used to knockdown the multi-drug resistance protein 1 (MDR1) gene product 
P-glycoprotein, thus, reducing cancer cell multidrug resistance (142).  
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1.7.1. Mechanism of gene silencing by using RNAi: 
miRNAs and siRNAs are ~19-25 nucleotide non-coding RNAs (ncRNAs)  capable of 
regulating gene expression at the transcriptional and translational levels. They are 
involved in various biological processes such as cell cycle regulation, differentiation, 
development, metabolism, neuronal patterning, apoptosis and aging (143, 144). Both 
miRNAs and siRNAs share most of the components of RNAi pathway. In the nucleus of 
eukaryotic cells, miRNA synthesis begins where an RNA polymerase II transcribes a 
long, capped and polyadenylated primary precursor (pri-miRNA), which is then cleaved 
into a hairpin-shaped nucleotide precursor of ~70-100 pre-miRNA by the ribonuclease III 
Drosha and the double-stranded DNA-binding protein DiGeorge Syndrome Critical 
Region Gene 8 (DGCR8)/Pasha. Endogenously-synthesised pre-miRNAs then 
translocate to the cytoplasm through the nuclear export factor, exportin 5/ Ras-related 
nuclear protein (Ran) guanosine-5'-triphosphate (GTP), where the ribonuclease III Dicer 
and the double-stranded RNA-binding protein TRBP (HIV-1 transactivating response 
(TAR) RNA-binding protein) process pre-miRNAs into a 19-25 nucleotide miRNA duplex. 
In addition, exogenous long double stranded RNAs (dsRNAs) delivered into the cell are 
cleaved in the cytoplasm by the endoribonuclease III Dicer into short duplex siRNAs. 
Subsequently, miRNA or siRNA duplex is incorporated into the RNA-induced silencing 
complex (RISC) and drives the RISC to the target mRNA. RISC contains Argonaute 2 
(Ago-2) which cleaves and releases one strand from the dsRNA, resulting in an 
activated form of RISC with a single-strand RNA (guide siRNA) that directs the 
specificity of the target mRNA recognition through complementary base pairing. 
Consequently, translation inhibition may occur through mRNA cleavage and degradation 
in cases of perfect complementarity to the 3’-untranslated region (3'-UTR) of the target. 
In this case Ago-2 cleaves the target mRNA between bases 10 and 11 relative to the 5′ 
end of the siRNA antisense strand, thereby causing mRNA degradation and gene 
silencing. Alternatively, translation inhibition occurs without mRNA degradation in cases 
of partial complementarity to the 3'-UTR of the target (145-147). The mechanism of 
biogenesis of miRNA and gene silencing through RNAi pathway is illustrated in Figure 4. 
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Figure 4: Genes can be regulated post-transcriptionally by miRNAs and siRNAs. miRNA 
genes are transcribed mainly by RNA polymerase II into an immature form of about 80 
nucleotides in length called primary miRNAs (pri-miRNAs) which are capped and 
polyadenylated. The stem loop structure of the pri-miRNA is recognised in the nucleus by the 
RNase III enzyme Drosha and its partner DGCR8 and it is further processed to the ~70-
nucleotide precursor miRNA (pre-miRNA). The hairpin-shaped pre-miRNA is then transported 
from the nucleus to the cytoplasm by Ran GTP and exportin-5 (XPO5), where it is loaded by the 
RNase III enzyme Dicer–TRBP complex and cleaved into a ~22 nucleotide double-stranded 
miRNA. This duplex is then loaded into the miRNA-associated multiprotein RNA-induced 
silencing complex (RISC), which includes the Argonaute proteins, and the guide strand (mature 
single-stranded) miRNA (red) is preferentially retained in this complex. Synthetic siRNA can be 
directly delivered to cells and enters the RNAi pathway when it assembles with RISC. In this 
case a transport mechanism such as receptor-mediated delivery introduces the siRNA into cells. 
The siRNA is recognised by RISC which then mediates cleavage of the target mRNA for gene 
silencing. The Figure is adapted and redrawn from reference number 145. 
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It is clear that RNAi can be potent and versatile tools for gene silencing. 
Therapeutic application of siRNAs in human, however, requires effective delivery to the 
correct intracellular location to interact with the RNAi machinery within the targeted cell. 
To achieve these objectives, systemically-administered siRNA must survive in the 
circulation long enough to reach target tissues, enter the desired cells, escape the 
endosome and/or delivery packaging and, finally, become incorporated into the RISC.  
However, the major challenge for the use of siRNA in the clinic as a therapeutic tool 
remains to be efficient intracellular siRNA delivery to target sites following systemic 
administration (148-151). 
 
The key to efficacious siRNA application in vitro and in vivo is overcoming the 
difficulty of delivering siRNA selectively into target cells. Because of their high molecular 
weight (~14 kDa) and strong polyanionic nature (~40 negative phosphate charges in 
their backbone), naked siRNAs cannot easily pass through cell membranes. Thus, 
delivery systems are required to facilitate access to intracellular sites of action (152). 
Delivery has, therefore, been one of the major challenges for the application of RNAi 
technology. Various means of delivery have been developed and tested in murine and 
non-human primate models, ranging from the injection of naked siRNA into a target 
organ (153-155) to systemic delivery of the RNA in nanoparticles (156). For most of 
these approaches, covalent conjugation of siRNAs requires chemical reactions which 
could be detrimental to the activities or release of the therapeutic siRNA (157). One such 
delivery approach which will be described in this study in detail is the conjugation of cell-
surface receptor targeting mAb fragment and charge interaction with siRNAs.  
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1.7.2. Delivery methods for therapeutic siRNA: 
Under normal physiological conditions, nucleic acids, including siRNA, carry a net 
negative charge on the sugar-phosphate backbone. In order to enter the cell, siRNA first 
come into contact with the lipid bilayer of the cell membrane whose head groups are 
also negatively charged. For this reason most mammalian cells cannot take up siRNA, 
thus, intravenous injection of naked siRNA often fails to achieve significant silencing 
effects (152, 158). Therefore, a protocol to promote uptake is required for effective 
delivery of siRNA as therapeutics. Targeted delivery of siRNAs provides such a 
mechanism, as well as providing tissue specificity in gene silencing. However, the 
approach faces many of the same issues of targeted delivery of small molecule drugs, 
including stability in the blood, target tissue accumulation and penetration, 
pharmacokinetics and biodistribution. In addition and unlike many small molecule drugs 
that can passively diffuse into surrounding cells, siRNAs need to be internalised and 
then delivered to the proper subcellular localisation in the cytosol to achieve effective 
gene silencing. The commonly used methods to transfer RNAi molecules into cells in 
vitro are electroporation, lipid-based transfection reagents and using nanoparticles. 
Unfortunately, when employed in vivo, these methods are not cell-specific and, thus, 
limit their utility for delivering RNAi to target specific organs, or specific cell types within 
that organ (159). 
 
1.7.3. Targeted delivery of siRNA using antibody-protamine fusion proteins: 
The clinical success of in vivo applications of RNAi hinges on the development of new 
delivery methods. Therefore, the current study aimed at developing an efficient strategy 
to deliver siRNAs into desired cells via cell-surface receptors to achieve maximal 
therapeutic benefits, decrease the amount of siRNA required and avoid nonspecific 
silencing and toxicity in bystander cells. To achieve this, recombinant proteins were 
engineered with the positively charged amino acid residues of protamine peptide and 
anti-CD22 scFv to bind siRNA and deliver into desired cells in vitro and, ultimately, in 
vivo. Thereby, a complex between anti-CD22 scFv-protamine targeting proteins and 
siRNA will be prepared through electrostatic interaction between the positively charged 
protamine peptides and the negatively charged siRNAs. This assembled complex may 
obviate the need for aggressive and reagent-wasteful chemical reactions and, possibly, 
preserve the activities of the targeting moieties. In this regard, a number of studies have 
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used engineered scFv-protamine fusion proteins for directed delivery of siRNA into 
cancer cells via receptor-mediated endocytosis (160-162). As a proof of concept, the 
Fab of mAb F105 with specificity for HIV-1 envelope fused with protamine (F105-P) was 
used to deliver siRNAs to cells transfected to express HIV envelope glycoprotein gp160. 
siRNA complexed with the antibody-protamine fusion protein (F105-P) by electrostatic 
interactions did not require covalent coupling for effective delivery. gag siRNA, against 
HIV gag polyprotein structure, delivered with F105-P fusion protein reduced HIV 
replication in previously infected CD4+ primary T cells. The proportion of productively 
infected cells declined from 85% in untreated cultures to 36% when 1 nM of gag siRNA 
was added (160). In addition, the effective delivery of siRNAs was further evaluated in 
B16 subcutaneous melanoma tumour models in vivo expressing HIV gp160 (env). 
Intravenous or intratumoral injection of F105-P-complexed with siRNAs delivered 
siRNAs into env+ tumours but not into normal tissues or env- tumours. Because this 
method can also be generalised for other targets, similarly, an anti-ErbB2-protamine 
fusion protein was used to deliver siRNAs specifically to ErbB2-expressing (v-erb-b2 
avian erythroblastic leukaemia viral oncogene homolog 2, ErbB2+) breast cancer cells 
(160). In another study, it was shown that a scFv-protamine fusion protein targeting the 
human integrin lymphocyte function-associated antigen-1 (LFA-1) resulted in efficient 
delivery of siRNAs and cell type-specific gene silencing in primary lymphocytes, 
monocytes and dendritic cells (161). Furthermore, it was shown that targeted delivery of 
PLK1 siRNA by the fusion protein anti-ErbB2 scFv-protamine in vivo using Her2+ breast 
cancer models in mice significantly suppressed Her2+ breast cancer growth and 
metastasis (162).  
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1.8. Targeted gene therapy for the induction of apoptosis in cancer cells: 
A common hallmark of aberrant cells including cancer cells is their ability to evade 
apoptosis by survival signals, or by defects in cell death signal transduction pathways 
(163). Therefore, a permanent eradication of neoplastic cells through apoptosis is 
required for cancer treatment (164). On the basis of this knowledge, an important goal of 
cancer drug development would be to facilitate apoptosis in neoplastic cells. 
Consequently, cancer gene therapy represents a somewhat special category for gene 
therapy because its intended goal is the destruction of the cancer cell rather than its 
correction or preservation. In this respect, the current study was intended to apply siRNA 
knockdown of genes in B lymphocytes to evaluate their impact on survival by inducing 
cell death.  
 
Apoptosis was first described in a landmark paper as a controlled cell deletion 
mechanism, which plays a complementary but opposite role to mitosis in the regulation 
of animal cell populations (165). Accordingly, apoptosis was defined as an active, 
inherently-programmed phenomenon that can be initiated, or inhibited by a variety of 
environmental stimuli, both physiological and pathological. The structural features of 
apoptosis comprise nuclear and cytoplasmic condensation and breaking up of the cell 
into a number of membrane-bound apoptotic bodies. These fragments shed from dying 
cells are then phagocytosed by neighboring cells, or by phagocytic cells (165). 
Apoptosis is central to various physiological processes and the maintenance of tissue 
homeostasis in multicellular organisms (3, 163-165). Even more important is a causative 
or contributing role of apoptosis to various human diseases, for instance accumulation of 
cancer cells or failure to eradicate transformed cells. Emerging knowledge about 
molecular mechanisms of apoptosis dysregulation in cancer has revealed a plethora of 
potential drug targets and, hence, made it possible to devise novel approaches, which 
exploit this process to treat cancer (3, 163). Apoptosis-triggering therapeutics comprises 
of two distinct mechanistic approaches. Pro-apoptotic strategies directly induce 
apoptosis such as introduction of pro-apoptotic molecules, modulation of anti-apoptotic 
molecules, or restoration of the function of tumour suppressor genes. Alternatively, 
permissive strategies modulate survival signaling pathways thereby facilitating the 
activation of apoptosis such as targeting of oncogenic signaling pathways (166-173). 
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1.8.1. Pathways and mechanisms of apoptosis: 
Several pathways exist for triggering of apoptosis through caspase activation; two have 
been elucidated in detail and have been the subject of great interest in recent years. 
Thus, the apoptotic cell is believed to either receive and process extracellular death-
inducing signals “extrinsic apoptotic program” or sense and integrate a variety of 
intracellular signals, “intrinsic apoptotic program” (174). 
 
The intrinsic apoptotic pathway centres on mitochondria. The outer mitochondrial 
membrane is controlled by counterbalancing pro-apoptotic [Bcl-2 associated X protein 
(BAX), Bcl-2 homologous antagonist killer (BAK), Bcl-2 associated death promoter 
(BAD), BH3 interacting-domain death agonist (BID), Bcl-2 interacting mediator of cell 
death (BIM), Bcl-2 modifying factor (BMF), phorbol-12-myristate-13-acetate-induced 
protein 1 (Noxa)] and anti-apoptotic [B cell leukaemia/lymphoma 2 (BCL2), B cell 
leukaemia/lymphoma extra large (BCL-XL), Bcl-2 like protein 2 (BCL-W), myeloid 
leukaemia cell differentiation protein 1 (MCL1)] members of the Bcl-2 family of proteins 
(175, 176). BCL2 and other anti-apoptotic proteins are inhibitors of apoptosis acting in 
large parts by binding to and, thereby, suppressing pro-apoptotic triggering proteins. In 
most cases of cell death, the point of no return is permeabilisation of the outer 
mitochondrial membrane to the release of apoptogenic proteins (177). Multiple signals 
converge on mitochondria, including DNA damage, microtubule disruption and growth-
factor deprivation, causing these organelles to release cytochrome c (cyt c) and other 
apoptogenic proteins such as second mitochondria-derived activator of caspases/ 
Diablo homolog (Smac/Diablo), HtrA serine peptidase 2 (OMI/Htr2A) , apoptosis-
inducing factor (AIF) and endonuclease G into the cytosol. When cyt c binds the 
caspase-activating protein, apoptotic protease-activating factor 1 (Apaf1), this triggers its 
oligomerisation into a heptameric complex that binds pro-caspase-9, forming a 
multiprotein structure known as the “apoptosome” (175, 176). Apaf1 and pro-caspase-9 
then bind through their caspase recruitment domains (CARDs), thereby, a cascade of 
caspases are activated such as caspase-9 which in turn activates downstream effector 
proteases such as pro-caspase-3. Consequently, proteolytic activities of activated 
caspases induce the multiple cellular changes associated with the apoptotic program 
(178, 179). 
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In contrast, the extrinsic death receptor apoptotic pathway relies on tumour 
necrosis factor (TNF) family death receptors for triggering apoptosis. These death 
receptors contain a cytoplasmic death domain (DD), which enables their intracellular 
interaction with downstream adapter proteins, linking these receptors to specific 
caspases (180). Upon ligand binding, TNF family receptors oligomerise and their 
cytoplasmic death domains cluster in the membrane, recruiting caspase-binding adaptor 
proteins, including the bipartite adapter Fas-associating protein with death domain 
(FADD) that contains both a death domain (DD) and a death effector domain (DED) 
(181). The DED of FADD binds DED-containing pro-caspases such as caspases-8 and -
10, forming a “death-inducing signaling complex” (DISC) and resulting in caspase 
activation by an “induced proximity” mechanism (182, 183). The intrinsic and extrinsic 
pathways of apoptosis are explained in Figure 5. 
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Figure 5: Mechanisms of intrinsic and extrinsic pathways of apoptosis. The intrinsic or 
mitochondrial pathway of apoptosis is controlled by the Bcl-2 family of pro- and anti-apoptotic 
proteins. When activated upon receiving a variety of apoptosis-triggering signals, pro-apoptotic 
proteins oligomerise to produce mitochondrial outer membrane permeabilisation (MOMP), 
release of apoptogenic proteins and thus activation of caspase-3 and -7. In the extrinsic or death 
receptor pathway, receptor ligation (TRAIL, CD95L and TNF) triggers the membrane bound 
death inducing signaling complex (DISC) formation, caspase-8 activation and cell death. The 
Figure is adapted and redrawn from reference number 176.  
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 Stabilisation of mitochondrial integrity is a key mechanism for both the survival 
of malignant cells and for resistance to chemotherapy (184, 185). A well-established 
family of proteins that has a significant impact on mitochondrial integrity by influencing 
the permeability of the mitochondrial membrane is the BCL2 family. Proteins of the 
BCL2 family have been identified as key regulators of apoptosis (175, 176). Myeloid cell 
leukaemia 1 (MCL1), an anti-apoptotic member of the BCL2 family genes, is essential 
for development, differentiation and survival of human leukaemic lymphocytes and cell 
lines derived from multiple myeloma (186). MCL1 was originally identified as an early 
induction gene during differentiation of myeloid leukaemia cells (186). Previous studies 
have confirmed that MCL1 requirement is critical for the survival of both normal and 
malignant B cells (187, 188). MCL1 protein exerts an anti-apoptotic function by binding 
and sequestering the pro-apoptotic members Bak and Bax that can form pores in the 
mitochondrial membrane leading to cytochrome c (cyt c) release into the cytoplasm and, 
thus, activating downstream caspases. Additionally, MCL1 interacts with several BH3-
only pro-apoptotic proteins that act to induce oligomerisation of Bak and Bax (189, 190). 
 
 In contrast to BCL2, MCL1 is not only found in mitochondrial membranes but 
also in the nucleus and cytoplasm (191). Several modes of action have been suggested 
for the anti-apoptotic activity of MCL1. For example, MCL1 was suggested to block cyto 
c release from mitochondria by interacting with pro-apoptotic members of the BLC2 
protein family, for example Bim (192), Bak (193, 194) and NOXA (195). Furthermore, 
MCL1 was shown to interact with truncated Bid and, thereby, inhibit intrinsic as well as 
extrinsic apoptotic signaling (196). 
 
 The MCL1 gene has been reported to be overexpressed in many human 
malignancies, including hepatocelluar carcinoma, CLL, colorectal carcinoma, breast 
cancer and B cell non-Hodgkin's lymphoma (197-201). More importantly, MCL1 
contributes to the resistance of cancer cells to the induction of apoptosis by 
chemotherapeutic agents, radiation and other agents (202). In transgenic mice, 
overexpression of MCL1 was shown to promote immortalisation of haematopoietic cells, 
while in knock-out mice loss of MCL1 resulted in peri-implantation embryonic lethality 
(203).  
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 In addition to the direct role of anti-apoptotic proteins upregulation in the evasion 
mechanism of apoptosis in cancer, other mechanisms such as amplification of cell 
proliferation and survival kinases also negatively regulate apoptotic pathways (204). 
One of these kinases is the polo-like kinase-1 (PLK1). The polo-like kinases (PLKs) are 
a family of mitotic serine/threonine protein kinases that are structurally and functionally 
related (205). Mammalian PLK1 plays a pivotal role in the maturation of centrosomes, 
entry into M phase, spindle formation and cytokinesis (206, 207). Furthermore, PLK1 
was found to contribute to DNA synthesis where it plays a role in pre-replication complex 
formation (208). 
 
 PLK1 gene expression occurs at low levels during the early phase of the cell 
cycle and is mediated by a repression mechanism involving a promoter element termed 
cell cycle-dependent element/cell cycle gene homology region (CDE/CHR). However, its 
levels accumulate throughout DNA synthesis (S) and gap 2 (G2) phases with a sharp 
increase in enzymatic activity occurring prior to the onset of mitotic (M) phase (209-213). 
PLK1 gene is oncogenic and constitutive expression of the enzyme was shown to cause 
transformation of NIH3T3 cells (214). Additionally, PLK1 is upregulated in many human 
malignancies and is widely considered to be a potential therapeutic target (207). 
 
Hypothesis 
 
Hypothesis:  
This study is based on the knowledge that faulty regulations of gene expression and/or 
intracellular signaling pathways result in defective apoptosis in B lymphocytes including 
neoplastic transformation in patients with leukaemias and lymphomas. 
  
CD22 is a membrane protein expressed exclusively on B lymphocytes. The 
working hypothesis of the study is that a scFv of mAb to CD22 can be used to target 
therapeutic agents to B lymphocytes in disease setting including leukaemias/lymphomas 
to induce cell death. 
 
 A number of the pathogenic lesions in neoplastic B lymphocytes are known to 
exist. Therefore, the study was intended to target key defect(s) by attaching siRNA 
specific for the defective target gene to a truncated protamine peptide fused to anti-
CD22 scFv for specific delivery to B lymphocytes. In this way, either the survival of 
defective B lymphocytes or their biology could be altered. Following internalisation of the 
fusion protein/siRNA complex, the proton sponge phenomenon (pH buffering effect), 
presumably, causes the release of the cargo from endolysosomal compartment. In this 
respect, the cationic protamine peptide is expected to have a high pH buffering 
capability and thus becomes protonated and resists the acidification of endosomes. As a 
result, protons will be pumped from the cytosol into the endosomes with the attempt to 
lower the pH. This proton pumping action is followed by passive entry of chloride ions, 
increasing ionic concentration and, thereby, water moves into the endolysosome. 
Ultimately, osmotic pressure causes swelling and rupture of endosomes, releasing their 
contents to the cytosol. Following endosomal escape and un-packaging, siRNA is 
released and incorporated into the RNAi pathway forming RISC for specific silencing of 
the target mRNA (215-217). The proposed mechanism involved in the delivery of siRNA 
to B cells is illustrated in Figure 6. 
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Figure 6: Mechanisms and pathways involved in the delivery of siRNA and targeting 
selected genes. This delivery system utilises a natural mechanism which is receptor-mediated 
endocytosis. Anti-CD22 scFv-protamine-His6/siRNA complex specifically binds to and 
internalises via CD22 receptor. Following internalisation, the endosome fuses with lysosomes 
forming endolysosome. siRNA is then expected to be released to cytoplasm because of the pH 
buffering effect of the cationic protamine peptide.  
 
Aims of the Study 
 
Aims of the Study: 
The overall aim of the present study is to provide proof of principle for a novel approach 
to target and modify the pathophysiology of aberrant B lymphocytes in pathological 
settings including B cell leukaemias and lymphomas. The approach involves using 
engineered recombinant scFv of anti-CD22 mAbs and a protamine peptide to attach to 
and specifically deliver siRNA to target signaling pathways and transcription factors in B 
lymphocytes. 
 
The study specifically aims to: 
1. Identify and use monoclonal anti-CD22 antibodies that would be internalised 
selectively into B lymphocytes. 
2. Generate recombinant anti-CD22 scFv-protamine fusion proteins that retain the ability 
to bind specifically to and be internalised by B lymphocytes via CD22. 
3. Deliver siRNA to target specific genes with critical roles in modulating B lymphocyte 
functions. 
4. Assess the veracity of the selectivity of delivery using truncated protamine peptide 
fused with recombinant proteins to their intended target cells.  
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2.1. Cell lines: 
2.1.1. Mouse leukaemia B cell line, BCL1-3B3: 
The mouse leukaemia B cell line, BCL1-3B3 (kindly provided by Professor M J Glennie; 
University of Southampton) was cultured in RPMI 1640 (Lonza Group Ltd., Switzerland) 
with 10% heat-inactivated foetal bovine serum (HI-FBS), 2.0 mM L-glutamine, 100 IU/mL 
Penicillin and 100 IU/mL Streptomycin, 1.0 mM sodium pyruvate and 0.05 mM 2-
mercaptoethanol (2-ME). The cells were maintained in a humidified incubator at 37°C 
with 5% CO2. 
The mouse leukaemia B cell line, CW13.20-3B3 (clone of BCL1) was purchased 
from the ATCC (Middlesex, UK) and cultured in RPMI 1640 (ATCC®) which contained 
10 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid (HEPES), 1.0 mM sodium 
pyruvate, 4.5 g/L glucose and 1.5 g/L sodium bicarbonate and supplemented with 2.0 
mM L-glutamine, 10% non-heat-inactivated FBS [ATCC®] and 100 IU/mL Penicillin and 
100IU/mL Streptomycin [Hybri-Max™, Sigma-Aldrich Inc, Poole, UK] and 0.05 mM 2-ME.  
 
2.1.2. The mouse hybridoma cell line, Cy34.1.2: 
The Cy34.1.2 mouse hybridoma line, which produces a mAb to mouse CD22.2, was 
purchased from the ATCC and grown in DMEM medium supplemented with 10% HI-
FBS, 2.0 mM L-glutamine, 100 IU/mL Penicillin, 100 IU/mL Streptomycin. The cells were 
cultured in a humidified incubator at 37°C with 5% CO2 in the air. 
 
2.1.3. SF9 insect cell line: 
The SF9 insect cells (Invitrogen Ltd, Paisley, UK) were grown in the serum-free SF-900 
II medium (Invitrogen Ltd) supplemented with 50 IU/mL Penicillin and 50 IU/mL 
Streptomycin and incubated at 27°C in a humidified incubator with no CO2.   
 
2.1.4. HighFive insect cell line: 
The HighFive insect cells (Invitrogen Ltd) were grown in the serum-free ExpressFive® 
medium supplemented with 50 IU/mL Penicillin and 50 IU/mL Streptomycin and 20 mM 
L-glutamine and incubated at 27°C in a humidified incubator.    
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2.1.5. HEK293T human cell line:   
HEK293T human cells were grown in DMEM medium supplemented with 10% HI-FBS, 
100 IU/mL Penicillin, 100 IU/mL Streptomycin and 2.0 mM L-glutamine. The cells were 
cultured in a humidified incubator at 37°C with 10% CO2.  
 
2.1.6. CHO-S cell line: 
The CHO-S Hamster cells (Invitrogen Ltd) adapted to suspension culture were grown in 
Freestyle CHO-S expression medium supplemented with 8.0 mM L-glutamine and 
incubated at 37°C humidified 10% CO2 incubator with rocking at 225 rpm. 
 
2.1.7. HEK293F cell line: 
The HEK293F FreeStyle™ 293-F human cells (Invitrogen Ltd), adapted to high density 
and serum-free suspension culture, were cultured in the FreeStyleTM 293 expression 
medium in suspension culture at 125 rpm rocking and 8% CO2 at 37°C.  
 
2.1.8. HF28 RA human follicular lymphoma B cell line: 
Human follicular lymphoma HF28 RA (EBV-positive) B cells were kindly provided by 
Professor Pelkonen (University of Kuopio, Kuopio, Finland). The cells were cultured at 
37°C in a humidified incubator with 5% CO2 in the air in RPMI 1640 medium 
supplemented with 5% HI-FBS, 2.0 mM  L-glutamine, 100 IU/mL Penicillin, 100 IU/mL 
Streptomycin, 10 mM HEPES buffer, 1.0 mM sodium pyruvate and 2.0 mM 2-ME.  
 
2.1.9. L3/Bcl-2 B cell line: 
L3/Bcl-2 cells, Burkitt’s lymphoma B cell line L3055 (EBV-negative) which was stably 
transfected with anti-apoptotic bcl-2, were kindly provided by Professor John Gordon 
(University of Birmingham). The cells were cultured in RPMI 1640 medium 
supplemented with 10% HI-FBS, 2.0 mM L-glutamine, 100 IU/mL Penicillin and 100 
IU/mL Streptomycin. The cells were cultured at 37°C in humidified incubator with 5% 
CO2 in the air. 
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2.1.10. Jurkat T cell line: 
Jurkat T cell human leukaemia line was maintained in RPMI 1640 medium 
supplemented with 10% HI-FBS, 10 mM HEPES, 2.0 mM L-glutamine, 100 IU/mL 
Penicillin and 100 IU/mL Streptomycin. The cells were maintained at 37°C with 5% CO2 
in the air. 
 
2.1.11. U-937 histiocytic lymphoma cell line: 
U-937 human histiocytic lymphoma cells were maintained in RPMI 1640 supplemented 
with 10% HI-FBS, 2.0 mM L-glutamine and 10.0 mM HEPES, at 37°C in a humidified 
incubator with 5% CO2 in the air.  
 
2.1.12. A375Ppuro and A375Ppuroβ6 cell lines: 
αvβ6-negative A375Ppuro and αvβ6-positive A375Ppuroβ6 cell lines were generated 
from the human melanoma cell line A375P, which was infected with pBabe retroviruses 
encoding Puromycin resistance or, in addition, cDNA for human β6 (218). The cells were 
grown in DMEM supplemented with 10% HI-FBS and 2.0 mM L-glutamine and 
maintained in 10% CO2 and at 37°C. 
 
2.1.13. DX3Ppuro and DX3Ppuroβ6 cell lines: 
αvβ6-negative DX3Ppuro and αvβ6-positive DX3Ppuroβ6 cell lines (113) were cultured 
in DMEM supplemented with 10% HI-FBS and 4.0 mM L-glutamine. The cells were 
maintained in 10% CO2 and at 37°C.  
   A375Ppuro, A375Ppuroβ6, DX3Ppuro, DX3Ppuroβ6 and VB6 cell lines were 
kindly provided by Dr. John F Marshall (Barts Cancer Institute, Queen Mary University of 
London). 
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2.1.14. The VB6 human cell line: 
VB6 is a keratinocyte oral squamous cell carcinoma-derived cell line transfected to 
express integrin ανβ6. The cell line was established by retroviral transfection of the ανβ5 
expressing human V3 cell line (engineered from the αv-negative H357 OSCC line 
transfected with αv cDNA) with β6 cDNA for constitutive high expression of the ανβ6 
heterodimer (218). The cells were maintained in complete keratinocyte growth medium 
(KGM) which is composed of Minimum Essential Medium-α base medium (MEM-α) 
supplemented with 10% HI-FBS, 10 ng/mL epidermal growth factor (EGF), 0.4 μg/mL 
hydrocortisone, 5.0 μg/mL insulin, 18 mM adenine, 3.0 mM L-glutamine and 1.0 x 10-10 
M cholera toxin (Sigma-Aldrich Inc). The cells grow as adherent monolayers and were 
kept in an incubator with 10% CO2 at 37°C. 
 
2.2. Production and purification of anti-CD22.2 mAb: 
The mouse Cy34.1.2 hybridoma cell line was cultured in complete DMEM medium and 
supernatant collected for purification of the mAb. The mouse anti-mouse CD22.2 mAb 
produced by Cy34.1.2 was then purified by affinity chromatography using PROSEP-G 
column (a protein G column; Millipore, Billerica, USA). The column was initially prepared 
by passing 5x column volumes of freshly prepared 6 M guanidine HCl and then 
regenerated with 10x column volumes of HCl pH 1.5 (0.0316M) followed by 5x column 
volumes of phosphate-buffered saline (PBS) pH 7.4. The supernatant was filtered 
through a 0.2 µm filter to remove cell debris before loading onto the column followed by 
washing with 5x column volumes of 2x PBS containing 0.02% NaN3. mAb bound to 
PROSEP-G beads was then eluted with 3 M potassium thiocyanate (KSCN) in PBS 
followed by 2x column volumes of PBS. Optical density values of the collected elution 
fractions were determined using a Nanodrop spectrophotometer (Thermo Fisher 
Scientific Inc., Warrington, UK) and aliquots with purified mAbs dialysed extensively 
against PBS using a 2-18/32” dialysis membrane (Medicell International Ltd, London, 
UK) for 48 hours at 4oC. Purity of the isolated mAb was determined by electrophoresis 
using a pre-cast NuPAGE Novex Bis Tris Mini Gel (Invitrogen Ltd) under non-reducing 
and reducing conditions.  
Chapter Two 
 
56 
 
2.3. Conjugation of purified anti-mouse CD22.2 mAb with AlexaFluor®488: 
The purified anti-mouse CD22.2 mAb was conjugated with AlexaFluor®488 
fluorochrome dye using AlexaFluor®488 Monoclonal Antibody Labeling kit (Invitrogen 
Ltd). The conjugated mAb was tested against BCL1-3B3 cells to assess reactivity of the 
antibody with CD22.2 molecules on mouse B cells. The degree of labeling was 
determined according the manufacturer’s instructions: 
A small amount of the purified conjugated antibody was diluted (1:2) in PBS and 
absorbance measured at both 280 nm (A280) and 494 nm (A494). The concentration of 
protein in the sample was calculated using the following equation: 
Protein concentration (M) = [A280 – (A494 x 0.11)] x dilution factor / 203,000 
Where 203,000 is the molar extinction coefficient in cm-1M-1 of IgG at 280 nm and 
0.11 is a correction factor for the fluorophore’s contribution to the absorbance at 280 nm. 
Concentration of the protein at 280 nm (A280) = 4.82 mg/mL 
Dilution: 2x  
Absorbance at 280 nm (A280) = 0.031 
Absorbance at 494 nm (A494) = 0.001 
Protein concentration (M) = 1.52 x 10-7 
 
Calculating the degree of labeling: 
Moles dye per mole protein = A494 x dilution factor / 71,000 x protein concentration (M) 
Where 71,000 cm-1M-1 is the approximate molar extinction coefficient of the 
AlexaFluor®488 dye at 494 nm. For IgGs, the labeling with 4–9 moles of 
AlexaFluor®488 dye per mole of antibody is optimal. Based on these calculations, the 
degree of labeling of the mAb was 0.9266 moles dye per mole protein. 
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2.4. Detection of CD22.2 on B lymphocytes by flow cytometry:  
BCL1-3B3 cells were stained for fluorescence activated cell sorting (FACS) analysis 
using the purified AlexaFluor®488 labeled anti-CD22.2 and PE labeled anti-mouse 
CD19 (BD Biosciences, Oxford, UK). The cells were washed in ice-cold staining buffer 
(PBS containing 0.1% NaN3 and 2% FBS) and pellets resuspended in ice-cold staining 
buffer and their number adjusted to 0.5-1 x 107 cells/mL. The stained cells were 
incubated for 20 minutes on ice, washed 3 times and resuspended in ice-cold staining 
buffer. The stained cells were analysed using a FACS Calibur flow cytometer (BD 
Biosciences) by gating on live cells with the forward and side scatter properties of 
lymphocytes. Mouse IgG1κ isotype control conjugated with FITC (BD Biosciences) was 
used as a control for background staining.  
 
2.5. Analysis of CD22.2 mAb internalisation on B cells by Confocal Laser 
Scanning Microscopy (CLSM): 
BCL1-3B3 cells (105 cells) were stained with AlexaFluor®488 anti-CD22.2 in RPMI 
medium on ice for 30 minutes. The cells were then incubated for various time points (0, 
30 and 60 minutes) at 37°C and then the reactions stopped by adding cold medium 
followed by centrifugation at 4°C and washing of the cells. Simultaneously, cells were 
also stained in separate tubes with AlexaFluor®488 isotype control. All stained cells 
were washed once with ice-cold staining buffer (5% FBS in PBS) and then incubated 
with proteinase K (VWR International Ltd, Soulbury, UK) (50 μL of ice-cold PBS 
containing 2 mg/mL proteinase K final concentration) on ice for 30 minutes (219). The 
cells were then washed 2x with PBS and fixed in 2% PFA in PBS for 20 minutes on ice. 
The cells were then stained with 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI, 
1:5000) for 5 minutes at 4°C and washed 2x with PBS, resuspended in 50 μL PBS, 
mounted on poly-L-lysine coated slides using Dako fluorescent mounting medium (Dako 
UK Ltd, Cambridge, UK) and examined by an LSM 510 confocal microscope. 
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2.6. Polymerase chain reaction (PCR) amplification:  
For PCR amplification using Thermus aquaticus (Taq) DNA polymerase (Promega, 
Southampton, UK), a PCR mastermix (94 μL) was prepared by combining 5x GoTaq® 
Flexi Buffer 20 μL, MgCl2 (25 mM) 6 μL, dNTPs (Invitrogen Ltd) (10 mM) 2 μL, forward 
primer (Sigma-Aldrich Inc) (10 mM) 5 μL, reverse primer (Sigma-Aldrich Inc) (10 mM) 5 
μL, dH2O 55 μL and 2 units (1 μL) of GoTaq® Flexi DNA Polymerase. From the cDNA of 
either the VH, or Vκ genes about 20 ng were then added to the mastermix. For other 
PCR reactions, about 20 ng template DNA was added to the mastermix accordingly. 
 
For PCR amplification using Pfu polymerase (Promega), a PCR mastermix was 
prepared by mixing Pfu DNA polymerase 10x reaction Buffer (200 mM Tris-HCl, 100 mM 
KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, 1.0% Triton® X-100, 1 mg/mL nuclease-free 
BSA, pH 8.8) 5 μL, dNTP mix, 10 mM each: 1 μL, upstream primer (10 μM): 1 μL, 
downstream primer (10 μM): 1 μL, 2 units/µL of Pyrococcus furiosus (Pfu) DNA 
polymerase: 0.5 μL and dH2O to final volume of 50 μL. Approximately 20 ng of plasmid 
DNA template was added to the mastermix. 
 
All the primer sequences are detailed in the Appendix. GoTaq® and Pfu 
polymerase PCR kits were all from Promega. 
 
From the PCR reaction, 5 μL was mixed with 4 μL of dH2O and 1 μL of 10x 
bromophenol blue loading dye (3.9 mL glycerol in TAE buffer, 0.025 g bromophenol 
blue, 0.025 g xylene cyanol and dH2O to 10 mL total volume) and was separated on 1% 
agarose gel with 0.5x TAE buffer (0.02 M Tris-acetate, 0.5 mM EDTA, pH 8.0) at 120 V 
for 40 minutes. 1k Plus DNA ladder (Invitrogen Ltd) was run alongside samples. 
Ethidium bromide (Sigma-Aldrich Inc) or SyberSafe stain (Invitrogen Ltd) at 1 μg final 
concentration was incorporated in 1% agarose gel to visualise DNA under UV light and 
image was captured using a gel documentation system (Uvitec Ltd, Cambridge, UK). 
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2.7. RNA extraction, cDNA synthesis, poly-G-tailing and amplification of 
immunoglobulin VH and VL genes: 
Total RNA was extracted using the RNAqueous®-4PCR Kit (Applied Biosystems, 
Warrington, UK). Cy34.1.2 hybridoma cells (1 x 106 cells) were pelleted by centrifugation 
at 1200 rpm for 5 minutes at 4°C and then lysed with 500 μL of Lysis/Binding solution. 
The cell lysate was clarified by centrifugation and an equal volume of 64% ethanol was 
added. The lysate/ethanol mixture was applied to the filter cartridge and centrifuged at 
10,000 rpm for 1 minute at room temperature. The flow-through was discarded and the 
cartridge washed with 700 μL of Wash Solution #1 (containing guanidinium thiocyanate) 
and centrifuged at 10,000 rpm for 1 minute at room temperature. The cartridge was then 
washed twice with 500 μL Wash Solution #2/3 and put in a fresh collection tube and 
RNA eluted with 50 μL pre-heated (70°C) Elution Solution and centrifuged at 14,000 rpm 
for 30 seconds at room temperature. To each 9 μL RNA solution, 1 μL of 10x DNase I 
buffer (100 mM Tris, 25 mM MgCl2 and 1 mM CaCl2) and 1 μL of DNase I (RNase-free) 
were added and incubated at 37°C for 30 minutes. To precipitate the DNase I, 1 μL of 
the slurry DNase inactivation reagent was added to the RNA solution, incubated at room 
temperature for 2 minutes and centrifuged at 10,000 g for 1 minute. Purity of the RNA 
was assessed by measuring the A260/A280 ratio using a Nanodrop spectrophotometer. 
Agarose gel electrophoresis was carried out to verify integrity of the RNA and to observe 
the 28S and 16S rRNA bands. Then, cDNA for both VH and VL were synthesised using 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) [10x Reverse 
Transcriptase buffer 2 μL, 25x dNTP Mix (100 mM) 0.8 μL, Cγ1 or Cκ1 primer (10 mM) 2 
μL, Reverse Transcriptase (50 U/μL) 1 μL, RNase inhibitor 1 μL, nuclease-free H2O 3.2 
μL and total RNA (1.0 μg/μL) 10 μL (20 μL total reaction volume)]. The Cγ1 and Cκ1 
primers within the 5’ end of the constant regions of mouse γ1 and κ chains were 
designed based on the IMGT® database, the international ImMunoGeneTics information 
system® (http://www.imgt.org/). The primer designed for mouse γ1 for the cDNA was 
called Cγ1: 5’AGTTAGTTTGGGCAGCAGAT3’, and that for the κ chain was Cκ1: 
5’GTAGAAGTTGTTCAAGAAGCACAC3’. The cDNA synthesis reaction [step 1: 25°C for 
10 minutes, step 2: 37°C for 120 minutes and step 3: 85°C for 5 minutes] was performed 
in a thermal cycler (MJ Research PTC-200 Peltier Thermal Cycler, Global Medical 
Instrumentation Inc, California, USA) for 1 hour at 37°C using total RNA. The 
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inactivation reaction was carried out at 70°C for 10 minutes. cDNA was purified using 
the PureLink PCR Purification Kit (Invitrogen Ltd). cDNA was poly guanine-tailed at the 
5’ end using the enzyme terminal deoxynucleotidyl transferase  (TdT, Promega) 
[terminal transferase 5x buffer 8 μL, cDNA (1 ng/μL) 25 μL, dGTP (20 mM) 2 μL, TdT 
(30 units) 1 μL and H2O 4 μL]. The poly-G tailing reaction was carried out at 37°C for 60 
minutes and the reaction stopped by heating at 70°C for 10 minutes. Tailed cDNA was 
purified using PureLink PCR Purification Kit (Invitrogen Ltd) and amplified by anchored 
PCR. The anchored PCR was carried out using a poly-(C) primer with a restriction site 
complementary to the poly-(G) tail (anchor primer: 
5'ACGAATTCTAGAGTCGACCCCCCCCCCCCCC3') together with a primer 
complementary to mouse γ1 constant region upstream of the Cγ1 site used for the cDNA 
synthesis (nested primer Cγ2, 5’GCCAGTGGATAGACAGAT3’). The nested primer for 
the κ light chain was upstream of the cDNA primer Cκ1 site (Cκ2, 
5’AGATGTTAACTGCTCACTGGAT3’). All primers were desalted and purchased from 
Sigma-Aldrich Inc. The poly-(C) primer was allowed to extend for 15 minutes at 70°C 
before adding the nested primers Cγ2 or Cκ2. The PCRs were performed using GoTaq® 
polymerase. From the poly-G-tailed cDNA of either the VH or Vκ, 2 μL was then added to 
the mastermix. The PCRs were carried out using the following conditions: denaturation 
at 95°C for 30 seconds, annealing at 62.9°C for 30 seconds, extension at 72°C for 1 
minute and heated lid at 110°C (G-Storm thermal cycler, Gene Technologies Ltd, 
Somerton, UK). The PCR products were analysed on 1% agarose gels and purified by 
gel extraction using the PureLink Quick Gel Extraction Kit (Invitrogen Ltd) and the 
recovered poly-G-tailed cDNA used for TA cloning.  
 
2.8. Plasmid DNA mini-preparation: 
Mini-preparations of plasmid DNA were carried out using a PureLink Quick Plasmid 
Miniprep Kit (Invitrogen Ltd) according to the manufacturer’s instructions. Transformed 
colonies of DH5α Escherichia coli (E. coli) bacteria were picked and cultured in 5 mL 
Luria-Bertani (LB) broth with 5 µL Carbenicillin (100 mg/mL) overnight at 37°C. Next 
day, 1.5 mL of bacterial cultures were centrifuged at 12,000 g for 4 minutes at room 
temperature and cell pellets resuspended in resuspension buffer with RNase A and 
lysed with lysis buffer for 5 minutes. The lysates were centrifuged at 12,000 g for 10 
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minutes at room temperature to remove debris and proteins precipitated from the lysates 
using precipitation buffer. The supernatant was loaded onto spin columns, centrifuged at 
12000 g for 1 minute at room temperature and columns washed with wash buffer 
containing ethanol. The columns were centrifuged at 12,000 g for 1 minute at room 
temperature and plasmid DNA eluted with 75 µL pre-heated (70°C) Tris-EDTA (TE) pH 
8.0 buffer. The extracted plasmid DNA was analysed by restriction digestion and 
sequencing.  
 
2.9. Plasmid DNA maxi-preparation: 
Maxi-preparations were carried out using PureLink™ HiPure Plasmid DNA Purification 
Kits (Invitrogen Ltd) according to the manufacturer’s instructions. To expand the plasmid 
DNA from transformants, 250 mL bacterial culture from the transformed DH5α E. coli in 
LB broth medium with Carbenicillin (100 mg/mL) overnight at 37°C was used. Next day, 
the bacterial culture was centrifuged at 5,000 g for 10 minutes at 4°C and the cell pellet 
resuspended in resuspension buffer (R3) containing RNase A until homogeneous and 
lysed with lysis buffer (L7) for 5 minutes at room temperature with gentle mixing. The 
lysates were precipitated with the precipitation buffer (N3) and mixed immediately until 
the mixture was homogeneous then centrifuged at 5,000 g for 30 minutes at 4°C to 
clarify the lysates from debris and proteins precipitated from the lysates using 
precipitation buffer. The supernatant was carefully removed and loaded onto the 
equilibrated column (HiPure Maxi Column was pre-equilibrated with 30 mL Equilibration 
Buffer (EQ1)) and the solution allowed to drain by gravity flow. The column was then 
washed once with 60 mL Wash Buffer (W8) allowing the solution to drain by gravity flow. 
Next, the plasmid DNA was eluted from the column by adding 15 mL Elution Buffer (E4) 
and the flow-through collected in a sterile tube. The plasmid DNA was precipitated by 
adding 10.5 mL isopropanol to the eluate, mixed well and centrifuged at 5,000 g for 30 
minutes at 4°C. The supernatant was discarded and the DNA pellet washed with 70% 
ethanol and centrifuged at 5,000 g for 30 minutes at 4°C. The supernatant was removed 
and DNA pellet air-dried and resuspended in 500 μL TE buffer pH 8.0.  
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2.10. Preparation of competent Escherichia coli: 
Bacterial glycerol stocks (stored at -80°C) were regrown at 37°C overnight by initiation of 
5 mL starter cultures without antibiotics. Next day, a large scale (500 mL) bacterial 
culture was grown at 37°C (with shaking at 250 rpm), until the OD600 reached 0.4-0.6 
then centrifuged at 4°C for 10 minutes at 5000 rpm. The supernatant was discarded and 
bacterial pellet resuspended in ice-cold 0.1 M MgCl2 and centrifuged at 4°C for 10 
minutes at 2000 rpm. The supernatant was discarded and bacteria resuspended in ice-
cold 0.1 M CaCl2. The bacteria were centrifuged at 2000 rpm for 20 minutes at 4oC. The 
supernatant was discarded and cells resuspended in ice cold 0.1 M CaCl2 containing 
14% glycerol, 100 μL aliquots of competent bacteria were prepared in 1.5 mL pre-chilled 
Eppendorf tubes on dry ice and were stored at -80oC. 
 
For preparation of competent DH5α E. coli and DH10BacTM E. coli, cells were 
grown in LB broth without Carbenicillin and for HB2151 E. coli, cells were grown in 2xTY 
(16 g tryptone, 10 g yeast extract and 5 g NaCl in 1 litre dH2O) without Carbenicillin. 
 
2.11. Gel extraction for the purification of DNA: 
DNA was extracted using a PureLink® Quick Gel Extraction Kit (Invitrogen Ltd) 
according to the manufacturer’s instructions: the agarose gel containing the desired 
DNA fragment was excised, weighed and placed into a clean microcentrifuge tube and 
solubilised with 3 volumes Gel Solubilisation Buffer (L3) on a 50°C hot block for 15 
minutes with mixing. After the gel slice was dissolved, the mixture was loaded onto a 
Quick Gel Extraction Column inside a wash tube and centrifuged at 12,000 g for 1 
minute. Then, 700 μL of Wash Buffer (W1) containing ethanol was added to the column 
and centrifuged at 12,000 g for 1 minute, the flow-through was discarded and the 
column centrifuged again at maximum speed for 3 minutes to remove residual Wash 
Buffer and ethanol. The DNA was eluted with 50 μL Elution Buffer (E5) by incubation for 
1 minute at room temperature and centrifugation at 12,000 g for 1 minute. 
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2.12. Ligation reactions and bacterial transformation: 
PCR products as well as plasmid vectors were digested with appropriate enzymes. 
Digested fragments were separated on 1% agarose gels according to fragment size with 
0.5x TAE. DNA fragments of interest were excised from the gel and purified using the 
PureLink® Quick Gel Extraction Kit. For the ligation reaction, insert DNA (PCR product 
or digested DNA fragment) was combined with the vector DNA backbone and ligated at 
4°C overnight with T4 DNA ligase (NEB Inc., Ipswich, UK) in a final volume of 20 µL.  
 
The ligation reaction [plasmid DNA, PCR product, 2.0 µL of 10x ligase buffer, 1.0 
µL of T4 DNA ligase (400,000 U/mL) and dH2O to a final volume of 20 µL] was 
incubated at 4°C overnight. For bacterial transformation, 100 μL of DH5α  E. coli was 
thawed on ice and mixed with the ligation reaction and incubated on ice for 30 minutes. 
The bacteria were then heat-shocked at 42°C on a pre-warmed hot block for 90 seconds 
and returned immediately onto ice for 2 minutes. Fresh LB medium without antibiotics 
was added to the transformed bacteria and incubated at 37°C in a shaker incubator (225 
rpm) for 2 hours. LB agar plates [10 g Bacto-tryptone, 5 g yeast extract, 10 g NaCl, 15 g 
agar, 1 L dH2O. pH 7.5] with Carbenicillin (100 mg/mL) were inoculated with 400 μL of 
the bacterial cultures and incubated overnight at 37°C. Next day, the plates were 
checked for bacterial colonies and single colonies selected and expanded for DNA mini-
preparations. 
 
2.13. TA cloning and bacterial transformation:  
Taq DNA polymerase, which was used to amplify the poly-G tailed cDNA, preferentially 
adds an adenine to the 3’ end of PCR products. The PCR products were cloned into 
linearised pCR®2.1 vector (Invitrogen Ltd) that has a complementary 3’ thymine 
overhang. The ligation reaction between pCR®2.1 linear plasmid DNA and the Cγ2 or 
Cκ2 PCR product was performed overnight at 4°C using T4 DNA ligase. Next day, to 
use blue/white colour screening for recombinants and maintain antibiotic selection, 
ligated plasmid DNA was transfected into chemically-competent DH5α E. coli cells and 
LB agar plates with Carbenicillin (100 mg/mL) and 40 mg/mL bromo-chloro-indolyl-
galactopyranoside (X-Gal) were inoculated with the bacteria and incubated overnight at 
37°C. The next day, plates were checked for colonies and white colonies selected and 
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expanded for mini-DNA preparations. The principle of TA cloning depends on disruption 
of lacZ gene which is illustrated in Figure 7. pCR®2.1 vector uses the lac operon which 
encodes the β-galactosidase gene lacZ. This enzyme catalyses the breakdown of 
lactose; it can also degrade X-Gal, which turns blue when it is broken down by β-
galactosidase. Colonies that produce β-galactosidase (i.e. the lacZ gene is intact or the 
PCR product is not inserted) turn blue while colonies that do not produce β-
galactosidase (i.e. the PCR product inserted into the lacZ gene) remain white. 
Successful ligation of a foreign DNA into lacZ abolishes production of functional β-
galactosidase (220). VH- and Vκ-containing plasmid DNAs were digested using EcoRI 
restriction enzyme (NEB Inc.) and the plasmid DNAs sequenced using M13 forward and 
reverse primers. Part of the TA cloning vector pCR®2.1 sequences showing the lacZ 
gene, unique restriction sites and M13 priming sites are shown in Figure 8.  
 All the sequencing reactions (Sanger sequencing) were performed at the 
Genome Centre, Queen Mary University of London.  
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Figure 7: Schematic map of the TA cloning vector pCR®2.1 illustrating the insertion site 
of a PCR product within the lacZ gene. Linearised pCR™2.1 has a 3'-T overhang for direct 
ligation of Taq-amplified PCR products, a versatile polylinker with flanking EcoRI sites for easy 
excision of inserts and M13 forward and reverse primer sites for sequencing. The figure depicts 
disruption of the lacZ gene with insertion of VH or VL PCR product in the positive clones. lacZα 
gene: bases 1-545, M13 reverse priming site: bases 205-221, T7 promoter: bases 362-381, M13 
(-20) forward priming site: bases 389-404, f1 origin: bases 546-983, Kanamycin resistance ORF: 
bases 1317-2111, Apm resistance ORF: bases 2129-2989 and pUC origin: bases 3134-3807. 
 A A  VH or VL PCR product 
F1 ori PlacZ PlacZ VH or VL PCR product 
Kanamycin Ampicillin pUC ori 
pCR®2.1 TA cloning vector, 3929 bp
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                                                                                                                               HindIII             KpnI           SacI 
  M13 reverse primer   lacZα ATG                  |      ||      || 
CAG GAA ACA GCT ATG AC C ATG ATT ACG CCA AGC TTG GTA CCG AGC  
 Q   E   T   A   M   T   M   I   T   P   S   L   V   P   S    
GTC CTT TGT CGA TAC TG G TAC TAA TGC GGT TCG AAC CAT GGC TCG  
            10           20           30            40            
 
           BamHI         SpeI                                                      BstXI                      EcoRI          Insertion 
 ||      ||      |           |              ||    |      site  
TCG GAT CCA CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC GGC TT A  
 S   D   P   L   V   T   A   A   S   V   L   E   F   G   L    
AGC CTA GGT GAT CAT TGC CGG CGG TCA CAC GAC CTT AAG CCG AA T  
     50           60            70           80           90             
 
                 EcoRI                                                           BstXI                          NotI           AvaI   XhoI 
    |     |             |             ||        ||    | 
GCC GAA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT 
 A   E   F   C   R   Y   P   S   H   W   R   P   L   E   H    
CGG CTT AAG ACG TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA 
            100          110          120           130           
 
      XbaI             ApaI 
    |     | |     |                  T7 promoter 
GCA TCT AGA GGG CCC AAT TCG CCC TAT AGT GAG TCG TAT TA C AAT  
 A   S   R   G   P   N   S   P   Y   S   E   S   Y   Y   N 
CGT AGA TCT CCC GGG TTA AGC GGG ATA TCA CTC AGC ATA AT G TTA  
     140          150           160          170          180             
 
                       M13 forward primer 
TCA CTG GCC GTC GTT TTA C AA CGT CGT GAC TGG GAA AAC 
 S   L   A   V   V   L    Q   R   R   D   W   E   N 
AGT GAC CGG CAG CAA AAT G TT GCA GCA CTG ACC CTT TTG 
            190         200          210          220 
 
Figure 8: Sequence of pCR®2.1 containing a portion of the lacZ gene sequence and 
unique restriction sites. The insertion site of PCR products is within the lacZ gene and M13 
forward and reverse priming sites are also indicated. 
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2.14. Analysis of nucleotide sequences of the VH and VL of the Cy34.1.2 mAb: 
Nucleotide sequences of the VH and VL genes of Cy34.1.2 mAb were analysed by 
carrying out a Basic Local Alignment Search Tool (BLAST) search in the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). The leader sequences of 
the signal peptide at the N-terminal end of the VH and VL were determined by analysis of 
the variable regions of both VH and VL genes using a bioinformatics protein 
hydrophobicity plot (http://www.vivo.colostate.edu/molkit/hydropathy/). The output 
interface of the bioinformatics tool generated a hydrophobicity plot of the signal peptide. 
According to the Kyte-Doolittle scale, which constitutes the basis of the analysis for 
detecting hydrophobic regions in proteins, each amino acid has a specific value and 
those with a hydrophobic nature have positive values (221). 
 
2.15. Generation of anti-CD22.2 scFv cDNAs: 
In order to generate anti-CD22.2 single chain fragment of variable regions (scFv), cDNA 
was produced from the mRNA of the VH and VL of the Cy34.1.2 mAb. The cDNAs were 
then poly-G tailed at the 5’UTR regions and amplified by PCR. The PCR products were 
cloned into the pCR®2.1 TA vector (Invitrogen Ltd) and sequenced with M13 forward 
primer. After obtaining the information about the VH and VL genes, specific primers were 
designed to amplify the cDNA for the VH and VL genes incorporating restriction sites to 
enable cloning of the DNA fragments in-frame into restriction sites within the multiple 
cloning site (MCS) of the plasmid DNA for expression of recombinant proteins. To obtain 
the scFv, a sequence encoding the (Gly4Ser)3 linker was incorporated between the VH 
and VL cDNAs. Two different clones were constructed. The scFv cDNA was fused at its 
C-terminal end with a hexahistidine purification tag to generate scFv-His6 and the 
second construct was fused at its C-terminal end with the truncated protamine peptide 
and a hexahistidine tag to generate scFv-protamine-His6. Both constructs were cloned 
into the transfer vector pFastBacTM1, a plasmid donor vector constructed so that it can 
propagate in two different host species. 
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2.16. Construction and cloning of anti-CD22.2 scFv-His6 and scFv-protamine-His6 
into expression vectors using the baculovirus shuttle vector: 
For this approach, the Bac-to-Bac® Baculovirus Expression System (Invitrogen Ltd) was 
used. This expression system is based on site-specific transposition of an expression 
cassette from a recombinant donor plasmid DNA vector (pFastBacTM1) (Figure 9). This 
allowed for the generation of an expression construct containing the genes of interest, 
into a baculovirus shuttle vector (bacmid) propagated in E. coli. 
 
 
 
 
 
 
      
 
Figure 9: A schematic diagram of the transfer donor vector pFastBacTM1. The figure depicts 
a donor vector with left and right Tn7 transposable elements which is the basis of site-specific 
transposition of the expression cassette into the recipient vector during recombination. This 
vector was previously used to clone mIFNβ-MMP-1-11E scFv in our department with restriction 
sites HindIII, EcoRI, NotI, XhoI, SalI, XbaI and ApaI in the MCS. The anti-CD22.2 scFv-His6 and 
scFv-protamine-His6 expression cassettes were cloned into the MCS between HindIII and ApaI 
restriction sites. f1 origin: bases 2-457, Ampicillin resistance gene: bases 589-1449, pUC origin: 
bases 1594-2267, Tn7R: bases 2511-2735, Gentamicin resistance gene: bases 2802-3335 
(complementary strand), Polyhedrin promoter (PPH): bases 3904-4032, Multiple cloning site 
(MCS): bases 4037-4142, SV40 polyadenylation signal: bases 4160-4400 and Tn7L: bases 
4429-4594.  
MCS SV40 pA Gentamicin PPH Tn7L Tn7R 
Ampicillin pUC ori f1 ori 
pFastBacTM1 donor vector, 4775 bp
HindIII 
EcoRI 
NotI 
XhoI 
SalI 
XbaI 
ApaI 
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2.17. DNA preparation and plasmid manipulation: 
The plasmid vector pFastBacTM1 mIFNβ-MMP-1-11E was digested with SalI and XbaI 
restriction enzymes to remove the VL sequence and was purified by gel extraction to 
prepare the vector for subcloning of the new VL DNA sequence. Concomitantly, both VH 
and VL genes of the mAb Cy34.1.2 were amplified by PCR from TA cloned plasmid DNA 
miniprep using specific primers designed to incorporate the restriction sites in a PCR 
extension. The VH primers were: VH forward primer with HindIII restriction site 
(underlined) and start codon (bold): 5’CAGAAGCTTATGAGATGGAGCTGTATC3’; VH 
reverse primer with XhoI restriction site (underlined): 
5’CGCTCGAGACAAAGTAGAATGAGTAAGT3’. The VL primers were: a common VL 
forward primer with SalI restriction site (underlined): 
5’GGCGGGTCGACGGATATTGTGATGACGCAG3’ and two different reverse primers: 
VL1 reverse primer (VL1) with an EcoRI restriction site (underlined) for construction of 
anti-CD22.2 scFv-protamine-His6 expression cassette : 
5’TCGGAATTCCGGAAGTTCTAGATTTT3’ and the second primer VL2 reverse primer 
(VL2) with an NheI restriction site (underlined) for construction of anti-CD22.2 scFv-His6 
expression cassette:  5’TCGGCTAGCCGGAAGTTCTAGATTTT3’ (Figure 10). The PCR 
mastermixes were prepared according to GoTaq® PCR kit. From the cDNA of either the 
VH or Vκ genes 6 μL were then added to the mastermix. The PCRs were performed 
using GoTaq® polymerase in a G-Storm thermal cycler (Gene Technologies Ltd, 
Somerton, UK) with the conditions described in Table 1.  
 
Table 1: PCR conditions using GoTaq® polymerase to amplify Cy34.1.2 VH and VL 
genes from pCR®2.1 TA cloning vector.  
 
Step Time Temperature Cycles 
Start cycle   30x 
Denaturation 30 seconds 95°C 
30x Annealing 30 seconds 55°C 
Extension 1 minute 72°C 
    
Heated lid  110°C  
 
Chapter Two 
 
70 
 
  
 
 
 
Figure 10: An illustration of the strategy for the construction of in-frame anti-CD22.2 
scFv-His6 and scFv-protamine-His6 expression cassettes. The native signal peptide 
sequence located at the N-terminus is in-frame with the VH which is connected with a short 
glycine-serine linker peptide to the VL for flexibility and a hexahistidine at the C-terminus 
followed by a stop codon in scFv-His6 (top). The 75 nucleotide sequence comprising the human 
truncated protamine domain is cloned in-frame between the VL and the His-tag sequence in 
scFv-protamine-His6 construct (bottom). 
 
Amplified VH and VL PCR products were purified using the PureLink PCR 
Purification Kit (Invitrogen Ltd). The VH DNA was then digested with HindIII and XhoI 
restriction enzymes; the VL1 DNA was digested with SalI and EcoRI enzymes and VL2 
DNA was digested with SalI and NheI enzymes. Later, the digested DNA of VH, VL1 and 
VL2 were purified from agarose gel using the PureLink Quick Gel Extraction Kit 
(Invitrogen Ltd) and recovered DNAs used for cloning.  
 
cDNA for the truncated human protamine used to generate anti-CD22.2 scFv-
protamine-His6 was composed of nucleotides encoding 21 amino acids: 
RSQSRSRYYRQRQRSRRRRRR (120). The truncated protamine cDNA was generated 
by annealing of two overhang HPLC-purified primers (Sigma-Aldrich Inc). An EcoRI 
restriction site was incorporated in the forward protamine oligo sequence and an XbaI 
restriction site was incorporated into the reverse protamine oligo primer. The forward 
protamine primer sequence: 
5'AATTCCGATCACAATCACGATCACGATACTACCGACAACGACAACGATCACGACG
HindIII                                                   XhoI                  SalI            NheI                   ApaI 
NH3+ (Gly4Ser)3 VH Signal peptide His6 VL2 COO
- 
Cy34.1.2 murine anti-CD22.2 scFv-His6 
HindIII                                                   XhoI                  SalI           EcoRI             XbaI                   ApaI  
Protamine NH3+ (Gly4Ser)3 VH Signal peptide His6 VL1 COO
- 
Cy34.1.2 murine anti-CD22.2 scFv-protamine-His6 
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ACGACGACGACGAT3’ and the reverse protamine primer sequence: 
3’GGCTAGTGTTAGTGCTAGTGCTATGATGGCTGTTGCTGTTGCTAGTGCTGCTGCT
GCTGCTGCTAGATC5’ were annealed by mixing 10x dilution of each primer stock (100 
mM), T4 DNA ligase buffer (10x) and sterile dH2O. The mixture was boiled for 5 minutes 
in a waterbath and left to cool. Next, a ligation reaction was set up by overnight 
incubation at 4°C for cloning of the VL1 and truncated protamine cDNA into the 
pFastBacTM1 vector backbone and then the VH to generate anti-CD22.2 scFv-protamine-
His6 construct.  
 
2.18. Construction of anti-CD22.2 scFv-His6 donor vector: 
The VL2 DNA PCR product was cloned into the pFastBacTM1 vector backbone between 
SalI and NheI sites. The resulting vector was digested with HindIII and XhoI, gel purified 
and used for cloning of VH DNA sequence (Figure 11). Positive clones were verified by 
restriction analysis and sequencing using SV40 poly-adenylation (SV40 pA) reverse 
primer: 5’GAAATTTGTGATGCTATTGC3’. 
 
2.19. Construction of anti-CD22.2 scFv-protamine-His6 donor vector: 
The VL1 DNA PCR product and the annealed protamine cDNA were cloned into the 
pFastBacTM1 vector backbone. The VL1 PCR product was cloned between SalI and 
EcoRI sites and the protamine cDNA was cloned between EcoRI and XbaI sites. Having 
confirmed that the VL1 and the truncated protamine sequences were subcloned, the 
plasmid pFastBacTM1 vector now containing VL1 and protamine was digested with 
HindIII and XhoI enzymes, gel purified and used for subcloning of the VH sequence 
(Figure 12). 
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Figure 11: Cloning strategy for the construction of anti-CD22.2 scFv-His6 in pFastBacTM 
donor vector. The expression cassettes were PCR-amplified and cloned between HindIII and 
ApaI sites in the order shown into the backbone of the vector. The donor vector was used later 
for transposition with the baculovirus shuttle vector by site-specific recombination using Tn7 
sites. 
 
 
 
 
 
 
 
Figure 12: Cloning strategy for the construction of anti-CD22.2 scFv-protamine-His6 in 
pFastBacTM donor vector. The expression cassettes were PCR-amplified and cloned between 
HindIII and ApaI sites in the order shown into the backbone of the vector. The donor vector was 
used later for transposition with the baculovirus shuttle vector by site-specific recombination 
using Tn7 sites. 
 
 
(Gly4Ser)3 VH Signal peptide His6 VL 
SV40 pA Tn7L Gentamicin PPH Tn7R 
Ampicillin pUC ori f1 ori 
pFastBacTM1 donor vector, 4775 bp
SV40 pA Tn7L Gentamicin PPH Tn7R 
Ampicillin pUC ori f1 ori 
(Gly4Ser)3 VH Signal peptide His6 VL Protamine 
pFastBacTM1 donor vector, 4775 bp 
HindIII                                                                           ApaI 
HindIII                                                                                                           ApaI 
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2.20. Generation of recombinant bacmids: 
Once the anti-CD22.2 pFastBacTM1 scFv-His6 and scFv-protamine-His6 were 
generated, purified DNA plasmids of the constructs were used to transform DH10BacTM 
E. coli for transposition into the baculovirus shuttle vector (bacmid). The process 
involves site-specific transposition of the expression cassettes from the donor vector to 
the recipient bacmid. The expression cassettes are flanked by left and right Tn7 
transposable elements from the pFastBacTM donor vector which can transpose with the 
help of a transposase enzyme produced by a helper plasmid to the baculovirus genome 
which has the mini-attTn7 site. The entire process occurs in the DH10Bac strain of E. 
coli (Figure 13). 
 
 Competent DH10Bac™ E. coli cells were transformed with 1 ng plasmid DNA 
pFastBacTM. The cells were heat-shocked for 90 seconds at 42°C and the transformed 
bacteria grown in 900 μL of LB medium and incubated at 37°C shaker incubator at 225 
rpm for 4 hours. For each transformation, 10-fold serial dilutions of the cells (10-1, 10-2, 
10-3 and 10-4) with LB medium were prepared. Then from each dilution, 100 μL of the 
bacterial culture were plated on LB agar plates containing 50 μg/mL Kanamycin, 7 
μg/mL Gentamicin, 10 μg/mL Tetracycline, 100 μg/mL X-gal and 40 μg/mL isopropyl-β-
D-galactoside (IPTG). The plates were incubated for 48 hours at 37°C. Since the 
transformation depends on blue/white colony selection, the white colonies were picked 
for analysis to verify the phenotype. Verification was carried out by selecting 10 white 
colonies and re-streaking them on fresh LB agar plates containing 50 μg/mL Kanamycin, 
7 μg/mL Gentamicin, 10 μg/mL Tetracycline, 100 μg/mL X-gal and 40 μg/mL IPTG. The 
plates were incubated overnight at 37°C.  Single colonies were picked for plasmid DNA 
minipreparation.  
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Figure 13: An illustration depicting the process of site-specific recombination of the expression cassettes from a donor vector to 
a recipient baculovirus vector. The expression cassettes are flanked by 3’ and 5’ Tn7 transposable elements from the pFastBacTM donor 
vector which can transpose, with the help of a transposase enzyme produced by a helper plasmid, from the donor vector to the baculovirus 
genome which has the mini-attTn7 site. The entire process occurs in DH10Bac strain of E. coli. 
Transposase  
Tetracyclin 
Helper plasmid 
(Gly4Ser)3 VH Signal peptide His6 VL 
(Gly4Ser)3 VH Signal peptide His6 VL Protamine 
MCS SV40 pA Gentamicin PPH Tn7L Tn7R 
Ampicillin pUC ori f1 ori 
Transposition 
mini-attTn7 M13 Forward  M13 Reverse 
Mini-F replicon AcMNPV Bacmid DNA Kanamycin 
Baculovirus genome 
pFastBacTM 
donor vector 
74 
HindIII                                                                                                 ApaI 
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2.21. Analysis of recombinant bacmids: 
Recombinant bacmid DNA is greater than 135 kb in size. Since restriction analysis is 
difficult to perform with DNA of this size, PCR analysis was used to verify the presence 
of the gene of interest in the recombinant bacmid. The bacmid DNA contains M13 
forward and M13 reverse priming sites flanking the mini-attTn7 site within the lacZα-
complementation region to facilitate PCR analysis. 
 
The PCRs were performed with M13 forward primer 5’GTTTTCCCAGTCAGAC3’ 
and M13 reverse primer 5’CAGGAAACAGCTATGAC3’ using GoTaq® polymerase. The 
PCRs were carried out using the conditions shown in Table 2. A schematic illustration 
for the expected PCR products is shown in Figure 39, page 146.  
 
Table 2: PCR conditions to amplify the gene of interest in the recombinant bacmid.  
Step Time Temperature Cycles 
Initial denaturation 3 minutes 93°C 1x 
Denaturation 45 seconds 94°C 
30x Annealing 45 seconds 55°C 
Extension 5 minutes 72°C 
Final extension 7 minutes 72°C 1x 
Heated lid  110°C  
 
2.22. Cloning of anti-CD22.2 scFv-His6 and scFv-protamine-His6 into pcDNA3 
vector for expression in mammalian cells: 
The baculoviral polyhedrin gene promoter (polh) that generally drives gene expression 
of baculoviruses is not active in mammalian cells; hence for expression of the 
recombinant proteins in mammalian cells the scFv DNAs were cloned into the pcLuc+ in 
place of the luciferase gene (Figure 14). Anti-CD22.2 scFv-His6 and scFv-protamine-
His6 expression cassettes were PCR-amplified using HindIII forward primer: 
5’CCAAAGCTTATGAGATGGAGCTGTATCATT3’ and ApaI reverse primer: 
5’AGCTCGGGCCCTCAATGGTGGTGGTGATGGTG3’. The PCRs were carried out 
using the conditions in Table 1. The plasmid pcLuc+ (222) was restricted with HindIII and 
ApaI enzymes to remove the luciferase gene (Luc+) and the backbone pcDNA3 used for 
subcloning of the expression cassettes anti-CD22.2 scFv-His6 and scFv-protamine-His6 
restricted with the same enzymes (Figure 15). Positive clones were confirmed by 
restriction digestion with HindIII and NdeI and by sequencing. 
75 
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Figure 14: A diagram showing the genetic map of pcDNA3. The anti-CD22.2 scFv-His6 and 
scFv-protamine-His6 expression cassettes were cloned into the MCS between HindIII and ApaI 
restriction sites. CMV promoter: bases 209-863, T7 promoter: bases 864-882, Polylinker: bases 
889-994, Sp6 promoter: bases 999-1016, BGH poly A: bases 1018-1249, SV40 promoter: bases 
1790-2115, SV40 origin of replication: bases 1984-2069, Neomycin ORF: bases 2151-2945, 
SV40 poly A: bases 3000-3372, ColE1 origin: bases 3632-4305 and Ampicillin ORF: bases 
4450-5310.  
MCS BGH pA f1 ori P CMV T7 Sp6 
Ampicillin Neomycin SV40 ColE1 SV40 
pcDNA3 vector, 5.4 kb 
HindIII 
KpnI 
BamHI 
BstXI 
EcoRI 
EcoRV 
BstXI 
NotI 
XhoI 
XbaI 
ApaI 
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Figure 15: Schematic diagrams showing the strategy used for inserting the anti-CD22.2 
scFv-His6 (top) and scFv-protamine-His6 (bottom) cDNA into the MCS of pcDNA3 for the 
construction of the mammalian expression vector. CMV promoter located upstream to the 
start codon of the VH gene’s native signal peptide drives expression of the recombinant protein. 
The native signal sequence of the VH gene was retained to allow secretion of the fusion proteins.  
(Gly4Ser)3 VH Signal peptide His6 VL Protamine 
pcDNA3 vector, 5.4 kb 
Ampicillin Neomycin SV40 ColE1 
MCS BGH pA f1 ori P CMV T7 SV40 Sp6 
(Gly4Ser)3 VH Signal peptide His6 VL 
pcDNA3 vector, 5.4 kb 
Ampicillin Neomycin SV40 ColE1 
MCS BGH pA f1 ori P CMV T7 SV40 Sp6 
HindIII                                                                                 ApaI 
HindIII                                                                                                        ApaI 
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2.23. Cloning of anti-CD22.2 scFv-His6 and scFv-protamine-His6 into the pHEN1 
phagemid for expression in bacteria: 
Both, the anti-CD22.2 scFv-His6 and scFv-protamine-His6 DNA expression cassettes 
were PCR-amplified with new primers (pHEN1 forward primer with NcoI restriction site 
(underlined) and the start codon (bold) downstream to the restriction site: 
5’GCCATGGCCCAGGTCCAACTGCAGCAGCCT3’ and pHEN1 reverse primer with 
NotI restriction site (underlined):  5’GCGGCC 
GCGGGCCCTCAATGGTGGTGGTGATG3’. The PCRs were performed using GoTaq® 
polymerase. From either the scFv-His6 or scFv-protamine-His6 cloned into pcDNA3, 
about 20 ng of the plasmid DNA was used in the PCR. The PCRs were carried out using 
the conditions in Table1. The PCR products were then cleaned, digested with NcoI and 
NotI restriction enzymes and gel purified for cloning into the plasmid vector pHEN1 
(223). The pHEN1 phagemid vector (Figure 16) was digested with NcoI and NotI 
enzymes. The competent HB2151 E. coli cells were transformed with the ligations and 
positive clones analysed by restriction digestion. 
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Figure 16: Schematic diagrams showing the genetic map and the strategy for cloning 
anti-CD22.2 scFv-His6 (top) and scFv-protamine-His6 (bottom) cDNA into pHEN1 
phagemid. The phagemid pHEN1 is a derivative of pUC119 plasmid. A pelB signal peptide 
precedes the multiple cloning site (MCS). The anti-CD22.2 scFv-His6 and scFv-protamine-His6 
expression cassettes were cloned into the MCS between NcoI and NotI restriction sites.  
fd-gene IIII pelB MCS P lacZ 
M13 origin colE1 ori Ampicillin 
(Gly4Ser)3 VH His6 VL 
pHEN1 phagemid, 4522 bp
fd-gene IIII pelB MCS P lacZ 
M13 origin colE1 ori Ampicillin 
(Gly4Ser)3 VH His6 VL Protamine 
pHEN1 phagemid, 4522 bp
NcoI                                                      NotI 
NcoI                                                                                 NotI 
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2.24. Cloning of anti-CD22.2 scFv-His6 and scFv-protamine-His6 at the C-terminal 
region of human latency associated peptide (LAP): 
Two antibody constructs without the native signal sequences were cloned downstream 
of the latency associated peptide (LAP) cDNA of human transforming growth factor beta 
(TGFβ). A cDNA sequence for the HRV3C cleavage site (LEVLFQGP) was cloned 
between the scFvs and the LAP to facilitate enzymatic removal of the antibody 
fragments from the LAP domain for secretion from cells. The cloning process involved 
PCR amplification of scFv-His6 and scFv-protamine-His6 using 5’ sense HPLC-purified 
HRV3C forward primer with BamHI site (underlined): 
5’ATATGGATCCCTCGAGGTTCTCTTTCAGGGACCCCAGGTCCAACTGCAGCAGCCT
3’ to incorporate the restriction site for cloning into LAP and the HRV3C cleavage site for 
enzymatic fragmentation of the protein and a 3’ poly-His reverse primer with NheI site: 
5’TGCAGCTAGCGGGCCCTCAATGGTGGTGGTGATG3’ to enable cloning into 
pcDNA3-hLAP vector backbone. The PCRs were performed using GoTaq® polymerase 
and the PCR conditions in Table 1. The PCR products were checked on an agarose gel 
and purified by gel extraction. The expression vector pcDNA3-hLAP-MMP-TGFβ was 
digested with BamHI and XbaI restriction enzymes; the PCR products were digested 
with BamHI and NheI enzymes. The digested vector backbone and the PCR products 
were purified by gel extraction and ligated using T4 DNA ligase at 4°C overnight. XbaI 
and NheI restriction sites have compatible cohesive ends that can restore the open 
reading frame when digested and ligated together. Positive clones were selected on 
Carbenicillin (100 mg/mL) LB agar plates and were analysed by restriction digestion 
(Figure 17). Positive clones were sequenced for their validity using T7 promoter forward 
primer 5’TAATACGACTCACTATAGGG3’, F-LAP forward primer 
5’ATTGAGGGCTTTCGCCTTAGC3’ and BGH reverse primer 
5’TAGAAGGCACAGTCGAGG3’. 
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Figure 17: Schematic diagram showing the strategy for cloning of the anti-CD22.2 scFv at 
the C-terminal region of human LAP with HRV3C cleavage site into pcDNA3. The signal 
sequence and LAP part from human TGFβ-LAP were cloned upstream of the cloning site in 
pcDNA3 mammalian expression vector. The expression cassettes of anti-CD22.2 scFv-His6 and 
scFv-protamine-His6 cDNA were PCR-amplified and cloned without the native signal sequence 
into the MCS between BamHI and XbaI sites.  
(Gly4Ser)3 VH His6 VL HRV3C 
Protamine (Gly4Ser)3 VH His6 VL HRV3C 
Ampicillin Neomycin SV40 ColE1 SV40 
BGH pA f1 ori P CMV T7 Sp6 hLAP ss | LAP MCS 
pcDNA3-hLAP vector, 5446 bp
BamHI                                                                                              XbaI 
Chapter Two 
 
82 
 
2.25. Cloning of anti-CD22.2 scFv-protamine-His6 into pDisplay mammalian 
expression vector using murine Ig kappa chain signal sequence: 
Proteins expressed from pDisplay™ vector are fused at the N-terminus to the murine Ig 
kappa chain leader sequence, which helps direct the protein to the secretory pathway. 
This has been studied before for several engineered antibodies in mammalian 
expression systems (224-227). Hence, mouse anti-CD22.2 scFv-protamine-His6 was 
cloned into pDisplay vector to investigate whether or not the choice of signal 
peptide may have an impact on the expression/secretion of the recombinant protein 
(Figure 18).  
  
 
 
                                                     
Figure 18: A schematic diagram showing cloning of anti-CD22.2 scFv-protmaine-His6 into 
modified pDisplay vector for expression in mammalian cells. The PCR-amplified expression 
cassette without the native signal sequence was cloned between SfiI and SacII sites in the MCS. 
Proteins expressed from pDisplay were fused at the N-terminus to the murine Ig kappa chain 
leader sequence to direct the protein to the secretory pathway. 
PCMV MCS Ig κ signal peptide myc PDGFR BGH T7 
TKpA Ampicillin PSV40/ori Kan/Neo f1 ori pUC 
Protamine (Gly4Ser)3 VH His6 VL 
pDisplay vector, 5.3 kb 
SfiI                                                                               SacII 
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 In order to clone the anti-CD22.2 scFv-protamine-His6 into modified pDisplay 
vector, scFv-protamine-His6 expression cassette was amplified by PCR using Cy34 SfiI 
forward primer: 5’ATAAGGCCCAGCCGGCCCAGGTCCAACTGCAGCAGCCT3’ and 
Cy34 SacII reverse primer: 5'ATATCCGCGGTTAATGGTGGTGGTGATGGTG3’. The 
PCRs were performed using Pfu DNA polymerase and the PCR conditions in Table 3. 
The PCR product was then cleaned and digested with SfiI and SacII restriction enzymes 
followed by gel extraction. The pDisplay mammalian expression vector that was 
modified to remove an N-terminal tag later, was digested with same restriction enzymes. 
The modified pDisplay vector was purified by gel extraction. Both PCR product and the 
vector backbone were ligated in a reaction overnight followed by transformation of DH5α 
E. coli in LB broth. Colonies resulting from the transformants were selected on 
Carbenicillin (100 mg/mL) LB agar plates and were processed for plasmid 
minipreparation. Positive clones were confirmed by restriction analysis and sequencing 
using T7 forward and BGH reverse primers. 
 
Table 3: PCR conditions for amplification of DNA fragments using Pfu polymerase. 
 
Step Time Temperature Cycles 
Initial denaturation 2 minutes 95°C 1x 
Denaturation 30 seconds 95°C 
35x Annealing 30 seconds 59°C 
Extension 2 minutes 72°C 
Final extension 5 minutes 72°C 1x 
Heated lid  110°C  
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2.26. Obtaining the cDNA for the anti-human CD22 scFv: 
cDNAs for the anti-human CD22 was kindly provided by Dr. Ira Pastan (National Cancer 
Institute; Center for Cancer Research, Bethesda, USA). Two cDNAs, BL22 and HA22, 
were provided in mammalian expression plasmids pMH112 and pMH113, respectively 
as described previously (228). 
 
BL22 was generated from anti-CD22 RFB4 IgG-producing hybridoma as 
described previously (59) and was originally obtained from the Royal Free Hospital 
School of Medicine, University of London. Briefly, light and heavy genes from RFB4 
were used to generate anti-human CD22 scFv by PCR-amplification using specific 
primers (229). This scFv was cloned into pDisplay vector (named pMH112) and later the 
Pseudomonas exotoxin A (PE38) was fused to anti-CD22 scFv to create RFB4 (scFv)-
PE38, or BL22 for B-cell leukaemia/lymphoma/CD22. A mutated form of anti-CD22 
named HA22 was generated by site-directed mutations in 3 amino acid residues in 
CDR3 region of the heavy chain from SSY to THW which increased affinity by ~15-fold. 
HA22 was then cloned into pDisplay vector and hence called pMH113 (230). 
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2.27. Preparation of pMH vectors and scFv cDNAs construct for cloning:  
Plasmid DNAs, pMH112 and pMH113 which encode BL22 and HA22 respectively, were 
received in dried formats on Whatman filter papers (500 ng/μL in 10 mM TE buffer, pH 
7.0). Upon receipt, the expression plasmids were recovered by cutting areas on the 
Whatman papers indicated by circles and rehydrating the Whatman paper with DNA in 
50 μL of 10 mM TE buffer, pH 7.0 for 10 minutes at room temperature followed by 
centrifugation at 12,000 rpm for 5 minutes. The recovered plasmids were transformed 
into DH5α E. coli and selected by Carbenicillin resistance using standard procedures. A 
selected colony was analysed by restriction digestion and sequencing.  
 
2.28. Construction of anti-human CD22 scFv-protamine-His6 in pcDNA6 
mammalian expression vector: 
The HA22 scFv was amplified by PCR from pMH113 vector with EcoRI forward primer 
(restriction site underlined): 5’GCGGGAATTCATGGAAGTGCAGCTGGTGGAG3’ and 
BglII reverse primer (restriction site underlined): 
5'AGCAGATCTGCTTTCCAGCTTGGTGCCTCCACC3’. Meanwhile, the DNA fragment 
that encodes truncated protamine-hexahistidine, generated earlier in this study for the 
mouse antibody constructs, was also amplified by PCR using BglII forward primer 
(restriction site underlined): 5’AGCAGATCTCGATCACAATCACGATGA3’ and NheI 
reverse primer (restriction site underlined): 5’AGCGCTAGCTCAATGGTGGTG 
GTGATGGTG3’. The PCR mastermixes were prepared for Pfu polymerase and the PCR 
conditions were the same as in Table 3. PCR products of HA22 scFv and protamine-
His6 were digested with EcoRl and NheI and purified by gel extraction for ligation with 
pcDNA6-interleukin-2 signal sequence (pcDNA6|IL2ss) digested with EcoRI and XbaI 
enzymes (Figure 19). Plasmid DNA minipreps from obtained clones were analysed by 
restriction digestion and sequencing. 
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Figure 19: A schematic diagram outlining the strategy for cloning HA22 scFv-protamine-
His6 into pcDNA6 with IL2ss. HA22 scFv was PCR-amplified with EcoRI forward and BglII 
reverse primers. The truncated protamine-hexahistidine was PCR-amplified with BglII forward 
and NheI reverse primers. PCR products were digested with the corresponding enzymes in the 
restriction sites of the primers. pcDNA6|IL2ss vector was digested with EcoRI and XbaI 
enzymes. The three pieces were combined in a ligation reaction to generate the expression 
vector depicted in the figure. 
PSV40 ori PCMV MCS IL2 ss BGH pA T7 f1 ori 
Protamine (Gly4Ser)3VH His6 VL 
EcoRI                                                                                             NheI 
EM7 pUC ori Blasticidin PSV40 pA Ampicillin 
pcDNA6|IL2ss, 5.1 kb 
Chapter Two 
 
87 
 
2.29. Construction of HA22 scFv-protamine-His6 in pDisplay mammalian 
expression vector: 
HA22 scFv-protamine-His6 DNA was also cloned into pDisplay vector which contains 
the murine Ig kappa chain signal sequence. The expression construct was generated by 
PCR amplification of HA22 scFv-protamine-His6 from pcDNA6|IL2ss plasmid with SfiI 
forward primer: 5’GGGGCCCAGCCGGCCATGGAAGTGCAGCTGGTGGAGTCT3’ and 
SacII reverse primer: 5'ATATCCGCGGTTAATGGTGGTGGTGATGGTG3’ using Pfu 
polymerase mastermix and conditions. PCR products and pDisplay vector were digested 
with SfiI and SacII enzymes, purified by gel extraction and used in ligation reaction. 
DH5α  E. coli were transformed with the ligation (Figure 20). Bacterial colonies from 
transformants were expanded for DNA minipreparations and the plasmid DNA minipreps 
analysed by restriction digestion and sequencing. 
 
 
 
Figure 20: A diagram showing cloning strategy of HA22 scFv-protamine-His6 into 
pDisplay expression vector. HA22 expression cassette was cloned between SfiI and SacII 
sites in the MCS. 
Protamine (Gly4Ser)3VH His6 VL 
PCMV MCS Ig κ signal peptide HA-tag myc PDGFR BGH T7 
TKpA Ampicillin PSV40/ori Kan/Neo f1 ori pUC 
pDisplay vector, 5.3 kb 
SfiI                                                                                                        SacII 
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2.30. Cloning plan to remove the haemagglutinin A epitope (HA tag) from the 
pDisplay expression vector: 
A modified construct of HA22 scFv-protamine-His6 was generated in pDisplay vector. 
The vector was modified to remove haemagglutinin A epitope tag which was present 
between the Ig kappa chain signal sequence and the MCS. Therefore, the vector was 
digested with HindIII and SfiI enzymes to release the DNA fragment between HindIII and 
SfiI sites which includes the haemagglutinin A epitope. Next, the region between HindIII 
and end of the leader signal sequence was amplified by PCR using pDisplay-F HindIII 
forward primer: 5’GACCCAAGCTTGGTACCGAGCTCGGATCCA3’ and pDisplay-R SfiI 
reverse primer: 5’TGGATAGGCCGGCTGGGCCCCGTCACCAGTGGAACCTGG3’ to 
retain the Ig kappa chain signal sequence in-frame with the expression cassette. The 
PCR product was digested with HindIII and SfiI enzymes and purified by gel extraction 
and used in a ligation reaction to clone back into the pDisplay vector which was 
restricted with the same restriction enzymes. A scheme illustrating the strategy for 
removal of HA tag is shown in Appendix 6, page 366. Following standard procedures, 
the resulting clone was confirmed by sequencing from both sides that flank the multiple 
cloning sites with pMH R-113 reverse 5’GGAGAGTTTCAGGGACCCTCCAGG 
CTTCACTAA3’ and T7 primers. In parallel, HA22 scFv-protamine-His6 DNA expression 
cassette was PCR-amplified from pcDNA6 construct and digested with SfiI and SacII 
enzymes. In addition, the modified pDisplay vector was digested with SfiI and SacII 
enzymes to use in a ligation reaction to combine the expression DNA and the vector into 
one construct. The generated expression vector was transformed into bacteria and 
positive clones selected for further analyses by restriction digestion and sequencing. 
PCR mastermixes and conditions were the same as described for Pfu polymerase. 
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2.31. Expression of anti-CD22.2 scFv-His6 and scFv-protamine-His6 fusion 
proteins in insect cells using recombinant baculovirus: 
The recombinant bacmid DNA for scFv-His6 and scFv-protamine-His6 were used to 
transfect insect cells to produce recombinant baculovirus and subsequently recombinant 
fusion proteins. The transfection of insect cells was carried out for 18 days by 
subsequent propagation of the baculovirus in SF9 insect cells for three rounds and 
expression of the fusion protein in the HighFive insect cells. The transfection procedure 
was as follow: in a 6-well cell culture plate, 9 x 105 SF9 cells per well were seeded in 2 
mL of Sf-900 II SFM growth medium (Invitrogen Ltd) containing 50 IU/mL Penicillin and 
50 IU/mL Streptomycin. The cells were allowed to attach to the wells at 27°C for at least 
1 hour. For each transfection, bacmid DNA:Cellfectin® Reagent complexes were 
prepared as follows in 12 x 75 mm sterile tubes: 1 μg of bacmid DNA diluted in 100 μL of 
unsupplemented Grace’s Medium (Invitrogen Ltd). The Cellfectin® Reagent is provided 
as a 1:1.5 (M/M) liposome formulation of the cationic lipid N, NI, NII, NIII-Tetramethyl-N, 
NI, NII, NIII-tetrapalmitylspermine (TM-TPS) and dioleoyl phosphatidylethanolamine 
(DOPE) in membrane-filtered water (Invitrogen Ltd). For transfection, 6 μL of Cellfectin® 
Reagent was diluted in 100 μL of unsupplemented Grace’s Medium. The diluted bacmid 
DNA and the diluted Cellfectin® Reagent were combined (total volume was 200 μL), 
mixed gently and incubated for 30 minutes at room temperature after which the volume 
was increased to 1 mL by addition of 0.8 mL of unsupplemented Grace’s Medium. The 
media from the cells were removed and cells washed once with 2 mL of 
unsupplemented Grace’s Medium. The transfection mixture was added to each of the 
SF9 cells and incubated at 27°C for 5 hours. Next, the DNA:lipid complexes were 
removed and 2 mL of complete Sf-900 II SFM growth medium added to the cells and 
incubated in a 27°C humidified incubator for 120 hours (5 days) when signs of viral 
infection were seen. Virally-infected insect cells typically display characteristics that can 
be identified using an inverted phase microscope at 250-400X magnification (Table 4).  
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Table 4: Phenotypic characteristics of the HighFive insect cells after transfection with the 
recombinant baculovirus. 
 
Signs of Infection Phenotype Description 
Early (first 24hours) Increased cell diameter A 25-50% increase in cell diameter may be seen Increased size of cell nuclei Nuclei may appear to "fill" the cells 
Late (24-72hours) 
Cessation of cell growth Cells appear to stop growing when compared to a cell-only control 
Granular appearance Signs of viral budding; vesicular appearance to cells 
Detachment Cells release from the plate or flask 
Very Late (>72hours) Cell lysis Cells appear lysed and show signs of clearing in the monolayer 
 
Once the transfected cells showed signs of late stage infection, the medium 
containing viruses from each well was collected and transferred to sterile tubes and 
centrifuged at 500 g for 5 minutes at 4°C to remove cells and large debris. The clarified 
supernatant was transferred to fresh tubes and this was called the P1 viral stock and 
stored in 2% HI-FBS at 4°C, protected from light. 
 
Next, the P1 baculoviral stock was propagated to obtain the highest viral titers 
and optimal protein expression. For amplification of the P1 baculovirus, 4 x 106 SF9 cells 
in a 25 cm2 flask were cultured in Sf-900 II SFM growth medium containing 50 IU/mL 
Penicillin and 50 IU/mL Streptomycin and incubated at 27°C for 1 hour to allow cells to 
attach. After 1 hour, the cells were inspected to verify attachment. From the P1 
baculovirus, 0.4 mL was added to each SF9 culture and cells incubated for 5 days in a 
27°C humidified incubator. Five days post-infection, the culture medium containing 
viruses in each flask were harvested to sterile tubes and centrifuged at 500 g for 5 
minutes at 4°C to remove cells and large debris. The supernatants were transferred to 
fresh tubes and these were the P2 baculoviral stocks. The P2 baculoviral stock stored in 
2% HI-FBS at 4°C, protected from light. 
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The recombinant baculovirus was further propagated to obtain P3 stock by 
transfection of 12 x 106 pre-attached SF9 cells in a 75 cm2 flask with 3 mL of P2 virus 
stock in Sf-900 II SFM growth medium and incubated at 27°C in a humidified incubator 
for 5 days. 
 
Once the recombinant baculovirus was generated, it was used to infect HighFive 
insect cells for protein expression. For expression of the recombinant proteins, 2 x 107 
HighFive insect cells were cultured in 162 cm2 flasks in ExpressFive growth medium 
containing 50 IU/mL Penicillin, 50 IU/mL Streptomycin and 20 mM L-glutamine and 
incubated at 27°C for 1 hour to allow cells to attach. HighFive insect cells were 
transfected by adding 2.5 mL of the P3 baculovirus to each culture flask containing the 
cells and incubated at 27°C for 72 hours. Three days post-infection the cultures were 
harvested and centrifuged at 500 g for 5 minutes at 4°C and both the supernatant and 
the cells analysed by Western blotting for protein expression. 
 
2.32. Expression of anti-CD22.2 scFv-His6 and scFv-protamine-His6 fusion 
proteins by transient transfection of mammalian HEK293T cells:  
For transient transfection with mammalian expression vectors (231), HEK293T cells 
were grown in complete DMEM growth medium to about 70% confluence. Cells were 
then washed once with PBS and trypsinised for 5 minutes at 37°C. The cells (1.5 x 106) 
were transferred to a 10 cm cell culture plate in 9 mL fresh medium and grown 
overnight. For each transfection, the DNA precipitation mixture was prepared in the 
order shown in Table 5. 
 
Table 5: Transfection of mammalian cells using calcium phosphate method.  
Component   Amount  
HBS 2x* 500 μL 
Sterile Distilled H2O To final volume of 1000 μL 
Plasmid DNA 20 μg 
CaCl2 (2.5M) 50 μL added dropwise with shaking 
  
Total volume 1000 μL 
 
Note: 
* HBS 2x is HEPES-Buffered Saline 2x (8 g NaCl, 0.2 g Na2HPO4-7H2O and 6.5 g HEPES, 500 mL dH2O. pH 7.0). 
HEPES is zwitterionic organic buffering agent 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid. 
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The mixture was left at room temperature for 20 minutes. The medium was then 
removed from the cells and 1 mL of the DNA precipitation mixture added to the plates. 
The plates were left at room temperature for 30 minutes with occasional tilting. The cells 
were then supplemented with 9 mL of fresh growth DMEM medium and plates incubated 
in a 37°C incubator overnight. Next day, the media were removed from the cells and 
replaced with 4 mL of serum-free DMEM growth medium and incubated at 37°C 
overnight. Next day, the supernatants were harvested, cells washed with PBS and then 
removed by scraping and kept for cell lysis and further analysis by Western blotting. 
 
2.33. Expression of anti-CD22.2 scFv-His6 and scFv-protamine-His6 fusion 
proteins by transient transfection of CHO-S cells: 
CHO-S cells were cultured in Freestyle CHO-S expression medium supplemented with 
8.0 mM L-glutamine. Transient transfection was performed using 25 kDa linear 
polyethylenimine (PEI) (Polysciences Inc., Northampton, UK). Stock solutions of PEI 
were prepared in water at a concentration of 1 mg/mL, pH7.0. CHO-S cells were 
cultured to a density of 2 x 106 cells/mL and transfected with 2.5 μg/mL of DNA. The 
transfection complex was formed at a DNA:PEI ratio of 1:2 in OPTI-MEM®I Reduced 
Serum Medium (Invitrogen Ltd) containing 150 mM NaCl, with a 10 minute incubation at 
room temperature prior to addition to the CHO-S culture. Culture supernatants were 
collected 3 days after transfection for analysis of protein content by Western blotting. 
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2.34. Expression of recombinant proteins in bacteria: 
The protocol was obtained from previous research work for expression of similar 
recombinant proteins in bacteria (232). Competent HB2151 E. coli bacteria were 
transformed with maxi-prep DNA from the previously obtained anti-CD22.2 scFv-His6 in 
pHEN1 phagemid vectors and inoculated into 2xTY agar (containing 1% glucose and 
100 μg/mL Carbenicillin) and grown overnight at 37°C. From the overnight grown 
bacteria (starter culture), 50 mL 2xTY broth (containing 1% glucose and 100 μg/mL 
Carbenicillin) were cultured at 37°C incubator with shaking at 225 rpm overnight. A 
large-scale (200 mL) 2xTY (containing 0.1% glucose and 100 μg/mL Carbenicillin) 
culture was then inoculated with 2 mL of this starter culture and incubated at 30°C with 
shaking at 225 rpm until the OD600 reached 0.8-0.9, then IPTG to a final concentration of 
1 mM was added to induce expression of the recombinant protein. The bacteria were 
grown overnight in a 30°C incubator with shaking at 225 rpm. Next day, the bacteria 
were pelleted by centrifugation at 5000 rpm for 20 minutes at 4°C. The culture 
supernatant was kept at 4°C for analysis of secreted recombinant proteins, the pellet 
was resuspended in 10 mL ice-cold TES buffer (0.2 M Tris-HCl, 0.5 mM EDTA and 0.5 
M sucrose), incubated on ice for 30 minutes and centrifuged at 5000 rpm for 20 minutes 
at 4°C. The supernatant (periplasmic extract) was transferred to a fresh tube and kept at 
4°C until analysed. The pellet was lysed with guanidinium lysis buffer (6 M guanidine 
HCl, 20 mM NaH2PO4 and 500 mM NaCl pH 7.8) at room temperature. EDTA-free 
Protease Inhibitor cocktail 1:20 (Calbiochem, Nottingham, UK) was added during lysis of 
the cells to inhibit the activity of all proteases. The cell lysate was sonicated on ice with 
three 5-second pulses at high intensity and then centrifuged at 3,000 g for 15 minutes to 
pellet cellular debris. The supernatant was transferred to a fresh tube and used for 
purification under denaturing conditions. The culture supernatant, periplasmic extract 
and the bacterial cell lysate were analysed by SDS PAGE and Western blotting. 
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2.35. Analysis of recombinant proteins by Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS PAGE) and Western blotting: 
 
2.35.1. Cell lysis: 
Harvested cells were centrifuged at 600 x g for 5 minutes and pellets lysed on ice for 15 
minutes by the addition of 100 μL of lysis buffer (50 mM HEPES pH 8.3, 420 mM KCl, 
0.1% NP-40, 1 mM EDTA) to each sample with vortexing for 15 seconds. Lysates were 
clarified by centrifugation at 16,000 g at 4°C for 10 minutes to remove cellular debris and 
clarified lysates were transferred to fresh tubes and stored on ice for immediate use or 
alternatively stored at –20°C for later use. 
 
2.35.2. SDS PAGE: 
The NuPAGE® electrophoresis system (Invitrogen Ltd) was used for SDS PAGE. Each 
sample (4 volumes) was mixed with one volume of 5x Laemmli buffer (0.313 M Tris-HCl, 
10% SDS, 0.05% bromophenol blue and 50% glycerol; pH 6.8) with 10% 2-
mercaptoethanol and boiled for 5 minutes for reduced samples, and 10 μL was loaded 
into each well of a NuPAGE® 4-12 % gradient or 10% precast Bis-Tris gel. All Blue 
protein ladder (Bio-Rad Laboratories Inc., Hertfordshire, UK) was loaded as a standard 
protein marker. The gel was run in 1x NuPAGE® MOPS SDS Running Buffer (50 mM 
MES [2-(N-morpholino)-ethanesulfonic acid], 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, 
pH 7.3) at 150 volts for 80 minutes.  
  
2.35.3. Coomassie blue staining of SDS PAGE gels: 
SDS PAGE gels were fixed in a solution of (50% (v/v) ethanol in dH2O and 10% (v/v) 
acetic acid) for 30 minutes and then immersed in the staining solution (0.1% (w/v) 
Coomassie Brilliant Blue (Sigma-Aldrich Inc), 20% (v/v) methanol in dH2O and 10% (v/v) 
acetic acid). Gels were incubated on a rotating platform until protein bands became 
visible. Gels were then washed with several changes of dH2O and de-stained in the de-
staining solution (50% (v/v) methanol in dH2O and 10% (v/v) acetic acid) with shaking 
until the background staining reduced and protein bands became visible. Finally, gels 
were stored in dH2O, scanned and data saved.  
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2.35.4. Silver nitrate staining of SDS PAGE gels: 
The Silver Stain Plus kit (Bio-Rad Laboratories Incs) was used for silver nitrate staining 
of SDS PAGE gels. After gel electrophoresis, gels were fixed in the fixative enhancer 
solution (reagent grade methanol 50% [v/v], reagent grade acetic acid 10% [v/v], fixative 
enhancer concentrate 10% [v/v] and dH2O 30% [v/v]) with gentle agitation for 20 minutes 
at room temperature followed by rinsing twice in 400 mL dH2O for 10 minutes with gentle 
agitation. Gels were then stained and developed with the staining and developing 
solutions (the staining solution was prepared within 5 minutes of use by mixing 35 mL 
dH2O with 5 mL silver complex solution [NH4NO3 and AgNO3], 5 mL reduction moderator 
solution [tungstosilicic acid], 5 mL image development reagent [formaldehyde] and, 
immediately before use, quickly added 50 mL of a room temperature development 
accelerator solution [Na2CO3]). The gels were then stained for approximately 20 minutes 
at room temperature or until desired staining intensity reached. Once the desired 
staining was reached, the reaction was stopped by placing the gel in 5% acetic acid for 
15 minutes. After stopping the reaction, gels were rinsed with dH2O for 5 minutes and 
photographed. 
 
2.35.5. Western blotting: 
For Western blotting, polyvinylidene fluoride (PVDF) membranes (GE Healthcare, 
London, UK), reactivated with reagent grade methanol, were used  to transfer proteins 
and gels were sandwiched between two layers of filter paper and sponges soaked in the 
NuPAGE® Transfer Buffer (proprietary composition). The inner chamber of the tank was 
filled with NuPAGE® Transfer Buffer and the outer chamber filled with water for cooling 
the tank. Proteins were transferred to the PVDF membrane electrophoretically for 2 
hours at 30 volts.  
 
2.35.6. Detection of recombinant proteins: 
When PVDF membranes were stained with horseradish peroxidase (HRP) conjugated 
anti-His mAb (Qiagen Ltd, Manchester, UK), membranes were first washed twice with 
Tris-buffered saline (TBS) buffer (10 mM Tris-HCl, pH 7.5 and 150 mM NaCl) for 10 
minutes at room temperature and then incubated for 1 hour in blocking buffer (0.1g 
Blocking Reagent added to 20 mL 1x blocking buffer, 10% [v/v] Tween-20 added for 
final concentration of 0.1% [v/v]) (Qiagen Ltd). After blocking, membranes were washed 
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twice for 10 minutes in TBS-Tween/Triton buffer (20 mM Tris-HCl, pH7.5; 500 mM NaCl; 
0.05% [v/v] Tween 20 and 0.2% [v/v] Triton X-100) at room temperature and 10 minutes 
wash with TBS buffer. The membranes were then incubated in anti-His mAb HRP 
conjugate (1/2000 in blocking buffer) at room temperature for 1 hour. After staining, the 
membranes were washed twice in TBS-Tween/Triton buffer for 10 minutes at room 
temperature and then once with TBS buffer for 10 minutes. The blots were developed 
using enhanced chemiluminescence (ECL) reagents (GE Healthcare) and exposed to 
autoradiography using Hyperfilm (GE Healthcare). Films were developed using the SRX-
101A tabletop processor (Konica Minolta, USA). 
 
Because of the high background noise with anti-His Ab from Qiagen Ltd, an 
alternative HRP conjugated anti-His Ab was used to probe His-tagged fusion proteins. 
Recombinant proteins were separated on 10% SDS PAGE and transferred to PVDF. 
The PVDF membrane was stained with HRP conjugated anti-His(C-term) mAb from 
Invitrogen Ltd. After the transfer, membranes were incubated in 10 mL blocking buffer 
containing 5% non-fat dry milk and 0.05% Tween-20 in PBS with gentle agitation on a 
rocker platform for 1 hour at room temperature. The membranes were then washed in 
20 mL wash buffer (0.05% Tween-20 in PBS) twice for 5 minutes with gentle agitation. 
The membranes were then stained with the HRP conjugated anti-His(C-term) mAb 
(1:5000) in blocking buffer and incubated with gentle agitation overnight at 4°C. The 
membranes were then washed with 20 mL wash buffer twice and bound HRP 
conjugated mAb revealed with ECL and exposed to autoradiography film and 
developed. 
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2.36. Purification of anti-CD22.2 scFv-His6 and scFv-protamine-His6 recombinant 
proteins under native conditions: 
Insect cells were lysed with the Insect Cell Protein Extraction Reagent (I-PER®) 
(contains a proprietary non-ionic detergent in 130 mM NaCl, 25 mM Tris-HCl; pH 7.5 
and a microbial growth inhibitor) (Fisher Scientific Ltd, Leicestershire, UK). The HighFive 
insect cells were harvested and the total number of cells determined. Cells were 
collected by centrifugation at 800 g for 5 minutes at room temperature and gently 
resuspended with an equal volume of PBS. The cells were washed twice with PBS and 
10 μL of EDTA-free Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific) was 
added to the I-PER® buffer to produce a 1x final concentration and 1 mL of the later was 
used to lyse 5 x 106 – 2 x 107 cells in the washed cell pellet. The cells were resuspended 
and vortexed for 5 seconds at medium speed and then incubated on ice for 10 minutes 
and centrifuged at 15,000 g for 15 minutes at 4°C. The supernatants containing soluble 
proteins were carefully transferred to new tubes and used for purification of the 
recombinant proteins by nickel affinity chromatography. Nickel-nitrilotriacetic acid (Ni-
NTA) agarose slurry (50%) in 30% ethanol was resuspended thoroughly and 1.5 mL 
poured into a sterile tube and pelleted by centrifugation at 800 g for 1 minute. The 
supernatant was gently aspirated and 6 mL sterile distilled water added to resuspend 
the resin. The resin was then centrifuged at 800 g for 1 minute before use. For 
purification of proteins under normal conditions, the resin was resuspended in 6 mL of 
native protein binding buffer (50 mM NaH2PO4 and 0.5 M NaCl; pH 8.0) and centrifuged 
at 800 g for 1 minute. Washing with native protein binding buffer was repeated three 
more times and the resin was finally loaded into the purification column. Insect cell 
lysates prepared under native conditions were added to the purification column and 
proteins allowed to bind for 60 minutes at 4°C using gentle agitation to keep the resin 
suspended in the lysate solution. The resin was allowed to settle by gravity and unbound 
proteins allowed to pass through the column and collected for further analysis. The 
column was washed with native protein binding buffer and then washed four more times 
with 8 mL native wash buffer (50 mM NaH2PO4 and 0.5 M NaCl with 10 mM imidazole; 
pH 8.0) and flow-through collected for analysis. The protein was eluted with 5 mL native 
protein elution buffer (50 mM NaH2PO4 and 0.5 M NaCl with 250 mM imidazole; pH 8.0) 
and 1 mL fractions collected and analysed by Western blotting. 
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2.37. Purification of anti-CD22.2 scFv-His6 and scFv-protamine-His6 recombinant 
proteins under denaturing condition: 
To purify recombinant protein under denaturing conditions, HighFive insect cell pellets 
were resuspended in 8 mL guanidinium lysis buffer (6 M guanidine HCl, 20 mM 
NaH2PO4 and 500 mM NaCl; pH 7.8). To inhibit all potential proteolysis, an EDTA-free 
cocktail of Protease Inhibitors (Calbiochem®) at 1:200 dilution was added during lysis of 
the cells in guanidinium lysis buffer. The lysate was passed through an 18-gauge needle 
four times and centrifuged at 3,000 g for 15 minutes to remove cellular debris and the 
supernatant was transferred to a fresh tube. To prepare the purification column, 2 mL of 
the Ni-NTA agarose was pipetted into a 10 mL purification column. The resin was 
centrifuged for 1 minute at 800 g and supernatant aspirated gently. To wash the nickel 
beads, 6 mL of sterile dH2O was added to resuspend the resin then allowed to settle by 
low speed centrifugation for 1 minute at 800 g and the supernatant aspirated. Then, the 
Ni-NTA agarose column was washed twice with 6 mL of denaturing binding buffer (8 M 
urea, 20 mM NaH2PO4 and 500 mM NaCl; pH 7.8). The resin was resuspended and 
allowed to settle by low speed centrifugation for 1 minute at 800 g and supernatant 
aspirated. From clarified insect cell lysates, 8 mL was applied to the prepared nickel 
resin and allowed to bind for 45 minutes at room temperature with gentle agitation on a 
rotating wheel to keep the resin suspended. The resin was then allowed to settle by 
gravity and the flow-through collected (unbound fraction). The column was washed twice 
with 4 mL denaturing binding buffer (8 M urea, 20 mM NaH2PO4 and 500 mM NaCl; pH 
7.8) and the flow-through collected. Next, the column was washed twice with 4 mL 
denaturing wash buffer (8 M urea, 20 mM NaH2PO4 and 500 mM NaCl; pH 6.0) and the 
resin allowed to settle again and flow-through collected for analysis. The column was 
washed twice with 4 mL denaturing wash buffer (8 M urea, 20 mM NaH2PO4 and 500 
mM NaCl; pH 5.3) for 2 minutes and resin allowed to settle by gravity. The flow through 
was collected for analysis. The protein was eluted with 3 mL of increasing 
concentrations of imidazole (10, 25, 50, 100 and 200 mM) in denaturing elution buffer (8 
M urea, 20 mM NaH2PO4 and 500 mM NaCl; pH 4.0). Proteins in the collected fractions 
were precipitated with trichloroacetic acid (TCA) for 10 minutes and washed with cold 
acetone and analysed with SDS PAGE and Western blotting. 
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2.38. Analysis of recombinant proteins from culture supernatants of insect cells 
obtained by centrifugal concentration: 
The HighFive insect cell supernatants were concentrated using a specialised 
Immobilized Metal Affinity Chromatography (IMAC) purification device by centrifugation. 
Culture supernatant (20 mL) was loaded onto 10 kDa molecular weight spin column 
(Vivapure Metal Chelate Maxi spin column; Vivaproducts, Inc. Littleton, USA) and 
centrifuged at 5,000 g for 2 hours to bring down the final volume to a 1 mL concentrated 
sample. The concentrated sample was then pipetted out into a clean tube and analysed 
by SDS PAGE and Western blotting. Precipitates from the concentration process that 
were lodged in the groove of the column were also collected and subjected to analysis 
by Western blotting.    
 
2.39. Analysis of recombinant proteins in culture supernatants of insect cells by 
precipitation with trichloroacetic acid (TCA): 
In order to detect recombinant proteins in culture supernatants, all proteins were 
precipitated with TCA. One volume of cold TCA stock solution (100% w/v) was added to 
four volumes of culture supernatants from the HighFive insect cell cultures and 
incubated at 4°C for 10 minutes then centrifuged at 14,000 rpm for 5 minutes. The 
supernatants from the centrifugation were discarded and pellets washed with 200 μL 
cold acetone and centrifuged again at 14,000 rpm for 5 minutes. The pellets were left to 
dry at 95°C on a hot-block. Because of the very strong acidity of TCA, 10 μL of 1 M 
NaOH was added to the pellet to neutralise the effect of strong acidic pH of TCA. The 
pellets were then resuspended in 5x Laemmli buffer and analysed by SDS PAGE and 
Western blotting. 
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2.40. Dialysis, refolding and ion-exchange chromatography purification of 
recombinant proteins: 
The recombinant proteins anti-CD22.2 scFv-His6 and scFv-protamine-His6 extracted 
from HighFive cell lysates were bound to nickel affinity chromatography columns and 
eluted under denaturing conditions with a minor modification (addition of 50 mM L-
glutamine to all purification buffers). The eluted recombinant protein fractions were 
dialysed to remove the urea and the proteins refolded in a refolding buffer (10 mM Tris, 
0.4 M L-arginine, 5 mM GSSH [reduced glutathione] and 0.5 mM GSSG [oxidized 
glutathione] supplemented with 6.0 M, 4.0 M, 2.0 M, 1.0 M and without urea; pH 8.0) 
over a period of 72 hours. The protocol was modified from a method used for the 
refolding of similar recombinant proteins (120). The eluted proteins were added to Slide-
A-Lyzer® Dialysis Cassettes 10 kDa molecular cutoff (Thermo Scientific) and dialysed 
against the refolding buffer with decreasing concentrations of 6.0, 4.0 and 2.0 M of urea 
to prevent aggregation of the proteins. This was carried out at room temperature 
followed by dialysis against 1.0 M and no urea in the refolding buffer at 4°C for 4 hours 
in each step. Ultimately, the buffer was exchanged to a fresh refolding buffer and 
dialysed overnight at 4°C. The protein samples were removed from the Slide-A-Lyzer® 
Dialysis Cassettes and stored at -20°C. 
 
 The next step was to purify the proteins by ion-exchange chromatography and to 
achieve this, the isoelectric point (PI) of the recombinant proteins anti-CD22.2 scFv-His6 
and scFv-protamine-His6 were calculated using the interactive bioinformatic database 
(http://isoelectric.ovh.org/) which measures the PI according to different scales. The 
average PI for the scFv-His6 and scFv-protamine-His6 were determined to be 7.268 and 
9.665, respectively.   
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The Q Sepharose™ Fast Flow HiTrap™ column (GE Healthcare) was used for 
the purification of scFv-His6 protein which has a net negative charge at pH 8.0 and, 
hence, needed an anion exchange column with positively charged resin. For the 
purification of the scFv-protamine-His6 protein which has a net positive charge at pH 
8.0, SP Sepharose™ Fast Flow HiTrap™ column, a cation exchange column which has 
a negatively charged resin, was used. The ion-exchange chromatography experiments 
were carried out at 4°C using fast protein liquid chromatography (FPLC) (Amersham 
Pharmacia, GE Healthcare) and the UNICORN™ controlled ÄKTAexplorer™ systems. 
The columns were first equilibrated with filter-sterilised cold buffer A (10 mM Tris, 0.4 M 
L-arginine, 5 mM GSSH [reduced glutathione] and 0.5 mM GSSG [oxidized glutathione]; 
pH 8.0) and then the proteins were diluted 1:2 with fresh refolding buffer and applied 
onto the equilibrated columns in the FPLC system for binding to the column. Unbound 
flow-through was collected. Bound proteins were eluted with filter-sterilised cold buffer B 
with gradient increase in NaCl (10 mM Tris, 0.4 M L-arginine, 5 mM GSSH [reduced 
glutathione] and 0.5 mM GSSG [oxidized glutathione] and 1 M NaCl; pH 8.0) and 0.5 mL 
fractions collected by fraction collector (Frac-950, Amersham Pharmacia). The dialysed 
protein sample, unbound flow-through and eluted fractions were analysed on reducing 
SDS PAGE gel and by Western blotting. 
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2.41. Small-scale purification of HA22 scFv-protamine-His6 recombinant fusion 
protein by nickel affinity chromatography: 
To purify proteins under native conditions and optimise the system, small-scale protein 
purification was carried out to study the effect of no-dialysis versus dialysis on binding of 
His-tagged recombinant HA22 fusion protein to nickel column. Culture supernatant from 
HEK293F cells was divided into two equal fractions (20 mL each). One fraction was 
dialysed against PBS for 48 hours and the other fraction left undialysed. Nickel agarose 
beads Ni-NTA were used to prepare nickel affinity purification columns. For purification 
under native conditions, the Ni NTA resin was washed and resuspended in 600 μL of 
native protein binding buffer (50 mM NaH2PO4 and 0.5 M NaCl; pH 8.0) and centrifuged 
at 800 g for 1 minute at room temperature. The resin was then mixed with 800 μL of 
either undialysed or dialysed culture supernatant and allowed to bind for 90 minutes at 
4°C using gentle mixing to keep the resin suspended in the protein solution. The 
resin/protein mixture was then loaded onto the purification column and allowed to settle 
by gravity. Unbound proteins passed through the resin and were collected for further 
analysis. The column was washed with native binding buffer (800 μL) and then washed 
four more times with 800 μL native wash buffer (50 mM NaH2PO4 and 0.5 M NaCl with 
20 mM imidazole; pH 8.0) and the flow-through collected for analysis. The fusion protein 
was then eluted with 2 mL native elution buffer (50 mM NaH2PO4 and 0.5 M NaCl with 
250 mM imidazole; pH 8.0) and analysed by Western blotting. 
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2.42. Large-scale purification of HA22 scFv-protamine-His6 by nickel affinity 
chromatography using FPLC system: 
Large-scale cultures of HEK293F cells were transfected using PEI and about 3 litres of 
culture supernatant collected 3 days post-transfection by centrifugation at 5,000 rpm at 
4°C for 10 minutes and frozen at -80°C until processed. All purification steps were 
performed at 4°C. Recombinant protein was purified using HiTrap 5 mL chelating HP 
nickel column (Amersham-Phrmacia, GE Healthcare) using an automated FPLC system. 
The culture supernatant was defrosted slowly at 4°C and filtered using a sterile vacuum 
filter unit, polyethersulfone (PES) membrane, with a 0.22 µm pore size low protein 
binding filter. The binding buffer (20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4) was used to 
wash the FPLC tubing and to equilibrate the column with 5 column volumes at a flow 
rate of 2 mL/minute. The column pressure limit applied was 2.0 megapascal (MPa). The 
filtered protein sample was loaded directly onto the equilibrated column at 2 mL/minute 
flow rate over a period of 24 hours and unbound sample washed out and collected for 
analysis. The column was then washed with 6 column volumes of 20 mM imidazole in 
the binding buffer and the wash collected for analysis. The bound protein was eluted 
with 30 mL of the elution buffer (20 mM NaH2PO4, 0.5 M NaCl and 250 mM imidazole; 
pH7.4) and 6 fractions of 5 mL each collected. A further elution was followed with 500 
mM imidazole and 3 fractions of 10 mL each collected to ensure that all His-tagged 
bound proteins had been eluted from the column. The column was then re-equilibrated 
with 5 column volumes of binding buffer. The sample load, wash and elution fractions 
were analysed by SDS PAGE and Western blotting. Purity of the protein was determined 
with Coomassie blue-stained gel.  Purified protein fractions were concentrated by 
centrifugation at 5,000 x g for 30 minutes in 10,000 MWCO Vivaspin spin columns. After 
centrifugation, the resulting supernatant and the flow through were resolved on SDS 
PAGE and Western blotting. 
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2.43. Cation exchange chromatography: 
The purified fusion protein obtained from the nickel affinity chromatography was 
subjected to further purification by cation exchange chromatography using a HiTrap SP 
FF column. A 1 mL HiTrap pre-packed SP FF (Fast Flow) Sepharose, cation exchanger 
column was installed on the FPLC system. The protein sample was dialysed against 20 
mM Tris-HCl pH 7.5 for 48 hours in Slide-A-Lyzer 10,000 MWCO cassette. The retrieved 
protein sample was then gently resuspended and centrifuged at 1,200 rpm for 5 minutes 
at 4°C. Before sample loading, the cation column was equilibrated with 5 column 
volumes of wash buffer (20 mM Tris-HCl; pH 7.5) and the protein sample supernatant 
loaded at a 0.5 mL/minute flow rate into the equilibrated column at a column pressure 
limit of 4.00 MPa. The protein was eluted with a gradient increase of elution buffer (20 
mM Tris-HCl and 0.5 M NaCl; pH 7.5) and fractions containing the purified protein 
identified by SDS PAGE and Western blotting.  
 
2.44. Concentration and PD-10 desalting of the protein: 
Eluted fractions of the protein were analysed on Coomassie blue-stained SDS PAGE 
gels and Western blots to determine purity and proportion of the protein in each fraction. 
Fractions that contained highly pure protein were pooled and concentrated using 10,000 
Da MWCO Vivaspin columns. Concentrated protein fractions were then desalted using 
pre-packed Sephadex G-25 medium in disposable PD-10 desalting columns to remove 
imidazole from the protein. The pooled protein fraction was divided to two equal volumes 
and each one eluted from the PD-10 column with either buffer A (20 mM NaH2PO4 and 
0.5 M NaCl; pH 7.4) or buffer B (20 mM Tris-HCl and 0.5 M NaCl; pH 7.4). For this 
purpose, the columns were equilibrated with five washes of 2.5 mL of binding buffer A or 
buffer B, followed by loading of 2.5 mL of the protein sample and elution with 3.5 mL of 
the binding buffer. Protein samples before and after PD-10 desalting were resolved by 
SDS PAGE and Western blotting. 
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2.45. Determination of protein concentration: 
Concentration of purified proteins was determined using bicinchoninic acid protein assay 
kit (Pierce® BCA Protein Assay, Thermo Scientific) in fractions that were eluted with 500 
mM imidazole. To generate a standard curve for measurement of protein concentration, 
2-fold serial dilutions of protein samples and bovine serum albumin (BSA) standard (2 
mg/mL in 0.9% NaCl and 0.05% NaN3) were prepared in the binding buffer (20 mM 
NaH2PO4 and 0.5 M NaCl; pH 7.4). From each dilution 25 μL were added in duplicates 
into each well of a 96-well microplate. Then, 50 μL of Working Reagent (WR, 50:1), 
prepared by mixing 50 parts of BCA Reagent A (Na2CO3, NaHCO3, C20H12N2O4 
[bicinchoninic acid] and Na2C4H4O6 [sodium tartrate] in 0.1 M NaOH) with 1 part of BCA 
Reagent B (4% CuSO4.5H2O) were added to each well. The plate was incubated at 
37°C for 30 minutes and the absorbance measured at 562 nm using a 
spectrophotometer. Protein concentration was determined by extrapolation from the 
linear equation of the standard curve obtained by plotting concentrations of BSA (µg/mL) 
versus absorbance using Microsoft Excel. 
 
2.46. Optimisation of HA22 fusion protein preservation: 
Recombinant protein was subjected to various storing conditions to optimise a method 
for maximal protein preservation. Fusion protein was, thus, stored either at 4°C, frozen 
at -80°C or stored in liquid N2 in 10% glycerol. Under each condition three aliquots were 
preserved in different buffers (20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4), (20 mM 
NaH2PO4 and 0.15 M NaCl; pH 7.4) or (20 mM Tris-HCl and 0.5 M NaCl; pH 7.4). All 
aliquots were retrieved after 10 days of storage and frozen samples defrosted slowly on 
ice. Visual observations for precipitate formation were noticed in some of the samples 
and all were re-analysed on Coomassie blue-stained SDS gels and by Western blotting.   
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2.47. Labelling of the recombinant protein with AlexaFluor®488: 
AlexaFluor®488 dye was selected for labeling the recombinant protein because the die 
is brighter and more photostable than fluorescein. According to the manufacturer’s 
instructions, the principle of the labeling using AlexaFluor®488 Microscale Protein 
Labeling Kit depends on the fact that tetrafluorophenyl (TFP) ester moiety in 
AlexaFluor®488 reactive dye solution reacts efficiently with primary amines of proteins 
to form stable dye-protein conjugates.  
 
For the labeling reaction, 500 μL of protein solution (200 μg/mL) was transferred 
to a reaction tube and mixed with 50 μL of sodium bicarbonate (pH 8.3) to give a final 
concentration of 0.1 M. Meanwhile, the AlexaFluor®488 TFP ester dye was dissolved in 
its vial immediately before use by addition of 10 μL of dH2O [11.3 nmol/μL reactive dye 
stock solution]. The appropriate volume of reactive dye solution was added to the 
reaction tube containing the pH-adjusted protein and mixed thoroughly by pipetting up 
and down several times. The reaction mixture was then incubated for 15 minutes at 
room temperature. The labeled protein was separated from the unbound dye by 
purification of the conjugated protein using resin gel in a spin column filter. For this 
purpose, the upper chamber of a spin filter in a collection tube was filled with 
resuspended resin gel and centrifuged at 16,000 g for 15 seconds. This was repeated 
until about half of the upper chamber was filled with resin gel. When the resin bed was 
at the correct level, the resin buffer was exchanged with the protein sample buffer (20 
mM NaH2PO4 and 0.5 M NaCl; pH 7.4). This buffer exchange was carried out through 
the resin bed several times by brief low-speed centrifugation. After the spin filter was 
prepared, 50 μL of the conjugate reaction mixture was added onto the center of the resin 
bed surface. The conjugate was collected by centrifugation at 16,000 g for 1 minute. The 
labeled protein was stored at -20°C protected from light. 
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2.48. Assessment of the HA22 fusion protein binding to CD22 on B cell lines by 
flow cytometry: 
In order to confirm that the purified HA22 fusion protein has retained its specificity, its 
binding to a panel of CD22-positive (HF28 RA and L3/Bcl-2) and CD22-negative (Jurkat 
and U937) cell lines was tested by flow cytometry. Cells grown to about 80% confluency 
were harvested, washed in ice-cold staining buffer (PBS containing 0.1% NaN3 and 2% 
FBS) and chilled on ice. The cells were centrifuged at 1300 rpm for 5 minutes at 4°C 
and resuspended in ice-cold staining buffer containing Fc blocking agent (10% mouse 
serum) (233) and incubated on ice for 15 minutes. Resuspended cells were transferred 
to FACS tubes and their number adjusted to 5 x 105 cells /mL in each FACS tube. The 
cells were washed once with ice-cold staining buffer and stained either with 
AlexaFluor®488 labelled HA22 fusion protein (2-10 μg/mL) or with unlabelled protein (3 
μg/mL) on ice for 1 hour. For unlabelled protein, the fusion protein was mixed with anti-
6X His tag® antibody [DyLight®650] (abcam, Cambridge, UK) (1:500) for 20 minutes on 
ice before they were added to the cells. Before the FACS acquisition, the cells were 
washed twice and resuspended in ice-cold staining buffer. In order to exclude dead cells 
from the analysis 2 µL of propidium iodide was added to the FACS tubes and live cells 
were gated for the analysis. Anti-6X His tag® antibody [DyLight®650] and unstained 
cells were used as controls. 
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2.49. Demonstration of binding to and internalisation of the HA22 fusion protein 
into B cells by confocal microscopy: 
For internalisation by confocal microscopy, CD22-negative Jurkat T cells and CD22-
positive HF28 RA B cells were cultured at a density of 1 x 105 cells/well in 900 μL 
complete growth medium. After cultivation overnight, the cells were washed with ice-cold 
PBS containing 2% FBS and chilled on ice. Simultaneously, HA22 fusion protein (10 μg) 
was mixed with siGLO Red non-specific fluorescently-labeled siRNA (100 nM final 
concentration) and incubated on ice for 20 minutes (1.8 molecules of HA22 fusion 
protein:8 molecules of siGLO Red ratio). The cells were then stained with the complex 
and incubated on ice for 45 minutes. Unbound HA22 protein/siGLO Red was washed off 
with pre-warmed RPMI-1640 and the cells incubated at 37°C for various time points (15, 
30, 45 and 60 minutes). The 0 time point was left on ice. At the end of the indicated time 
points, cells were kept on ice and washed once with ice-cold staining buffer and then 
incubated with proteinase K (2 mg/mL proteinase K in PBS) on ice for 30 minutes to 
remove surface bound molecules. The cells were then washed twice with PBS and fixed 
in paraformaldehyde (4% in PBS) for 10 minutes and treated with 0.1% Triton X-100 for 
5 minutes. The cells were then stained with DAPI (1:5000) for 5 minutes at 4°C and 
washed twice with PBS. The cells were mounted on poly-L-lysine coated slides using 
anti-fade mounting medium (6 mL Citifluor anti-fade, 2.4 g Mowiol 4.88 [Calbiochem], 6 
mL dH2O and 12 mL 200 mM Tris-HCl, pH 8.5). Samples were analysed on a Zeiss 
LSM710 confocal microscope (Zeiss, Welwyn Garden City, UK). 
 
2.50. Gel retardation assay: 
siRNA (100 nM) was mixed with various concentrations of either HA22 fusion protein 
(10–100 μg) or A20FMDV2-protamine peptide (0.2–20 μg) and incubated on ice for 30 
minutes. The mixture was then resolved on a 1% agarose gel containing 1 μg SYBER 
safe and visualised by UV illuminator. 
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2.51. siRNA for targeted genes: 
Synthetic siGENOME SMARTpool siRNAs were obtained from Dharmacon (Thermo 
Scientific) composed of pools of four duplexes of 19 bp in length with 3’ dinucleotide 
overhangs siRNAs. Cellular pathways and mechanisms that have roles in proliferation 
and survival were targeted with specific siRNAs. To achieve this, two genes were 
selected for targeting, MCL1 and PLK1. These genes are known to promote cell 
proliferation and survival. In addition, ITGB6 (integrin β6) was targeted to study tumour 
cell invasion using a specific targeting approach with A20FMDV2-protamine peptide. 
The specificity of selective binding of A20FMDV2 peptide to αvβ6 integrin has been 
clearly defined (113). 
 
All of the selected siRNAs are specific for human genes. Control siRNA for the 
housekeeping gene was siGAPDH (Ambion by Life Technologies Ltd, Paisley, UK) as a 
positive control. Negative control includes a non-specific scrambled siRNA which is 
known not to downregulate any gene (Ambion by Life Technologies Ltd). Gene target 
sequences for the siRNAs are shown in Table 6. 
 
Table 6: Gene designation, mRNA sequence targets and molecular weights of siRNAs. 
Gene-specific target siRNA mRNA target sequence Mol. Wt. of siRNA (g/mol) 
MCL1 gene – 10 noml siRNA  
siGENOME SMARTpool siRNA D-004501-41, MCL1 GCUACGUAGUUCGGGCAAA 13,403.0 
siGENOME SMARTpool siRNA D-004501-40, MCL1 GGACCAACUACAAAUUAAU 13,343.0 
siGENOME SMARTpool siRNA D-004501-39, MCL1 AGAACGAAUUGAUGUGUAA 13,343.0 
siGENOME SMARTpool siRNA D-004501-38, MCL1 CGAAGGAAGUAUCGAAUUU 13,358.0 
PLK1 gene – 10 nmol siRNA  
siGENOME SMARTpool siRNA D-003290-05, PLK1 CAACCAAAGUCGAAUAUGA 13,358.0 
siGENOME SMARTpool siRNA D-003290-06, PLK1 CAAGAAGAAUGAAUACAGU 13,343.0 
siGENOME SMARTpool siRNA D-003290-07, PLK1 GAAGAUGUCCAUGGAAAUA 13,358.0 
siGENOME SMARTpool siRNA D-003290-08, PLK1 CAACACGCCUCAUCCUCUA 13,403.0 
ITGB6 gene – 10 nmol siRNA  
siGENOME SMARTpool siRNA D-008012-01, ITGB6 GCUAAAGGAUGUCAAUUAA 13,343.0 
siGENOME SMARTpool siRNA D-008012-02, ITGB6 GAACGGCUCUUUCCAGUGU 13,403.0 
siGENOME SMARTpool siRNA D-008012-03, ITGB6 CAUCUCAGCUUAUGAAGAA 13,358.0 
siGENOME SMARTpool siRNA D-008012-05, ITGB6 GCCAACCCUUGCAGUAGUA 13,403.0 
Control siRNAs  
siRNA for GAPDH gene Proprietary sequence  
siGLO Red transfection indicator Proprietary sequence  
Scrambled siRNA (not targeting any known genes)  Proprietary sequence  
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2.52. Preparation of siRNA: 
Tubes containing siRNA were briefly centrifuged to ensure that all the siRNA content is 
collected at the bottom of the tube. siRNAs (10 nM) were resuspended in 500 µL of 1x 
Dharmacon siRNA buffer (20 mM KCl, 6 mM HEPES and 0.2 mM MgCl2; pH 7.5) diluted 
in sterile nuclease-free H2O. The solution (resuspended siRNA) was mixed gently and 
placed on an orbital mixer for 30 minutes at room temperature. The tubes were then 
centrifuged briefly to collect the solution at the bottom of the tube. A stock of 20 µM of 
each resuspended siRNA was aliquoted and kept at -80°C. The stocks were diluted in 
nuclease-free H2O before use. Resuspension of siRNAs was performed in a sterile 
hood. 
         
2.53. Cell transfection with siRNA using transfection reagents: 
HF28 RA human B cells were grown in complete RPMI 1640 medium without antibiotics. 
For cell transfection, 100 nM of siRNA was mixed with INTERFERin or jetPRIME™ 
(Polyplus-transfection, Nottingham, UK) or NeoFX transfection reagent (Ambion by Life 
Technologies Ltd) according to manufacturer’s instructions. Depending on the number of 
cells, an amount of the transfection reagent was mixed with siRNA and incubated at 
room temperature for 20 minutes. Before adding the mixture, fresh medium was added 
to the cells. The cells were incubated at 37°C for 3-5 days and then analysed for gene 
down regulation by real-time RT-PCR and reduction in protein levels by Western 
blotting. 
 
2.54. Delivery of siRNA to mRNA of MCL1 and PLK1 genes with the HA22 fusion 
protein to B cells via CD22: 
For the delivery of siRNA, cells were grown to about 80% confluency in antibiotic-free 
complete medium. Before transfection, fresh medium was added to the cells and the 
number of cells adjusted according to the scale of transfection. HA22 fusion protein 
(12.5 or 25 μg) was mixed with 100 nM of siRNA in a final volume of 100 μL. 
Protein/siRNA mixtures were incubated on ice for 30 minutes. The mixtures were then 
added to cells and incubated at 37°C for 2-5 days before analysis by real-time RT-PCR, 
Western blotting or cell viability assay. Etoposide was used as a positive cell death-
inducing control. A scrambled siRNA was used as a negative control.  
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2.55. Quantitative real-time PCR experiments: 
Quantitative RT-PCR (qRT-PCR) is an established technique for quantifying mRNA 
levels in biological samples. To perform qRT-PCR experiments, initially the assays were 
designed to make standards and reference genes for normalisation of data using the 
qRT-PCR facility (qStandard) at King’s College London. Later, qRT-PCR experiments 
were performed in our laboratory and qRT-PCR plates were read at the Genome Centre, 
Queen Mary University of London using ABI7900HT Fast system from Applied 
Biosystems. 
 
2.55.1. RNA extraction: 
RNA extraction was performed according to a modified method using the Qiagen 
RNeasy column kit. According to the manufacturer’s information, the kit extracts only 
RNA molecules that are > 200 nucleotides in length. For adherent cells, the medium was 
removed and the cells washed once with PBS. For non-adherent or suspension cells, 
the culture was centrifuged, medium removed and cells washed once in PBS. The cells 
were then lysed on ice by adding 300 µL of QIAzol (Qiagen Ltd) which preserves the 
integrity of the RNA. Cell lysates were clarified by centrifugation at 12,000 g for 5 
minutes at 4°C and the supernatant transferred to a fresh tube and mixed with 200 μL 
chloroform. The mixture was centrifuged at 12,000 g for 10 minutes at 4°C. The 
aqueous phase was transferred to a fresh tube and 1.5 volumes of 100% ethanol added. 
The mixture was transferred to an RNeasy spin column placed in a 2 mL collection tube 
to adsorb RNA onto the silica gel membrane of the spin column and centrifuged at 8,000 
g for 15 seconds. The flow-through was discarded and unwanted cellular contents 
(protein, DNA) washed away by adding 700 μL of RW1 buffer to the RNeasy spin 
column. The column was centrifuged at 8,000 g for 15 seconds. The column was then 
washed twice with 500 μL RPE buffer and the RNA eluted with 50 μL RNase-free H2O 
by placing the RNeasy spin column in a fresh 1.5 mL collection tube and centrifugation 
at 8,000 g for 1 minute. Quantity and quality of RNA were determined using a Nanodrop 
spectrophotometer and agarose gel, respectively. RNA was then stored at -20°C until 
used. 
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2.55.2. cDNA synthesis by reverse transcription: 
Total RNA isolated with QIAzol was reverse transcribed using a modified method. cDNA 
was made in triplicates for each sample by adding 1 μg of total RNA into each PCR 
reaction tubes. Template RNA was thawed on ice and prepared for genomic DNA 
elimination reaction (1:2 dilutions of 7x gDNA Wipeout Buffer 2 μL, variable amount of 
template RNA [microliters of total RNA calculated to give 1 μg] and RNase-free H2O to 
total volume of 14 μL). Genomic DNA elimination reaction was carried out for 4 minutes 
at 42°C and then tubes placed immediately on ice. Reverse transcription mastermix was 
prepared on ice (Quantiscript Reverse Transcriptase containing RNase inhibitor 1 μL, 5x 
Quantiscript RT Buffer containing Mg2+ and dNTPs 4 μL and RT Primer Mix 1 μL). 
Template RNA (14 μL) from entire genomic DNA elimination reaction was added to each 
tube containing the reverse transcription mastermix, mixed and kept on ice. cDNA 
synthesis reaction was carried out by incubation for 15 minutes at 42°C followed by 
incubation for 3 minutes at 95°C to inactivate the reverse transcriptase. “No-reverse 
transcription” negative control sample labelled ‘RT negative’ was used to determine if 
there is any DNA contamination by addition of nuclease-free water to the mastermix 
without RNA template. Prior to use in qPCR reaction, the cDNA was diluted 10-fold 
(1:10) with tRNA (10 μg/mL) in a 1.5 mL centrifuge tube. This dilution was repeated for 
the “RT negative” control as well. tRNA is used simply as a carrier to minimise 
adsorption of cDNA onto surfaces. The tRNA itself cannot be amplified by PCR. It has 
also been reported to minimise primer-dimers. Dilution of cDNA ensures that the salts 
and buffers in the RT enzyme mix are diluted sufficiently to allow the proper conditions 
such as salt concentrations and pH to be achieved for efficient qRT-PCR. Furthermore, 
dilution ensures that the concentration of primers (oligo-dT, random primers used in the 
RT reaction) in the cDNA is reduced and so is less likely to generate any non-specific 
amplification during PCR (234). 
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2.55.3. DNA standards of reference genes: 
For normalisation of qRT-PCR data, standards for reference genes and genes under 
investigation were designed and obtained from qStandard (King’s College London). The 
qRT-PCR standards in each vial contained 1 x 109 copies of dried DNA standard 
(amplicon) purified from PCR products. Standards were reconstituted in yeast tRNA (5 
μg/mL) dissolved in nuclease-free H2O. Standards were prepared from the reference 
genes in 0.5 mL tube by serial dilutions of the 107 copies/2 μL down to 101 copies/2 μL 
in tRNA (5 μg/mL). A standard curve was constructed from the dilutions of each 
reference gene.       
 
2.55.4. Setting up a qRT-PCR assay: 
In the first qRT-PCR run, the primers were tested to ensure amplification of only the 
specific product expected and determine the melting point of the amplicon generated. 
Although this step could be performed in a normal PCR block, a qPCR machine was 
used to perform this for two reasons: (a) to check when the product amplifies in real-time 
and (b) to run a melt curve to check specificity. Simultaneously, the ‘RT negative’ 
sample was also subjected to qRT-PCR. This sample should not amplify as there is no 
DNA in the sample. A mastermix was prepared in a 1.5 mL centrifuge tube by using 
Brilliant III UltraFast SYBER Green qPCR Master Mix (Agilent Technologies, Berkshire, 
UK) as shown in Table 7.  
 
Table 7: qRT-PCR mastermix for designed assays to generate the standards. 
Reagent Volume per reaction (μL) 
Brilliant III SYBER Green  qPCR mix (2x) 5.0 
Forward primer (10 μM, 500 nm final)   0.5 
Reverse primer (10 μM, 500 nm final 0.5 
Nuclease-free H2O 2.0 
  
Total per sample 8.0 
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   From the mastermix, 8 μL was added to each reaction in the PCR tubes 
containing either 2 μL tRNA for no-template control (NTC), 2 μL of RT negative sample 
or 2 μL of two diluted cDNA (template) tubes. The final reaction volume was 10 μL per 
tube. The tubes were capped and run in qPCR machine using the conditions shown in 
Table 8. To determine primer specificity, size of the PCR products were determined on 
2% agarose gels and compared with a 50 bp DNA ladder. 
 
Table 8: Cycling conditions for qPCR for gene standards. 
Step Time Temperature Cycles 
Activation 3 minutes 95°C 1x 
Amplification: 
Denaturation  5 seconds 95°C  
Annealing 1 second 57°C 40x Extension 1 second  57°C 
Melt  ramp from 65°C to 95°C rising by 1°C per step  
 
2.55.5. Measurement of gene expression by SYBER Green qRT-PCR: 
In the next qRT-PCR run to measure gene expression, a standard curve was 
constructed by making serial 10-fold dilutions of standards that contains 107 copies in 2 
μL. The final volume for each qRT-PCR reaction was 10 μL by adding 2 μL of template 
cDNA, or the diluted standards which contained from 107 to 101 copies per 2 μL to 8 μL 
of mastermix. SYBER qPCR kits come as a ready-to-use mix containing Taq 
polymerase enzyme, 10x polymerase buffer, dNTPs, SYBER dye and optimised Mg2+.   
qRT-PCR reactions were set up in a 384-well microplate in triplicates including NTC (no-
template control) as a negative control (i.e. tRNA only, no cDNA), cDNA (unknown 
quantity sample, RT reaction) and dilutions of 101 to 107 gene copy standards of 
reference genes. 
 
 The qRT-PCR mastermix was prepared as shown in Table 7 with the addition of 
0.3 μL of diluted (1:50 for a final concentration of 300 nM in the reactions) ROX 
reference dye (Agilent Technologies). Conditions of the qRT-PCR are shown in Table 9. 
The plate was then sealed, centrifuged briefly and the qRT-PCR run in an ABI7900HT 
Fast machine (Applied Biosystems) at the Genome Centre, Queen Mary University of 
London. 
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Table 9: qRT-PCR conditions for amplification of target genes.  
Cycles Duration of cycle Temperature 
1 3 minutes 95°C 
40 
5 seconds 95°C 
15 seconds 60°C 
  
 The data analysis software of qPCR machines allows for the generation of a 
standard curve and the calculation of the number of copies present in each of the 
unknown cDNA samples. For SYBER Green-based assays, the software can also check 
the melting temperature of the product generated in every one of the samples; this is 
called melting analysis. 
     
2.55.6. Targeted and reference genes 
Assays were designed to study the expression level of mRNA of genes under 
investigation using qRT-PCR. The most commonly used housekeeping genes as 
references for normalisation in qRT-PCR assays and the targeted genes are shown in 
Table 10. 
 
Table 10: Primer sequences of targeted and reference genes.  
 
Target genes 
 
Forward primer 
(5’ to 3’) 
Reverse primer 
(5’ to 3’) 
Myeloid cell leukaemia sequence1 (MCL1) CGGCAGTCGCTGGAGATTATC TGATGTCCAGTTTCCGAAGCA 
Polo-like kinase1 (PLK1) ACTGCCACCTCAGTGACATG ATCACAGAGCTGATACCCAAGG 
 
Reference genes 
 
Forward primer 
(5’ to 3’) 
Reverse primer 
(5’ to 3’) 
β-actin (ACTB) CACCATGTACCCTGGCATT CCGATCCACACGGAGTA 
β-2 microglobulin (B2M) CTCTCTCTTTCTGGCCTGGAG ACCCAGACACATAGCAATTCAG 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
Phosphoglycerate kinase (PGK1) CCTCGTTGACCGAATCACC AGCAGCCTTAATCCTCTGGT 
Transferrin receptor (TFRC) ATCTGAACCAATACAGAGCAGA
CAT 
GAGGAAGTGATACTCCACTCTC
AT 
 
Note: 
For MCL1, ACTB and B2M genes, assays are designed with intron-flanking primers which amplify 
genomic DNA if present in the samples. 
For PLK1, GAPDH, PGK1 and TFRC genes, assays are designed with intron-spanning primers. If 
genomic DNA is present in a sample it should not be amplified. Primers of this assay amplifies mature 
transcript.  
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2.56. CellTiter-Glo® luminescent cell viability assay: 
The CellTiter-Glo® Luminescent Cell Viability Assay is a method used to determine the 
number of viable cells in culture. Detection is based on using the luciferase reaction to 
measure the amount of ATP in viable cells. The amount of ATP in cells correlates with 
cell viability. Measurement of cell viability indirectly reflects amount of cell death under 
investigation. In order to measure cell viability in cell death induction experiments, after 
the incubation period, 100 µL of CellTiter-Glo® reagent was added to cells and 
incubated at room temperature for 20 minutes. Complete reagent mixing with cells was 
achieved by centrifugation at 1,200 rpm for 2 minutes at room temperature. The lysates 
were transferred to opaque-walled multiwell plates and relative light units (RLU) 
measured in Dynex Technologies MLX 96 Well Plate Luminometer (Dynex Technologies 
Inc., Sussex, UK). 
 
2.57. Measurement of activated caspase-3 and -7: 
The Caspase-Glo® 3/7 luminescent assay measures the activation of the cysteine 
aspartic acid-specific protease caspase-3 and -7. The assay is based on a luminogenic 
caspase-3/7 substrate, which contains the tetrapeptide amino acid sequence Asp-Glu-
Val-Asp sequence (DEVD) in a reagent optimised for caspase activity, luciferase activity 
and cell lysis. Accordingly, 50 μL of the Caspase-Glo® 3/7 Reagent was added to cells 
in each well of a 96-well microtiter plate for cell lysis, cleavage of the DEVD substrate by 
activated caspase-3 and -7 with release of aminoluciferin. Aminoluciferin would then 
generate luminescent signal by luciferase activity. Luminescence is proportional to the 
amount of activated caspase-3 and -7 present in the cells. The lysates were transferred 
to opaque-walled multiwell plates and the RLU measured in 96 Microplate Luminometer. 
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2.58. A20FMDV2-protamine peptide: 
A 42-mer fluorescence-labeled synthetic peptide with an RGD motif that combines the 
A20FMDV2 with the truncated protamine domain in a single peptide which is FITC-Ahx-
A20FMDV2-protamine (fluorescein isothiocyanate-aminohexanoic acid- 
NAVPNLRGDLQVLAQKVART-RSQSRSRYYRQRQRSRRRRRR) was obtained from 
PeptideSynthetics (Hampshire, UK). The peptide, which has a molecular mass of 
5566.33 g/mol, was generated in vitro using an automatic synthesiser and 10.8 mg of 
the product purified by reversed phase-HPLC in acetonitrile and H2O containing 0.1% 
trifluoroacetic acid and was supplied lyophilised. For the purpose of imaging studies, the 
peptide was labeled with FITC at the N-terminus. 
 
2.58.1. Resuspension of the peptide: 
Lyophilised FITC-Ahx-A20FMDV2-protamine peptide was brought to room temperature 
and resuspended in 192 μL of 100% DMSO (1.1 g/mL) to give a final stock 
concentration of 10 mM. The peptide was aliquoted and frozen at -20°C and further 
diluted with the growth medium before adding it to cells. 
 
2.59. Binding to αvβ6 integrin and internalisation of A20FMDV2-protamine peptide 
by confocal microscopy: 
For internalisation by microscopy, monolayers of αvβ6-negative (A375Ppuro or 
DX3Ppuro) and αvβ6-positive (A375Ppuroβ6 or DX3Ppuroβ6) cells were plated onto 13 
mm diameter coverslips placed in a 4-well plate (Thermo Fisher Scientific Inc.) (2 x 104 
cells per well) overnight. The cells were washed with chilled DMEM and medium was 
replaced with ice-cold FITC-Ahx-A20FMDV2-protamine peptide (100 nM peptide/500 μL 
serum-free DMEM). After 15 minutes incubation on ice, unbound peptide was washed 
off with pre-warmed DMEM and cells incubated at 37°C for various time points (10, 20, 
30, 40, 50 and 60 minutes). For the 0 time point, the cells were left on ice. At the end of 
the indicated time points, the coverslips were removed, cells fixed in formaldehyde (4% 
in PBS) for 10 minutes and then treated with 0.1% Triton X-100 for 5 minutes. The cells 
were washed with PBS and stained with DAPI (1:5000) for 5 minutes. The coverslips 
were mounted on slides using anti-fade mounting medium. Samples were analysed 
using a Zeiss LSM710 confocal microscope (Zeiss, Welwyn Garden City, UK). 
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2.60. Delivery of siGLO Red siRNA with A20FMDV2-protamine peptide: 
Monolayers of αvβ6-negative A375Ppuro and αvβ6-positive A375Ppuroβ6 cells were 
plated onto 13 mm diameter coverslips placed in a 4-well plate (2 x 104 cells per well) 
overnight. Next day, FITC-Ahx-A20FMDV2-protamine peptide was diluted in growth 
medium to 10 µM and bound with siGLO Red siRNA (10 nM) for 15 minutes on ice. The 
cells were washed with DMEM, chilled on ice and medium replaced with ice-cold FITC-
Ahx-A20FMDV2-protamine/siGLO Red mixture. After 15 minutes on ice, unbound 
peptide/siRNA was washed off with pre-warmed DMEM and cells were incubated at 
37°C for various time points (15, 30, 45 and 60 minutes). The rest of the procedure was 
as described in the previous section to test for internalisation of the peptide by confocal 
microscopy. 
 
2.61. Delivery of siRNA for ITGB6 gene with A20FMDV2-protamine peptide: 
Monolayers of only αvβ6-positive VB6 cells were plated in a 12-well plate at a density of 
0.1-0.4 x 106 cells per well in 1 mL complete growth medium overnight. Next day, cells 
were washed and medium replaced with fresh DMEM. FITC-Ahx-A20FMDV2-protamine 
peptide was diluted in growth medium to 100 nM and bound with siRNA for ITGB6 (10-
100 nM) for 15 minutes on ice. The mixture was then added to cells and incubated at 
37°C for 3-5 days. Cells were harvested and analysed by Western blotting for ITGB6 
protein. 
 
2.62. Statistical analyses: 
Data analyses were conducted using the Microsoft Excel 2007 and GraphPad Prism 
software version 5.00 (GraphPad Software, California, USA). Values are given as mean 
± standard error of the mean (SEM) where n represents the number of experiments 
carried out. The significance of difference between two groups at a given time was 
determined by unpaired Student’s t-test.  
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In this chapter, methods for the isolation, fluorescence labeling, binding and 
internalisation assays by flow cytometry and confocal microscopy of the mouse anti-
CD22.2 mAb are presented and discussed. Furthermore, results on the generation of 
proteins by recombinant DNA technology, analysis, multi-step purification and test for 
biology of the fusion proteins are presented. 
  The objective was to identify and use a suitable anti-CD22 mAb in order to 
generate recombinant anti-CD22 scFv-protamine-His6 fusion protein that retains the 
ability to bind specifically to and be internalised by mature B cells. 
3.1. The Cy34.1.2 hybridoma as a source of anti-CD22.2 mAb: 
B cells are known to express an extensive array of surface molecules collectively termed 
Lyb and Ly antigens. Lyb-8.2, a murine B lymphocyte differentiation glycoprotein, is 
expressed on pre-B cells and on all mature B lymphocytes. The molecular weight of the 
protein is 95–105 kDa and its expression is controlled by a locus on chromosome 7. 
Mouse strains C57BL/6J, C57BL/10J, B10.D2, SJLJ, A.CA, A/J, AL/N, BALB/c, 
C3H/HeJ, CBA/J, C57L/LJ, C58, RF/J, SWR/J, CE/J, C3H.SW, CBA/N, (CBA/N x 
BALB/c)F1 ♂ and ♀ (DBA/2 x BALB/c)F1 are positive for Lyb-8.2. The Cy34.1.2 
hybridoma was generated from DBA/1 mice immunised with spleen cells of B10.D2 
mice. The hybridoma secretes non-cytotoxic IgG1 antibody which identifies Lyb-8.2 
antigen on B lymphocytes from the strains mentioned above (235).    
 
3.2. Isolation of the anti-CD22.2 mAb from culture supernatants of Cy34.1.2 
hybridoma: 
The mouse Cy34.1.2 mAb was purified from culture supernatants of the hybridoma 
using protein G-coated beads (Millipore). Integrity and purity of the purified mAb was 
assessed on a Coomassie blue-stained SDS-PAGE gel. A sample of the purified mAb 
was analysed under non-reducing and reducing conditions (Figure 21). The non-
reducing gel showed a ~150 kDa band representing the intact IgG. When the purified 
mAb was analysed under reducing conditions, there were two main bands, ~25 kDa and 
~50 kDa bands representing the light and the heavy chains of the mAb, respectively. 
Minor contaminations of the mAb could also be seen on the gels. A pre-stained protein 
marker was used to determine the molecular mass of each band. Concentration of the 
protein at 280 nm (A280) = 4.82 mg/mL.  
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Figure 21: SDS PAGE analysis of affinity purified mAb Cy34.1.2. Approximately 96, 72, 48 
and 24 μg/mL of the purified protein were subjected to gel electrophoresis on a 10% pre-cast 
NuPAGE gel under non-reducing condition (top) or reducing condition (bottom). The proteins 
were reduced using 2-mercaptoethanol added to the denaturing sample buffer and incubated for 
10 minutes at 95°C. Protein bands were visualised by Coomassie brilliant blue staining 
(SimplyBlueTM SafeStain, Invitrogen). No or minimal contamination with BSA (66.5 kDa) and 
other protein impurities can be seen.   
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 3.3. Expression of CD22.2 on mouse B cells was detected by flow cytometry:  
CD22.2 expression on the mouse B cell line BCL1-3B3 was assessed using two 
antibodies, the commercial anti-CD22.2 FITC (Cy34.1, BD Biosciences) and the purified 
Cy34.1.2 mAb that was labelled with AlexaFluor®488 fluorescent dye. The cell line 
BCL1 is a clone of 13.20-3B3 derived from leukaemic peripheral blood B lymphocytes of 
BALB/c mice. The binding of anti-CD22.2 mAb was assessed by gating on positive living 
cells in the forward scatter. The cells were also stained with an isotype control and used 
as a negative control for background fluorescence staining during the acquisition. The 
FACS data were analysed using CellQuest software (Figure 22). 
Furthermore, binding and the kinetics of internalisation of CD22.2 receptor on BCL1-3B3 
B cells was assessed by confocal microscopy using AlexaFluor®488 conjugated anti-
CD22.2 mAb. The reason for using AlexaFluor®488 conjugated anti-CD22.2 mAb was 
to address the problem of rapid photobleaching associated with the use of the 
commercial FITC labelled anti-CD22.2 mAb (section 3.4, page 124). 
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Figure 22: Analysis of murine BCL1-3B3 B cells for CD22.2 expression by flow cytometry. 
The figure depicts FACS profiles for the BCL1-3B3 cells. Dot plots (A) showing the forward and 
side scatter for the cells; (B) illustrating cells stained with the isotype control mAb (FITC mouse 
IgG1 kappa) with fluorescence on the x-axis. CD22.2 staining using anti-CD22.2 Cy34.1 FITC 
commercial Ab (C) and using AlexaFluor®488-conjugated Cy34.1.2 mAb (D). 
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3.4. Kinetics of anti-CD22.2 internalisation in B cells by confocal microscopy:  
To study the kinetics of internalisation of CD22.2, BCL1-3B3 B cells that were stained 
with anti-CD22.2 FITC mAb and DAPI blue nuclear stain did not show CD22.2 on cell 
surface but the blue-stained nuclei of the cells were clearly seen under the microscope 
(data not shown) when examined by confocal laser scanning microscopy (CLSM). The 
reason for this could be due to the rapid photobleaching of the FITC fluorophore, which 
is a recognised problem. Therefore, preventing the fading of fluorescence intensity 
caused by the excitation light is very important for obtaining stable and accurate images 
(236). 
 
To address this problem, the purified Cy34.1.2 mAb was conjugated with 
AlexaFluor®488. The BCL1-3B3 cells were stained with the anti-CD22.2 
AlexaFluor®488 conjugated Cy34.1.2 mAb and analysed for expression and kinetics of 
internalisation of the surface CD22.2 by CLSM. The cells were analysed for CD22.2 
internalisation at different time points incubated at 37°C. Demonstration of binding and 
internalisation by confocal microscopy was thus improved significantly by prevention of 
photobleaching and fading using AlexaFluor®488 dye. The analysis showed that the 
anti-CD22.2 was rapidly endocytosed by the cells with clear internalisation visible after 
30 minutes. Cells were also stained with DAPI (Figure 23).  
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Figure 23: Confocal microscopic analysis of the kinetics of CD22.2 internalisation 
following Cy34.1.2 AlexaFluor®488 binding. Membrane binding of Cy34.1.2 AlexaFluor®488 
to CD22.2 on murine BCL1-3B3 B cells (A and B) at 4°C followed by internalisation into the cell 
after 30 minutes incubation at 37°C (C and D) and 60 minutes (E and F). CD22.2 internalisation 
is evident from capping and punctate staining of endocytic vesicles (arrows) visible in cells 
incubated at 37°C. Cells stained with the isotype control AlexaFluor®488 anti-mouse IgG1 at 4°C 
(G). The nuclei are stained with DAPI. Slides were examined with 63x oil immersion lens in LSM 
710 Zeiss confocal microscope.  
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3.5. Quality and integrity of RNA extracted from Cy34.1.2 hybridoma cells 
assessed on agarose gel: 
Isolation of intact RNA is essential for many techniques regardless of the downstream 
application. The most common method used to assess the quality of total RNA is to run 
an aliquot of the RNA sample on an agarose gel. Intact total RNA obtained from 
eukaryotic samples will have clear 28S and 18S rRNA bands. The 28S rRNA band 
should be approximately twice as intense as the 18S rRNA band. This 2:1 ratio 
(28S:18S) is a good indication that the RNA is completely intact.  
  The A260/A280 ratio at 1:20 dilution of RNA extracted from the Cy34.1.2 hybridoma 
cells was 2.08. Analysis of the RNA by electrophoresis showed two bands of 1900 bp 
and 4800 bp which are rRNA bands of 18S and 28S, respectively (Figure 24). The 28S 
rRNA band was approximately twice as intense as the 18S rRNA band; this 2:1 ratio 
indicates intact RNA. 
 
Figure 24: Analysis of quality and integrity of total RNA extracted from Cy34.1.2 
hybridoma cells. Total RNA was run on a 1% agarose gel and shows two distinct ribosomal 
bands corresponding to 18S (1900 bp) and 28S (4800 bp) RNA species.  
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3.6. Poly-G tailing and amplification of cDNAs for the VH and VL genes of Cy34.1.2 
mAb by PCR for cloning: 
Sequences of the VH and VL of the Cy34.1.2 anti-CD22.2 mAb were not known at the 
start of this study. The family group, to which the VH and VL of Cy34.1.4 belong, was 
unknown and no primers could, therefore, be designed to anneal with the leader 
sequences of either chain. To amplify the cDNA of the two genes, a sequence 
composed of guanine bases (poly-G tail) was, therefore, intentionally added to the 
5’UTR sequence of the VH and VL using the enzyme terminal deoxynucleotidyl 
transferase (TdT). Amplification of the VH and VL genes would then be possible with the 
aid of a primer specific to the poly-G tail (namely, poly-C primer with a restriction site) 
and primers that anneal to sequences within the 5’ of the CH1 and Cκ of the mAb. cDNA 
was made from RNA after concentrating the RNA by precipitation with 0.3 M sodium 
acetate and ethanol. The newly-synthesised cDNA was extracted with equal volumes of 
phenol:chloroform and used for the poly-G tailing reaction.  
 
Using commercially-available PCR purification kits, a considerable amount of 
material was lost during cleaning of the cDNA. To solve this problem, columns packed 
with sterile Sephadex G-25M were made for this purpose. cDNAs for the VH and VL 
genes were then passed through a size-exclusion column (Sephadex G-25M PD10, GE 
Healthcare) to remove excess dNTPs, primers and salts from the solution, the enzyme 
reverse transcriptase and buffer. The filtrates which contained the purified cDNAs were 
then used in the poly-G tailing reaction. Tailed cDNAs were passed through the 
Sephadex G-25M size-exclusion column again to remove excess dGTPs, salts in the 
solution, TdT and the caccodylate buffer and then used for the PCR. The PCR products 
of both VH and VL cDNA were analysed on a 1% agarose gel and DNA bands extracted 
using PureLink® Quick Gel Extraction Kit. The purified PCR products were used for TA 
cloning (Figure 25). 
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Figure 25: Agarose gel electrophoresis for the analysis of nested PCR products of VH and 
VL genes using primers in the Cγ and Cκ and a primer for the poly-G tail. cDNAs were 
amplified using internal primers in the Cγ and Cκ and a primer to the poly-G tail.  
 
The predicted size of cDNA for both the VH and VL genes would be ~330 bp. 
Analysis of the products showed multiple bands with slightly different sizes on the 
agarose gel. The presence of multiple bands is likely to be due to the fact that the length 
of the added poly-G sequence is inconsistent and results in more G bases added onto 
the 5’UTR leader sequence of some of the cDNA molecules than others. There was also 
a low cDNA yield for both the VH and VL genes due to the considerable loss of cDNA 
during the purification process.  
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3.7. PCR products of VH and VL genes of Cy34.1.2 mAb were analysed: 
PCR products of the poly-G-tailed cDNA for the VH and the VL genes were cloned into 
the linearised pCR®2.1 TA vector and used to transform DH5α E. coli and DNA 
minipreparations from positive transformants used in sequencing. This was achieved by 
cloning the PCR product for the VH and the Vκ genes of Cy34.1.2 mAb into the pCR®2.1 
plasmid (Figure 26).  
 
 
Figure 26: Restriction analysis of pCR®2.1 plasmid DNA constructed with PCR products 
for the VH and the VL genes of Cy34.1.2 mAb. The nested PCR products generated using 
anchor and internal primers were cloned into the pCR®2.1 plasmid. The resulting pCR®2.1 
plasmid construct DNAs were restricted with EcoRI to release the VH (top) and the VL (bottom) 
cDNA. Plasmid DNAs with inserted PCR products for the VH and the VL genes of Cy34.1.2 mAb 
were sequenced and analysed by NCBI/BLAST search.  
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3.8. Determination and analysis of nucleotide sequences of the VH and VL of 
Cy34.1.2 mAb: 
Nucleotide sequences of the VH and VL genes of Cy34.1.2 were analysed using Basic 
Local Alignment Search Tool (BLAST) in the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/). BLAST, an algorithm for comparing primary 
biological sequence information such as amino acids or nucleotides, enables you to 
compare a query sequence with a library of sequences and identify library sequences 
that resemble the query sequence above a certain threshold. The database allows 
specialised IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) for particular species. The 
process involved entry of the nucleotide sequence into an interactive program and 
selection of the species (in this case mouse for Cy34.1.2 mAb VH and VL) and the library 
(KABAT). The database will automatically search and align the query to all available 
sequences and matches the query sequence with the closest relating germ-line gene 
families. Accordingly, the IgBLAST searches generated alignments with related germ-
line nucleotide sequences and similarity was observed with the IgH-VJ558 VH1 gene 
family for the mouse immunoglobulin VH gene family. The VL gene family was 
determined as the Igκ-V24/25 subgroup. Based on the alignments it was then possible 
to identify the framework (FWR) and the hypervariable regions [complementarity 
determining regions (CDRs)] of the VH and VL genes. In parallel, the sequence of the 
signal peptide at the N-terminal end of the mAb was determined by analysis of the 
variable region of both VH and VL genes using a bioinformatics protein hydrophobicity 
plot as described in chapter two. Full length nucleotide sequences of VH and VL genes 
after sequencing from TA cloning vector are shown in Appendix 2, pages 341 and 342 
respectively. Results of analyses of the nucleotide sequences and amino acids of the 
signal peptide are shown in Figure 27. The process of sequence analysis is described in 
section 2.14, page 67.   
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Cy34.1.2 VH gene nucleotide sequence:                                                                                            |                  Native signal sequence                       |                    
                ATG AGA TGG AGC TGT ATC ATT CTC TTC TTG GTA GCA ACA GCT ACA AGT GTC GAC TCC     
                 M   R   W   S   C   I   I   L   F   L   V   A   T   A   T   S   V   D   S 
                |                                  FWR1 
Rearranged      CAG GTC CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG          
a.a              Q   V   Q   L   Q   Q   P   G   A   E   I   V   R   P   G   T   S   V   K 
IgH-VJ558 VH1   ... ... ... ... ... ... ... ... ... GAG CTT ... AAG ... ... GCT ... ... ...  
a.a.             Q   V   Q   L   Q   Q   P   G   A   E   L   V   K   P   G   A   S   V   K    
 
                                                          | |     CDR1        | |  
Rearranged      CTG TCC TGT AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG 
a.a              L   S   C   K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K    
IgH-VJ558 VH1   ... ... TGC ... ... TCT ... ... ... TTC ACA AGC TAC ... ... CAC ... ... ...  
a.a.             L   S   C   K   A   S   G   Y   T   F   T   S   Y   W   M   H   W   V   K   
  
                                  FWR2                    | |       
Rearranged      CAA AGG CCT GGA CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT 
a.a              Q   R   P   G   Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y    
IgH-VJ558 VH1   CAG ... ... ... ... ... ... ... ... ATT ... GAG ... ... ... ... ... ... ...         
a.a.             Q   R   P   G   Q   G   L   E   W   I   G   E   I   D   P   S   D   S   Y    
 
                                  CDR2            | |             FWR3 
Rearranged      ACT AGG TAC AAT CAA GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC 
a.a              T   R   Y   N   Q   E   F   K   G   K   A   T   L   T   V   D   T   S   S    
IgH-VJ558 VH1   ... AAC ... ... ... AAG ... ... ... ... ... ... ... ... ... ... AAA ... ... 
a.a.             T   N   Y   N   Q   K   F   K   G   K   A   T   L   T   V   D   K   S   S 
 
Rearranged      ACC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC 
 a.a             T   T   A   Y   M   Q   L   S   S   L   T   S   E   D   S   A   V   Y   F   
IgH-VJ558 VH1   AGC ... ... ... ... ... ... ... ... ... ... TCT ... ... ... ... ... ... ... 
a.a.             S   T   A   Y   M   Q   L   S   S   L   T   S   E   D   S   A   V   Y   F 
  
                        | |            CDR3                 | 
Rearranged    TGT GCA AGA TCG GAC TAT ACT TAC TCA TTC TAC TTT  
a.a            C   A   R   S   D   Y   T   Y   S   F   Y   F         
IgH-VJ558 VH1 ... ... ... ... ... ... ... ... ... ... ... ...JH2 
a.a.           C   A   R   S   D   Y   T   Y   S   F   Y   F      
 
Cy34.1.2 VL gene nucleotide sequence:             |                               FWR1                                                          
Rearranged  GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA ACA TCA GCT 
a.a          D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G   T   S   A 
Igκ-V24/25  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...     
a.a.         D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G   T   S   A 
                          | |               CDR1                                  | |   
Rearranged  TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT TAT TTG 
a.a          S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T   Y   L    
Igκ-V24/25  ... ... TCT ... AGT ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
a.a.         S   I   S   C   S   S   S   K   S   L   L   H   S   N   G   I   T   Y   L 
                                            FWR2                          | | 
Rearranged  TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG TCC 
a.a          Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M   S    
Igκ-V24/25   ... ... ... ... ... ... ... ... ... ... ... ... ... ...  ATA ... CGG ... ...     
a.a.         Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   R   M   S 
               CDR2       | |               FWR3  
Rearranged  AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC 
a.a          N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F    
Igκ-V24/25  ... ... ... ... ... ... ... ... ... ... ... GGC ... ... ... ... ... ... ...    
a.a.         N   L   A   S   G   V   P   D   R   F   S   G   S   G   S   G   T   D   F 
                                                                              | | 
Rearranged  ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA 
a.a          T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q    
Igκ-V24/25  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
a.a. 
                    CDR3       |  
Rearranged   AAT CTA GAA CTT CCG  
a.a           N   L   E   L   P    
Igκ-V24/25   ATG ... ... ... ...    
a.a.          M   L   E   L   P  
Figure 27: Nucleotide sequences of the Cy34.1.2 mAb VH and VL genes. The native secretion signal 
sequence, framework regions (FWRs) and complementarity determining regions (CDRs) are indicated. 
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3.9. Generation and cloning of Cy34.1.2 anti-CD22.2 scFv-His6 and scFv-
protamine-His6 constructs: 
The construction and use of a scFv from the Cy34.1.2 mAb to deliver therapeutic 
molecules, or siRNA/miRNA has a number of potential advantages. These include, at 
least theoretically, a weak stimulatory effect on B lymphocytes to which it binds, 
reduction in toxicity and a relatively small molecular size, yet retaining the affinity for 
binding to the receptor. In addition, antibody engineering using recombinant DNA 
technology will allow scFv to be equipped with different tags.  
 
One of the key aims of this study is to engineer a fusion protein that combines the 
ability of anti-CD22 scFv to specifically target disease-causing B lymphocytes and carry 
therapeutic siRNA with the ability to change fate and biology B lymphocytes. For this 
purpose, the VH and VL chains were fused to a highly positively charged peptide, a 
truncated domain from human protamine (RSQSRSRYYRQRQRSRRRRRR) which has 
a known strong ability to bind siRNA and target these to B cells. The siRNA to be used 
would be intended to target key signaling molecules and proteins that are specifically 
upregulated in disease settings such as B cell leukaemia/lymphoma and other diseases 
mediated by B cell abnormalities. Thus to achieve the objective of constructing and 
generating scFv with the truncated protamine and a histidine purification tag, the PCR 
products of the poly-G-tailed cDNA for the VH and the VL genes were cloned into the 
linearised pCR®2.1 TA vector and used to transform DH5α E. coli, and DNA maxi-
preparations from positive transformants used in subcloning procedures to construct the 
scFv cDNAs. 
 
3.10. Analysis of the plasmid pFastBacTM1 donor vector by restriction digestion in 
preparation for cloning: 
The plasmid pFastBacTM1 donor vector containing mIFNβ-MMP-1-11E scFv-His6 
expression cassette (237) was analysed by restriction digestion to assess the feasibility 
of cloning the VH and the VL genes into the multiple cloning site (MCS) (Figures 28 and 
29). The vector has left and right Tn7 transposable elements which flank the cloning 
sites that encompass the expression cassette. This enables the plasmid to donate the 
DNA fragment flanked by transposons to a recipient vector.  
Chapter Three 
 
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Schematic map of the pFastBacTM1 donor vector illustrating the insertion sites 
of mIFNβ-MMP-1-11E scFv-His6 expression cassette. This construct was used to generate 
the mouse anti-CD22.2 scFv-His6 and scFv-protamine-His6 constructs using similar restriction 
sites. Genetic map of the construct is also shown in Appendix 3, page 354. 
PPH MCS SV40 pA Tn7L Tn7R Gentamicin 
Ampicillin f1 ori pUC ori 
HindIII            EcoRI    NotI    XhoI      SalI    XbaI           ApaI 
VH (Gly4Ser)3 His6 COO- NH3+ mIFNβ MMP VL 
1-11E scFv 
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Figure 29: Restriction digestion of the pFastBacTM1 plasmid (mIFNβ-MMP-1-11E scFv-
His6) to assess suitability for cloning the VH and the VL genes of Cy34.1.2 mAb. The 
pictures depict results of restriction digestion of pFastBacTM1 with HindIII, EcoRI, NotI, XhoI, 
SalI, XbaI and ApaI. Plasmid DNA was digested with individual enzymes to linearise the vector 
(top), or with EcoRI, NotI, XhoI, SalI, XbaI and ApaI restriction endonucleases in double 
restriction digestion reactions with HindIII enzyme to release DNA fragments from the vector at 
MCS (bottom). 
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3.11. VH and the VL gene cDNA amplification by PCR with specific primers for 
cloning into the pFastBacTM1 donor vector: 
The cDNAs for the VH and the VL genes of the Cy34.1.2 mAb cDNA cloned into the 
pCR®2.1 vector were PCR-amplified with specific nested primers internal to the Cγ and 
Cκ primers used for the first round of PCRs and also primers to anneal to the leader 
sequence of the VH and the VL genes as determined by sequencing. The PCR products 
were intended for insertion into the MCS of the pFastBacTM1 transfer donor vector.  
 
For the purpose of the experiments to be carried out, two constructs were 
generated. One construct was to consist of the scFv of the Cy34.1.2 mAb without the 
protamine peptide using VL2 reverse primer for PCR amplification of VL genes and one 
scFv with the protamine peptide using VL1 reverse primer for PCR amplification of VL 
genes. It was necessary to do this so that the scFv alone would be used as a control for 
any biological changes induced in the B lymphocytes independent of delivered siRNA. 
For this purpose the cloning strategy was altered such that for the scFv-His6 construct, 
PCR-amplified VL genes using VL2 reverse primer was cloned followed by the VH and 
His6-tag (Figure 10 top, page 70) while for the scFv-protamine-His6 construct the order 
of cloning was to ligate the VL genes PCR product using VL1 reverse primer and the 
truncated protamine in one reaction and then ligate the VH into the vector backbone 
(Figure 10 bottom, page 70). Results of the PCR reactions and restriction digestion of 
the PCR DNA fragments and the pFastBacTM1 vector are shown in Figure 30. 
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Figure 30: Preparation of PCR products and vector for cloning. PCR products of VH (384 
bp), VL1 and VL2 (300 bp) cDNAs are shown (top). The VH and VL genes were amplified with 
primers to incorporate specific restriction sites that enable cloning into the MCS of the 
pFastBacTM1 vector. VH DNA with HindIII and XhoI restriction sites, VL1 DNA with EcoRI and SalI 
restriction sites and VL2 DNA with SalI and NheI restriction sites. PCR products and vector (with 
SalI and XbaI) were restricted and purified by gel extraction (bottom).   
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Schematic illustrations for restriction digestion and cloning process of the 
pFastBacTM1-IFNβ-MMP-1-11E scFv to replace the VL and VH genes of 1-11E scFv with 
Cy34.1.2 scFv is shown in Figure 31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Schematic illustrations showing the cloning process and restriction digestion 
of the pFastBacTM1-IFNβ-MMP-1-11E vector to generate the scFv-His6. Successful cloning 
of the Cy34.1.2 VL is confirmed by restriction digestion of the new construct (pFastBacTM1-VL2) 
with SbfI and SnaBI enzymes (top). Furthermore, the new Cy34.1.2 scFv-His6 construct 
(pFastBacTM1-VH/VL2-His6) was verified by restriction digestion with MfeI enzyme (bottom). 
1-11E scFv 
HindIII            EcoRI    NotI    XhoI      SalI    NheI           ApaI 
New VL2 
VH (Gly4Ser)3 His6 COO- NH3+ mIFNβ MMP VL 
SnaBI  
SbfI 
pFastBacTM1
                     HindIII         XhoI      SalI    NheI           ApaI 
New VL2 
VH (Gly4Ser)3 His6 COO- NH3+ VL 
MfeI 
New VH MfeI 
pFastBacTM1
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3.12. Confirmation of the cloning of the VL2 cDNA into the vector backbone by 
restriction analysis and sequencing: 
Result of analysing VL2 cloning showed that the cDNA was successfully incorporated 
into the pFastBacTM plasmid backbone between SalI and NheI site as indicated by 
digestion with SbfI and SnaBI (Figure 32). This restriction digestion is to confirm 
generation of pFastBacTM1-IFNβ-MMP-1-11E scFv with 1-11E's VL replaced with Cy34 
VL2 cDNA. 
 
 
Figure 32: Cloning of VL2 into the pFastBacTM1 plasmid. The gel image shows results of the 
restriction digestion of the pFastBacTM1 vector (after cloning of the VL2 cDNA; named 
pFastBacTM1-VL2) with SbfI and SnaBI. The SbfI site is unique to the insert VL cDNA and the 
SnaBI site is located in the vector backbone outside the insert region. Restriction analysis with 
SbfI and SnaBI has, as expected, generated two fragments 4787 bp 1252 bp. All the VL2 clones 
analysed were positive for the correct inserts and were further confirmed by sequencing. 
 
 
Once the insertion of the VL2 into the plasmid was confirmed, the VH cDNA was 
prepared to be ligated into the construct between HindIII and XhoI in the new plasmid 
DNA backbone pFastBacTM1-VL2 which was digested with the same restriction enzymes 
(Figure 33).  
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Figure 33: Preparation of the VL2/pFastBacTM1 construct for cloning of the VH of mAb 
Cy34.1.2. The top photograph depicts the result of plasmid DNA maxiprep with the VL2 insert 
after restriction with HindIII and XhoI enzymes to prepare it for the cloning of VH DNA in the next 
stage. VL2 construct and the VH cDNA after restriction digestion and purification by gel extraction 
(bottom).  
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3.13. Cloning of in-frame VH gene cDNA into the FastBacTM1-VL2 construct: 
Once the pFastBacTM1-VL2 construct was generated the VH was sub-cloned in between 
the HindIII and XhoI sites, colonies analysed by restriction digestion and those with the 
correct inserts verified by sequencing (Figure 34). 
 
Figure 34: Restriction digestion of plasmid DNA to verify the successful cloning of the VH 
of Cy34.1.2 mAb into the VL2/pFastBacTM1 construct. The image depicts results of restriction 
digestion of plasmid DNA minipreps with MfeI to verify insertion of the Cy34.1.2 VH. All the 
clones had the correct insert as the two expected DNA fragments were generated: 4788 bp 
against 747 bp. 
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3.14. Annealing of overhang protamine primers to generate the cDNA for the 
truncated protamine sequence:  
In order to generate the scFv of mAb Cy34.1.2 containing the designated protamine 
peptide, overhanging primers for the truncated protamine sequence were designed and 
generated. The HPLC-purified overhanging primers were annealed by incubating equal 
volumes of 10x dilution of each primer stock (100 mM) with T4 DNA ligase buffer (10x) 
and sterile distilled water. The mixture has then boiled for 5 minutes and left to anneal 
gradually overnight. Individual and annealed primers were checked by agarose gel 
electrophoresis (Figure 35).  
                     
  |EcoRI|                                                                                     |XbaI| 
5' AA TTC CGA TCA CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA TCA CGA CGA CGA CGA CGA CGA T      3’ 
           R   S   Q   S   R   S   R   Y   Y   R   Q   R   Q   R   S   R   R   R   R   R   R    
3’      G GCT AGT GTT AGT GCT AGT GCT ATG ATG GCT GTT GCT GTT GCT AGT GCT GCT GCT GCT GCT GCT AGA TC 5’ 
 
Figure 35: Gel electrophoresis of free and annealed primers used for the protamine 
sequence. The HPLC-purified primers [10 mM] were annealed by incubation with T4 DNA ligase 
buffer by boiling (5 minutes) and overnight cooling.   
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Schematic illustrations for restriction digestion and cloning process of the 
pFastBacTM1-IFNβ-MMP-1-11E scFv to replace the VL and VH genes of 1-11E with 
Cy34.1.2 scFv-protamine is shown in Figure 36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Schematic illustrations showing the cloning process and restriction digestion 
of the pFastBacTM1-IFNβ-MMP-1-11E vector to generate the scFv-protamine-His6. 
Successful cloning of the Cy34.1.2 VL1-protamine is confirmed by restriction digestion of the 
new construct (pFastBacTM1-VL1-protamine) with EcoRI (top). The new Cy34.1.2 scFv-
protamine-His6 construct (pFastBacTM1-VH/VL1-protamine-His6) was verified by restriction 
digestion with MfeI enzyme (bottom). 
HindIII          EcoRI   NotI  XhoI      SalI          XbaI           ApaI 
1-11E scFv VL1-protamine 
VH (Gly4Ser)3 His6 COO- NH3+ mIFNβ MMP VL1    protamine 
EcoRI
pFastBacTM1
                 HindIII       XhoI     SalI  EcoRI     XbaI          ApaI 
VL1-protamine 
VH (Gly4Ser)3 His6 COO- NH3+ VL1    protamine 
pFastBacTM1
New VH 
MfeI 
MfeI 
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3.15. Cloning of the VL1 gene cDNA with protamine peptide DNA: 
The VL1 PCR product and the cDNA for the protamine peptide were ligated between 
SalI and XbaI sites in the plasmid DNA that was restricted using the corresponding 
enzymes. For this cloning, the plasmid backbone pFastBacTM1 was linearised by 
digestion with SalI and XbaI enzymes. Then, the VL1 PCR product was digested with 
SalI and EcoRI enzymes so that it can be ligated with the protamine cDNA which has 
EcoRI and XbaI overhang restriction sites. Positive clones containing the appropriate 
inserts were identified by restriction analysis (Figure 37) and confirmed by sequencing.   
 
 
Figure 37: Generation of constructs for VL1 and protamine peptide. Plasmid DNA minipreps 
for colonies selected following co-ligation of the VL1 and protamine gene cDNAs were analysed 
by restriction digestion. Plasmid DNAs were digested with EcoRI which resulted either in 
linearisation of the vector if the cloning was not successful, or in generation of two fragments of 
800 bp and 5263 bp. Colonies containing the appropriate inserts were verified by sequencing. 
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3.16. Cloning of the VH gene cDNA into the pFastBacTM1-VL1-protamine construct: 
Once the pFastBacTM1-VL1-protamine construct was generated, the VH gene cDNA was 
sub-cloned in between the HindIII and XhoI sites and miniprep DNAs from colonies of 
transformants were analysed by restriction digestion (Figure 38) and those with the 
correct inserts verified by sequencing. 
 
 
 
Figure 38: Cloning of the Cy34.1.2 VH DNA into the pFastBacTM1-VL1-protamine construct. 
Plasmid DNA minipreps digested with MfeI resulted in two DNA fragments of 4788 bp and 747 
bp in correct clones containing the VH DNA. 
 
 
 
 
Full sequencing data showing the validity of the in-frame nucleotide sequences for the 
construction of anti-CD22.2 scFv-His6 and scFv-protamine-His6 pFastBacTM1 donor 
vectors is shown in Appendix 2, pages 343 and 344 respectively. In addition, the genetic 
maps with unique restriction sites of both constructs are shown in Appendix 3, pages 
355 and 356 respectively. 
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3.17. Generation of recombinant bacmids for protein expression: 
Successful generation of infectious recombinant baculoviruses was accomplished by 
site-specific transposition of the expression cassettes containing the VH and VL genes of 
the Cy34.1.2 mAb into a baculovirus genome. The transposition was carried out such 
that the donor plasmid vector with an open reading frame downstream to the promoter 
region of the polyhedrin gene of the baculovirus shuttle vector (bacmid) propagated in 
DH10Bac E. coli. To achieve protein production, the Bac-to-Bac® Baculovirus 
Expression System was used. 
 
Since the recombinant bacmid DNA is greater than 135 kb in size, restriction 
analysis is difficult to perform. Therefore, PCR analysis was used to verify the presence 
of the genes of interest in the recombinant bacmid. For this purpose, the pUC/M13 
forward primer: 5’CCCAGTCACGACGTTGTAAAACG3’ and pUC/M13 reverse primer: 
5’AGCGGATAACAATTTCACACAGG3’ were used to hybridise to sites flanking the mini-
attTn7 site within the lacZα-complementation region to facilitate PCR amplification 
(Figures 39 and 40).  
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Figure 39: Schematic map illustrating the PCR analysis of recombinant bacmid. The 
pFastBacTM1 donor vector with the gene of interest inserted at MCS is transposed by site-
specific recombination with the bacmid genome. The bacmid DNA is >135 kb. Verification of the 
insertion of the gene of interest is difficult using classical restriction endonuclease digestion 
analysis. Hence, PCR amplification was used to confirm that the gene of interest has transposed 
to the bacmid. The pUC/M13 amplification primers were directed at sequences on either side of 
the mini-attTn7 site within the lacZ α-complementation region of the bacmid. If transposition has 
occurred, the PCR product produced by these primers would be 2,300 bp plus the size of the 
insert.  
 
 
pFastBacTM1 alone 
Cy34.1.2 murine anti-CD22.2 scFv-protamine-His6 expression cassette 
Cy34.1.2 murine anti-CD22.2 scFv-His6 expression cassette 
M13 F priming site to 
start of MCS is 1654 bp 
MCS to M13 R 
priming site is 597 bp 
PCR product = M13 F site to MCS + expression cassette + end of MCS to M13 R site  
M13 F Mini-attTn7 
AcMNPV bacmid genome 
M13 R 
Kanamycin  Mini-F replicon 
PPH MCS SV40 pA Tn7L Tn7R Gentamicin 
Ampicillin f1 ori pUC ori 
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Figure 40: Assessment of recombinant baculoviruses by PCR. M13 forward and reverse 
primers were used to amplify from the M13F priming site which is 1654 bp upstream to the MCS 
and M13R priming site which is 597 bp downstream to the MCS. Expected sizes for the PCR 
products: pFastBac™1 alone, ~300 bp; Bacmid transposed with pFastBac™1, ~2300 bp + size 
of genes of insert (770 bp for scFv-His6 and 840 bp for scFv-protamine-His6). The PCR 
products were also verified with three sequencing primers (M13 F, PPH F and SV40 pA R 
primers).    
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 When incorporation of genes of interest into the recombinant bacmids was 
established, the PCR products from the bacmid DNA were further analysed by restriction 
digestion to confirm release of the scFv-His6 and scFv-protamine-His6 expression 
cassettes and this was verified by agarose gel electrophoresis (Figure 41). A schematic 
illustration explaining the PCR amplification to confirm generation of the recombinant 
baculoviruses is shown in Figure 39, page 146.  
 
 
Figure 41: Restriction analysis of the PCR products amplified from the generated 
bacmids with M13 F and R primers to release the expression cassettes. The PCR products 
were restricted with HindIII and ApaI enzymes. Positive control is anti-hen egg lysozyme scFv-
IL10-V5-His6 in bacmid.   
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3.18. Propagation of recombinant baculoviruses in SF9 cells and recombinant 
protein expression in HighFive cells: 
The first step in the transfection procedure was to optimise the time course period for 
infecting the SF9 insect cells to propagate the baculoviruses (BV). To achieve this, SF9 
cells were infected with the BV for 3-day and 5-day intervals independently when the 
first propagated BV stock was prepared (P1 BV). The second and third baculovirus 
stocks were similarly prepared 3-days and 5-days after transfection (P2 and P3 BV 
respectively). The results revealed that the 3-day transfection approach does not 
generate enough BV to successfully infect SF9 cells in the next two stages (P2 and P3) 
of BV propagation. Therefore, SF9 insect cells were routinely infected with the BV at 
each stage for 5 days and the P3 round of BV propagation used to infect the HighFive 
insect cells for expression of recombinant proteins. Different time points and titers of the 
P3 BV were used to optimise recombinant protein production in the HighFive insect 
cells. Although intracellular expression of the proteins was confirmed in the time course 
and titration experiments (Figures 42 and 43) but secretion of the proteins was 
inconclusive. 
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Figure 42: Expression of recombinant scFv-His6 and scFv-protamine-His6 proteins. 
Expression of recombinant proteins was studied by Western blotting using HRP-conjugated anti-
His mAb. The figure shows a Western blot membrane for the result of studying the effect of 
different incubation times for infecting the insect cells with the baculovirus on the generation of 
recombinant proteins in the HighFive insect cells. Positive control included in the experiment 
was mIFNβ-MMP-1-11E scFv-His6. 1-11E scFv is recombinant protein with specificity for human 
modified collagen type II.  
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Figure 43: Western blot analysis showing the effect of P3 baculovirus levels on 
recombinant protein expression. The Western blot membrane depicts the level of scFv-His6 
and scFv-protamine-His6 proteins at day 4 post-infection in the HighFive cells pellet. Positive 
control protein is mIFNβ-MMP-1-11E scFv-His6. 4-12% gradient pre-cast gel under non-
reducing conditions. 
 
 
 Once the optimal time for BV stock generation and infection were determined, 
the next step was to determine whether the recombinant proteins are secreted or 
retained inside the insect cells. To test this, culture supernatants and pelleted cells 
obtained after harvesting the HighFive insect cells were analysed. The culture 
supernatant was concentrated 20 times through a specialised Immobilized Metal Affinity 
Chromatography (IMAC) purification device by centrifugation. Results from this 
experiment showed that the recombinant proteins are retained inside the cells and not 
secreted (Figure 44). 
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Figure 44: Western blot analysis for recombinant proteins scFv-His6 and scFv-protamine-
His6 production in HighFive insect cells. The presence of recombinant proteins inside cells 
and in culture supernatants was analysed 3 days post-transfection. The HighFive insect cell 
supernatants were concentrated using an IMAC purification device. About 20 mL of the culture 
supernatants were concentrated to 1 mL through 10 kDa cut-off molecular weight spin column 
(Vivapure Metal Chelate Maxi spin columns). The concentrated sample was then analysed by 
Western blotting. Precipitates formed inside the column after concentration of protein samples 
were also analysed alongside the cell lysates and supernatants (right). 4-12% gradient pre-cast 
gel under reducing conditions. Western blot was exposed for 30 seconds. 
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3.19. Purification of recombinant proteins under native conditions: 
Since the recombinant proteins were not secreted, protocols were designed to isolate 
the proteins from the HighFive cell lyastes. For this purpose, the Insect Cell Protein 
Extraction Reagent (I-PER®; Thermo Fisher Scientific) was used. This reagent contains 
a proprietary non-ionic detergent in 130 mM NaCl and 25 mM Tris-HCl; pH 7.5 and a 
microbial growth inhibitor (the exact composition of this extraction reagent was not 
provided by the manufacturer). According to the manufacturer, the I-PER® buffer is a 
non-denaturing reagent that retains the protein in native form. Cells were then lysed with 
the buffer and the expressed proteins were detected in the lysates (Figure 45).  
 
 
Figure 45: Comparative analysis of the recombinant proteins extracted using I-PER® lysis 
buffer or 10% SDS (Laemmli buffer). 10% gel was run under reducing conditions. The 
Western blot was revealed with HRP-conjugated anti-His(C-term) mAb were exposed for 1 
minute. 
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The I-PER® lysates obtained from insect cells were then clarified by 
centrifugation and applied to nickel affinity columns prepared for purification under 
native conditions. The results showed that the proteins were not able to bind to nickel 
beads in the column and, hence, not obtained upon elution (Figure 46).  
 
 
Figure 46: Detection of recombinant proteins scFv-His6 and scFv-protamine-His6 affinity 
purified under native conditions. Western blotting analysis of scFv-His6 (left) and scFv-
protamine-His6 (right) proteins obtained from HighFive insect cell lysates using the I-PER® 
followed by protein purification using nickel columns. The salt concentration of the lysates was 
adjusted from 130 mM NaCl to 300 mM NaCl by adding an appropriate volume of 5 M NaCl for 
optimal purification using immobilized nickel-chelated resin. Samples were reduced and run on 
4-12% pre-cast SDS gels. Western blots were detected with anti-His mAb. The film was 
exposed for 5 minutes.  
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3.20. Assessment of HRP-conjugated anti-His mAbs for optimisation of the 
Western blotting protocol: 
One major obstacle to the identification of the recombinant proteins was a high 
background obtained with the Qiagen HRP-conjugated anti-His mAb. In order to reduce 
the background staining with the chemiluminescence reagents, different blocking buffers 
were assessed including 3% [w/v] BSA in TBS buffer and 1% [w/v] alkali-soluble casein 
in TBS. However, these blocking buffers did not reduce background nor improved the 
detection. Therefore, a different detection Ab for His-tag was tried in the Western blotting 
experiments. The results revealed that HRP-conjugated anti-His(C-term) mAb from 
Invitrogen improved detection of the recombinant protein (Figure 47). 
 
Figure 47: Optimisation of Western blotting for the detection of recombinant scFv-His6 
and scFv-protamine-His6 proteins. The figure shows the analysis of recombinant protein 
expression using the new HRP-conjugated anti-His (C-term) mAb. All HighFive insect cell 
lysates were prepared by incubation with Laemmli buffer (10% SDS) for 5 minutes at 95°C. The 
positive control protein is mIFNβ-MMP-1-11E scFv-His6. The negative control is HighFive insect 
cell lysate which was used to exclude detection of any endogenous histidine-containing protein 
that could be present in cells and thereby interfere with the detection system. The presence of 
recombinant proteins was revealed with the HRP-conjugated anti-His (C-term) mAb (Invitrogen) 
and the film exposed for 1 minute. 
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3.21. Comparative assessment of different insect cells for the expression of 
recombinant scFv-His6 and scFv-protamine-His6 proteins: 
The SF9 cell line is highly susceptible to infection with AcMNPV baculovirus and can be 
used with all baculovirus expression vectors. The SF9 cell line was used to isolate and 
propagate recombinant baculoviral stocks. Because the whole transfection procedure 
takes 18-days, which is a lengthy process, a question has arisen to whether or not the 
SF9 cells could possibly express and secrete the recombinant proteins. To investigate 
the possibility that SF9 insect cells can produce recombinant proteins in secretable 
forms, which would render the protocol less time-consuming, culture supernatants and 
lysates of infected SF9 cells were analysed by Western blotting. The results revealed 
that although the SF9 cells propagated the baculovirus, it was not ideal for the 
expression and secretion of the recombinant proteins of interest (Figure 48). 
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Figure 48: Comparative analysis of HighFive and SF9 insect cells for recombinant scFv-
His6 and scFv-protamine-His6 protein production. Supernatants and cell lysates were 
analysed for recombinant proteins production on a 10% pre-cast gel under reducing conditions. 
Cell lysates were prepared by incubation with the Laemmli buffer (10% SDS). Recombinant 
proteins were detected with the HRP-conjugated anti-His(C-term) mAb and film exposed for 1 
minute.  
Chapter Three 
 
158 
 
3.22. cDNAs of scFv-His6 and scFv-protamine-His6 were cloned into pcDNA3 for 
expression in a mammalian system: 
Because the recombinant proteins were produced but not secreted by the insect cells, 
attempts were made to express the recombinant proteins in mammalian cells including 
HEK293T and CHO-S cells. Although genes of the baculovirus are expressed under the 
control of the polyhedrin gene promoter (polh), the baculoviral promoters that are 
generally used for insect cells are not active in mammalian cells. Thus, the polh 
promoter cannot drive expression of genes in mammalian cells (238, 239). Therefore, 
the pFastBacTM1 plasmid donor vector which encodes the scFv-His6 or scFv-protamine-
His6 could not be used for expression in mammalian cells. For this reason, scFv-His6 
and scFv-protamine-His6 cDNAs from the plasmid pFastBacTM1 were PCR amplified so 
they could be cloned into the pcDNA3 plasmid vector (Figure 49 top) which has the CMV 
promoter for expression in mammalian cells. The expression cassettes were cloned into 
pcDNA3 using the native signal sequence of the antibody for secretion from mammalian 
cells. A schematic illustration for the cloning strategy is shown in Figure 15, page 77. 
Positive clones from transformants were analysed by restriction digestion (Figure 49 
bottom) and sequencing.  
Full sequencing data showing the in-frame nucleotide sequences for the expression 
constructs is shown in Appendix 2, pages 345 and 346. The genetic maps with unique 
restriction sites of both constructs are shown in Appendix 3, pages 357 and 358 
respectively. 
 
 
Chapter Three 
 
159 
 
 
 
Figure 49: Cloning of scFv-His6 and scFv-protamine-His6 DNA into pcDNA3 for 
expression in mammalian cells. Restriction digestion of pcLuc+ and the pFastBacTM1 vectors 
with HindIII and ApaI enzymes to release the luciferase gene (Luc+) and scFv DNA  inserts, 
respectively (top left). PCR amplification of scFv-His6 and scFv-protamine-His6 DNAs to 
incorporate HindIII and ApaI restriction sites (top right). The amplified products were digested 
with the corresponding enzymes, extracted by gel purification and used for ligation with the 
linearised pcLuc+ plasmid. The ligation reactions were carried out at 4°C overnight and DH5α  E. 
coli transformed with the ligation reactions. Analysis of DNA minipreps by restriction digestion 
with HindIII and NdeI to check for the fidelity of the positive clones (bottom).  
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 For expression of the recombinant proteins, HEK293T and CHO-S cells were 
transfected with scFv-His6 and scFv-protamine-His6 in pcDNA3 vector and three days 
post-transfection culture supernatants and cell lysates were analysed by Western 
blotting. Analysis of supernatants and lysates showed no protein production (results are 
not shown). The vectors were re-sequenced and checked for stop codons and the 
transfection experiments repeated three times for each cell system. 
 
3.23. Cloning of cDNAs of scFv-His6 and scFv-protamine-His6 into pHEN1 
phagemid for expression in bacteria: 
The cloning strategy involved PCR amplification of the scFv-His6 and the scFv-
protamine-His6 DNA expression cassettes with primers that enable cloning into the MCS 
of pHEN1 plasmid. The DNAs were cloned in-frame downstream of the pectate lyase B 
(pelB) signal sequence of the Gram-negative bacterium Erwinia carotovora in the 
pHEN1 vector. The PCR products of scFv-His6 and scFv-protamine-His6 and the vector 
were digested with NcoI and NotI enzymes (Figure 50). A schematic illustration for the 
cloning strategy is shown in Figure 16, page 79. Transformants that were positive clones 
(Figure 51) were further analysed by restriction digestion and sequencing.    
Full sequencing data showing the in-frame nucleotide sequences for the anti-CD22.2 
scFv-His6 pHEN1 expression construct is shown in Appendix 2, page 347. The genetic 
map of the construct with unique restriction sites is shown in Appendix 3, pages 359. 
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Figure 50: Cloning of scFv-His6 and scFv-protamine-His6 DNA into pHEN1 plasmid. PCR 
amplification of scFv-His6 and scFv-protamine-His6 DNAs to incorporate NcoI and NotI 
restriction sites (left). The amplified products were digested with NcoI and NotI enzymes, 
extracted by gel purification and used in the ligation reaction with the vector backbone. 
Restriction digestion of pHEN1 plasmid with NcoI and NotI restriction enzymes to prepare the 
vector for cloning (right). 
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Figure 51: Restriction digestion analysis of plasmid DNA minipreps to determine positive 
clones. Positive clones were sequenced with LMB3 forward (5’CAGGAAACAGCTATGAC3’) 
and pHEN1 reverse primers. 
 
After induction with IPTG, expression of the recombinant proteins in the HB2151 
E. coli culture was assessed by testing the bacterial culture supernatants, periplasmic 
extracts and the cell pellet by Western blotting. Results from the analysis showed that 
scFv-protamine-His6 was not produced (data not shown) while only the scFv-His6 was 
produced but not secreted to the periplasmic space which indicated inclusion body 
formation with insoluble proteins (Figure 52).  
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Figure 52: Western blotting analysis for the production of scFv-His6 recombinant protein 
in HB2151 strain of Escherichia coli. Supernatant, periplasmic extract and lysates of inclusion 
bodies isolated from bacterial cells were analysed on Western blotting for the production and 
secretion of the recombinant protein. Proteins were detected with HRP-conjugated anti-His(C-
term) mAb.  
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3.24. Cloning of scFv-His6 and scFv-protamine-His6 at the C-terminus of human 
LAP with HRV3C protease cleavage site for expression in a mammalian system: 
Because secretable proteins were not obtained from the eukaryotic insect cells and 
bacteria, a different expression system was assessed. This involved the use of latency 
associated peptide (LAP) of TGFβ protein to shield the recombinant proteins while they 
make their way through cellular secretory pathways. This assumption was partly based 
on the fact that there is a possibility for electrostatic interactions between the positive 
charges of protamine peptide and cell membrane though the scFv per se without 
protamine was also not secreted. Another reason for using LAP protein was to assess 
the human LAP signal peptide because the LAP of TGFβ is a secreted protein. 
 
For this purpose, the constructs were PCR-amplified with specific primers to incorporate 
the human rhinovirus type 14 3C (HRV3C) cleavage site. HRV3C cleavage site has a 
recognition sequence Leu-Glu-Val-Leu-Phe-Gln-↓-Gly-Pro that can be cleaved with 
HRV3C protease. This was to help cleave the recombinant proteins for separation of the 
scFv proteins from the LAP shell. The human LAP with pcDNA3 vector backbone was 
prepared for cloning. Ligation reactions were then set up between the PCR-amplified 
products and the vector backbone (Figure 53) and the resulting transformants were 
further analysed for the validity of the constructs (Figure 54). Sequencing data is shown 
in Appendix 2, pages 348 and 349. The genetic maps are shown in Appendix 3, pages 
360 and 361.  
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Figure 53: Cloning of scFv-His6 and scFv-protamine-His6 DNA at the C-terminal region of 
human LAP with the HRV3C cleavage site. Restriction digestion of hLAP-MMP-TGFβ in 
pcDNA3 with BamHI and XbaI enzymes to remove MMP-TGFβ DNA fragment (top). PCR 
amplification of scFv-His6 and scFv-protamine-His6 DNAs to incorporate the HRV3C cleavage 
site (bottom). 
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Figure 54: Restriction analysis of plasmid DNA minipreps with EcoRI and SbfI to confirm 
fidelity of positive clones. Positive clones from restriction analysis of hLAP-HRV3C-scFv-His6 
(top) and hLAP-HRV3C-scFv-protamine-His6 (bottom) were further analysed by sequencing with 
F-LAP forward and BGH reverse primers. 
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3. 25. Analysis of recombinant LAP proteins expression in mammalian cells: 
CHO-S cells were transiently transfected with the expression constructs using PEI. An 
aliquot of supernatant was harvested at three different time points of the culture. The 
culture supernatants and clarified cell lysates were analysed by Western blotting. For 
detection of LAP-engineered proteins, goat anti-LAP antibody (goat IgG polyclonal 
antibody to human LAP TGFβ1 at 1:1000 (0.1 μg/μL) in blocking buffer) and HRP-
conjugated secondary antibody (mouse anti-goat at 1:1000 in blocking buffer) were used 
to detect the proteins. The results showed endogenous LAP of TGFβ was produced and 
secreted by CHO-S cells and the positive control (hLAP-agg-IFNβ) but not the LAP-
HRV3C-scFv-His6 or LAP-HRV3C-scFv-protamine-His6 constructs (Figure 55). The 
same samples were analysed by Western blotting with HRP-conjugated anti-His(C-term) 
mAb but the proteins were not detectable (data not shown). 
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Figure 55: Expression of recombinant proteins cloned at the C-terminal region of LAP 
protein. CHO-S cells were transfected with the expression vectors using PEI. The positive 
control for the expression system is hLAP-agg-IFNβ. Aliquots of culture supernatants were 
collected at different time points (days 3, 5 and 6) to test for the peak of protein expression. 
Polyclonal goat IgG anti-human LAP antibody was used to probe the proteins using HRP-
conjugated secondary mouse anti-goat IgG Ab. Expected Mw t. of recombinant proteins were 
131.65 kDa for hLAP-HRV3C-scFv-His6 and 138.68 kDa for hLAP-HRV3C-scFv-protamine-
His6. The positive control is hLAP-aggrecan-IFNβ in pcDNA3. SDS gel was run under non-
reducing conditions to see monomer and dimer formation. Recombinant proteins were not 
detectable with HRP-conjugated anti-His(C-term) mAb for the same samples.   
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3.26. Cloning of anti-CD22.2 scFv-protamine-His6 into pDisplay vector with murine 
Ig kappa chain signal peptide for expression in a mammalian system: 
Proteins expressed from pDisplay™ vector are fused at the N-terminus to the murine Ig 
kappa chain signal sequence, which is a well-known signal peptide that directs proteins 
to the extracellular space. The ability of Ig kappa chain signal peptide to impel secretion 
of the recombinant protein was tested following from the expression of the anti-human 
CD22.2 scFv-protamine-His6 protein (reasoning and outcome of this approach will be 
discussed in detail in chapter 4). To achieve this, the anti-CD22.2 scFv-protamine-His6 
was cloned into pDisplay vector to investigate whether, or not, the choice of a different 
signal peptide can result in the secretion of the recombinant proteins. 
 
The construct (Appendix 3, page 362) was successfully generated by inserting 
the PCR-amplified product of scFv-protamine-His6 into pDisplay vector (Figure 56) and 
confirmation of the validity of the construct by restriction analysis (Figure 57) and 
sequencing (Appendix 2, page 350).    
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Figure 56: Cloning of scFv-protamine-His6 DNA into pDisplay vector. scFv-protamine-His6 
DNA was amplified by PCR to incorporate SfiI and SacII sites, followed by digestion and gel 
extraction. pDisplay vector was digested with SfiI and SacII enzymes and after gel purification it 
was ligated with the processed PCR product.  
 
 
 
Figure 57: Restriction digestion analysis of plasmid DNA minipreps. All plasmid DNA 
minipreps were digested with BamHI and either SbfI or MfeI enzymes. Positive clones were 
determined and sequenced with T7 forward and pMH R-113 reverse primers. 
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To investigate the impact of murine Ig kappa chain signal peptide on secretion of 
the recombinant protein, CHO-S, HEK293T and HEK293F cells were transiently 
transfected with plasmids from the positive clones. Results from Western blotting 
showed no secretion of the protein (data not shown).    
 
 
3.27. Purification of recombinant proteins under denaturing conditions: 
Having established that the recombinant proteins were not secreted using a mammalian 
cell system after trying different approaches, attempts were made to purify the 
recombinant proteins from the cell lysates of transfected HighFive insect cells under 
denaturing conditions using 6 M guanidinium lysis buffer. For small-scale purification, 
about 800 μL of clarified cell lysates were mixed with 200 μL of nickel agarose 
resuspended in denaturing binding buffer. At the time of lysing the cells on ice, a cocktail 
of six protease inhibitors with broad specificity for aspartic, cysteine, and serine 
proteases as well as aminopeptidases (1:200) was added to the cells. After preparation 
of the nickel affinity chromatography columns under denaturing conditions, most of the 
recombinant proteins that passed over the nickel column did not bind and were detected 
in the flow-through. There was also some degradation, or low molecular weight fragment 
generation, from the scFv-protamine-His6 flow through (Figure 58). Because of 
formation of precipitates and crystals in the 6 M guanidinium lysis buffer at 4°C, it was 
not possible to perform the protein purification at 4°C. This may partly explain the low 
molecular weight fragments detected in the Western blotting. A cocktail of EDTA-free 
protease inhibitors was, therefore, used during cell lysis to prevent degradation by 
proteolytic enzymes liberated during cell lysis.  
 
 
 
 
 
 
 
 
Chapter Three 
 
172 
 
 
 
Figure 58: Western blotting analysis of recombinant proteins purified under denaturing 
conditions. HighFive insect cells were lysed on ice using 6 M guanidinium HCl for 15 minutes. 
Clarified lysates containing the recombinant proteins were added to the nickel column. Sample 
load, unbound flow-through, washes and elution fractions were collected and analysed on a 10% 
pre-cast gel under reducing conditions, transferred onto PVDF membrane and protein bands 
detected with HRP-conjugated anti-His(C-term) mAb.  
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3.28. Assessment of HRP-conjugated Staphylococcal protein A for the detection 
of recombinant proteins: 
Staphylococcal protein A (SpA), a 56 kDa cell wall protein from Staphylococcus aureus, 
which interacts with the Fc region of most immunoglobulins and also the Fab fragments 
of a proportion of serum immunoglobulins that are encoded by the human VH3 family of 
genes. The binding of SpA to the VH regions is restricted to antibodies encoded by a 
subset of the VH3 family (V3-23 and related genes in humans) and the S107 and J606 
families in mice (240). Interaction of HRP-conjugated SpA with the expressed 
recombinant proteins was assessed to see if this reagent could be used both for 
detection and purification. For this purpose, the HRP-conjugated SpA was assessed for 
binding to the recombinant proteins by Western blotting. The experiments showed that 
the SpA-HRP did not bind to the recombinant proteins (data not shown). 
 
3.29. Improvements in the purification of recombinant proteins: 
Several attempts were made to purify the recombinant proteins under native and 
denaturing conditions. However, all were ineffective. Although the recombinant proteins 
were extracted with I-PER®, they did not bind to nickel columns under native conditions. 
Therefore, an alternative approach used was to denature the recombinant proteins and 
attempt binding them to the nickel column under denaturing conditions. The results from 
the latter approach showed that most of the protein did not bind as it was collected in the 
flow-through fraction. In order to address these problems and implement modifications 
that could increase binding of the denatured recombinant proteins to the nickel affinity 
column, a number of possibilities were considered. One approach was to add 50 mM L-
arginine, or L-glutamine to all the buffers to improve purification. Thus, 50 mM L-
glutamine was added to all the buffers used for purification under denaturing conditions. 
This enhanced binding of the recombinant proteins to the nickel column when the 
binding was carried out for 90 minutes at room temperature. After binding, washing and 
elution, the samples were analysed by Western blotting and a great improvement was 
noted (Figure 59). 
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Figure 59: L-glutamine (Glu) improves purification of recombinant proteins using nickel 
affinity chromatography. Western blotting analysis of recombinant proteins expressed in 
HighFive insect cells following the addition of 50 mM L-glutamine to all buffers used in the 
purification of recombinant proteins. HighFive cells were lysed with 6 M guanidinium lysis buffer 
and clarified lysates purified using nickel-affinity chromatography under denaturing conditions. 
Addition of 50 mM L-glutamine to the binding, wash and elution buffers significantly improved 
binding and elution of the proteins. Unbound flow-through, washes and elution fractions were 
analysed on a 10% pre-cast SDS PAGE gel and transferred to PVDF membrane and probed 
with HRP-conjugated anti-His(C-term) mAb. 
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 Having optimised the system for recombinant protein purification under 
denaturing conditions with the addition of 50 mM L-glutamine, the eluted protein 
fractions were dialysed to remove the urea and then further purified. For this purpose, 
ion exchange chromatography was used. The average isoelectric points [PI] were 7.268 
and 9.665 for scFv-His6 and scFv-protamine-His6 proteins, respectively. Based on this, 
the Q Sepharose™ Fast Flow HiTrap™ anion exchanger column was used for scFv-
His6 protein and an SP Sepharose™ Fast Flow HiTrap™ cation exchange column was 
used for scFv-protamine-His6 protein. After performing the purification at 4°C using 
FPLC, the elution fractions were analysed by Western blotting but the proteins were not 
detectable (data not shown). At this stage, more intracellularly trapped proteins were 
produced by insect cell transfection. These proteins were hereafter only purified through 
nickel affinity chromatography under the optimal conditions. The proteins were refolded 
and analysed by silver staining of SDS PAGE gels and Western blotting (Figure 60) and 
then tested for binding to CD22.2 receptor on BCL1-3B3 B cells. 
 
3.30. Assessment of the refolded recombinant proteins by flow cytometry for 
binding to CD22.2 on mouse B cells: 
Flow cytometry was carried out to verify binding of the recombinant proteins to CD22.2 
on BCL1-3B3 B cells. Total protein concentration of the refolded protein was 
determined, scFv-His6 (330 μg/mL) and scFv-protamine-His6 (600 μg/mL). From each, 
about 100 μg/mL of protein was used for staining of 1 x 106 cells/mL. A dilution of 1:500 
of anti-6X His tag® DyLight®650 antibody was used as a secondary detection antibody. 
Results of the FACS data showed no binding of the recombinant proteins to BCL1-3B3 
B cells (Figure 61).    
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Figure 60: Analysis of refolded recombinant proteins by silver staining and Western 
blotting. The protein yields resulting from nickel affinity and cation exchange chromatography 
are not yet suitable for labeling with fluorescent dyes. Therefore, proteins were tested, indirectly 
using anti-6X His tag® DyLight®650 antibody, for binding to CD22.2 receptor on BCL1-3B3 B 
cells. 
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Figure 61: FACS analysis to assess binding of refolded recombinant proteins to the 
CD22.2 receptor on mouse BCL1-3B3 B cells. (A) Forward and side scatter of unstained B 
cells. The cells show high background staining from non-specific binding of the anti-6X His tag® 
DyLight®650 antibody (B). In (C) and (D), binding of scFv-His6 and scFv-protamine-His are 
tested respectively after staining with the secondary antibody. In (E) the histogram profile of 
binding is compared. 
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3.31. Discussion: 
B cell targeted therapies have broad-spectrum applications for many diseases. This 
study describes a new approach for targeting pathogenic B cells in disease, including 
malignant B cells in leukaemias and lymphomas.  
  
CD22 is a constitutively expressed receptor that is endocytosed and recycled and 
can be used to shuttle cargo between the cell surface and the endosomal compartments 
of B cells (93). CD22 is of considerable interest as a therapeutic target for B cell directed 
therapies. Its expression is restricted to the B cell lineage with nearly all mature B cells 
expressing membrane CD22, with the exception of plasma cells. To treat CD22+ B cell 
leukaemias/lymphomas, several approaches including using anti-CD22 antibodies 
alone, or in conjugated forms, as well as combination immunotherapies have been 
developed (82, 89 and 90). 
 
A promising treatment approach for B cell malignancies includes the use of new 
combinatorial therapies including biological agents such as mAbs and 
chemotherapeutics. For example, CMC-544, now called inotuzumab ozogamicin, a 
potent immunoconjugate of the chemotherapeutic agent calicheamicin combined with a 
humanised IgG4 anti-CD22 mAb (G5/44), has shown potent cytotoxicity against CD22+ 
B cell lymphoma in cell lines and preclinical models (241). Recently, inotuzumab 
ozogamicin was assessed and shown significant activity in adults and paediatric patients 
with relapsed and refractory B cell acute lymphoblastic leukaemia (ALL) (242). However, 
toxicities from the chemotherapeutic drugs limit their potential applications. Therefore, 
there is an urgent need for the development of new therapeutics.  
  
Over the past several years, generations of recombinant fusion proteins, including 
anti-CD22 scFv immunotoxin conjugates BL22 and HA22 were assessed in clinical trials 
for the treatment of CD22+ B cell malignancies and proved to be effective with reduced 
toxicities (230).  
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The approach explored in this study is based on using scFv of mAbs with 
specificity for CD22 to deliver siRNA to modulate the biology and fate of malignant B 
lymphocytes. The potential of this approach was demonstrated by using purified anti-
CD22 mAb and testing the kinetics of its binding to membrane CD22 and internalisation 
by B cells. For this purpose, the mouse mAb anti-CD22.2, specific for the CD22.2 allele, 
purified from the Cy34.1.2 hybridoma was examined. When the kinetics of internalisation 
was studied by CLSM using the AlexaFluor®488-conjugated anti-CD22.2 mAb, the 
surface-bound antibody/receptor complex on B cells was shown to traffic to the 
intracellular compartments soon after incubation of the cells at 37°C for 15 minutes. 
Most of the receptor-bound antibody was clustered inside the cytoplasm and more of the 
complex was located intracellularly after 60 minutes at 37°C. Slicing through various cell 
planes using Z-stacking in confocal microscopy confirmed the intracellular localisation of 
the receptor-antibody complex. Binding and internalisation, thus, confirmed the 
foundation and suitability of this approach. Several investigators have shown binding 
and internalisation of anti-CD22 mAb and constitutive endocytosis of CD22 receptor (83-
94). Similarly, the current experiments have shown that binding of anti-CD22.2 mAb 
AlexaFluor®488 to CD22 resulted in internalisation after about 15 minutes of incubation 
with BCL1-3B3 B cells at 37°C which is consistent with the kinetics of internalisation (t1/2) 
reported to be about < 1 hour from the cell surface (82).  
  
In order to engineer the anti-CD22.2 scFv fusion protein with the truncated 
protamine domain and hexahistidine purification tag, the cDNAs for the VH and the VL 
genes were first generated and then a poly-G tail nucleotides sequence was added onto 
the 5’UTR sequence of the VH and VL cDNA using the TdT. TdT polymerase, belongs to 
the nucleotidyltransferase superfamily, catalyses repetitive addition of mononucleotides 
from dNTPs to the terminal 3´-OH of a DNA initiator in an untemplated fashion (243, 
244). The VH and VL genes were then amplified using nested PCR amplification. A 
similar approach to PCR-amplify VH and VL genes of C2 hybridoma cells was used and 
shown in a previous study (245). The VH and VL poly-G tailed cDNA PCR products were 
then used in TA cloning. The viability of TA cloning has been shown previously in 
several studies to quickly clone a given gene in order to obtain sequence information or 
to simply amplify enough DNA for traditional cloning methods (246-249). Based on 
Chapter Three 
 
180 
 
alignments with related germ-line nucleotide sequences in the IgBLAST search, the VH 
and VL genes families for the mouse anti-CD22.2 IgG1 mAb were determined. To 
establish an expression system for scFvs that would allow easy cloning of the VH and VL 
domains and production of large amounts of correctly processed and secreted scFvs, 
baculoviruses were used to transfect insect cells. The baculovirus expression vector 
system exhibits many advantages including high expression level (250), capacity for 
large DNA fragment insertions (251) and proper protein refolding, disulfide bond 
formation and post-translational modifications (252). For this purpose, the constructs 
were generated in a donor plasmid vector (pFastBacTM1) which was then transferred to 
baculovirus genome by site-specific transposition.  
  
The baculovirus Autographa californica multinucleocapsid NPV (AcMNPV), which 
was used in the current study, has a genome of 134 kb. Thus, recombinant baculovirus 
particles can accommodate large amounts of foreign DNA (253).  
  
The strategy for efficient generation of recombinant baculoviruses is based on 
site-specific transposition in DH10BacTM E. coli which contains the baculovirus shuttle 
vector (bacmid). Bacmid DNA contains a mini-F replicon, which allows autonomous 
replication and stable segregation of plasmids at low copy number, a selectable 
Kanamycin resistance marker and attTn7, the target site for the bacterial transposon 
Tn7, all inserted into the polyhedrin (polh) locus of AcMNPV. The mini-Tn7 element on 
the donor plasmid pFastBacTM1, contains the gene of interest, transposes to the target 
plasmid (bacmid) in DH10BacTM E. coli when Tn7 transposition function by the 
transposase is provided by a helper plasmid in the DH10Bac. The foreign gene is then 
expressed under the control of the baculovirus promoter polh when the resulting 
composite bacmid is introduced into insect cells (254, 255). In this case, the 
recombinant bacmid was engineered to carry the scFv-His6 or scFv-protamine-His6 
constructs. 
 
The ability to process and perform posttranslational modifications on secreted 
proteins is a major strength of the baculovirus expression vector system which has 
contributed to its increased use (250-252). However, yields of secreted proteins by 
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insect cells may suffer due to incomplete processing and aggregation (256-259). 
Intracellular retention of the recombinant anti-CD22.2 scFv-His6 and scFv-protamine-
His6 proteins was an indication of difficulty with secretion of the protein. In support of the 
speculation of retention of the recombinant proteins, investigators have shown that in 
addition to mature length polypeptides, protein precursor polypeptides have been 
observed to accumulate in insect cells as well (260). In another study, a significant 
fraction of immunoglobulin light chain (Cκ) expressed in insect cells was also observed 
to accumulate as aggregates at a higher molecular weight than the processed 
polypeptide chains. These preprocessed immunoglobulin polypeptides are believed to 
include the unprocessed signal peptide sequence (261). 
 
Signal peptides, needed to direct proteins to the various cellular compartments, 
must be cleaved to obtain a functional protein. Upon membrane translocation, the signal 
peptide is removed by a signal peptidase complex that is membrane-bound to the 
endoplasmic reticulum in eukaryotic cells or bound to the cellular membrane in 
prokaryotic cells (262).  
 
The function of the signal peptide in the secretion process is to direct the newly 
synthesised polypeptide into the translocation machinery of the cellular membrane 
(263). Without removal of the signal peptide the protein may aggregate and remain 
within incorrect compartments such as endoplasmic reticulum and be prevented from 
further passage along the secretion pathway (264, 265). Consequently, the yields of 
secreted proteins can be drastically reduced. A previous study has shown that signal 
peptidase overexpression resulted in increase of the processing of antibody scFv 
fragments. Such results demonstrate that low signal peptidase activity can limit the 
production of recombinant proteins (265).  
 
In a strategy to enhance recombinant protein secretion, a number of investigators 
used a novel secretion signal from bacterial endotoxin (proprietary sequence). This 
signal, engineered on constructs intended for the production of recombinant proteins in 
prokaryotes and eukaryotes, allowed the secretion of recombinant protein in all cases 
(266). 
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Previous studies have shown that DNA inserts cloned in-frame with the gp64 
signal sequence can produce target proteins that may be secreted from the recombinant 
baculovirus-infected insect cells (267). In this regard, efforts were invested in the current 
study to swap the native signal sequence of the anti-CD22.2 scFv with the baculovirus 
gp64 signal sequence for enhanced expression and secretion of the recombinant 
proteins from insect cells. Therefore, the pBACTM-6 transfer plasmid (Merck Chemicals 
Ltd, Nottingham, UK) was first used to clone the anti-CD22.2 scFv-His6 and scFv-
protamine-His6 cDNA expression cassettes. Then, these transfer plasmids were used 
for recombination by site-specific transposition to baculovirus genome (bacmid). 
pBACTM-6 is a baculovirus transfer plasmid that contains a 20 amino acid gp64 signal 
peptide sequence capable of directing high levels of proteins into the secretory pathway 
of infected insect cells. However, this cloning process was not pursued further because 
of obtaining the anti-human CD22 scFvs BL22 and HA22 from the National Cancer 
Institute. Henceforth, the new expression construct was made from anti-human CD22 
(HA22) which is described in detail in chapter four. Nevertheless attempts were made to 
purify the mouse recombinant proteins produced by insect cells under both native and 
denaturing conditions although these proteins were retained intracellularly. 
 
The findings reported in this chapter are in agreement with a previous study to 
produce anti-HER2 scFv-protamine in insect cells using baculovirus expression system 
(120). These investigators encountered difficulties to express and secrete recombinant 
protein. Additionally, they showed that the scFv fusion proteins could only be extracted 
from cell pellets by using strong denaturants such as 6 M guanidinium HCl. Further to 
the low protein yield they obtained, an extensive refolding process was required to 
recover binding activity of the scFv-protamine protein (120). 
 
Various expression systems were used in the current study for the production of 
the recombinant proteins, including insect, mammalian and bacterial cells.  
 
One possible explanation for lack of recombinant protein secretion from 
mammalian cells is an increase in the level of phosphorylation of eukaryotic translation 
initiation factor 2 (eIF2), which can inhibit polypeptide chain initiation completely. This 
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proposition is based on findings from previous studies which attempted to produce 
recombinant proteins in mammalian systems. According to these studies, a major 
mechanism that limits translational rates in vivo and in vitro is phosphorylation of eIF2 on 
the α-subunit at Ser51 (eIF2α) (268). During translation initiation, eIF2, guanosine 
triphosphate (GTP) and methionyl initiator transfer RNA (Met-tRNAiMet) form a ternary 
complex that interacts with the 40S ribosomal subunit and the translation initiation 
complex (269). When the anti-codon of the Met-tRNAiMet in the ternary complex base 
pairs with the mRNA initiation codon, this triggers hydrolysis of the GTP and release of 
eIF2 in the guanosine diphosphate (GDP)-bound form. Release of GDP from eIF2 and 
regeneration of eIF2-GTP is facilitated by the guanine nucleotide exchange factor 
eIF2B. Phosphorylation of the α-subunit of eIF2 increases its affinity for GDP by 100-fold 
so that eIF2B cannot catalyse nucleotide exchange and remains bound to eIF2-GDP. 
Because the eIF2B is usually 10 times less abundant than eIF2, small increases in the 
level of eIF2α phosphorylation can completely inhibit polypeptide chain initiation 
because eIF2B becomes sequestered in an inactive form, which prevents eIF2 recycling 
(270). Furthermore, efficient in vitro protein synthesis in cell-free systems has been 
limited by phosphorylation of eIF2α factor (270). This phosphorylation has been 
explained by the activation of the eIF2α kinases in the cell-free systems. In an attempt to 
overcome this limitation, investigators have shown that protein synthesis in a hybridoma 
extract was increased by 3-4 folds after addition of growth arrest and DNA damage 
inducible protein (GADD34), which stimulated eIF2α dephosphorylation (270). Similar 
results were obtained by supplementation of cell extracts with the vaccinia virus K3L 
protein, which can also be phosphorylated by the eIF2 kinases due to its structural 
resemblance to eIF2α (271, 272). In addition, it has been shown that the mRNA 5′-m7G-
cap structure and 3′-poly(A) tail act synergistically to stimulate translation in vivo (273).  
 
An alternative approach for the production of recombinant proteins would be the 
use of in vitro cell-free translation systems. Cell-free translation systems are increasingly 
used for the production of recombinant proteins that are either toxic, or difficult to 
produce in high yields in mammalian cells (274, 275). However, many mammalian cell-
free systems have limited yield or do not reproduce the properties of translation in vivo. 
Thus, the cell-free system cannot perform these post-translational modifications. 
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Until writing this thesis, extensive efforts were made to express the recombinant 
proteins from mammalian cells backed up with auxiliary range of additional approaches. 
Hypothetically, it may be possible that electrostatic interactions of amino acid side 
chains on the protamine peptide to hamper secretion of the protein through the 
secretory pathway. It is a well-known fact that eukaryotic cell membranes from the 
cytoplasmic side usually confer a net negative charge because of the abundance of 
anionic phospholipid phosphatidylserine. This will facilitate trapping of the recombinant 
proteins due to the fact that protamines have a high content of positively charged amino 
acids, particularly arginine (276). The positive charge of the protamine peptide could, 
therefore, be a hurdle for the secretion, or exportation of the recombinant protein.  
 
Because of similarities in the amino acid sequences between the truncated 
protamine peptide (RSQSRSRYYRQRQRSRRRRRR) and human immunodeficiency 
virus 1 (HIV-1) trans-activator of transcription protein transduction domain (TAT-PTD) 
peptide (YGRKKRRQRRR), there is a possibility of difficulty in secretion of the 
recombinant proteins rich in cationic amino acids. There are suggestions from previous 
studies addressing problems with secretion of TAT-fusion proteins. In a study that 
compared different TAT-fusion proteins (TAT-EGFP, TAT-srIκBα, TAT-RBD), the major 
fraction of fusion proteins was found in the cell lysate, and only a small amount of the 
fusion proteins was present in the supernatant (277). In another study, several variants 
of HIV1-TAT-PTD with different numbers of cationic amino acids, secretion levels 
decreased with an increase in cationic charge (278). Similar to HIV1-TAT-PTD, 
protamine is cationic in nature. 
 
Because of the possibility of entrapment of anti-CD22.2 scFv-protamine-His6 
recombinant protein within producing cells, a method was used to protect and shield the 
charges on the protein while making its way through the cellular secretory pathway. 
Although this approach could be questioned because the scFv-His6 was also not 
expressed in mammalian cells, nevertheless, both anti-CD22.2 scFv antibody fragments 
were cloned at the C-terminal region of the latency associated peptide (LAP) of TGFβ. 
The “LAP-cleavage site-cargo” protein technology, generated in our department (279), 
comprises the LAP shell of TGFβ engineered to harbor a therapeutic moiety that will be 
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released by proteolytic cleavage of a cleavable site between the cargo and the LAP. The 
technology provides latency to the delivery and specificity of the therapeutics to disease 
sites. By using LAP protein here it would then be possible to shield the positive charges 
of the protamine peptide on scFv-protamine-His6. An additional reason for using the 
LAP construct was to investigate whether or not the human LAP signal sequence could 
drive secretion. For this purpose, the constructs generated comprised human LAP 
followed by HRV3C cleavage site and C-terminus scFv-His6 or scFv-protsmine-His6. 
Human LAP signal sequence was retained in the vector backbone to drive expression 
and secretion of the proteins. Unexpectedly, however, the proteins were not produced 
when the supernatants and cell lysates were analysed by Western blotting. Only the 
positive control construct did allow production. In addition to the distinguishing 
characteristic of LAP in providing latency, it would have been advantageous also for 
purification process. LAP can bind heparin-agarose columns and this protein purification 
platform is well-established and optimised for purification of LAP-associated proteins. 
 
Further possible explanation for lack of scFv-protamine-His6 production/secretion 
could be attributed to the presence of a furin cleavage site. Furin is a mammalian 
endoprotease which recognises and cleaves the amino acid sequences RXRR or 
RXKR, where X can be any amino acid. It is mainly localised in the trans-Golgi network 
but can translocate between the trans-Golgi network and the cell surface (280). 
Therefore, the presence of these furin sites in protamine peptide would possibly result in 
protamine peptide being cleaved from fusion proteins that are secreted via the secretory 
pathway. In support to this hypothesis, a study has introduced mutations to destroy the 
furin cleavage sites without affecting TAT protein transduction ability. Using this system 
with the modified TAT, appropriate protein processing, correct folding and secretion of 
TAT fusion protein was achieved (281). 
 
Further investigation of the signal peptide was pursued in the present study by 
using the murine immunoglobulin kappa light chain secretory signal. This signal peptide 
is derived from the first 21 amino acids (METDTLLLWVLLLWVPGSTGDAA) of the 
secretory signal which has been described to drive good expression/secretion of 
recombinant proteins (282). In another study, investigators also showed that with the 
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murine Ig κ-chain secretory signal peptide, efficient secretion of recombinant human 
UDP-N-acetyl-α-D-galactosamine polypeptide N-acetylgalactosaminyl-transferase 2 
(GalNAc-T2) protein was achieved in insect SF9 and mammalian HEK293T cells (283). 
 
A mammalian expression vector, pDisplayTM, which contains the murine Ig kappa 
chain signal peptide was, therefore, used for cloning and production of anti-CD22.2 
scFv-protamine-His6 protein. Results from the transient transfection experiments using 
HEK293F and CHO-S cells showed no protein production using this approach. It is 
worth mentioning, however, that the use of pDisplayTM vector resulted in production and 
secretion of recombinant anti-human CD22 scFv-protamine-His6 protein (discussed in 
detail in chapter four). 
 
In view of the fact that previous studies (284, 285) have reported the successful 
expression of scFv molecules in prokaryotic expression systems, such as Escherichia 
coli (E. coli), the anti-CD22.2 scFv constructs were cloned into pHEN1 phagemid. Using 
pHEN1 plasmid, a bacterial expression vector used in phage display, expression and 
secretion of engineered proteins are known to be directed to periplasmic space under 
pelB signal peptide. The secretion of a recombinant protein to the bacterial periplasm or 
the extracellular medium is advantageous because secreted proteins are more easily 
accessible; less contaminated with cellular proteins and usually have authentic N-
termini. In addition, periplasmic or extracellular protein folding is improved and 
proteolysis is less extensive compared with cytoplasmic productions. The secretion 
capacity is, therefore, an important trait of viable production hosts. In the absence of an 
N-terminal signal peptide for periplasmic secretion, recombinant polypeptides expressed 
in bacteria accumulate in the cytoplasm. The fusion to suitable leader peptides allows 
for the translocation of unfolded precursors into the periplasm. The pelB signal 
sequence has proven to be successful in periplasmic production and precise processing 
of recombinant scFv antibodies and shown to direct recombinant proteins to the 
periplasmic space of the bacteria (284, 285). 
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Transformants obtained from cloning into pHEN1 plasmid were only positive for 
anti-CD22.2 scFv-His6 and production, but not secretion, of the recombinant protein in 
HB2151 E. coli cells was detected. Failure of pelB signal peptide to direct recombinant 
proteins into the periplasmic space has been reported in a previous study in an attempt 
to produce secretable scFv protein from bacteria. According to this study, there can be a 
number of possible explanations such as overloading of the secretion apparatus, the 
sequence following the pelB leader sequence in the antibody scFv fragment might 
negatively influence transport and processing or give rise to the production of insoluble 
antibody. In addition, the exact cleavage position by signal peptidase I recognition 
motive could have been altered; therefore the newly synthesised polypeptide will not be 
directed to the periplasmic space (285). 
 
Although there have been reports on high production levels of soluble 
recombinant antibody fragments in E. coli, it still remains a troublesome host for the 
production of many recombinant antibody fragments. Previous studies have shown that 
recombinant antibody fragments have a tendency to generate inclusion bodies in E. coli 
and, thus, requiring additional refolding steps in order to achieve sufficient amounts of 
functional antibodies (286, 287). Nevertheless, several refolding systems for recovery of 
soluble and active scFv and Fab fragments from non-native aggregates have been 
reported and were shown to be promising (24, 288 and 289). 
 
Generally, the ease, timescale and throughput favour engineering of antibody 
fragments in a bacterial expression system. One caveat is that antibody fragments are 
multi-domain proteins with multiple disulfides, which may not be correctly produced 
during E. coli expression. The odd incidence of obtaining anti-CD22.2 scFv trapped in a 
misfolded state in bacterial inclusion bodies was cumbersome and the purification was, 
therefore, not pursued further. 
 
Due to the fact that insect cells were the only eukaryotic host cells that could be 
used to produce recombinant proteins, extensive experiments were, therefore, invested 
in purifying and refolding the recombinant proteins. 
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To purify and retrieve the proteins from clarified cell pellets lysates under 
denaturing conditions using 6 M guanidinium lysis buffer, a major improvement in protein 
purification was achieved only after addition of 50 mM L-glutamine to all the buffers used 
for protein purification under denaturing conditions.  
 
In a previous study, investigators have demonstrated that the addition of 50 mM 
L-arginine (Arg) and 50 mM L-glutamine (Glu) to protein sample solutions significantly 
increased achievable protein concentration and improved the protein stability (290). 
These amino acids function by prevention of protein aggregation and thus help protein 
solubilisation. L-arginine and L-glutamine, oppositely charged in the pH range 5–7, 
together form a highly-soluble arginine glutamate salt. The efficiency and anti-
aggregational effects of arginine glutamate salt has been established in previous studies 
(291-297). Furthermore, it has been established that when Arg and Glu are added 
together, provide the most efficient inhibition of protein aggregation (298). 
 
Nickel affinity purified recombinant proteins, after the addition of L-glutamine, 
were refolded and regardless of protein contaminants, scFv proteins were tested for 
binding to CD22.2 on B cells by flow cytometry. Results of these experiments showed 
that protein renaturation and refolding were ineffective as no binding could be 
demonstrated. 
 
Although anti-CD22.2 recombinant proteins were expressed in insect cells and in 
bacteria, but not in mammalian systems, there are a number of explanations for lack of 
expression of the recombinant proteins in a mammalian system.  
 
The biosynthesis of secretary and membrane proteins in the endoplasmic 
reticulum (ER) is strictly monitored by a mechanism called ER quality control to ensure 
that only properly folded and assembled proteins are allowed to reach their final 
destination (299). Generally, a higher recombinant protein production is achieved by 
targeting naturally secreted proteins to the secretory pathway, where post-translational 
modifications, like protein folding, assembly and gycosylation, take place, as compared 
with a cytoplasmic localisation (300, 301). Proteins reach their proper folding and 
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conformation by the action of the folding-refolding machinery assisted by a set of folding 
chaperones, which mainly reside in the ER lumen (302-305). When stress affects the 
protein-folding mechanism in the ER, or when too many secretory proteins are 
synthesised and transported into the ER lumen, the folding-refolding system becomes 
overloaded and the proteins cannot achieve their proper conformation anymore. In this 
way, unfolded or misfolded proteins can accumulate which may compromise ER 
activities, for example protein synthesis and folding needed for cellular housekeeping, 
due to a decrease in essential proteins (306). 
 
Recombinant protein production is a demanding process for the host cell, as an 
additional foreign protein needs to be produced besides the endogenous proteins. In 
some cases, production of this foreign protein leads into the activation of the unfolded 
protein response (UPR) and this can both positively and negatively influence the 
recombinant protein yield. For example, investigators have found in yeast that the 
overexpression of anti-fluorescein 4-4-20 scFv variants activated the UPR response, 
which in turn led to a reduction of the scFv yield (307, 308). Further, others have shown 
that disrupting the endoplasmic reticulum-associated degradation (ERAD) pathway in 
filamentous fungi led to an enhanced protein expression by delaying protein degradation 
(309). 
 
Misfolded or faulty proteins produced as a result of mutations or affected by 
stresses, are retrotranslocated from the ER into the cytosol for degradation by the 26S 
proteasome after modification with polyubiquitin chains, by the ERAD process (310). 
During the ERAD process, misfolded proteins are recognised by the ER-degradation 
enhancing α-mannosidase-like protein (EDEM) and then transferred from the ER to the 
cytosol (retrotranslocated) as unfolded polypeptide chains through the translocon 
channel for degradation (311). However, how other toxic species, such as severely 
aggregated proteins, are eliminated from the ER is largely unknown. 
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Although production of secretable and properly folded anti-CD22.2 scFv proteins 
was not achieved, there has been profound progress in knowledge acquisition while 
generating and constructing the expression vectors. An array of molecular approaches 
and protein expression and purification systems were used to optimise the systems for 
the best-case-scenario in the next step that follows. By the time these efforts were made 
to obtain functional recombinant mouse anti-CD22.2 scFv proteins, anti-human CD22 
scFv cDNAs were obtained courtesy of Dr. Ira Pastan (National Cancer Institute, Center 
for Cancer Research, Bethesda, USA). Subsequently, recombinant fusion protein was 
generated in properly folded and secreted forms from serum-free cultures of mammalian 
cells.  
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This chapter describes methods used for the generation, purification, preservation and 
functional analyses of a soluble engineered anti-human CD22 recombinant protein. 
HA22, an anti-human CD22 scFv-protamine-His6, was generated as a secreted protein 
in serum-free cultures of HEK293F cells. Extensive attempts were made to produce and 
isolate high purity HA22 fusion protein. The dual functional property of the protein is in 
its ability to bind to CD22 on B cells and also to electrostatically bind with siRNAs. It is 
for the first time that such studies have succeeded in the generation of proteins tagged 
with protamine in secretable and soluble forms from serum-free cultures of mammalian 
cells with high purity. Results of the specificity of binding, kinetics of internalisation and 
delivery of siRNA into B cells and the effects of gene downregulation are presented. 
 
 
4.1. Assessment of CD22 receptor expression on human B cell lines by flow 
cytometry: 
Expression of CD22 on human B cell lines HF28 RA and L3/Bcl-2 was assessed by flow 
cytometry. Anti-human CD22 AlexaFluor®647 (AbD serotec) and anti-human CD19 
FITC (BD Biosciences) were used for this purpose. The B cell lines were stained with 
the anti-CD19 and anti-CD22 Abs as described in the Materials and Methods chapter 
(section 2.4). Both B cell lines were shown to be positive for CD19 and CD22. Positive 
cells in the forward scatter were analysed by gating on live cells and excluding dead, or 
dying cells by propidium iodide (PI) staining (Figures 62 and 63). 
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Figure 62: Analysis of human HF28 RA follicular lymphoma B cells by flow cytometry for 
CD19 and CD22 expression. The figure shows the dot plot profile of the forward and side 
scatter for the cells (A) and expression of CD19 (B) and CD22 expression (C). (D) Shows the B 
cell population which were double positive for both CD19 and CD22 expression. 
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Figure 63: Analysis of human L3/Bcl-2 Burkitt’s lymphoma B cells by flow cytometry for 
CD19 and CD22 expression. (A) Shows the dot plot profile of the forward and side scatter of 
the cells. Expression of CD19 and CD22 are shown in B and C, respectively. The B cell 
populations which were double positive for both CD19 and CD22 expression are shown in D. 
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4.2. The generation of the anti-human CD22 scFv-protamine-His6 construct: 
For the construction and generation of the anti-human CD22 scFv-protamine-His6 
cDNA, plasmid DNA pMH112 (BL22) and pMH113 (HA22) were obtained courtesy of Dr. 
Ira Pastan (National Cancer Institute, Center for Cancer Research, Bethesda, USA). 
Sequences of anti-human CD22 scFvs BL22 and HA22 were reported in previous 
studies (229, 312) and are shown in Figure 64. The dry format plasmids were retrieved 
and expanded in preparation for cloning as described earlier in the Materials and 
Methods (section 2.27). Subsequent to mini- and maxi-preparations, the plasmids were 
digested with BamHI to confirm the presence of the inserts (Figure 65). To create the 
engineered antibody fragment, truncated protamine peptide and hexahistidine tag were 
attached to HA22 scFv from pMH113. 
Schematic illustrations showing the genetic maps of pMH112 and pMH113 constructs 
containing anti-human HA22 (mutant) scFv with unique restriction sites are shown in 
Appendix 4, page 364 and Appendix 5, page 365 respectively. 
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RFB4 heavy chain (VH): 
Rearranged RFB4  ATG GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG  
a.a.              M   E   V   Q   L   V   E   S   G   G   G   L   V   K   P   G   G   S   L   
IGHV5S21         ............AAG.....................GAA..................................... 
a.a.             .............K.......................E...................................... 
                                                                 |       CDR1      | 
Rearranged RFB4  AAA CTC TCC TGT GCA GCC TCT GGA TTC GCT TTC AGT ATC TAT GAC ATG TCT TGG GTT 
a.a.              K   L   S   C   A   A   S   G   F   A   F   S   I   Y   D   M   S   W   V    
IGHV5S21         ....................................ACT.........AGC.....GCC.................                
a.a.             .....................................T...........S.......A..................      
                                                                 |       CDR2         
Rearranged RFB4  CGC CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC GCA TAC ATT AGT AGT GGT GGT GGT  
a.a               R   Q   T   P   E   K   R   L   E   W   V   A   Y   I   S   S   G   G   G   
IGHV5S21         ........................................................................GAT. 
a.a.             .........................................................................D.. 
                                                       | 
Rearranged RFB4  ACC ACC TAC TAT CCA GAC ACT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC 
a.a.              T   T   Y   Y   P   D   T   V   K   G   R   F   T   I   S   R   D   N   A    
IGHV5S21         TAC.ATC.........GCA......................................................... 
a.a.             .Y...I...........A..........................................................                
 
Rearranged RFB4  AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AAG TCT GAG GAC ACA GCC ATG TAT  
a.a.              K   N   T   L   Y   L   Q   M   S   S   L   K   S   E   D   T   A   M   Y    
IGHV5S21         AGG......................................................................... 
a.a.              R.......................................................................... 
                                 |                                       CDR3          | 
Rearranged RFB4  TAC TGT GCA AGA CAT AGT GGC TAC GGT AGT AGC TAC GGG GTT TTG TTT GCT TAC TGG 
a.a.              Y   C   A   R   H   S   G   Y   G   S   S   Y   G   V   L   F   A   Y   W    
IGHV5S21          ...............CGA.......................................................... 
a.a.              ................R...........................................................                
 
Rearranged RFB4  GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA  
a.a.              G   Q   G   T   L   V   T   V   S   A   
IGHV5S21         ...................................... 
a.a.             ...................................... 
 
RFB4 light chain (VL): Rearranged RFB4  GAT ATC CAG ATG ACC CAG ACT ACA TCC TCC CTG TCT GCC TCT CTG GGA GAC AGA GTC  
a.a.              D   I   Q   M   T   Q   T   T   S   S   L   S   A   S   L   G   D   R   V    
IGKV10-J1        ................ACA........................................................ 
a.a              ............................................................................  
 
                                 |                  CDR1                   | 
Rearranged RFB4  ACC ATT AGT TGC AGG GCA AGT CAG GAC ATT AGC AAT TAT TTA AAC TGG TAT CAG CAG 
a.a.              T   I   S   C   R   A   S   Q   D   I   S   N   Y   L   N   W   Y   Q   Q   
IGKV10-J1        ........................................................................... 
a.a.             ........................................................................... 
                                                             |           CDR2          | 
Rearranged RFB4  AAA CCA GAT GGA ACT GTT AAA CTC CTG ATC TAC TAC ACA TCA ATA TTA CAC TCA GGA   
a.a.              K   P   D   G   T   V   K   L   L   I   Y   Y   T   S   I   L   H   S   G   
IGKV10-J1        ........................................................AGA................. 
a.a.             .........................................................R.................. 
 
Rearranged RFB4  GTC CCA TCA AGG TTC AGT GGC AGT GGG TCT GGA ACA GAT TAT TCT CTC ACC ATT AGC 
a.a.              V   P   S   R   F   S   G   S   G   S   G   T   D   Y   S   L   T   I   S   
IGKV10-J1        ........................................................................... 
a.a.             ........................................................................... 
                                                                 |        CDR3         
Rearranged RFB4  AAC CTG GAG CAA GAA GAT TTT GCC ACT TAC TTT TGC CAA CAG GGT AAT ACG CTT CCG 
a.a.              N   L   E   Q   E   D   F   A   T   Y   F   C   Q   Q   G   N   T   L   P 
IGKV10-J1        ........................ATT................................................ 
a.a.             .........................I.................................................                
                       | 
Rearranged RFB4  TGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC AAA   
a.a.              W   T   F   G   G   G   T   K   L   E   I   K 
IGKV10-J1        ............................................... 
a.a.             ............................................... 
Figure 64: Nucleotide and amino acid sequences of the mouse anti-human CD22 scFv RFB4 (BL22) 
heavy (VH) and light (VL) chains. Arg45 in the VH and Gly100 in the VL (shown in red) are mutagenised 
to Cys44 and Cys100, respectively to create the high affinity disulfide-stabilised HA22 scFv. 
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Figure 65: Agarose gel electrophoresis showing restriction analysis of plasmid vectors 
pMH112 and pMH113 with BamHI enzyme. Expected size of DNA fragment to be released 
from the digestions is 541 bp. There are two BamHI sites, therefore, a single digestion resulted 
in the release of the DNA fragment. The plasmid DNA was then sequenced with T7 forward and 
pMH R-113 primers and fidelity of the inserts confirmed. 
 
4.3. Construction of the anti-human CD22 scFv-protamine-His6 in pcDNA6|IL2ss 
for expression in mammalian systems: 
pcDNA6|IL2ss expression vector, routinely used in our department, drives expression 
and secretion of recombinant proteins. For this purpose, the protamine peptide and 
hexahistidine DNA fragment, generated earlier in this study for the mouse antibody 
constructs, was PCR-amplified using specific primers (BglII F forward and NheI R 
reverse primers with the corresponding restriction sites) compatible with the scFv and 
pcDNA6|IL2ss backbone. HA22 scFv was also PCR-amplified with specific primers 
(EcoRI F forward and BglII R reverse primers with the corresponding restriction sites) for 
insertion into the plasmid backbone together with protamine-His6 (section 2.28, page 85 
and Figure 19, page 86). Only one construct of the engineered anti-human CD22 was 
generated from HA22 scFv by ligation of PCR products with pcDNA6|IL2ss vector 
backbone which was then digested with EcoRI and XbaI enzymes (Figure 66). 
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Figure 66: Agarose gel electrophoresis showing PCR amplification of the protamine-His6 
and HA22 scFv and restriction digestion of pcDNA6|IL2ss vector. The protamine-His6 DNA 
fragment, 87 bp, was amplified from the mouse Cy34.1.2 pFastBacTM1 scFv-protamine-His6 
construct,digested with BglII and NheI enzymes and purified by gel extraction (top). HA22 scFv 
was also PCR-amplified with EcoRI forward and BglII reverse primers, digested using the 
corresponding enzymes for use in the ligation reaction (bottom left) with the vector backbone. 
pcDNA6|IL2ss vector was digested with EcoRI and XbaI, gel extracted and used in the ligation 
reaction (bottom right). 
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 A schematic illustration depicting the construction of the in-frame DNA 
expression cassette of anti-human CD22 scFv-protamine-His6 is shown in Figure 67. 
This construct is consisted of the heavy chain (VH) which is linked through a flexible 
glycine-serine linker at its C-terminus with a light chain (VL) N-terminus followed by a 
truncated protamine and hexahistidine tag.  
 
 
 
 
 
 
 
 
 
 
Figure 67: A schematic figure depicting HA22 scFv-protamine-His6 construct generated 
by the attachment of EcoRI-HA22-BglII DNA to BglII-truncated protamine-His6-NheI DNA 
fragment. The combined DNA fragment was ligated into pcDNA6|IL2ss backbone. The vector 
backbone was restricted with EcoRI and XbaI. Because the two NheI sites are present in the 
vector backbone, the vector was digested with XbaI enzyme instead of NheI so that XbaI and 
NheI sites could then ligate together as these two sites have compatible cohesive ends. 
 
 
 PCR products of HA22 scFv and protamine-His6 amplification were ligated with 
pcDNA6|IL2ss backbone DNA after purification of the DNA fragments by gel extraction. 
The ligation reaction was used for bacterial transformation and plasmid minipreps from 
the transformants were analysed by restriction digestion (Figure 68). Positive clones 
were further analysed by sequencing (Appendix 2, page 351). Plasmids from positive 
clones were expanded by maxipreparations and used for protein expression by transient 
transfection of mammalian cells. 
 
 
 
  
 
 
 
EcoRI                                                                  BglII                                         NheI 
Protamine NH3+ (Gly4Ser)3 VH His6 VL COO
- 
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Figure 68: Restriction digestion of pcDNA6|IL2ss plasmid DNA minipreps with EcoRI and 
BamHI to identify positive clones. Positive clones were identified by the release of a 381 bp 
fragment. These were further analysed by sequencing using T7 forward and BGH reverse 
primers. 
 
 
4.4. Transient transfection of HEK293T and CHO-S cells for the expression of 
recombinant HA22 protein: 
The pcDNA6|IL2ss-HA22 scFv-protamine-His6 construct was used for the expression of 
the protein in CHO-S and HEK293T cells. Results from the analysis of culture 
supernatants and cell lysates did not confirm expression of the protein (data not shown). 
The validity of the correct insertion of the in-frame construct was confirmed for a second 
time by re-sequencing the plasmid DNA. Transfection experiments were repeated in 
HEK293T cells including the original pMH113 vector which has HA22 scFv alone. 
pMH113 is HA22 scFv fused with haemagglutinin A, c-myc and PDGFR transmembrane 
domain as has been reported in a previous study (313). Analysis of culture supernatants 
and cell lysates of transfected cells showed expression from the original pMH113 vector 
but not pcDNA6|IL2ss (Figures 69 and 70).  
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Figure 69: Western blot analysis for expression of anti-human CD22 (HA22) from the un-
modified vector pMH113 and the pcDNA6|IL2ss by transient transfection of HEK293T 
cells. HA22 in pMH113 vector was tagged with c-Myc and PDGFR transmembrane domain. 
Following expression and secretion, HA22 protein from pMH113 will remain bound 
extracellularly to HEK293T cells via the PDGFR transmembrane domain. Rabbit anti-myc 
antibody (1:1000) and secondary HRP-conjugated anti-rabbit antibody (1:1000) were used for 
the detection of the protein on a reducing SDS PAGE gel. The blot was exposed for 1 minute.  
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Figure 70: Western blot analysis of anti-human CD22 (HA22) production using the original 
vector pMH113 or with pcDNA6|IL2ss by transient transfection of HEK293T cells. The 
figure depicts sample duplicates from Figure 69 probed with HRP-conjugated anti-His(C-term) 
mAb. No proteins were expressed from the pcDNA6 construct. 
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4.5. Cloning of HA22 scFv-protamine-His6 into pDisplay vector for expression in 
mammalian systems: 
pMH113 vector has a murine Ig kappa chain signal peptide which drives 
expression/secretion of the recombinant protein. Attempts were made to determine 
whether changing the signal peptide could decipher the hurdle of protein expression and 
secretion. Therefore, HA22 scFv-protamine-His6 DNA fragment was PCR-amplified and 
cloned into the pDisplay vector. HA22 scFv-protamine-His6 DNA fragment was cloned 
into the pDisplay vector to investigate the effect of the IL2 and murine Ig kappa chain 
signal peptides on secretion of HA22 recombinant protein. The DNA fragment that 
codes for scFv-protamine-His6 was PCR-amplified from pcDNA6|IL2ss with SfiI forward 
and SacII reverse primers. PCR products and the pDisplay vector were digested with 
SfiI and SacII enzymes, purified by gel extraction and ligated (Figure 71). In order to 
generate the construct in the pDisplay vector, the ligation reaction was set up between 
the PCR product and the vector backbone (section 2.29, page 87; a schematic 
illustration of the cloning strategy is shown in Figure 20, page 87). The ligation reaction 
was used to transform bacteria and colonies from the transformants were expanded for 
DNA mini-preparations and plasmid DNA minipreps analysed by restriction digestion 
(Figure 72) and sequencing. 
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Figure 71: Agarose gel electrophoresis of PCR-amplified HA22 scFv-protamine-His6 and 
restrction digestion of pDisplay vector with SfiI and SacII enzymes. PCR products of HA22 
scFv-protamine-His6, right, (823 bp) and pDisplay (left) were digested with SfiI and SacII 
enzymes, extracted by gel purification and ligated together.  
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Figure 72: Analysis of plasmid DNA minipreps on agarose gel electrophoresis. Positive 
clones for HA22 scFv-protamine-His6 inserts were confirmed by visual observation of the 
released DNA fragment by restriction digestion with BamHI enzyme. Positive clones were also 
confirmed by sequencing. 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
 
206 
 
4.6. Expression and secretion of recombinant HA22 protein from HEK293T cells: 
HA22 scFv-protamine-His6 in pcDNA6|IL2ss, or in pDisplay vectors was used for 
transient transfection of HEK293T cells. After 3 days of transfection, the cultures were 
harvested and centrifuged at 5000 rpm for 5 minutes at 4°C. Culture supernatnats and 
cell lysates were resolved on SDS PAGE gel and the protein detected with HRP-
conjugated anti-His(C-term) mAb. Protein expression and secretion was only seen from 
pDisplay vector (Figure 73).  Interestingly, the recombinant protein was not detected in 
the cell lysates. This might be explained by the fact that the majority of the recombinant 
protein is directed through the secretory pathway to extracellular space after being 
produced.    
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Figure 73: Western blot analysis of recombinant protein HA22 scFv-protamine-His6 
production and secretion by HEK293T cells. HA22 protein was detected in clarified culture 
supernatants of pDisplay-transfected cells (lanes 7 and 8) but not in pcDNA6|IL2ss transfected 
cells (lanes 4, 5 and 6). Cells were lysed in lysis buffer (50 mM HEPES, 420 mM KCl, 0.1% NP-
40, 1 mM EDTA, pH8.3) and resolved on a 4-12% gradient SDS PAGE gel under reducing 
conditions. Recombinant protein was not detected in cell lysates of either pcDNA6|IL2ss or 
pDisplay vector transfected cells (lanes 11, 12, 13, 14 and 15).   
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4.7. Expression and secretion of recombinant HA22 protein in serum-free cultures 
of HEK293F cells: 
HEK293T mammalian cells, widely used for recombinant protein production, are an 
established expression system as it endows proteins with relevant post-translational 
modifications. However, the use of HEK293T cells has limitations for mass production of 
recombinant proteins for experimental purposes. Since the cells are growing in adherent 
monolayers, large-scale cultures are usually not possible due to limited space of culture 
vessel surfaces. Furthermore, the cells are growing in complete medium with 10% HI-
FBS which is then replaced 24 hours after transfection with serum-free medium. 
Growing the cells in serum-free medium is essential so that pure recombinant protein 
devoid of contamination with proteins of animal origin be obtained which is required for 
most experimental purposes. This problem was previously dealt with by using HEK293F 
cells adapted for growing in serum-free media. More important is the adaptation of the 
cells to grow in suspension cultures which helps to grow bulk cultures in large cell 
culture flasks. The floating HEK293F cells were grown to a density of ~2 x 106 cells/mL 
in serum-free FreeStyle growth medium at the time of transfection. The cells were 
transiently transfected with the pDisplay plasmid expression vector using PEI as 
described earlier in the Materials and Methods chapter (section 2.33). 
 
In order to investigate the transfectability of linear polyethylenimine (PEI, 25 kDa) 
and also determine the optimal ratio of DNA:PEI complex formation for maximal yield of 
the protein, initially two different ratios of PEI was used to form the complex before 
addition to cells. Results from the titration of PEI ratios showed that DNA:PEI at 1:3 ratio 
has a superior transfectability and yields more protein compared with the 1:1 ratio 
(Figure 74). Therefore for subsequent expression experiments the 1:3 ratio was used.  
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Figure 74: Comparative analysis by Western blotting of expression/secretion of the 
recombinant protein from HEK293F cells. The figure represents the outcome of experiments 
to identify the optimal DNA:PEI ratio for the expression efficiency. Culture supernatants and 
clarified cell lysates were subjected to reducing 10% SDS PAGE electrophoresis and the 
proteins were detected with HRP-conjugated anti-His(C-term) mAb and films were exposed for 1 
minute. Lanes 1, 2, 3 and 4 refer to the same sample load from HEK293F cultures (30 mL) 
transfected with pDisplay vector for production of recombinant proteins. 
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The first choice for HA22 protein purification was nickel affinity chromatography 
due to the presence of a C-terminal hexahistidine tag. Prior to purification, proteins were 
analysed on a non-reducing gel. 
 
 The results obtained from non-reducing gels may possibly indicate that the 
hexahistidine tag was not inhibited functionally by the conformation of the recombinant 
protein intramolecular moieties. This has assured possible binding of an exposed 
hexahistidine tag to the nickel column (Figure 75). Additionally, no protein dimers were 
seen on the Western blots. Furthermore, density of the protein bands on the Western 
blot was measured to determine the difference between the relative amount of protein 
ratio due to the effect of 1:1 and 1:3 DNA:PEI.  Consequently, ~2.03 fold more protein 
was obtained using DNA:PEI ratio at 1:3 than DAN:PEI ratio at 1:1. This was calculated 
from the densitometry TotalLab 1D Quant software based on images of Figure 75. 
 
 
Figure 75: Western blot analysis of HA22 recombinant protein from culture supernatants 
under non-reducing conditions. No dimer formation or protein aggregates could be detected 
on the blot. The poly-histidine tag was not concealed in protein intramolecular structure instead it 
was exposed and bound to nickel column. The protein was detected with HRP-conjugated anti-
His(C-term) mAb after 1 minute exposure of the films. Lanes 1, 2, 3 and 4 refer to the same 
sample load from HEK293F cultures (30 mL) transfected with pDisplay vector for production of 
recombinant proteins. 
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4.8. Optimisation of recombinant protein purification: 
Following on from the previous experiments of expression/secretion of HA22 protein, 
optimal DNA:PEI ratios for high transfectability and detection under non-reducing and 
reducing conditions were determined. The next set of experiments were to study 
whether dialysis of the culture supernatant would be necessary and whether the 
hexahistidine tagged protein can bind to the nickel column and be retrieved in the elution 
fractions. For this purpose, culture supernatants harvested from the transfection 
experiments were tested to confirm HA22 protein expression and secretion by Western 
blotting. Culture supernatants were divided into two fractions, one was kept undialysed 
at 4°C and the other dialysed for 24 hours against native binding buffer for nickel affinity 
purification (50 mM NaH2PO4 and 0.5 M NaCl; pH 8.0). The dialysis was carried out 
using a Slide-A-Lyzer 10,000 MW cut-off cassette at 4°C. Protein samples from 
undialysed and dialysed culture supernatants were bound to the nickel column for 90 
minutes at 4°C.  
 
Unbound proteins were washed away with native binding buffer, the column was 
then washed with 6 column volumes of native wash buffer (50 mM NaH2PO4 and 0.5 M 
NaCl with 20 mM imidazole; pH 8.0) and bound proteins eluted with the native elution 
buffer (50 mM NaH2PO4 and 0.5 M NaCl with 250 mM imidazole; pH 8.0). Loaded 
samples, unbound flow-through, wash and elution fractions from undialysed and 
dialysed supernatants were analysed on SDS PAGE gel and by Western blotting. 
Results from these experiments showed that the hexahistidine tagged protein bound to 
the nickel column and was obtained in the elution fractions, but dialysis resulted in 
significant loss of the protein (Figure 76).  
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Figure 76: Small-scale protein purification using nickel affinity chromatography. The effect 
of dialysis on the purification of recombinant HA22 was studied by Western blotting. The results 
provide evidence for significant loss upon the dialysis of culture supernatants. Recombinant 
protein in the supernatants and different fractions were analysed on 10% precast SDS PAGE gel 
under non-reducing (top) and reducing (bottom) conditions. The protein was detected with HRP-
conjugated anti-His(C-term) mAb. The X-ray films were exposed for 1 minute.  
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4.9. Large-scale production and purification of recombinant HA22 protein under 
native conditions using nickel affinity chromatography and FPLC: 
Having optimised key aspects of the production and purification systems, large-scale 
production and purification of the fusion protein was initiated. For this purpose, early-
passages of HEK293F cells were grown in fresh medium in large flasks on an orbital 
shaker at a rate of 95 rpm at 37°C with 8% CO2 in air. The cultures were then 
transfected at a density of 2 x 106 cells/mL using a 1:3 DNA:PEI ratio. Culture 
supernatants were collected 3 days post transfection by centrifugation at 5000 rpm at 
4°C for 5 minutes and frozen at -80°C until used. Before application to the column, 
culture supernatants were defrosted gradually at 4°C and filtered using a sterile vacuum 
low protein-binding filter unit with a polyethersulfone (PES) membrane (0.22 µm). The 
HiTrap 5 mL chelating HP nickel column was installed on the FPLC system (Amersham 
Pharmacia, GE Healthcare) and pre-equilibrated with cold filter-sterilised binding buffer 
(20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4). Based on the data obtained from the 
available variables of small-scale protein purification, the FPLC system was adjusted for 
the large-scale purification scenario. Details of the set-up are described in the Materials 
and Methods chapter (section 2.42, page 103).    
 
The process of protein purification on nickel affinity chromatography beginning 
with column equilibration, sample loading, washes and elution fraction collection was 
monitored and recorded by the FPLC system on a chromatogram recorder (Figure 77). 
The sample load, unbound flow-through, wash and elution fractions were analysed for 
purity on a Coomassie blue-stained SDS PAGE gel and Western blotting (Figure 78).  
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Figure 77: Nickel affinity chromatogram showing protein purification process under native conditions using FPLC. F3 indicates 
loading of culture supernatants containing HA22 protein onto the nickel column and collection of unbound flow-through. Fractions A1 to A7 
represent protein impurities removed from the column by washing. Elution fractions A8 to A11 were collected and analysed on a 
Coomassie blue-stained gel and by Western blotting. X-axis: volume (mL); Y-axis: optical density (OD) at 280 nm. 
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Figure 78:  Analysis of the efficiency of recombinant HA22 protein purification on nickel affinity 
columns. The figure depicts Western blot (top) and Comassie blue-stained (bottom) analyses of 
loaded culture supernatants, unbound flow-through, wash and elution fractions following purification of 
the recombinant protein by nickel affinity chromatography. The analyses reveal no loss in the 
unbound, flow-through or wash fractions (A2-A4). The protein of the expected size can be seen in the 
elution fractions (A8-A11). The Coomassie blue-stained gel (bottom) shows the level of contaminants 
and impurities. The protein was detected with HRP-conjugated anti-His(C-term) mAb. 
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4.10. Purification of recombinant HA22 protein using ion exchange chromatography: 
Elution fractions of nickel affinity purified protein were subjected to further purification by ion 
exchange chromatography. The isoelectric point (pI) of the HA22 fusion protein was 
estimated using a bioinformatics tools to be ~4.5. Accordingly, the net positive charge of the 
protein favours the use of cation exchange chromatography. For this purpose, the buffer was 
first exchanged by dialysis into a buffer that is compatible with cation exchange (20 mM Tris-
HCl; pH 7.5). Based on the Coomassie blue-stained gel and the Western blotting data, the A9 
fraction (His-A9) had significant protein content. Therefore, this fraction was processed for the 
cation exchange chromatography. It was noted that during the first few hours of buffer 
exchange, the protein started to form white precipitates within the dialysis membrane. The 
dialysis was stopped and protein sample retrieved from the dialysis cassette. The protein 
sample was gently resuspended and centrifuged at 1400 rpm for 2 minutes at 4°C. The 
supernatant was transferred to a fresh tube and 50 mM L-glutamine added to help protein 
solubilisation as carried out previously for the mouse recombinant proteins. This helped to 
clarify the protein sample. In parallel, the protein precipitate in the pellet was resuspended in 
the binding buffer (20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4) with the addition of 50 mM L-
glutamine. Only the clarified supernatant was added to the cation exchange HiTrap SP FF 
column. This was due to the fact that the tubing system of the FPLC system is thin and any 
impurity or precipitate would clog and damage the system. Therefore, it was not possible to 
use the resuspended protein precipitate of the A9 fraction (His-A9) through the FPLC system 
capillaries. Similar to nickel affinity chromatography, protein purification through cation 
exchange chromatography was monitored and recorded by the FPLC system chromatogram 
recorder (Figure 79). The sample load, wash and elution fractions were analysed by Western 
blotting but inexplicably most proteins were detected at low molecular weights (Figure 80). 
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Figure 79: Cation exchange chromatogram showing the profile of protein purification under native conditions on FPLC. The 
elution fraction A9 (His-A9) of HA22 protein from the nickel affinity purification step was applied onto a cation exchange column. From 
cation exchange chromatography purification, the fractions A1 to A9 indicate sample loading and the fractions A10 to B5 indicate elution 
fractions which were analysed by Western blotting.  
 
Gradient of NaCl 
concentration 
217 
Chapter Four 
 
 
 
Figure 80: Western blot analysis of purified protein A9 fraction (His-A9) from cation 
exchange chromatography. Fraction A9 (His-A9) was dialysed against Tris-HCl, pH 7.5,which 
resulted in the formation of precipitates, some of which were dissolved back into solution by 
gentle resuspension. The sample was loaded onto HiTrap SP cation exchanger column and 
eluted with a gradient of elution buffer (20 mM Tris-HCl, 2 M NaCl, pH 7.5). The blot shows 
analysis of the sample load, wash and elution fractions. Degradation was observed for all the 
fractions analysed except for the precipitate from the A9 fraction (His-A9) which contains a high 
amount of the recombinant protein. 
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The various steps in the purification process of proteins (sample load, unbound flow-
through, wash and elution fractions) were analysed by Western blotting and on a 
Coomasie blue-stained gel. However, for HA22 fusion protein which is a unique protein, 
the spectrum of analysis has revealed that a significant amount of non-specific protein 
contaminants can be removed on the nickle column by using 250 mM imidazole in the 
wash buffer. Thus, high purity fusion protein was isolated by using 500 mM imidazole in 
the elution buffer.   
 
High proportions of pure recombinant HA22 fusion proteins were detected in the 
elution fractions using 500 mM imidazole. The elution fractions with highly pure protein 
isolated using 500 mM imidazole were analysed by Western blotting and on a 
Coomassie blue-stained gel (Figure 81).  
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Figure 81: Comparative analysis of HA22 fusion protein obtained by elution with different 
concentrations of imidazole. After loading the column with culture supernatant containing 
recombinant protein, bound HA22 was eluted with buffer containing either 250 mM imidazole 
(fractions A10 and A11) or 500 mM imidazole (fractions E1 - E3) on the nickel affinity column. 
Elution with 500 mM imidazole yielded more protein as shown by Western blotting (top) and 
Coomassie blue-stained gel (bottom). 
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4.11. Removal of imidazole from the purified recombinant HA22 protein by dialysis 
and desalting: 
The effect of dialysis on protein loss was established previously (section 4.8). Therefore, 
although it was deemed not the best option for removal of imidazole from all of the 
purified protein but a small volume was dialysed against the binding buffer (20 mM 
NaH2PO4 and 0.5 M NaCl; pH 7.4) to remove imidazole. The protein sample was then 
analysed by Western blotting before and after dialysis. Results from the Western blot 
analysis confirmed that a significant amount of the protein would be lost during dialysis 
(Figure 82). Changes of volumes before and after dialysis were not observed. 
 
 
Figure 82: Effect of imidazole dialysis on HA22 fusion protein content. The protein sample 
was analysed before and after dialysis by Western blotting. The analysis shows a significant loss 
of the protein during the dialysis process. The analysis was carried out using a 10% SDS PAGE 
gel under reducing conditions. 
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 As an alternative step to dialysis, imidazole was removed from the protein 
sample by buffer exchange on PD-10 Sephadex G-25 desalting column. The result from 
the PD-10 desalting was encouraging and almost the same amount of protein was 
retrieved after the desalting process (Figure 83). 
 
 
Figure 83: Western blot analysis of HA22 fusion protein samples before and after removal 
of imidazole by desalting. The yield of protein after PD-10 desalting is the same as before PD-
10 desalting. The dilution factor of the protein from the variation of elution buffer volume was 
compensated for before and after PD-10 desalting by loading 15 μl and 21 μl of the protein 
sample respectively on 10% SDS PAGE gel under reducing conditoins. 
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4.12. Removal of haemagglutinin A epitope (HA tag) from the recombinant HA22 
fusion protein:  
In the original pDisplay vector, the nucleotide sequence which encodes haemagglutinin 
A epitope (YPYDVPDYA) precedes the MCS in-frame with the signal peptide. The 
murine Ig kappa chain signal peptide is fused at the C-terminus with the HA tag. Initially, 
removal of the HA tag was not possible for the cloning. After construction of the 
expression vector with HA22 scFv-protamine-His6, a fragment of DNA that overlaps the 
signal peptide upstream of the HA tag was PCR-amplified in a way that is compatible 
with the start site of HA22 scFv (SfiI site). Therefore, the construct was restricted with 
HindIII and SfiI enzymes to release a DNA fragment upstream of the signal peptide 
which includes the haemagglutinin A epitope. Then, a DNA fragment for the region 
between HindIII and end of the leader signal sequence was amplified by PCR using 
specific primers to restore the SfiI site (Figure 84). The construct (vector backbone) 
which was digested with HindIII and SfiI enzymes was ligated with the PCR product 
(digested with the same enzymes) and the ligation reaction was used to transform 
bacteria. Transformants were expanded from positive colonies and plasmid minipreps 
analysed by restriction digestion and sequencing (Appendix 2, page 352). The genetic 
map for the construct is shown in Appendix 3, page 363.  
A schematic illustration emphasising the process of removal of HA tag from pDisplay 
expression vector is shown in Appendix 6, page 366. 
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Figure 84: Agarose gel electrophoresis of the cloning process for removal of HA tag. 
pDisplay vector was digested at the unique HindIII site upstream to and the start site of MCS 
including signal peptide and HA tag with HindIII and SfiI enzymes (upper left). The DNA 
fragment between HindIII site and end of signal peptide was PCR-amplified (upper right). 
Positive clones from ligation reaction were analysed by restriction digestion (bottom) and 
sequencing. 
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New batches of the protein were produced on a large scale using the modified 
pDisplay vector without the HA tag. Modifications in the purification process on nickel 
affinity chromatography consisted of using 50 and 250 mM imidazole concentrations in 
the wash buffers to wash and remove the protein impurities on the nickel column. Then 
additionally pure protein was eluted with 500 mM imidazole. These modifications, 
documented in the legend to the chromatogram in Figure 85, were incorporated into the 
FPLC program. Isolation of pure protein was made feasible because of these 
modifications. The content of the fractions obtained from the protein purification process 
was analysed by Western blotting and on a Coomassie blue-stained gel (Figures 86 and 
87). Cation exchange chromatography was avoided for additional purification because of 
precipitation of the protein, as shown earlier and also because only purification through 
nickel affinity chromatography has yielded a highly pure protein which was used to test 
for biological activity.  
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Figure 85: Nickel affinity chromatogram of HA22 protein purification using FPLC under optimal conditions. F3 indicates loading of 
culture supernatants containing HA22 fusion protein onto the nickel column and collection of unbound flow-through. Fraction A1 represents 
wash of the column with 50 mM imidazole in the washing buffer. Fraction A2 represents wash of the column with 250 mM imidazole in the 
washing buffer to remove protein impurities. HA22 fusion protein was collected in elution fractions A3 to A11 using 500 mM imidazole in the 
elution buffer. Sample load, unbound flow-through, 50 mM and 250 mM imidazole washes and all elution fractions were analysed on 
Coomassie blue-stained gel and by Western blotting. X-axis: volume (mL); Y-axis: optical density (OD) at 280 nm. 
Sample loading and 
flow-through collection 
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Figure 86:  Analysis of recombinant HA22 fusion protein after purification on nickel 
affinity columns using different concentration of imidazole. The figure show the analysis of 
the loaded sample, unbound flow-through, wash and elution fractions by Western blotting. The 
figure shows that most of the proetin bound to the column with no protein loss detected in the 
unbound flow-through. 
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Figure 87:  Analysis of recombinant HA22 fusion protein after purification on nickel 
affinity columns with different concentration of imidazole. The figure shows the analysis of 
the loaded sample, unbound flow-through, wash and elution fractions on a Coomassie blue-
stained gel (top) for isolation of highly pure protein using nickel affinity chromatography and 
Western blotting (bottom). 
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4.13. Concentration of purified recombinant HA22 protein for assessing optimal 
storage and usage: 
For convenience of use, the purified recombinant protein was concentrated by 
centrifugation using 10 kDa MW cut-off spin columns. The elution fractions of (90 mL) 
were pooled (fractions A3 to A11) and concentrated 18 times through an Immobilized 
Metal Affinity Chromatography (IMAC) spin column. Pooled fractions were loaded onto 
the column and centrifuged at 5000 rpm for 5 hours to reduce the volume to 5 mL of 
concentrated protein. Subsequent to pooling and concentration using IMAC spin 
column, HA22 fusion protein was then subjected to PD-10 desalting to remove the 
imidazole from the fusion protein. The pooled fraction was divided to two equal volumes 
and each was eluted from the PD-10 column with either buffer A (20 mM NaH2PO4 and 
0.5 M NaCl; pH 7.4) or buffer B (20 mM Tris-HCl and 0.5 M NaCl; pH 7.4). Aliquots of 
the protein samples were then compared before and after PD-10 desalting by Western 
blotting (Figure 88).  
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Figure 88: Western blot analysis of concentrated recombinant HA22 fusion protein. 
Aliquots of concentrated recombinant HA22 protein were compared before and after PD-10 
desalting. Pooled concentrated protein fractions were desalted using PD-10 desalting columns 
to remove imidazole. The pooled fraction was divided to two equal volumes and each eluted 
from the PD-10 column with either buffer A (20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4) or buffer 
B (20 mM Tris-HCl and 0.5 M NaCl; pH 7.4). Because the volume of protein sample added to the 
equilibrated columns was 2.5 mL and the volume of elution buffer A or B was 3.5 mL the 
difference in volume before and after elution is accounted for by using more of the protein on the 
Western blot. Protein samples were analysed on 10% precast SDS PAGE gel under reducing 
conditions and the X-ray film was exposed for 1 second. 
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4.14. Quantification of HA22 fusion protein using BCA assay: 
Bicinchoninic acid (BCA) protein quantification assay was used to determine protein 
concentration. This was measured from the linear regression equation of the standard 
curve by plotting known concentrations of BSA (µg/mL) against optical density at 562 
nm (Figure 89). 
 
 
Figure 89: Quantification of purified recombinant HA22 fusion protein. The BCA assay is 
based on using a standard curve plot of absorbance (OD) at 562 nm versus known 
concentrations of BSA (µg/mL). The solid line is a point-to-point graph through the plotted 
standards. The dashed line is linear regression for the entire set of standard points. Accordingly, 
concentration of the recombinant HA22 protein was determined from the straight line equation. 
The concentrations were 228.5 μg/mL in elution buffer A (20 mM sodium phosphate, 0.5 M 
NaCl) buffer and 272.2 μg/mL in elution buffer B (20 mM Tris-HCl, 0.5 NaCl) buffer. 
 
4.15. Optimisation of protein preservation: 
Following protein quantification, methods for optimal protein preservation were 
investigated. For this purpose, aliquots of the protein were either stored at 4°C, frozen at 
-80°C without glycerol or at -195°C in liquid N2 in 10% glycerol. For each storage 
condition, three aliquots were preserved in (20 mM NaH2PO4 and 0.5 M NaCl; pH 7.4), 
(20 mM NaH2PO4 and 0.15 M NaCl; pH 7.4) or (20 mM Tris-HCl and 0.5 M NaCl; pH 
7.4). All aliquots were retrieved after 10 days of storage, defrosted on ice and analysed 
by Western blotting and on a Coomassie blue-stained SDS PAGE gel.  
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Results from these experiments revealed that storage of the purified protein at -
80°C was better at conserving the protein than the other methods (Figures 90 and 91). 
 
Figure 90: Western blot analysis of stored the HA22 fusion protein stored under different 
storage conditions. The experiments were carried out to determine optimal storage conditions 
for the recombinant protein. The analyses showed that freezing of the protein at -80°C was best 
at conserving protein entity during long-term storage.  
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Figure 91: Analysis of HA22 fusion protein after storage under conditions described in 
Figure 90. The protein bands shown on the Western blot (top) and a Coomassie blue-stained 
SDS PAGE gel (bottom) are run under reducing conditions. The results show no sign of protein 
degradation. The Western blot was exposed for 6 minutes.    
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4.16. HA22 fusion protein binds specifically to CD22 on human mature B cells:  
To assess whether the purified recombinant HA22 protein retains its binding and 
specificity to CD22 on positive B cell lines (HF28 RA and L3/Bcl-2) while not reacting 
with CD22-negative cells (Jurkat and U937) flow cytometry analyses were carried out. 
The cells were incubated with the purified HA22 protein (2.7 μg) for 45 minutes on ice, 
then overlaid with a fluorescently-labeled anti-His Ab (anti-6X His tag® antibody 
[DyLight® 650] (1.56 mg/mL) at a dilution of 1:500–1:800) as a secondary Ab for an 
additional 15 minutes on ice. The cells were washed, resuspended in staining buffer and 
analysed. In parallel, cells stained with anti-6X His tag® antibody [DyLight® 650] Ab 
were used as control for non-specific background staining. The results indicated that 
HA22 protein bound specifically to CD22 on B cells (Figure 92).  
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Figure 92: Flow cytometry analysis for the binding of purified recombinant HA22 protein 
to CD22. Cells were incubated with purified recombinant HA22 protein for 45 minutes on ice and 
then overlaid with anti-His6 DyLight650 to show binding to CD22+ B cells (A and B) but not 
Jurkat T or U937 histiocytic cells (C and D respectively). Mean fluorescence intensity (MFI) is 
shown on the histograms.  
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4.17. Binding and internalisation kinetics of the recombinant HA22 protein and the 
delivery of siRNA into B cells: 
In addition to specificity to CD22, purified recombinant HA22 protein was assessed by 
confocal microscopy for binding to membrane CD22, internalisation and the delivery of a 
red fluorescently-labeled scrambled siRNA (siGLO Red) into B cells. To study the 
kinetics of internalisation and delivery of siRNA, AlexaFluor®488-labeled HA22 fusion 
protein (10 μg) was mixed with siGLO Red siRNA (100 nM) and incubated on ice for 20 
minutes. The complex was then incubated with the HF28 RA B cells or with Jurkat T 
cells for 45 minutes on ice. Excess protein/siRNA was washed off and the cells 
incubated at 37°C for 30 or 60 minutes. After washing the cells and treatment with 
proteinase K on ice, the cells were counterstained with DAPI and mounted for 
examination. The confocal microscopy data showed that HA22-AlexaFluor®488 bound 
specifically to B cells. Internalisation was observed after 30 minutes and extended to 60 
minutes. Significantly, HA22 fusion protein did not bind Jurkat cells (Figure 93). In 
addition to these, Z-stacking imaging has also confirmed intracellular localisation of the 
protein/siGLO Red complex (Figure 94).   
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Figure 93: Confocal microscopic analysis for the binding and internalisation of purified 
recombinant HA22 protein and the delivery of siRNA into B cells. Membrane binding of 
HA22-AlexaFluor®488/siGLO Red (siRNA) to CD22 receptor on HF28 RA B cells at 0’ time point 
(A and B) at 4°C followed by internalisation into the cells after 30 minutes of incubation at 37°C 
(C and D). E and F depict cytoplasmic localisations of siGLO Red siRNA (red) following 60 
minutes incubation at 37°C. (G) Shows membrane binding of HA22AlexaFluor®488 (green) to 
CD22 on HF28 RA B cells stained on ice and (H) shows the lack of HA22AlexaFluor®488/siGLO 
Red binding to Jurkat T cells which are CD22 negative (on ice).  
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Figure 94: Z-stacking confocal microscopy images for intracellular localisation of HA22 
fusion protein/siGLO Red complex in HF28 RA B cells. The Z-stacking slices are based on 
the images shown in Figure 93 (C and D) after incubation of HF28 RA B cells for 30 minutes at 
37°C. The yellow arrow indicates peptide/siRNA complex inside the cells. 
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4.18. Confirmation of protein/DNA interaction by gel retardation assay: 
The gel mobility retardation assay confirmed electrostatic interactions between HA22 
fusion protein and pcLuc+ plasmid DNA. To demonstrate retardation of migration of the 
plasmid DNA through the gel, a constant amount of plasmid DNA (2 μg) was mixed with 
increasing concentrations of HA22 protein (1–6 μg) and incubated on ice for 30 minutes. 
The mixture was then resolved on a 1% agarose gel containing 1 μg SYBER safe dye 
and visualised under UV light. This assay demonstrated hindrance of movement of the 
plasmid DNA through the gel as an indication of DNA/protein interaction (Figure 95). 
 
 
Figure 95: Agarose gel electrophoretic mobility shift assay. The experiment illustrates 
retardation of plasmid DNA migration due to complex formation by electrostatic interaction 
between the positively charged protamine domain of HA22 fusion protein and the negatively 
charged pcLuc+ plasmid.  
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4.19. Delivery of siRNA to mRNA of the anti-apoptotic protein MCL1 and cell cycle 
kinase PLK1 with the HA22 fusion protein: 
Evasion of apoptosis is one of the characteristic hallmarks of cancer cells including 
malignant B cells. Therefore, reversal of this defect has been widely considered to be an 
efficacious strategy for cancer therapy (3, 163). 
 
Induction of apoptosis in cancer cells can be achieved by several means, 
downregulation of specific genes with a role in survival of malignant cells is one 
approach. In order to accomplish this, I studied whether downregulation of anti-apoptotic 
or cell cycle kinase genes with a role in cell survival and proliferation is sufficient to 
instruct B cells to die by apoptosis. For this purpose, the anti-apoptotic myeloid cell 
leukaemia sequence 1 (MCL1) gene (isoform 1 splice variant) and the cell cycle kinase 
polo-like kinase 1 (PLK1) gene were targeted using a SMARTpool of siRNA to mRNA of 
these genes (siMCL1 and siPLK1 respectively). To carry out these experiments, HA22 
fusion protein was mixed with siMCL1 or siPLK1, incubated on ice for 20 minutes and 
then added to HF28 RA B cells. The INTERFERin or NeoFX transfection reagents were 
used as positive controls for siRNA delivery. After the indicated time points, the cells 
were harvested and analysed for viability using CellTiter-Glo® assay. Results from 
kinetic experiments to downregulate the MCL1 gene have shown a significant reduction 
in B cell viability up to 96 hours (Figure 96). 
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Figure 96: Cell viability assay for B cells following MCL1 gene downregulation. 
SMARTpool of siRNAs to mRNA of the anti-apoptotic MCL1 gene (siMCL1) delivered with HA22 
fusion protein caused significant B cell death which was obvious up to 96 hours in the kinetic 
study despite the high turnover rate of MCL1 decay (~30 minutes). HF28 RA B cells (200 x 103 
cells/well in 500 μL of medium) were grown in quadruplets. HA22 fusion protein (50 μg)/siMCL1 
(100 nM) at the molar ratio of 9.44/8 protein/siRNA molecules was used. Each experimental unit 
was compared individually with non-transfected cells at the indicated time points. Etoposide was 
used as a positive inducer of cell death. Luminescence detection is based on using the 
luciferase reaction to measure the amount of ATP in viable cells which correlates with cell 
viability. Measurement of cell viability indirectly reflects amount of cell death under investigation. 
Luminescence was measured as relative light units (RLU). Data analysed by GraphPad Prism 
and Microsoft Excel using unpaired student t-test; n=4; NS: non significant; *: p≤0.05; **: p≤0.01. 
Error bars are for the standard error of the mean (SEM). 
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Further cell viability experiments were conducted to test the hypothesis that HA22 
fusion protein is non-cytotoxic when added to cells alone. To investigate this possibility, 
recombinant HA22 protein at a concentration of 25 µg/mL was added to cells with, or 
without siRNA concomitantly. In these experiments HF28 RA B cells were grown to 
~60% confluence at a density of 2 x 106 cells/mL in complete growth medium without 
antibiotics. The kinetics of MCL1 downregulation was studied at two different time 
points. HA22 protein at 12.5 or 25 µg/mL was mixed with either scrambled siRNA or 
siMCL1 and added to the cells. The protein alone showed no cytotoxicity. Further, the 
scrambled siRNA did not interfere with viability of the cells. In contrast, siMCL1 delivered 
with the protein resulted in significant reduction of cell survival. Moreover, high protein 
concentration was shown to deliver more siMCL1 into B cells (Figure 97).     
 
Figure 97: Cell viability assay for B cells following MCL1 gene downregulation. Each 
experimental unit was compared individually with non-transfected cells at the indicated time 
points. HA22 fusion protein at a concentration of 25 µg mixed with 100 nM of siMCL1 
significantly reduced cell viability after 48 and 96 hours. However, no reduction in cell viability 
was seen using scrambled siRNA at both time points or with siMCL1 at 12.5 µg for 48 or 96 
hours. In contrast, the rate of B cell proliferation continued as expected when the cells were 
incubated with scrambled siRNA delivered with HA22 protein. Unpaired student t-test; n=3; NS: 
non significant; *: p≤0.05. **: p≤0.01. The data are presented as the mean ± SEM. 
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 To provide further proof for the specific delivery of siRNAs into RNA-inducing 
silencing complex (RISC) using HA22 fusion protein, the cell cycle kinase gene PLK1 
was targeted. Similar to the delivery of siRNA for MCL1 in the previous section, siRNA to 
mRNA of PLK1 gene (siPLK1) was mixed with two different concentrations of HA22 
fusion protein. The mixture was added to HF28 RA B cells as described for the previous 
experiments. Results from this experiment have shown significant reduction in the 
survival of B cells (Figure 98).  
 
 
Figure 98: Downregulation of PLK1 gene in B cells with HA22/siPLK1 promotes cell death. 
Each experimental unit was compared individually with non-transfected cells at the indicated 
time points. HA22 fusion protein at a concentration of 25 µg mixed with 100 nM of SMARTpool 
siRNA to PLK1 (siPLK1) reduced B cell survival and caused significant cell death at both time 
points (48 and 96 hours). In contrast, neither scrambled siRNA/HA22 (25 µg) nor siPLK1 
delivered with 12.5 µg HA22 caused reduction in cell viability. Turnover rate of PLK1 gene is 
~7.66 seconds. Unpaired student t-test; n=3; NS= non-significant; *: p<0.05. Data are presented 
as the mean ± SEM. 
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 To confirm type of cell death because of downregulation of MCL1 gene, 
activation of caspase-3 and -7 were measured using Caspase-Glo®3/7 assay. For this 
purpose, HF28 RA B cells were transfected either with HA22 fusion protein alone, 
transfection reagent with siMCL1 or HA22 fusion protein and siMCL1 at two different 
concentrations. Results from these experiments showed increases in activated caspase-
3 and -7 with decreases in the number of viable B cells in the siMCL1 treated cells but 
not the non-transfected, mock or scrambled siRNA transfected cells (Figures 99 and 
100). In addition to reduction in the number of viable B cells and activation of caspase-3 
and -7, the mRNA level of MCL1 gene was shown by real-time PCR (qRT-PCR) to be 
reduced by ~2.5 fold when the cells were treated with HA22 fusion protein/siMCL1 
complex for 48 hours (Figure 101).      
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Figure 99: Cell viability assay for B cells following MCL1 gene downregulation. Each 
experimental system was compared individually with non-transfected cells at the indicated time 
points. HA22 fusion protein at a concentration of 25 µg was mixed with 100 nM of siMCL1 and 
this mixture significantly reduced cell viability after 48 and 96 hours. However, no reduction in 
cell viability was seen using scrambled siRNA at both time points or with siMCL1 at 12.5 µg for 
48 or 96 hours. In contrast, the rate of cell proliferation continued as expected when the cells 
were incubated with scrambled siRNA delivered with HA22 fusion protein. Unpaired student t-
test; n=3; NS: non significant; *: p≤0.05. **: p≤0.01. The data are presented as the mean ± SEM. 
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Figure 100: Caspase-3 and -7 activation in B cells following MCL1 gene downregulation. 
The Caspase-Glo®3/7 assay was carried out on the same samples that were tested for B cell 
viability and analysed as shown in Figure 99. With a decrease in the number of viable B cells 
there was simultaneous increase in luminescence which was proportional to caspase-3 and -7 
activation. HA22 fusion protein at a concentration of 12.5 or 25 μg/siMCL1 (100nM) at 2.36/8 or 
4.72/8 protein/siRNA molar ratios were mixed and added to cells. However, no significant 
caspase-3 and -7 activation was seen in non-transfected, mock, scrambled or when using 
transfection reagent. Each experimental system was compared individually with non-transfected 
cells at the indicated time points. Unpaired student t-test; n=3; NS: non significant; *: p≤0.05. **: 
p≤0.01. The data are presented as the mean ± SEM. 
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Figure 101: Quantitative real-time PCR for MCL1 mRNA in B cells following gene 
downregulation. The experiment was carried out in tandem with the CellTiter-Glo® and 
Caspase-Glo®3/7 assays shown in Figures 99 and 100. mRNA levels of MCL1 gene were 
determined by real-time PCR. Fold changes in MCL1 expression were normalised to the 
expression of β-actin (ACTB), β-2 microglobulin (B2M), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), phosphoglycerate kinase (PGK1) and transferrin receptor (TFRC) 
housekeeping genes using ABI 7900HT software version 2.4.1. After 48 hours treatment of the 
cells, no significant reduction in mRNA levels was observed the experiments except for cells 
treated with HA22 fusion protein (25 μg)/siMCL1 (100nM) at 4.72/8 protein/siRNA molar ratio. 
The level of MCL1 mRNA was not significantly reduced with etoposide. Etoposide kills 
eukaryotic cells by inhibition of topoisomersae II enzyme activity rather than degradation of 
MCL1 protein. Experimental units were compared using unpaired student t-test. n=3; NS: non 
significant; *: p≤0.05. The data are presented as the mean ± SEM. 
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4.20. Discussion: 
Therapeutics based on RNAi hold promise for the treatment of numerous diseases 
including cancer. In recent years, both viral and non-viral methods for the delivery and 
expression of siRNA molecules have been used (314). Examples of non-viral delivery 
systems include using peptides, proteins, aptamers, cationic polymers and liposomes 
(315-320). Some of these agents are not suitable for systemic in vivo delivery due to 
factors such as instability in serum, undesirable pharmacokinetics, costs or feasibility of 
scaling-up to obtain therapeutic quantities. In addition to meeting these criteria, effective 
intracellular delivery of therapeutic genes is important and requires targeting to disease 
relevant tissues to minimise potentially toxic side effects of either the agent or 
associated siRNA. For example, viral vectors have been shown to be extremely efficient 
in gene transfer, but alteration in target specificity can result in a decrease in infectivity 
of the recombinant virus. In addition to concerns about safety and immunogenicity of 
viral vectors, these findings have spurred the development of non-viral vectors with 
targeting capacities for selective gene delivery (314).  
 
One approach used for delivering siRNA to specific cells is by small proteins, or 
polypeptides that contain a receptor-binding, or cell-homing domain to direct the 
complex to the surface of the desired cell population. These approaches require RNA 
binding capability, a property sometimes conferred using cationic peptide sequences 
that electrostatically interact with negatively charged siRNA backbones (321). Thus, a 
highly effective targeting gene delivery can be achieved by using engineered 
recombinant scFv antibody fragments (322-324). 
 
The results presented in this chapter describe the construction and generation of 
a biologically functional recombinant anti-CD22 scFv antibody fragment with specificity 
to human CD22.  
  
The increasing demand for recombinant proteins to be used for treatment and 
structural studies justifies the need for a rapid and scalable expression system. In this 
regard various expression systems have been used for the production of recombinant 
scFv proteins, including bacterial, yeast, insect and mammalian cells (325). 
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Currently, about 60–70% of all recombinant pharmaceutical proteins are 
produced in mammalian cells because their proper polypeptide folding, secretion and 
post-translational apparatus are better suited to produce antibodies indistinguishable 
from those produced in the human body. Many of these recombinant proteins are 
expressed in immortalised cell lines such as Chinese Hamster Ovary cells (CHO), 
mouse myeloma cells (NS0), baby hamster kidney cells (BHK), human embryonic 
kidney cells (HEK293) and human retinal cells. For instance, it has been shown that 
industrial levels of IgG production in CHO cells achieved about 5-12 g/L as result of an 
improved high producer cell line, optimised serum-free production media as well as 
optimised and prolonged production processes at very high cell densities (326). 
 
Stable expression technologies, based on integration of transgenes into the host 
genome are currently the most important systems to produce recombinant proteins in 
mammalian cells. The development of these technologies is costly because it involves 
considerable investments of time, labour, materials and equipment. More efficient 
methods for generating proteins are needed for faster evaluation of therapeutic proteins 
and for the analysis and screening in high-throughput formats such as proteomics. 
Transient gene expression in mammalian cells such as CHO and HEK293 cells is 
considered well-suited to fill these needs, with the capabilities to generate large 
quantities of products within a relatively short timeframe (327, 328). In this respect, 
successful production of recombinant antibodies in mammalian cells has been reported 
in previous studies (329-331).  
 
To address the first aim of the work described in this thesis, extensive 
experiments were carried out to generate and test recombinant anti-human anti-CD22 
scFv-protamine-His6 protein (henceforth called HA22 fusion protein). This scFv was 
shown to have retained specificity for binding to CD22 receptor on human B cells and 
able to be internalised by CD22+ B cells. 
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Production of HA22 scFv by incorporating its cDNA into pMH113 vector has been 
described previously (228). The RFB4 IgG-producing hybridoma produces and secretes 
a mAb with specificity for human CD22 (59). Generation and use of the recombinant 
scFv immunotoxin BL22 as a therapeutic agent in clinical studies for treatment of 
patients with CD22+ B cell malignancies has been described (229). BL22, for B cell 
leukaemia/lymphoma/CD22, is the immuntotoxin generated by attaching RFB4 IgG scFv 
with Pseudomonas exotoxin A (PE38) to create RFB4(scFv)-PE38. BL22 was then 
cloned into pDisplay vector (named pMH112). A mutated version of anti-CD22, called 
HA22 was generated by creating mutations in 3 amino acid residues in CDR3 region of 
the heavy chain from SSY to THW which increased affinity to human CD22 receptor by 
~15 fold (230). 
 
The HA22 scFv cDNA was used in the current study to construct a vector for 
expression in mammalian systems. To create this, the truncated protamine peptide and 
a hexahistidine tag were cloned at the C-terminus of HA22 scFv and the entire DNA 
fragment was then cloned into pcDNA6|IL2ss. This construct was used for expression of 
the recombinant protein in mammalian cells. The results showed that the protein was not 
expressed by CHO-S or HEK293T cells using pcDNA6|IL2ss. This was predicted to be 
due to inability of the IL2 signal sequence (IL2ss) to drive expression/secretion of the 
recombinant HA22 fusion protein. The finding that HA22 fusion was not 
expressed/secreted using IL2ss is in disagreement with a previous study which has 
shown secretion of recombinant proteins using the IL2 signal sequence (332). Thus, 
these investigators showed that the native coding sequence of IL2 was sufficient to 
cause secretion of recombinant murine cytokines, IL2 and gamma-interferon (γ-IFN) by 
transfected Trypanosoma cruzi protozoan parasite. Furthermore, they showed that the 
γ-IFN was produced and secreted only when the γ-IFN signal sequence was replaced by 
the IL2ss (332).  
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In order to investigate the effect of a different signal sequence, 
expression/secretion of the original HA22 scFv in pMH113 vector was studied. Protein 
expression and secretion was confirmed in HEK293T cells using pMH113 vector 
(pDisplay). Therefore, the DNA expression cassette was cloned back from 
pcDNA6|IL2ss into the original pDisplay vector which has the murine Ig kappa chain 
signal peptide. Protein expression and secretion was confirmed in the HEK293T culture 
and in the serum-free culture of HEK293F cells. The HEK293F cells were then used for 
large-scale transient transfection for its advantages such as higher transfectability, 
suspension cultivation in serum-free conditions and cost-effective scalability. Previous 
studies have also shown the successful expression/secretion of recombinant proteins 
using the murine Ig kappa chain signal peptide (282, 283).  
 
Analyses of protein expression in HEK293F cells by Western blotting showed that 
~2.03 fold more protein yield was obtained using DNA:PEI at 1:3 ratio compared with 
1:1 ratio. It has been reported that the DNA:PEI ratio is considered important to the 
optimisation of DNA compaction during transfection of human umbilical vein endothelial 
cells (HUVEC) and A549 human lung carcinoma cells (333). These observations are 
also consistent with a previous study which demonstrated that the transfection efficiency 
of DNA:PEI at 1:4 and 1:6 ratio work better than 1:1 ratio in CHO-S cells to produce 
recombinant proteins because the amount of PEI can affect the particle size of DNA:PEI 
complexes (334). PEI transfection vehicle, a cationic polymer, combines and condenses 
DNA into positively charged particles, which bind to anionic cell surface residues and are 
transported into cells via endocytosis. Inside the cell, PEI inhibits acidification of 
endosomes which will then lower the osmotic potential, hence swelling and eventual 
rupture of the organelle (‘‘proton sponge effect’’) and, thus, release of the complex into 
the cytoplasm (335-338). The emphasis of this mechanism is important because by 
extrapolation from those studies it could be presumed that HA22 fusion protein which 
contains the cationic protamine peptide causes a “proton sponge effect” for the liberation 
of the siRNA cargo from the endosome/lysosomes compartment. In addition, due to 
factors such as low cost of materials, simplicity in handling and facility in large-scale 
operations, transfection with calcium phosphate and PEI have been the most widely 
used technique among numerous commercially available transfection agents (339).  
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The effect of dialysis on the recombinant protein was also studied and proved to 
be troublesome because of significant loss of the recombinant protein. Although HA22 
fusion protein was obtained in secretable form from transfected HEK293F cell cultures, 
presumably with a properly folded and disulfide-stabilised structure, but the possibilities 
of improper folding, dimer formation or concealed hexahistidine tag were examined. For 
this purpose, the protein was analysed under non-reducing conditions as well as 
reducing conditions. No dimer formation, protein aggregates or notably concealed 
hexahistidine tag was noticed under non-reducing conditions. In a previous study, it has 
been reported that difficulty of binding of histidine tagged recombinant proteins to nickel 
column or inability to retrieve the protein by elution is possibly because of a change in 
the conformation of recombinant proteins concealing the histidine tag (340).  
 
The next issue to address was to determine the optimal concentration of 
imidazole. Unexpectedly, large amounts of impurities were removed from the nickel 
column with washes using 50 and 250 mM imidazole. Consequently, pure yields of 
HA22 fusion protein of the correct molecular size were obtained by using 500 mM 
imidazole in the elution buffer. In agreement with the present study, investigators have 
shown that CB515 scFv generated from a complement-independent bactericidal 
monomeric IgM mAb (26 kDa) against a relapsing fever caused by Borrelia species was 
obtained to high purity when the histidine tagged scFv was eluted from nickel column 
using 500 mM imidazole. The CB515 scFv was produced as soluble protein extracted 
from the periplasmic space of E. coli (341). In another study, investigators produced 
recombinant scFvPOM1 and scFvPOM2 from anti-PrPc mAbs directed against the 
epitopes of mouse prion protein PrPc. scFvPOM1 and scFvPOM2 proteins were 
expressed as soluble proteins and isolated from periplasmic extracts of E. coli cultures. 
After binding to nickel column and washing off the impurities, pure proteins were eluted 
with elution buffer containing 500 mM imidazole pH7.0 (342). HA22 fusion protein is a 
positively charged protein and hence its binding to nickel-coated beads was expected to 
be strong; thereby a higher competitive concentration of imidazole (500 mM) was 
needed to elute the protein. A recent report about significance of supercharged proteins 
has also shown that 500 mM imidazole was needed to obtain pure recombinant proteins 
(343). 
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Previous studies have shown that scFvs typically have low thermal stability and 
tend to denature or aggregate under conditions of practical uses, thus, limiting their 
biomedical and biotechnological applications (344, 345). For this reason, optimal 
conditions of storage for protein preservation was determined by investigating the effect 
of storage and freezing at 4°C, -80°C without glycerol or at -195°C in liquid N2 in 10% 
glycerol respectively. These conditions were assessed based on a technical resource 
obtained from a biotechnology company (Thermo Scientific, 
http://www.thermoscientific.com/). Analyses of the protein by Western blotting and on a 
Coomassie blue-stained SDS PAGE gel of protein retrieved after preservation confirmed 
that storage at -80°C was the best for long-term preservation of the protein. 
 
Final modification in the protein structure involved removal of the haemagglutinin 
A epitope (HA) tag at the N-terminus of HA22 protein. The HA tag was removed by 
modifying the pDisplay vector backbone so that the signal peptide is unaffected because 
this HA tag was preceded by Ig kappa-chain signal peptide. Elimination of HA epitope 
was carried out to minimise the possibility of non-specific binding of the HA tag to cell 
surface receptors on T cells. In support of this notion, a previous study revealed that 
CD4+ T cells can recognise epitopes within the influenza HA protein and that naive T 
cells specific for HA epitopes undergo significant expansion (346). 
 
The immediate issue to address, subsequent to obtaining the protein, was 
whether HA22 fusion protein has retained its binding to CD22. Data form the flow 
cytometry analyses showed that the HA22 fusion protein bound specifically and only to 
CD22+ B cells HF28 RA and L3/Bcl-2. 
 
This new delivery system, fusion protein, for siRNA that utilises CD22-mediated 
endocytosis relies on the specificity of the recombinant protein and ability to form 
electrostatic interactions with siRNA. siRNA is a negatively charged molecule because 
of the phosphate group in the nucleotides backbone. Therefore, it will be possible for 
siRNA to form electrostatic interactions with positively charged protamine. Despite the 
fact that HA22 fusion protein was shown by confocal microscopy to deliver a red-labeled 
siRNA (siGLO red) intracellularly, the robustness of this interaction was validated by gel 
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mobility retardation assay. Thus, binding of a plasmid DNA (pcLuc+) to cationic HA22 
fusion protein was confirmed by observation of resistance of DNA migration using 
electrophoretic mobility gel shift assay (EMSA). In support of this, a previous report has 
shown retardation of DNA movement due to DNA/protein interaction (347). Similarly, 
siRNA/protein interaction was observed in another study using EMSA (348). 
 
A number of studies have used engineered scFv-protamine fusion proteins for 
directed delivery of siRNA into cancer cells via receptor-mediated endocytosis. For 
antibody-mediated targeted delivery of siRNA in vivo, anti-HIV1 envelope scFv-
protamine was complexed with siRNA and used to deliver siRNAs to cells transfected to 
express HIV envelope glycoprotein gp160 as a proof of concept (120). Similarly, an anti-
ErbB2 scFv-protamine fusion protein was shown to deliver siRNAs specifically to ErbB2-
expressing (ErbB2+) breast cancer cells (160). In another study it was shown that a 
scFv-protamine fusion protein targeting the human integrin lymphocyte function-
associated antigen-1 (LFA-1) allowed efficient delivery of siRNAs and cell type-specific 
gene silencing in primary lymphocytes, monocytes and dendritic cells (161). Recently, it 
has been shown that targeted delivery of PLK1 siRNA with the fusion protein anti-HER2 
scFv-protamine in vivo using Her2+ breast cancer models in mice significantly 
suppressed Her2+ breast cancer growth and metastasis (162).  
 
The induction of apoptosis in aberrant B cells including cancer cells is one of the 
objectives of targeted therapies in cancer. The results shown in this chapter confirmed 
that this objective could be accomplished. In order to achieve this, siRNA was used to 
downregulate a specific gene involved in B cell survival. The question asked was 
whether downregulation of the anti-apoptotic MCL1 gene, or the cell cycle kinase PLK1 
gene using siRNA could be sufficient to induce apoptosis. 
 
Most conventional cytotoxic agents indirectly induce apoptosis through DNA 
damage and cell cycle arrest. However, malignant cells frequently acquire defects, 
including oncogene activation and downregulation of apoptotic signaling pathways, 
thereby, allowing the cells to evade apoptosis (3, 163). For these reasons and the high 
levels of toxicity frequently observed with standard chemotherapeutic drugs, recent 
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approaches to cancer therapy have focused on targeting key components of pathways 
shown to be fundamental to tumour survival and disease progression (349). This 
approach is intended to circumvent acquired drug resistance pathways and re-sensitise 
the malignant cell to apoptosis. 
 
Previous studies have shown that the anti-apoptotic BCL-2 family member, MCL1 
is highly expressed in haematopoietic stem cells (HSCs) and it is essential for promoting 
their survival (350, 351). Furthermore, it has been shown that deletion of MCL1 during 
early lymphocyte differentiation increases apoptosis and arrests development at the pro-
B cell stage (352). In addition, overexpression of MCL1 has been reported in various 
forms of leukaemia (353, 354).  
 
Therefore, MCL1 gene was selected for targeted downregulation using siRNA. 
For this purpose, siRNA to MCL1 (siMCL1) was either delivered with 12.5 or 25 µg of 
HA22 fusion protein or delivered with NeoFX or INTERFERin transfection reagent to B 
cells. The results revealed significant reduction in B cell viability after 48 and 96 hours 
using siMCL1/HA22 complexes. However, no reduction in cell viability was seen using 
scrambled siRNA, HA22 fusion protein alone or siMCL1 delivered with transfection 
reagent.  
 
Whilst reduction in B cell viability was observed using HA22 fusion 
protein/siMCL1 complex, an intriguing finding was that no reduction in B cell viability was 
seen using the lipid based NeoFX or INTERFERin transfection reagents. There is, 
however, a possible explanation for this phenomenon. Lipid nanoparticles (LNPs) are 
the most advanced siRNA delivery system to date, having recently shown therapeutic 
efficacy in clinical trials (355). Although efforts to understand the physicochemical 
properties of nanoparticles that contribute to efficient cellular delivery are ongoing, the 
cellular processes that determine the efficiency of nanoparticle-mediated siRNA delivery 
remain largely unclear (356, 357). In this regard, investigators have recently examined 
the cellular uptake of AlexaFluor®647–labeled siRNA to green fluorescent protein (GFP) 
complexed with LNPs using cellular trafficking probes in combination with automated 
high-throughput confocal microscopy. HeLa cells, NPC1 fibroblasts and stably-GFP-
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transfected LLC-PK1 epithelial cells were used for this purpose. These experiments 
showed that siRNA delivery was substantially reduced as ~70% of the internalised 
siRNA underwent exocytosis through escape of LNPs/siRNA complexes from late 
endosomes/lysosomes and the genes under investigation were unaffected. 
Furthermore, these studies showed that Niemann-Pick type C1 (NPC1), a protein that 
resides in the limiting membrane of endosomes and lysosomes and mediates 
intracellular cholesterol trafficking, is an important regulator of the major recycling 
pathways of LNP-delivered siRNAs. Thus, NPC1-deficient cells showed enhanced 
cellular retention of LNPs inside late endosomes and lysosomes and increased gene 
silencing of the target gene (358).  
 
In the current experiments, HA22 fusion protein alone did no show any cytotoxic 
effect on HF28 RA treated B cells as B cell viability was not reduced. In agreement with 
this finding, a previous study has shown that HA22 scFv on its own is non-cytotoxic 
unless toxicity is attached to it using either a cytotoxic drug or a toxin for therapeutic 
purposes (359). 
 
The scFv of mutated BL22, HA22 which has higher affinity for CD22 was shown 
to be resistant to proteolytic digestion and, therefore, with increased anti-tumour activity 
because of less intracellular degradation (360, 361). HA22 immunotoxin, called 
Moxetumomab pasudotox, is currently in development by the biologics division of 
AstraZeneca and MedImmune and is in Phase III trial for the treatment of patients with 
mature B cell malignancies: (http://www.astrazeneca.com/, 
http://www.medimmune.com/). 
 
Treatment with Moxetumomab pasudotox led to complete remission in patients 
with relapsed/refractory hairy cell leukaemia (HCL) and improved outcome in patients 
with chronic lymphocytic leukaemia (CLL) and paediatric acute lymphoblastic leukaemia 
(ALL) (230). In addition, results from a recent single-cycle pharmacokinetic and 
pharmacodynamic study in cynomolgus monkeys supported the clinical benefits of 
Moxetumomab pasudotox immunotoxin in patients with CD22+ B cell malignancies 
(362).  
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BL22 recombinant immunotoxin is composed of the scFv of anti-CD22 RFB4 mAb 
fused with a 38 kDa truncated Pseudomonas aeruginosa exotoxin derivative (PE38) 
(228, 230). Following internalisation of BL22, the C-terminus translocation domain of the 
PE38 toxin, which contains a REDL sequence (KDEL ER-targeting motif sequence for 
ER retrieval), binds intracellularly to the Lys-Asp-Glu-Leu endoplasmic reticulum protein 
retention receptor 1 (KDEL receptor) that carries it to the endoplasmic reticulum. The 
toxin is then translocated to the cytosol where its adenosine diphosphate (ADP)-
ribosylating enzyme domain inactivates translation elongation factor 2 (EF2), thereby 
inhibiting protein synthesis and apoptotic cell death (363). The mechanism of leukaemic 
cell killing was reported in a previous study to be through lowering MCL1 protein level 
and unleashing the pro-apoptotic Bak protein, thereby, inducing caspase-3-mediated 
apoptosis (364). 
 
With regards to downregulation of MCL1 gene, several studies have reported that 
downregulation of MCL1 leads to sensitisation of tumour cells to different treatment 
regimens in vitro, as has been shown for cholangiocarcinoma, chronic myelogenous 
leukaemia, sarcoma and malignant melanoma (365-368). It has also been reported that 
the anti-apoptotic protein MCL1 is a rapidly inducible protein with a short half life of ~20-
40 minutes (369-372). Therefore, MCL1 differs from other members of the Bcl-2 family in 
having a short half-life and inhibition of its expression and/or neutralisation of its anti-
apoptotic function could probably make MCL1-dependent cells more susceptible to 
induction of apoptosis (373). Consequently, interference with the synthesis of MCL1 
could have an effect on protein levels and be of potential therapeutic use in many types 
of cancers. In this respect, investigators have shown that targeting of MCL1 gene with 
siRNA renders hepatocellular carcinoma cells more sensitive to chemotherapy in vitro. 
Thus, it was reported that siRNA to MCL1 gene mRNA efficiently downregulated MCL1 
expression in the human hepatoma cell lines Hep3B and HepG2 treated with cisplatin, 
mitomycin C and 5-Fluorouracil, led to activation of caspase-3 and -9 and increased 
apoptosis rates from ~20% to ~60% (202). 
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Consistent with findings by other investigators, the present study of MCL1 gene 
downregulation by HA22/siMCL1 resulted in reduced B cell viability and activation of 
caspase-3 and -7.  However it remains to determine how exactly degradation of MCL1 
protein by HA22/siMCL1 initiates apoptosis. In a previous study, investigators revealed 
that downregulation of MCL1 results in permeabilisation of the outer mitochondrial 
membrane and consequently release of the apoptogenic cytochrome c (cyt c) and 
apoptosis-inducing factor (AIF) into cytoplasm. These in turn activated caspase-9 and 
instructed the human leukaemia cells to die by apoptosis (374). In the current study, 
quantitative RT-PCR analysis has shown that HA22 fusion protein (25 μg)/siMCL1 (100 
nM) complex added to HF28 RA B cells decreased MCL1 mRNA level by ~2.5 fold after 
48 hours. In contrast, in a recent study investigators reported ~0.5 fold decrease in 
MCL1 mRNA level in association with the induction of apoptosis in CD84+ B cells from 
patients with CLL treated with anti-CD84 antibody. Furthermore, these investigators 
reported downregulation of CD84 expression and its immune-mediated blockade 
induced cell death in vitro and in vivo which was associated with reduction of MCL1 
expression (375).  
 
In parallel to MLC1, downregulation of the cell cycle kinase PLK1 gene has been 
shown to cause cell cycle arrest and apoptosis as it has been shown to be 
overexpressed in cancer (207). In the current study, cell viability assays showed that 
100 nM siRNA to mRNA of PLK1 gene delivered with HA22 fusion protein via CD22 
reduced B cell viability. This is consistent with a study in which investigators tested the 
therapeutic potential of anti-HER2 scFv-protamine/siRNA delivery in vivo using mice 
models xenografted with human breast cancer biopsies. These investigators assessed 
whether PLK1 siRNAs complexed with anti-HER2 scFv-protamine fusion protein (F5-P) 
could suppress Her2+ breast cancer cell lines and primary human cancers in orthotopic 
breast cancer models (162). PLK1-siRNAs at 30, 50 and 100 nM mixed with F5-P fusion 
protein inhibited target gene expression, reduced proliferation and induced apoptosis of 
Her2+ breast cancer cell lines and primary human cancer cells in vitro without triggering 
an interferon response. Intravenous injection of F5-P/siPLK1 complexes concentrated in 
orthotopic Her2+ breast cancer xenografts and persisted for at least 72 hours. The result 
was suppression of PLK1 gene expression and hence induction of tumour cell 
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apoptosis. Further, intravenous injection of F5-P/siPLK1complexes (20 μg of F5-P/40 μg 
siPLK1 in 1:6 F5-P/siPLK1 molar ratio) retarded Her2+ breast tumour growth, reduced 
metastasis and prolonged survival without evident toxicity (162). In a previous study, 
delivery of 100 nM of siPLK1 to human prostate cancer cells in vitro using 
oligofectamine transfection reagent resulted in induction of apoptosis (376). In a further 
study, PLK1 was targeted using a vector-based siRNA to the gene in HeLa cells. 
Results of this study showed that after 24 hours of transfection, PLK1 depletion inhibited 
cell proliferation, decreased viability and resulted in cell-cycle arrest and apoptosis 
(377). Other investigators used ~56 nM siRNA to downregulate PLK1 gene in colon, 
breast, cervix and lung cancer cell lines and shown that siRNA targeted to PLK1 
decreased cell proliferation by ~66-99% after 48 hours of transfection and apoptosis was 
increased from ~5% to ~ 50% (378). 
 
One of the advantages that targeted therapy provides over standard 
chemotherapies is less toxic side effects because of less damage to normal cells (1, 
379). However, some of the adverse effects associated with chemotherapy can be 
improved upon, for instance by using liposome-based drugs. Liposome-based 
nanoparticle delivery systems have improved anti-cancer effects because they can 
improve the pharmacokinetics and pharmacodynamics of their associated drugs (380). It 
is expected that sustained release of anti-cancer drugs from the liposomes (approximate 
diameter ~60-150 nm) and passive diffusion of the released drugs throughout the 
tumour interstitial fluid results in uptake by tumour cells (381). However, because tumour 
vessels lack tight junctions between adjacent vasculature endothelial cells, the size of 
the gaps between the cells that line tumour blood vessels, ~100-600 nm (382, 383), is 
large enough to allow the extravasation of most liposomes from the vessel into the 
tumour interstitial space. This in turn can have detrimental effects on the healthy 
surrounding tissues. As a consequence, targeted anti-cancer drug delivery has more 
advantages because first, the high drug ratio relative to liposome-drug conjugates can 
be obtained and, second, specificity to target the desired cells can be increased for 
example through the multivalent presentation of univalent ligands such as scFv 
fragments (380). 
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With regards to therapeutic siRNAs, an advantage would be the potential for the 
development of co-delivery systems of various anti-cancer drugs and therapeutic 
siRNAs for synergistic effect. For example, in a previous study it was demonstrated that 
siRNA to MCL1 gene could be formulated in cationic solid lipid nanoparticles (cSLN) for 
co-delivery with paclitaxel to cancer cells concomitantly. These nanoparticles were 
composed of 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine and were prepared by 
emulsification solidification technique. For co-delivery of therapeutic siRNA, 20 nM of 
human MCL1 specific siRNA was complexed with paclitaxel/cSLN. The results showed 
that the MCL1 mRNA levels were significantly reduced in human epithelial carcinoma 
KB cells treated with siMCL1/paclitaxel/cSLN complexes. Furthermore, in mice 
xenografted with KB cells, intra-tumoural injection of siMCL1/paclitaxel/cSLN complexes 
significantly reduced the growth of tumours (384). 
 
In addition to the cited advantages, the use of siRNA can be advantageous in 
cancer patients who are resistant to chemotherapeutic drugs or small molecule 
inhibitors. For example, a chemical library for screening several compounds identified 
ABT-737 small molecule, a pan Bcl-2 inhibitor that binds Bcl-2/Bcl-xL (but not MCL1) 
with high affinity to disrupt their interaction with Bax/Bak and enhance the apoptotic 
signals, especially when combined with chemotherapeutic drugs (385). Upon binding of 
ABT-737, pro-apoptotic proteins such as Bid and Bim are prevented from heterodimer 
formation with anti-apoptotic Bcl-2 family proteins, thereby promoting Bax and Bak 
activation through oligomer formation (385). ABT-737 has been shown in preclinical 
studies, as a single agent or in combination with other chemotherapeutic drugs, to be 
effective against acute myeloid leukaemia (AML) (386), multiple myeloma (387), 
lymphoma (388), CLL (389), small cell lung cancer (390) and ALL (391). Although ABT-
737 is a promising agent in development for cancer therapy, high level of MCL1 
expression in small cell lung cancer cells (390) and other types of cancer cells (389, 
392) has been associated with resistance to ABT-737. Therefore, because MCL1 
overexpression is associated with resistance to ABT-737, inhibition of MCL1 expression 
may potentiate the cytotoxicity of ABT-737. 
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In conclusion, results presented in this chapter provide evidence of proof of 
principle for the approach and that this siRNA delivery approach can fulfill and establish 
the foundation for the next step. As the focus and interest of future studies, these involve 
the ability to induce apoptosis as a means for therapy. Therefore, future plans will focus 
on validation and reliability of the approach on how to specifically and selectively target 
aberrant cells, for example cancer cells in vivo using models of B cell leukaemias and 
lymphomas. The above mentioned in vitro experiments have clearly shown that the fate 
of mature B cells can be changed following controlled post-transcriptional 
downregulation of gene expression. In this study, this has been achieved by specific 
targeting of B cells using CD22 engineered mAb to deliver siRNA to downregulate 
genes with roles in B cell survival.  
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Harnessing A20FMDV2-protamine Peptide for 
Targeted Delivery of siRNA to Tumour Cells 
expressing αvβ6 Integrin 
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My chosen study direction is based on, and leading to, development of innovative 
targeted therapies for cancer, essentially with the aim of inducing apoptosis in cancer 
cells through gene silencing. Thus, the approach embarked on exploiting siRNA delivery 
to B cells using engineered scFv-protamine proteins to achieve this objective. While 
carrying out these studies, a number of investigators reported a specific protein derived 
from foot-and-mouth-disease virus that binds specifically and with high affinity (~3-6 
nmol/L) to αvβ6 integrin  which is highly expressed on cancer cells (113, 393). This 
interesting finding was highly relevant to my studies and prompted experiments to 
address two possibilities. First, whether the protamine peptide can override the 
specificity of targeting using a synthetic peptide containing A20FMDV2 and the arginine-
rich protamine peptide used to deliver siRNA directly to solid tumour cells; second, to 
verify the fidelity of siRNA delivery with A20FMDV2-protamine peptide to αvβ6-positive 
tumour cells. This was important because of the positive charge of the peptide which 
raises the possibility of non-specific interaction with cells irrespective of scFv specificity. 
For this purpose, I carried out experiments to specifically deliver siRNA with the 
protamine peptide attached to A20FMDV2 to tumour cells through receptor-mediated 
endocytosis.   
 
This chapter describes the analysis of A20FMDV2-protamine peptide for the 
specificity of its binding and internalisation into cancer cells expressing αvβ6 integrin.  
 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
 
264 
 
5.1. Generation of αvβ6 integrin-specific A20FMDV2-protamine peptide: 
A 42-mer A20FMDV2-protamine peptide was synthesised by fusing the αvβ6 integrin-
binding domain of A20FMDV2 (NAVPNLRGDLQVLAQKVART) with the truncated 
protamine domain (RSQSRS RYYRQRQRSRRRRRR) (PeptideSynthetics, Hampshire, 
UK). According to the manufacturer, the FITC labeled peptide was produced on an 
automatic synthesiser, purified and provided in a lyophilised format. For the purpose of 
imaging studies, the peptide was labeled with FITC at the N-terminus. Because FITC 
can not be directly attached to the N-terminus of an alpha amino acid as the thiourea 
bond is not stable. Alternatively, aminohexanoic acid (Ahx), a derivative and analogue of 
lysine, was used as a spacer as the FITC is stable on Ahx. In addition, the Ahx will 
provide a certain degree of protection against attack of the peptide by proteases (394). 
According to PeptideSynthetics, the FITC-Ahx-A20FMDV2-protamine peptide was first 
separated on a High Performance Liquid Chromatography (HPLC) column before being 
introduced to mass spectrometer. The peptides were eluted from the HPLC column 
using a linear increasing gradient of 0-80% organic solvent acetonitrile over 20 minutes, 
so that the peptides elute in order of their hydrophobicity (Figure 102). This separation 
step was crucial, since it is often assumed during the analysis that only a single peptide 
species enters the mass spectrometer during each cycle. The peptides were ionized 
before entering the mass spectrometer for the detailed analysis of the amino acid 
composition (Figure 103). The product was purified in acetonitrile and water containing 
0.1 % trifluoroacetic acid prior to lyophilisation. The product would therefore be present 
as its trifluoroacetic acid salt. Lyophilised FITC-Ahx-A20FMDV2-protamine peptide was 
resuspended in 192 μL of 100% DMSO (1.1 g/mL) to give a final stock concentration of 
10 mM. Aliquots of the peptide were frozen at -20°C and further diluted with the growth 
medium before use. 
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Figure 102: HPLC chromatogram depicting the purity of FITC-Ahx-A20FMDV2-protamine 
peptide according to the manufacturer, PeptideSynthetics. Signals generated from the 
peptide are detected by the instrument in the detector over time. This implies that, the signal 
increases and the chromatogram displays a "peak." Each peak in the chromatogram, labeled 
with retention time, indicates the presence of a chemical in the sample. Retention time indicates 
how long it takes for a compound to come out of the HPLC column. The first few small peaks in 
the chromatogram (around 2-3 minutes) are "noise" from the sample injection and those are 
ignored. The large peak represents the purified peptide in the sample. HPLC parameters include 
run conditions using 0-80% acetonitrile linear gradient over 20 minutes. Solvents are (water and 
0.1% TFA) and (acetonitrile and 0.1%TFA). Flow rate is 1 mL/minute. Column is C18 5u 100A. 
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Figure 103: Mass spectrometry analysis of FITC-Ahx-A20FMDV2-protamine peptide 
according to the manufacturer, PeptideSynthetics. Component structure of the peptide was 
determined based on positively-charged ions seen on the spectrum. Electrospray ionization 
(ESI) was used in producing ions from the peptide because it overcomes the propensity of these 
molecules to fragment when ionized. Mass spectrometry parameters are ESI: +VE ion; 
molecular weight: 5599.3 Daltons; ions shown are (+9) 623.1, (+8) 700.9, (+7) 800.9 and (+6) 
934.1. A 1 mass unit variance was considered within the range of the equipment used; in this 
case the mass spectrometer used was a micro mass ZMD 4000 ESI.  
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5.2. Analysis of the specificity and kinetics of internalisation of FITC-Ahx-
A20FMDV2-protamine peptide by αvβ6-positive cells: 
In order to assess the feasibility that using a truncated protamine peptide to deliver 
siRNA into cells will not compromise targeted delivery of A20FMDV2-protamine peptide 
to tumour cells expressing αvβ6 integrin was carried out. 
 
For assessment of internalisation by confocal microscopy, adherent monolayers 
of αvβ6-negative A375Ppuro and αvβ6-positive A375Pβ6 cells were grown on 13 mm 
diameter coverslips placed in 4-well plates. Binding and internalisation assays revealed 
that the peptide retained its ability to specifically bind αvβ6 integrin on the cell 
membrane when cells were stained with the FITC labeled peptide on ice. In parallel, 
cells that did not express the integrin were also stained with the peptide but these did 
not show membrane staining. Furthermore, following incubation of the cells at 37°C, 
clustering of the peptide was observed in the cytoplasm of the αvβ6-positive cells. The 
kinetic data confirmed that the peptide bound specifically to and was internalised only by 
αvβ6-positive cells (Figure 104). 
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Figure 104: Confocal microscopy analysis of the binding to and kinetics of internalisation 
of FITC-Ahx-A20FMDV2-protamine peptide to αvβ6 integrin expressing cells. Cells at ~2 x 
104 per well are plated onto 13 mm diameter coverslips in a 4-well plate overnight. Next day, 
cells are washed and replaced with ice-cold FITC-Ahx-A20FMDV2-protamine peptide (100 nM 
peptide/500 μL serum-free DMEM) and incubated for 15 minutes on ice. Cells are then 
incubated at 37°C for 15 and 30 minutes, fixed in 4% formaldehyde, stained with DRAQ5TM (far 
red) nuclear counter stain and mounted on slides. A and B represent A375Pβ6 cells stained with 
the peptide on ice at the start of the kinetics study (0 time point on ice) and then at 37°C for 15 
(C and D) and 30 minutes (E and F), respectively. The figures show a clear marginal staining in 
A375Pβ6 cells, followed by clustering and internalisation of the peptide at different time points 
(indicated by yellow arrows). G, H and I represent A375Ppuro cells stained on ice and then 
incubated for 15 and 30 minutes at 37°C, respectively. Some of the green staining seen in β6-
negative cells (H) could be due to non-specific entrance of truncated forms of the peptide. Slides 
are analysed using a Zeiss LSM710 confocal microscope using oil immersion 63x objective lens. 
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5.3. Peptide/DNA and peptide/siRNA complex formation were confirmed by gel 
retardation assay: 
A constant amount of siRNA (100 nM) or plasmid DNA (200 ng/µL) was mixed with 
increasing concentrations of FITC-Ahx-A20FMDV2-protamine peptide and the mixture 
then resolved by  1% agarose gel electrophoresis. Gel retardation assays confirmed the 
formation of stable peptide/DNA and peptide/siRNA complexes (Figures 105 and 106). 
 
  
Figure 105: Agarose gel electrophoretic mobility shift assay indicating peptide/DNA 
complex formation. The gel shows retarded migration of DNA due to complex formation by 
electrostatic interaction between the positively charged protamine and the negatively charged 
pcLuc+ plasmid.  
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Figure 106: Agarose gel electrophoretic mobility shift assay indicating peptide/siRNA 
complex formation. The image shows retardation of migration of siRNA due to complex 
formation by electrostatic interaction between the positively charged protamine and the 
negatively charged siRNA (scrambled siRNA). The peptide/siRNA complexes in the agarose gel 
were exposed for 5 seconds (top) or 15 seconds (bottom) to UV light. The yellow arrow indicates 
siRNA. 
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5.4. FITC-Ahx-A20FMDV2-protamine peptide specifically delivers siGLO Red 
siRNA into αvβ6-positive cells: 
Binding and kinetics of internalisation for FITC-Ahx-A20FMDV2-protamine peptide 
showed selectivity of peptide delivery. Experiments on the delivery of siGLO Red with 
the peptide were then performed to verify the ability of the A20FMDV2-protamine 
peptide to form a stable complex with siRNA and to selectively deliver into cells was 
carried out using αvβ6-negative (A375Ppuro or DX3Ppuro) and αvβ6-positive (A375Pβ6 
or DX3Pβ6) cells. To achieve this, the peptide was diluted in growth medium to 10 µM 
and bound with siGLO Red siRNA (10 nM) for 15 minutes on ice. Adherent cells grown 
overnight on coverslips in 4-well plates were washed and the mixture added to cells. The 
results from these experiments showed that the peptide formed a stable complex with, 
and delivered siGLO Red siRNA specifically to αvβ6-positve A375Pβ6 cells only 
(Figures 107 and 108). 
 
 
 
Figure 107: Confocal microscopy images confirming the lack of A20FMDV2-protamine 
peptide/siGLO Red complex binding to and internalisation by αvβ6-negative A375Ppuro 
cells. The complex did not bind to cells incubated on ice (A) nor was it internalised when the 
cells were incubated at 37°C for 30 minutes (B). Cells (~2 x 104 per well) are plated overnight, 
then incubated with FITC-Ahx-A20FMDV2-protamine peptide (10 μM)/siGLO Red (10 nM) in 
serum-free DMEM for 15 minutes on ice then incubated at 37°C for 30 minutes. Cells are then 
fixed in 4% formaldehyde, stained with DAPI and mounted on slides. The figures represent 
merging of FITC, DAPI and siGLO Red.  
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Figure 108: Confocal microscopy images demonstrating specific binding and delivery of siGLO Red siRNA combined with 
FITC-Ahx-A20FMDV2-protamine peptide to αvβ6-positive cells. Cells at ~2 x 104 per well are plated onto 13 mm diameter 
coverslips in a 4-well plate overnight. The peptide was mixed with the siGLO Red on ice for 15 minutes and then added to cells. The 
figures depict membrane binding of the peptide (10 μM)/siGLO Red (10 nM) complex to αvβ6-positve A375Pβ6 cells when the cells 
were kept on ice for 15 minutes (at 0 time point) (A to D) followed by intracellular localisation of the complex when cells were 
incubated at 37°C for 30 minutes (E to H).   
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 Selective delivery of siGLO Red siRNA with the peptide was further confirmed 
using another matched pair of cell lines, DX3Ppuro and DX3Ppuroβ6. DX3 is a human 
melanoma cell line which is infected with pBabe retroviruses encoding the Puromycin 
resistance gene or, in addition, cDNA for human integrin β6 as described in a previous 
study (113). Accordingly, DX3Ppuro and DX3Ppuroβ6 cell lines were stably transfected 
either with a Puromycin resistance gene or Puromycin resistance gene and human 
integrin β6 respectively (113). Following membrane binding of the peptide/siGLO Red 
complex to cells on ice and subsequent to incubation at 37°C, obvious internalisation 
was observed in DX3Pβ6 cells. Intracellular focal clustering of peptide/siGLO Red 
complexes was clearly seen in the cytoplasm of these cells (Figure 109). Furthermore, 
intracellular localisation of the peptide/siGLO Red was confirmed by taking slices of Z-
stacking images through different planes of DX3Ppuroβ6 cells incubated for 45 minutes 
at 37°C (Figure 110).    
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Figure 109: Kinetic study by confocal microscopy for the specific delivery of siGLO Red 
siRNA with FITC-Ahx-A20FMDV2-protamine peptide to αvβ6-positive cells. Cells at ~2 x 
104 per well are plated onto 13 mm diameter coverslips in a 4-well plate overnight. The 
A20FMDV2-protamine peptide (10 μM)/siGLO Red (10 nM) complex was added to DX3Ppuro 
cells to which they neither bound to the membrane nor internalised (A, C and E). In contrast, 
membrane binding of the peptide/siGLO Red complex to DX3Pβ6 cells on ice (0 time point) (B) 
followed by intracellular localisation of the complex after incubation of the cells at 37°C for 30 
and 45 minutes (D and F) respectively, can be clearly seen (yellow arrows). DAPI nuclear 
staining: blue. 
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Figure 110: Z-stacking confocal microscopy images demonstrating intracellular 
localisation of FITC-Ahx-A20FMDV2-protamine/siGLO Red complex in DX3Pβ6 cells. The 
Z-stacking slices are based on the image F shown in Figure 109 after incubation of DX3Ppuroβ6 
cells for 45 minutes at 37°C. The yellow arrow indicates peptide/siRNA complex inside the cells. 
The figures represent merging of FITC (green), DAPI (blue) and siGLO Red (red).  
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5.5. Delivery of siRNA to ITGB6 gene by FITC-Ahx-A20FMDV2-protamine peptide 
via αvβ6 integrin: 
In addition to the objective of testing for specificity of delivery of the truncated protamine 
peptide, FITC-Ahx-A20FMDV2-protamine was further investigated for its ability to 
modulate the biology of invasive carcinoma cells. The specific aim was to alter survival, 
or invasion that enables tumour cells to spread via αvβ6 integrin and, thereby, hinder 
tumour growth and invasion. For this purpose, siRNA to integrin β6 mRNA was delivered 
via the αvβ6 receptor. To investigate this, adherent monolayers of αvβ6-positive VB6 
cells were used. FITC-Ahx-A20FMDV2-protamine peptide was diluted in the growth 
medium to 100 nM and bound with varying concentrations of siITGB6 (50, 100 and 150 
nM) for 15 minutes on ice. The mixtures were then added to cells and incubated at 37°C 
for 5 days. The effect of ITGB6 downregulation was studied at the protein level by 
Western blotting. Results from these experiments showed a reduction in ITGB6 
expression at the protein level. The peptide alone at 1000 nM resulted in the reduction 
of ITGB6 protein level. This could be explained by the fact that engagement of the 
integrin receptor with the peptide might result in receptor-mediated endocytosis of the 
complex and, ultimately, degradation of the receptor without being recycled back to cell 
surface. Additionally, siITGB6 delivered with the peptide reduced expression of ITGB6 
protein (Figure 111). However, the result from transfection of cells with 100 nM of 
siITGB6 using NeoFX transfection reagent did not show reduction of the ITGB6 protein.   
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Figure 111: Western blot analysis of integrin β6 protein downregulation. The peptide 
without siRNA at 1000 nM reduced ITGB6 expression and also 100 nM of the peptide with 
siRNA to ITGB6 resulted in the reduction of ITGB6 protein level. The cells were also analysed 
for the level of expression of GAPDH housekeeping gene to exclude any toxicity due to the 
peptide or off-target effect from the siRNA. Integrin β6 was detected with goat polyclonal anti-
integrin β6 antibody (1:200) and revealed with secondary HRP-conjugated anti-goat IgG 
antibody (1:2000). αv integrin subunit is 150 kDa. 
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5.6. Discussion: 
Targeted therapies have a number of advantages over standard therapies including the 
delivery of the therapeutic specifically to the desired cells so achieving maximal 
therapeutic effects and minimising the adverse effects associated with the treatment (2). 
However, several challenges for all targeted therapeutic approaches remain. For 
example, in the case of the targeted therapy I have been developing it is possible that 
the protamine peptide could override the targeting molecule to which it is attached in 
order to directly mediate uptake into cells. 
 
Protamines are a group of arginine-rich cationic proteins that function to package 
spermatids DNA in vertebrate species (46, 47). Because of condensation of large 
amounts of DNA, ~50 kb DNA in each protamine/DNA particle (48), therefore, one major 
advantage of using the protamine peptide is the nucleic acid-binding property which 
allows condensation of siRNA or DNA and hence facilitation of intracellular delivery. In 
recent years, protamine has attracted growing interest as a cell penetrating peptide, as it 
possesses potency in mediating cellular translocation of its payloads such as siRNA 
(395-397). Furthermore, studies have shown that truncated protamine exhibits low 
toxicity (398, 399). 
 
Protamine salts have been used in combination with liposomal preparations as a 
non-specific cell delivery mechanism of nucleic acids such as plasmid DNA into cells 
because of their characteristic arginine-rich and strongly basic aliphatic nature (400). 
The first attempts to deliver oligonucleotides with nanoparticles consisting only of 
protamine and oligonucleotide were described previously (401, 402). In these studies, 
investigators have complexed phosphodiester antisense oligonucleotides (ODNs) 
against the c-myc proto-oncogene with protamine peptide and showed increased 
cellular uptake into human histiocytic lymphoma U937 cells (401). Furthermore, complex 
formation between ODN and protamine particles was confirmed by gel mobility shift 
assay (402). Other investigators also showed that protamine can be used in the delivery 
of ODNs into cells such as albumin/protamine/oligonucleotide nanoparticles (403, 404). 
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In the experiments described in this chapter, selectivity in targeting was examined 
in a well-defined cell system based on delivery through αvβ6 integrin receptor by fusing 
protamine peptide to αvβ6 integrin-specific A20FMDV2 peptide. The FITC-A20FMDV2-
protamine peptide was synthesised commercially to examine (a) non-specific delivery of 
unconjugated peptide into αvβ6-positive and -negative cells and (b) to explore targeted 
delivery and activity of the peptide conjugated with siRNA. 
 
αvβ6 integrin belongs to a large family of heterodimeric transmembrane receptors 
that mediate cell-substratum adhesion. It is an epithelial specific integrin that is not 
expressed in healthy adult epithelia but is upregulated during wound healing and in 
cancer (101, 102). αvβ6 integrin has been shown to inhibit apoptosis, modulate invasion 
and promote carcinoma progression (405).        
 
In a previous study it has been shown that a 35 kDa HS1-associated protein X-1 
(HAX-1), a binding partner protein of the β6 cytoplasmic tail, regulates cancer cell 
motility and invasion via αvβ6 internalisation by clathrin-mediated endocytosis. Hence, 
the kinetics of αvβ6 internalisation was shown to be 15-30 minutes and reached a 
steady-state level inside the cells as studied by relative decrease of band intensity of 
both αv and β6 subunits on a Western blot after downregulation of the HAX-1 gene 
using siRNA (406). Thus αvβ6 integrin can be efficiently targeted with A20FMDV2 
peptide. A20FMDV2, which shows specificity and forms stable binding to αvβ6 integrin, 
is a 20-mer peptide derived from the VP1 coat protein of the foot-and-mouth-disease 
virus (407).  
 
For the first aim, initial confocal microscopy experiments confirmed that the FITC-
A20FMDV2-protamine peptide did not mediate non-specific uptake into αvβ6-negative 
cells. Thus, specific binding and internalsiation of the FITC-A20FMDV2-protamine 
peptide was confirmed in αvβ6-positive cells after 15 minutes. This was an important 
experiment because it both confirmed previous observations of A20FMDV2 binding 
characteristics such as internalisation by αvβ6-expressing cells using both fluorescently-
labeled and radio-labeled A20FMDV2 peptides with similar kinetics (408). In the same 
study, they have also tested specificity of binding of A20FMDV2 peptide to αvβ6 integrin 
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by flow cytometry using either biotinylated diethylene triamine penta-acetic acid (DTPA)-
A20FMDV2 or a scrambled peptide (A20FMDV2ran). A375Pβ6 or A375Ppuro cells 
incubated with either peptide at different concentrations (0.001–10 μM), showed specific 
binding of DTPA-A20FMDV2 peptide. The affinity of DTPA-A20FMDV2 peptide, shown 
to bind only to A375Pβ6 cells, was at 1 nM concentration (408). 
 
The fact that the protamine domain did not directly mediate cell delivery is a good 
indication that it will not alter targeted delivery when fused with a scFv. Indeed in several 
previous studies investigators showed that protamine did not alter specificity of scFv 
delivery in these molecules and when the truncated human protamine was combined 
with scFv of mAbs it could deliver siRNA specifically to target cells (120, 160-162).  
 
This initial experiment also ensured that protamine did not override A20FMDV2 
peptide binding specificity which has been observed when another peptide was linked to 
A20FMDV2.  
 
However, in a previous work investigators reported that a liposomal drug 
consisting of H2009.1 tetrameric peptide liposomal doxorubicin overrides peptide ligand 
targeting to αvβ6 irrespective of ligand affinity or density (409). The H2009.1 peptide 
was originally selected from a phage display library against the non-small cell lung 
cancer (NSCLC) cell line H2009 (410) and was discovered to bind the integrin αvβ6 
(411). In contrast to the in vitro results, in vivo studies for αvβ6-specific H2009.1 
peptide/liposomal doxorubicin have demonstrated no difference in in vivo targeting or 
efficacy for H2009.1 peptide/liposomal doxorubicin, compared to control peptide and no 
peptide liposomes. The results highlighted that using a high affinity and high specificity 
H2009.1 tetrameric peptide in the context of liposomal doxorubicin targeting αvβ6 
overexpressed on tumour cells overrides the specificity of the peptide and does not 
guarantee enhanced efficacy of a liposomal drug in vivo (409).  
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The second aim was to examine targeted delivery with the FITC-A20FMDV2-
protamine peptide when complexed with siRNA. In the complex state, the positive 
charges of protamine will be neutralised so it is even less likely to mediate direct cell 
delivery but it is important to confirm that targeted delivery is maintained. To validate the 
method, the ability of the FITC-A20FMDV2-protamine peptide to form complexes with 
DNA or siRNA was tested. Thus, peptide/DNA and peptide/siRNA complex formation by 
electrostatic interactions were confirmed by gel retardation assays. Previous reports, 
using EMSA, have confirmed retardation of movement of DNA or siRNA when combined 
with positively charged peptides because of electrostatic interactions between cationic 
proteins and nucleic acids (347, 348). Furthermore, cell uptake and intracellular delivery 
of siRNA with the peptide was confirmed in confocal microscopy experiments. This was 
done using siGLO Red siRNA where cell uptake was demonstrated with similar kinetics 
as the uncomplexed peptide.  
 
Investigators have also explored the potential of A20FMDV2 to transport a 
therapeutic cargo intracellularly via αvβ6 internalisation (408). To do this, the peptide 
was conjugated with the radio-labeled indium-111 isotope (111In-DTPA-A20FMDV2) and 
was tested for internalisation in a mouse xenograft model bearing A375Pβ6 breast 
tumour cells. Results of single-photon emission computed tomography (SPECT) imaging 
confirmed specific binding and internalisation of 111In-DTPA-A20FMDV2 by A375Pβ6 
tumour cells within 20 minutes. Similar results from internalisation experiments 
performed by confocal microscopy showed membrane staining at the start (on ice) 
followed by localisation of the peptide in cytoplasm of A375Pβ6 cells by 30 minutes at 
37°C (408). 
 
Additionally, in another study A20FMDV2 peptide was incorporated into a 
recombinant adenovirus type5 (Ad5) which resulted in increased cytotoxicity on a panel 
of αvβ6-positive human carcinoma cell lines in vitro and enhancement in tumour uptake 
and improved tumour transduction in an αvβ6-positive xenograft model in vivo over the 
Ad5 wild type (412). 
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With regard to the FITC-A20FMDV2-protamine peptide, the intracellular delivery 
of siGLO Red provides no indication of siRNA activity. Thus, activity was analysed using 
siRNA to β6 subunit of integrin (siITGB6) and expression of β6 subunit protein was 
monitored by Western blotting. These studies proved inconclusive because the FITC-
A20FMDV2-protamine peptide alone resulted in the reduction of the β6 subunit protein. 
Retrospectively, downregulation of β6 subunit of integrin (ITGB6) was not the best target 
to study the effect of siRNA delivery with the FITC-A20FMDV2-protamine peptide. Thus, 
with further time it would be good to study and verify downregulation of genes with role 
in αvβ6-positive tumour survival and invasion using siRNA.  There are no studies to 
report inhibition of αv or β6 subunits using peptides, however recently investigators 
showed that the αvβ6-blocking 264RAD human mAb inhibits αvβ6 integrin and reduces 
tumour growth and metastasis in vivo (413). 
 
In conclusion, preliminary data from the results presented in this chapter provide 
experimental evidence for the objectives of using FITC-Ahx-A20FMDV2-protamine 
peptide in targeted therapeutic studies.   
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6.1. General discussion: 
Targeted therapies with mAbs have revolutionised medicine and are increasingly used 
for the treatment of a range of diseases, including chronic inflammatory diseases, solid 
tumours and haematological malignancies. However, there are still unmet needs for 
novel therapeutic approaches, especially for patients with relapsed/refractory diseases. 
Therapeutic agents with specificity for membrane proteins on malignant cells hold 
promise for improving the clinical outcome in cancer. CD22, a B cell-restricted 
membrane phosphoglycoprotein found on nearly all mature B lymphocytes including 
most B cell leukaemias and lymphomas, is potentially an ideal therapeutic target for B 
cell-directed therapies. CD22 is continually internalised and binding of anti-CD22 
antibodies induces rapid receptor-mediated endocytosis, making CD22, potentially, an 
attractive vital gateway for intracellular delivery of drugs (414).  
 
In B cell malignancies, CD22 expression has been reported in at least 60–80% of 
tumour samples (415). In this respect, anti-CD22 mAbs and antibody-drug conjugates 
have been investigated in B cell leukaemias and lymphomas. These malignancies 
include paediatric ALL, HCL, diffuse large B cell lymphoma (DLBCL), mantle cell 
lymphoma, marginal zone B cell lymphoma, Burkitt’s lymphoma, follicular lymphoma 
(FL) and CLL (416-421).  
 
RNAi is a powerful gene silencing process that holds promise in the field of 
cancer therapy. A major obstacle in the development of siRNA, as a cancer therapeutic, 
is the lack of a reliable mode of targeted delivery. Therefore, targeting delivery of siRNA 
via internalising cell surface receptors is an appealing strategy to improve tumour-
specific uptake. Thus, a highly effective targeting gene delivery method could be 
achieved by using recombinant scFv-protamine fusion proteins (322).  
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Similar to the results presented in this thesis which provide proof of concept for 
the use of antibody scFv specific for CD22 to target genes of interest using siRNA 
therapeutics, investigators showed suitability of targeting the CD22 receptor with kinetics 
of internalisation of ~30-60 minutes followed by degradation in ~8 hours (82-92) or 
recycling of the intracellular CD22 to the surface of the B cells (93). 
 
Therefore, gene constructs of the anti-CD22 scFv-protamine fusion protein were 
generated, expressed and purified. Similarly, in previous studies, investigators 
generated scFv-protamine fusion proteins for targeted delivery of siRNA to desired cells 
(120, 160 and 162).   
 
Several criteria for siRNA delivery has been explored in these studies including 
the demonstration that siRNA complexes with the protamine domain of HA22; that the 
protamine domain alone in the context of the A20FMDV2 peptide does not mediate non-
specific cell uptake and that CD22 specific intracellular delivery of fluorescently labelled 
siRNA was demonstrated through confocal microscopy. 
 
Successful escape of siRNA carriers from endosomes and release of the payload 
into the cytoplasm is integral to the efficiency of gene silencing. Previous studies 
showed that due to the acid nature of endosomal/lysosomal vesicles, pH-buffering 
agents can be widely exploited to promote cargo release (215-217). Hence, under acidic 
conditions, various macromolecules with a cationic nature have been shown to exhibit a 
“proton sponge effect”, such as PEI and its derivates. Previous studies have shown that 
histidine oligomers add endosomal escape functionality to C-terminus of a dsRNA 
binding domain (dsRBD) (422, 423). At neutral pH such as in the blood, histidine 
molecules are mainly deprotonated or uncharged while in acidic compartments such as 
the endosome; they become protonated and facilitate osmotic swelling that leads to 
cargo release (424). Therefore, the hexahistidine tag in HA22 fusion protein may also 
buffer acidify and thereby facilitate the release of cargo siRNA from the endolysosomal 
compartment. 
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Preliminary experiments provide proof of concept that siRNA can be delivered 
with HA22 fusion protein resulting in reduction of target mRNA and achieving biological 
effects. 
The HA22 fusion protein was shown to retain its ability to bind CD22 specifically 
and deliver siRNA into B cells. Studies were then carried out to verify that the capacity of 
the protamine peptide to bind to cell membranes did not override the specificity of the 
delivery system to solid tumour cells by targeting αvβ6 integrin. Selective expression of 
αvβ6 integrin on epithelial cells only during cancer has been well established (411). 
Since αvβ6 is internalised by a clathrin-mediated endocytosis mechanism (406), the 
potential of intracellular delivery of therapeutics has been explored using peptides such 
as A20FMDV2 peptide that can specifically bind to αvβ6 integrin (407). 
 
Experiments were then carried out to assess the effect of siRNA delivery on gene 
expression in relevant tumour cells. For this purpose, genes with roles in survival of 
malignant B cells were targeted. Because the siRNA sequence seeks out and destroys 
its target without affecting other genes, the use of siRNA therapeutics is an appealing 
treatment strategy for viral infections, cancer and dominantly inherited genetic disorders 
(425-428). siRNA has the potential as a therapeutic agent to target genes in the anti-
apoptosis pathway because it is now clear that many cancers overexpress anti-apoptotic 
proteins (429). Several anti-apoptotic proteins are expressed in cancer cells and can 
serve as targets for RNAi. These include FLIP, Bcl-2, Bcl-xL, Bcl-w, Mcl-1, survivin and 
XIAP (430). For example, in the current study siRNA was delivered with HA22 fusion 
protein to knockdown mRNA of the MCL1 gene, thereby activating the initiation of 
apoptosis in B cells. Preliminary experiments indicated that HA22 fusion protein was 
able to specifically deliver siRNA to downregulate the MCL1 gene via CD22 into B cells 
and consequently cause cell death as demonstrated by the cell viability assay and 
activation of caspase-3 and -7 along with confirmation of MCL1 mRNA downregulation 
through real-time PCR.  
 
 
Other molecules with anti-apoptotic properties, though not directly related to the 
apoptosis pathway, can also serve as targets for RNAi therapeutics. For example, the 
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mitotic serine/threonine protein kinase PLK1 is overexpressed in many types of human 
malignant tumours (431). PLK1 inhibitors are valuable anti-cancer drug candidates and, 
currently, they are being used in patients with several types of cancer to monitor efficacy 
and safety in clinical trials (432). siRNA to mRNA of PLK1 gene delivered with the HA22 
fusion protein via CD22 to B cells resulted in the downregulation of PLK1 gene and 
reduced cell viability. 
 
   Although the HA22 fusion protein provides an approach to target delivery to 
CD22 expressing B lymphocytes it will be important for therapeutic effect that delivered 
siRNA differentiates between cancerous and healthy CD22+ B cells, a concept that will 
be considered further in future perspectives. 
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6.2. Conclusions: 
Compared to other strategies such as antisense DNA oligonucletides (ASO) and 
ribozymes, RNAi is much more potent for gene downregulation (433). 
 
Important criteria for siRNA efficacy (measured as half-maximal inhibition levels 
or IC50 values) include thermodynamic end stability (434), target mRNA accessibility 
(435) and structural features (436). 
 
A major challenge to develop siRNAs as novel therapeutics for the treatment of a 
range of diseases is to overcome barriers to their delivery to target cells. siRNAs do not 
readily cross the cellular membrane because of their negative charge and size. Cellular 
delivery of chemically synthesised or in vitro transcribed siRNAs is usually achieved by 
using cationic liposome-based strategies. The disadvantage of cationic liposome-based 
siRNA complexes delivery schemes in vivo is the rapid liver clearance and lack of target 
tissue specificity (437, 438).  
 
Another barrier for using siRNA in therapies is their serum stability and protection 
against nucleases. In this regard, chemical modifications of siRNA such as 2’-methoxy 
(2’-OMe) and 2’-fluoro (2’-F) substitution in the siRNA backbone will improve serum 
stability and immunostimulatory properties but does not improve potency (439).  
 
In addition, immunostimulatory effect of siRNA must also be taken into account 
when using siRNA in vivo. Thus, long dsRNA is known to rapidly induce interferon 
responses by binding to double-stranded-RNA-activated protein kinase (PKR), 2′,5′-
oligoadenylate synthetase-RNase L system or several Toll-like receptors (TLRs). This is 
because the innate immune system recognises dsRNAs similar to invading RNA viruses 
(440). For example, it has been demonstrated that a particular sequence motif 
(5'GUCCUUCAA3') seems to be recognised by TLR7 in the endosomal compartment of 
plasmacytoid dendritic cells and activates immune responses (441). 
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There are also concerns about safe therapeutic use of siRNA because siRNA-
mediated immune induction seems to rely on endosome located TLR receptors (TLR7 
and TLR8) and hence compartmentalisation of the siRNA greatly influences cellular 
responses (442). 
 
In addition to the liposome-based siRNA delivery approach, other delivery 
methods for siRNAs include conjugation of cholesterol to the siRNA sense strand (443), 
cyclodextrin nanoparticles (444) and aptamer-siRNA conjugates (445). However, these 
methods are not cell-type specific. Therefore, the concept of targeting and intracellular 
delivery of siRNAs with scFv-protamine fusion proteins is likely to increase efficacy and 
reduce side effects. 
 
Generation of scFvs by engineering of therapeutic antibodies has a number of 
advantages. For example, scFvs are less likely to generate an immune response and 
the smaller size of fragments enables deeper penetration into tissues than the mAbs for 
tumour targeting (38, 39). Furthermore, antibody engineering allows increased affinity of 
the antibodies to their targets by mutagenesis of certain amino acids to increase 
polypeptide stability (42-44). In addition, the smaller size of scFvs makes them 
appropriate for diagnostic imaging (40, 41).  
 
The potential of using scFvs in biomedical applications has also been shown in 
several reported studies. For example, scFv antibody fragments can be used in 
immunoassays including ELISA (446), immunoblotting assay (447), antigen and 
antibody microarray (448), immunohistochemistry (449), immunofluorescence (450, 451) 
and flow cytometry (452, 453). Moreover, scFv antibodies have been successfully used 
to neutralise viral, bacterial and fungal pathogens in vitro and in vivo (454-456) which 
illustrates their potential use in therapy.  
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The half-life of whole antibodies especially chimeric, humanised or fully human 
IgG molecules can reach ~27 days in the blood in the human body (457). While antibody 
fragments such as Fab fragments or recombinant scFvs are rapidly cleared from the 
blood due to their short half-life and renal clearance (458, 459). Thus, repeated 
injections or infusions are required to maintain a therapeutically effective dose in the 
body (460). 
 
However, there are certain strategies to improve pharmacokinetic properties and 
thus dosing and therapeutic efficacy of recombinant antibodies. For example, 
PEGylation of proteins is a well-established strategy to improve pharmacokinetic 
properties by increasing the molecular mass and the hydrodynamic radius thus reducing 
renal clearance (461, 462). Furthermore, the introduction of N-glycosylation sites is 
another approach successfully applied to improve pharmacokinetic and 
pharmacodynamic properties of a few therapeutic proteins (463). 
 
Regarding the protamine attached to the scFv, there are also concerns about 
immunogenicity of the protamine. Protamine sulfate, a 5 kDa cationic polypeptide 
derived from salmon sperm (464), has been used in the clinic for treatment of patients 
who develop significant bleeding complications while receiving heparin (465). 
Furthermore, protamine sulfate is administered post-operatively to reverse the high 
concentrations of heparin required for patients undergoing cardiac surgery and 
cardiopulmonary bypass (466). Clinical use of protamine is, however, associated with 
several important adverse side effects, including potentially life-threatening systemic 
arterial hypotension and pulmonary artery hypertension (465). In addition, salmon 
protamine is shown to be immunogenic as the protamine-heparin complex was found in 
a mouse model to cause generation of anti-protamine/heparin antibodies (467). 
Furthermore, a recent clinical study has shown the production of anti-protamine/heparin 
antibodies in patients undergoing cardiac surgery (468). 
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In contrast to these observations, harnessing the truncated protamine has 
attracted growing interest as it possesses potency in mediating cellular translocation of 
its payloads (395-397) as it has been shown to be non-toxic (398, 399). However, it is 
hardly optimal to apply protamine alone for systemic administration due to its lack of 
selectivity in cellular association and tissue biodistribution, which could increase the risk 
of drug-induced toxic effect on normal tissues (469). 
 
However, the use of protamine for targeted delivery in the context of scFv 
antibody fragments should overcome the issue of non-specific targeting. It is important 
to note that in addition to the above observations regarding immunogenicity or side 
effects associated with use of protamine sulfate, it could be very different in case of 
delivery of siRNA where the truncated human protamine is covered and neutralised with 
bound siRNA. This could also be true for siRNA enabling it to evade TLR receptor 
recognition because of the masking effect of charge neutralisation by protamine.  
 
A dilemma for the use of anti-CD22 scFv-protamine fusion protein as a 
therapeutic tool to deliver siRNA into aberrant B cells is the downstream application for 
different diseases. For example, the objective of targeting siRNA for gene therapy to 
aberrant B cells could be different for cancer or inflammatory diseases.  In this regard, 
the goal of gene therapy in the treatment of autoimmune diseases is to restore immune 
homeostasis by modulation of cell physiology allowing basal activity required for cellular 
functions such as housekeeping and cell survival to avoid non-specific side effects. 
Therefore, there is the need for repeated and controlled administration of the siRNA to 
avoid off-target effects which could be difficult to achieve (470); whereas in cancer the 
objective of the gene downregulation is to kill the cancer cells (471). Furthermore, 
genome wide scanning in autoimmune diseases and clinical trials for biomarker 
identification has not yet revealed candidate genes that can be targeted in therapeutic 
designs (472). 
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6.3. Future perspectives: 
The remarkable progress made towards understanding the molecular and genetic basis 
of diseases in general and cancer in particular has transformed the discipline of gene 
therapy from theoretic concepts to practical applications. 
 
RNAi has evolved from a powerful laboratory tool utilised to reveal the function of 
novel genes to a potential therapeutic modality especially in viral infections, cancers and 
inherited genetic disorders.  
 
In cancer, a number of important oncogenic targets within many critical cellular 
pathways have been identified and RNAi-mediated gene silencing of these targets has 
produced encouraging results in vitro and in vivo. Translation of such findings to more 
complex clinical applications has made great progress in recent years. Hence, RNAi-
mediated silencing gene therapy can potentially be used in conjunction with 
chemotherapy, radiotherapy and/or immunotherapy. 
 
As more selective targeted delivery methods for RNAi therapeutics begin to 
develop, many challenges that currently exist in this system can be overcome and, 
thereby, exploit this powerful tool as an adjunct in the multimodality therapy of 
malignancies.  
 
 However, several critical issues associated with this approach must be resolved 
to permit realisation of its promise in humans and to progress to clinical trials. The keys 
to this transition and to paving the way for RNAi from bench to bedside will be safety, 
stability and efficacy. 
 
As with any novel therapy, a stringent test for gene silencing therapy strategies 
will be in vivo evaluation using relevant animal models of diseases. Importantly, in 
vivo trials will not only allow evaluation of the efficacy of the new therapeutic directly but 
also provides better clues on the physiological role of the putative cancer specific siRNA 
suppressors. 
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Further future studies, therefore, should focus on methods to investigate the use 
of anti-CD22 scFv-protamine fusion carrier protein with clinically relevant siRNA gene 
targets in CD22+ leukaemias/lymphomas B cells and its efficacy in vivo using animal 
tumour models.  
 
Over the past decade, mAbs targeting CD4, CD19, CD20, CD22, CD23, CD25, 
CD45, CD66 and CD122 have been studied and used in clinical trials for the treatment 
of leukaemias and significantly improved the treatment of haematological malignancies 
(473). For example, intracellular targeting of B cells through harnessing the 
internalisation of CD19 and CD22 receptors has been explored using anti-CD19 and 
anti-CD22 mAbs or their immunoconjugates (90). CD19 is a B cell restricted molecule 
expressed at all stages of B cell differentiation except for mature plasma cells (474). It 
constitutes an important component of the B cell receptor complex (BCR) involved in cell 
signaling and antigen processing (475) and is expressed in the majority of precursor B 
cell acute lymphoblastic leukaemias (ALL) and B cell non-Hodgkin’s lymphomas (NHL) 
(476). CD19 has long been recognised as a possible target in these malignancies, for 
example anti-CD19 immunoconjugates with ricin toxin, pokeweed antiviral protein and 
genistein have been used in clinical trials for the treatment of these B cell malignancies 
(477, 478). However, there are disappointing outcomes from initial clinical trials with 
these agents due to massive suppression in the number of B cells and also the 
increased toxicities associated with these therapies (473, 479 and 480). 
 
In comparison to CD19 targeting in B cells, CD22 makes a better target for 
intracellular delivery of therapeutics due to the fact that CD22 expression on B cells is 
restricted only to mature stages of B cell differentiation (59-64). Furthermore, rapid 
receptor-mediated endocytosis makes CD22 a better therapeutic target than CD19 for 
intracellular targeting (90).  
 
Moreover, constitutive endocytosis makes CD22 receptor an ideal target for 
therapeutic intervention in a broad spectrum of applications not only for B cell 
malignancies and autoimmune diseases but perhaps also for tumour vaccine 
development. For example, recently BiovaxIDTM vaccine was developed which is 
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composed of the clonal immunoglobulin molecule idiotype (ID) expressed on the surface 
of B cells from patients with B cell non-Hodgkin’s lymphoma (NHL). The isolated 
patient’s ID that can function as a tumour-specific antigen conjugated to the carrier 
protein keyhole limpet haemocyanin (KLH) can be administered into patients together 
with granulocyte-macrophage colony-stimulating factor (GM CSF). Results from phase II 
clinical trials have shown induced tumour-specific cellular and humoral immunity in 
patients with follicular lymphoma and mantle cell lymphoma (481). 
 
Similarly, it could be possible to target antigens to B cells via CD22 as a means 
for tumour vaccine development as B cells are capable of eliciting anti-tumour 
responses through the production of antibodies as well as serving as antigen-presenting 
cells (APCs) to induce T cell responses (482, 483). 
 
It will, therefore, be possible to deliver tumour antigens with anti-CD22 scFv to B 
cells to elicit anti-tumour immunity by engineering these antigens in tandem with anti-
CD22 scFv. This approach may offer a new avenue for vaccine development which may 
be of use not only for cancer therapy but also for infectious agents. 
  
One paradigm for improving cancer treatment is the development of targeting 
therapies that selectively deliver drugs to cancer cells, thus increasing drug 
accumulation in the tumour and decreasing toxicities and adverse effects of drugs. In 
this regard, both mAbs and peptide targeting ligands have been used to increase the 
efficacy and decrease the toxicity by actively targeting tumour cells and cells of the 
tumour microenvironment and the vasculature (484-492). 
 
Therefore, cancer treatment is evolving from systemic, non-specific, high-dose 
chemotherapies to a wide variety of specific targeted therapies. Yet better than 
specificity is a drug’s ability to discriminate between the cancer and the normal healthy 
counterpart of a particular cell type. Therefore, not only specificity but also selectivity of 
targeting is more desirable to minimise adverse effects on normal healthy cells and 
tissues. Then a drug’s ability to discriminate and affect only a particular gene, protein, 
signaling pathway or cell in preference to others in a cell population is selectivity (493). 
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Regarding selective targeting, for example, a number of haematological 
malignancies such as chronic myelogenous leukaemia (CML), ALL and AML is reported 
to be associated with a chromosomal translocation that produces the abnormal 
Philadelphia chromosome (494). This fusion between Ableson (Abl) tyrosine kinase 
gene at chromosome 9 and break point cluster (Bcr) gene at chromosome 22 encodes a 
chimeric oncogene protein, Bcr-Abl that is associated with uncontrolled activity of the Abl 
tyrosine kinase (495). This cancer-specific abnormality can then be selectively targeted 
using Bcr-Abl kinase inhibitors such as Imatinib and Dasatinib which can induce 
remission in patients with positive Philadelphia chromosome abnormality (496, 497). 
 
Another example for selectively targeting malignant CD22+ B cells while sparing 
the normal B cell counterparts is by targeting the zeta-chain associated protein kinase 
70 (ZAP-70). This is a 70 kDa ζ-chain CD3-receptor-associated protein tyrosine kinase 
(PTK) that operates in the T lymphocyte signaling pathways triggered by the stimulation 
of the T cell receptor (TCR) (498). 
 
In previous studies, investigators have reported that ZAP-70 is aberrantly 
expressed in a number of B cell malignancies including CLL, precursor B cell ALL, 
DLBL, MCL and very rare cases of classic Hodgkin’s lymphoma (499, 500). It has been 
reported that ZAP-70-associated PTK in CLL cells undergoes tyrosine phosphorylation 
following BCR ligation, indicating that ZAP-70 expression was associated with increased 
signal transduction via BCR complex which may contribute to the more aggressive CLL 
disease (501). Recently, investigators have used the tyrosine kinase inhibitor Gefitinib to 
selectively induce apoptosis in ZAP-70+ CLL cells through inhibition of BCR signaling 
(502). 
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Regarding specific targeting of the αvβ6-positive tumours, a large number of solid 
tumour malignancies were reported to express αvβ6 integrin including colon, gastric, 
non-small cell lung, skin, cervical, ovarian and head and neck cancers (104, 411, 503-
506). Despite promising preliminary data from Cilengitide, an experimental drug for the 
treatment of patients with αvβ6-positive tumours, its use as anticancer therapeutic has 
been discontinued due to failure in phase III clinical trials (507).  
 
Therefore, the development of novel targeted therapies remains urgently needed 
to improve overall survival in these cancers. A20FMDV2-protamine peptide holds the 
promise to justify its use for the targeted delivery of therapeutic siRNAs into these 
invasive cancers. Several genes with roles in invasion have been identified amongst 
which are hepatocyte growth factor receptor (HGFR), matrix metalloproteinase-9 
(MMP9), transforming growth factor β1 (TGFβ1) and αvβ6 integrin (508, 509). Future 
experiments should be carried out to provide proof of concept that targeting these genes 
with roles in invasion and spread of these tumour cells using the A20FMDV2-protamine 
peptide would prove to be useful.  
 
In summary, the findings in this study demonstrated that anti-CD22 scFv-
protamine fusion protein was produced in secretable forms from mammalian cells and 
can form complexes with siRNAs and deliver these specifically via CD22 to mature B 
cells. This provides “proof of concept” for a novel targeted gene delivery strategy into 
CD22+ B cells in disease settings particularly malignant B cells from patients with 
leukaemias and lymphomas.  
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Appendix 1: PCR and sequencing primers used in generation of Cy34.1.2 and HA22 
scFv constructs (Table 11). 
 
Table 11: Primer names, sequences, restriction sites and their purity.  
Primer name Primer sequence (5’ to 3’) Primer purity
PCR primers
Mouse Cγ1 γ1 for VH cDNA AGTTAGTTTGGGCAGCAGAT Desalted 
Mouse Cκ1 for VL cDNA GTAGAAGTTGTTCAAGAAGCACAC Desalted 
Poly-(G) tail anchor primer ACGAATTCTAGAGTCGACCCCCCCCCCCCCC Desalted 
Nested Cγ2 primer GCCAGTGGATAGACAGAT Desalted 
Nested Cκ2 primer AGATGTTAACTGCTCACTGGAT Desalted 
VH HindIII forward primer CAGAAGCTTATGAGATGGAGCTGTATC Desalted 
VH XhoI reverse primer CGCTCGAGACAAAGTAGAATGAGTAAGT Desalted 
Common VL SalI forward primer GGCGGGTCGACGGATATTGTGATGACGCAG Desalted 
VL1 EcoRI reverse primer TCGGAATTCCGGAAGTTCTAGATTTT Desalted 
VL2 NheI reverse primer TCGGCTAGCCGGAAGTTCTAGATTTT Desalted 
Protamine EcoRI forward oligo AATTCCGATCACAATCACGATCACGATACTACCGACAACGACAACGATCACGACGACGACGACGACGAT HPLC-purified 
Protamine XbaI reverse oligo CTAGATCGTCGTCGTCGTCGTCGTGATCGTTGTCGTTGTCGGTAGTATCGTGATCGTGATTGTGATCGG HPLC-purified 
M13 forward primer GTTTTCCCAGTCAGAC Desalted 
M13 reverse primer CAGGAAACAGCTATGAC Desalted 
pHEN1 NcoI forward primer GCCATGGCCCAGGTCCAACTGCAGCAGCCT Desalted 
pHEN1 NotI reverse primer GCGGCC GCGGGCCCTCAATGGTGGTGGTGATG Desalted 
HRV-3C BamHI forward primer  ATATGGATCCCTCGAGGTTCTCTTTCAGGGACCCCAGGTCCAACTGCAGCAGCCT HPLC-purified 
Poly-His NheI reverse primer TGCAGCTAGCGGGCCCTCAATGGTGGTGGTGATG Desalted 
Cy34 SfiI forward primer ATAAGGCCCAGCCGGCCCAGGTCCAACTGCAGCAGC CT Desalted 
Cy34 SacII reverse primer ATATCCGCGGTTAATGGTGGTGGTGATGGTG Desalted 
pMH113 EcoRI forward primer GCGGGAATTCATGGAAGTGCAGCTGGTGGAG Desalted 
pMH113 BglII reverse primer AGCAGATCTGCTTTCCAGCTTGGTGCCTCCACC Desalted 
Protamine-His6 BglII forward primer AGCAGATCTCGATCACAATCACGATGA Desalted 
Protamine-His6 NheI reverse primer AGCGCTAGCTCAATGGTGGTGGTGATGGTG Desalted 
HA22 SfiI forward primer GGGGCCCAGCCGGCCATGGAAGTGCAGCTGGTGGAGTCT Desalted 
HA22 SacII reverse primer ATATCCGCGGTTAATGGTGGTGGTGATGGTG Desalted 
pDisplay-F HindIII forward primer GACCCAAGCTTGGTACCGAGCTCGGATCCA Desalted 
pDisplay-R SfiI reverse primer TGGATAGGCCGGCTGGGCCCCGTCACCAGTGGAACCTGG Desalted 
Sequencing primers 
SV40 pA reverse primer GAAATTTGTGATGCTATTGC Desalted 
T7 promoter forward primer TAATACGACTCACTATAGGG Desalted 
F-LAP forward primer ATTGAGGGCTTTCGCCTTAGC Desalted 
LMB3 forward primer  CAGGAAACAGCTATGAC Desalted 
pHEN1 reverse primer GCGGCCGCGGGCCCTCAATGGTGGTGGTGATG Desalted 
BGH reverse primer TAGAAGGCACAGTCGAGG Desalted 
pMH R-113 reverse primer GGAGAGTTTCAGGGACCCTCCAGG CTTCACTAA Desalted 
 
Note: restriction sites are underlined; start codon is indicated in bold. 
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Appendix 2: Annotated sequences of the constructs used in this study. 
Shown below are the whole sequences from the engineered constructs presented in 
this study. Only known unique restrictions sites are shown. One letter code translation 
is shown for one open reading frame where * indicates termination of transcription 
(stop codon). Only the forward 5’ to 3’ strand is shown for each construct. Sequencing 
data and restriction analysis of the constructs were performed by using the 
SerialCloner version 2.6.1 and the CLC Sequence Viewer version 4.6.2 softwares. 
 
 
Annotated sequences for the following constructs are shown: 
 
Cy34.1.2 VH in pCR2.1 TA cloning vector  
Cy34.1.2 VL in pCR2.1 TA cloning vector  
Cy34.1.2 scFv-His6 in pFastBacTM1 
Cy34.1.2 scFv-protamine-His6 in pFastBacTM1 
Cy34.1.2 scFv-His6 in pcDNA3 vector with VH native signal sequence 
Cy34.1.2 scFv-protamine-His6 in pcDNA3 vector with VH native signal sequence 
Cy34.1.2 scFv-His6 in pHEN1 vector with pelB signal sequence 
Cy34.1.2 scFv-His6 in pcDNA3 with hLAP signal sequence-hLAP-HRV3C 
Cy34.1.2 scFv-protamine-His6 in pcDNA3 with hLAP signal sequence-hLAP-HRV3C 
Cy34.1.2 scFv-protamine-His6 in pDisplay vector with murine Ig κ chain signal sequence 
HA22 scFv-protamine-His6 in pDisplay vector with murine Ig κ chain signal sequence 
HA22 scFv-protamine-His6 in modified pDisplay vector with murine Ig κ chain signal sequence 
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Cy34.1.2 VH (Cγ2) gene nucleotide and amino acid sequences in pCR2.1 TA cloning vector:  
 
5’-- GCTCTCTATAGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGAT 
                     |EcoRI|      |poly-C sequence| 
  ATCTGCAGAATTCGGCTTACGAATTCTGTCGACCCCCCCCCCCCCCGCTCACAGTTACTA 
                |start codon| …………..       native signal sequence ……. 
  GGCACACAGGACCTCACC ATG AGA TGG AGC TGT ATC ATT CTC TTC TTG GTA GCA ACA GCT 
                      M   R   W   S   C   I   I   L   F   L   V   A   T   A 
   …………………………….     | 
  ACA AGT GTC GAC TCC CAG GTC CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG 
   T   S   V   D   S   Q   V   Q   L   Q   Q   P   G   A   E   I   V   R   P   G 
  ACT TCA GTG AAG CTG TCC TGT AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC 
   T   S   V   K   L   S   C   K   A   S   G   Y   T   F   T   D   Y   W   M   N 
                                                           | MfeI | 
  TGG GTG AAG CAA AGG CCT GGA CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT 
   W   V   K   Q   R   P   G   Q   G   L   E   W   F   G   A   I   D   P   S   D 
  AGT TAT ACT AGG TAC AAT CAA GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC 
   S   Y   T   R   Y   N   Q   E   F   K   G   K   A   T   L   T   V   D   T   S 
  TCC ACC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC 
   S   T   T   A   Y   M   Q   L   S   S   L   T   S   E   D   S   A   V   Y   F 
  TGT GCA AGA TCG GAC TAT ACT TAC TCA TTC TAC TTT GACTACTGGGGCCTAGGCACCACT 
   C   A   R   S   D   Y   T   Y   S   F   Y   F    
                                                      |EcoRI| 
CTCACAGTCTCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCAAGCCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCC
GAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCG
GAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAAC
CTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGAGAGGCGGTTTTGCTATTGGGCGCTCTTCGCTTCCTCGCTCACTGACTCGG
CGCTCGGCGTCGGCTGCGGCGAGCGATCTCACT -- 3’ 
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 Cy34.1.2 VL (Cκ2) gene nucleotide and amino acid sequences in pCR2.1 TA cloning vector:  
5’ -- AGGGGATACAATTTCCACAGGAAACAGTATGACCATGATTACGCCAAGCTTGGTACCGAGC 
                                             |EcoRI|    |poly-C sequence| 
TCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCGGCTTACGAATTCTAGAGTCCCCCCCCCCCCCCACGAGGTTCTCTGCTCAGCT
TCTGGGGCTGCTTGTGCTCTGGATCCCTGGATCCACTGCA 
                  GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA 
                   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G  
                       |  SbfI  | 
  ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT 
   T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T  
  TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG 
   Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M  
  TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC 
   S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F  
  ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA  
   T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q    
  | XbaI | 
AAT CTA GAA CTT CCG TGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGGGCTGATGCT 
 N   L   E   L   P                                      |EcoRI|   
  GCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTAAGCGAATTCTGCAGATATCCATCACACTGGCGGCCGCT 
CGAGCATGCATCTAGAGGGCCCAATCGCCCTGGAGATGGC  -- 3’ 
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Cy34.1.2 scFv-His6 nucleotide and amino acid sequences in pFastBacTM1 vector: 
 
5’TCCTAGTGCGCGCTGCGGTGGTGCTGACCCCGGATGAAGTGGTTCGCATCCTCGGTTTTCTGGAAGGCGAGCATCGTTTGTTCGCCCAGG
ACTCTAGCTATAGTTCTAGTGGTTGGCTACGTATACTCCGGAATATTAATAGATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAA
ATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCACCATCGGGCGCGGAT
CCAAGGTACCACCGCCA  
 
 AAG CTT ATG   
  K   L   M    
 AGA TGG AGC TGT ATC ATT CTC TTC TTG GTA GCA ACA GCT ACA AGT GTC GAC TCC CAG GTC   
  R   W   S   C   I   I   L   F   L   V   A   T   A   T   S   V   D   S   Q   V    
 CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT   
  Q   L   Q   Q   P   G   A   E   I   V   R   P   G   T   S   V   K   L   S   C    
 AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAG AGG CCT GGA   
  K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P   G    
                              | MfeI | 
 CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA   
  Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N   Q    
 GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG   
  E   F   K   G   K   A   T   L   T   V   D   T   S   S   T   T   A   Y   M   Q    
 CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC TAT ACT   
  L   S   S   L   T   S   E   D   S   A   V   Y   F   C   A   R   S   D   Y   T    
 TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT   
  Y   S   F   Y   F   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G    
 GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA   
  G   G   S   T   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G    
                      |  SbfI  | 
 ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT   
  T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T    
 TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG   
  Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M    
 TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC   
  S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F    
 ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA   
  T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q      
  | XbaI |                  |  hexahistidine tag  | 
AAT CTA GAA CTT CCG GCT AGA CAC CAT CAC CAC CAC CAT TGA GGGCCCGAGCTTGTCGAGAAG   
 N   L   E   L   P   A   R   H   H   H   H   H   H   *       
   
  TACTAGAGGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTAAAAAACCTCCCACACTCCGC 3’  
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Cy34.1.2 scFv-protamine-His6 nucleotide and amino acid sequences in pFastBacTM1 vector: 
 
5’TCCTACCTCGCGCTGCGGTGGTGCTGACCCCGGATGAAGTGGTTCGCATCCTCGGTTTTCTGGAAGGCGAGCATCGTTTGTTCGCCCAGG 
ACTCTAGCTATAGTTCTAGTGGTTGGCTACGTATACTCCGGAATATTAATAGATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAA
ATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCACCATCGGGCGCGGA 
TCCAAGGTACCACCGCCA AAG CTT ATG   
                    K   L   M    
  AGA TGG AGC TGT ATC ATT CTC TTC TTG GTA GCA ACA GCT ACA AGT GTC GAC TCC CAG GTC   
   R   W   S   C   I   I   L   F   L   V   A   T   A   T   S   V   D   S   Q   V    
  CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT   
   Q   L   Q   Q   P   G   A   E   I   V   R   P   G   T   S   V   K   L   S   C    
  AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAG AGG CCT GGA  
   K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P   G   
                               | MfeI |  
  CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA   
   Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N   Q    
  GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG   
   E   F   K   G   K   A   T   L   T   V   D   T   S   S   T   T   A   Y   M   Q    
  CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC CAT ACT   
   L   S   S   L   T   S   E   D   S   A   V   Y   F   C   A   R   S   D   H   T    
  TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT   
   Y   S   F   Y   F   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G    
  GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA   
   G   G   S   T   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G 
                       |  SbfI  |    
  ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT   
   T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T    
  TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG   
   Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M    
  TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC   
   S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F    
  ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA AAT   
   T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q   N    
                  |EcoRI| 
  CTA GAA CTT CCG GAA TTC   
   L   E   L   P   E   F    
|                                  truncated protamine                                    | 
CGA TCA CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA TCA CGA CGA CGA CGA CGA CGA TCT AGA 
 R   S   Q   S   R   S   R   Y   Y   R   Q   R   Q   R   S   R   R   R   R   R   R   S   R 
|   hexahistidine tag | 
CAC CAT CAC CAC CAC CAT TGA GGGCCCGAGCTT   
 H   H   H   H   H   H   *       
   
  GTCGAGAAGTATGGGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTAAAAAACCTCCCACACTCCTCACTCGG 3’ 
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Cy34.1.2 scFv-His6 nucleotide and amino acid sequences including the VH native signal sequence in 
pcDNA3 vector: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
 
          |VH 
… TTCCTTAG ATG AGC TGT ATC ATT CTC TTC TTG GTA GCA ACA GCT ACA AGT GTC GAC TCC CAG 
            M   S   C   I   I   L   F   L   V   A   T   A   T   S   V   D   S   Q 
  GTC CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC 
   V   Q   L   Q   Q   P   G   A   E   I   V   R   P   G   T   S   V   K   L   S 
  TGT AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAG AGG CCT 
   C   K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P 
                                   | MfeI | 
  GGA CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT 
   G   Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N 
  CAA GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG 
   Q   E   F   K   G   K   A   T   L   T   V   D   T   S   S   T   T   A   Y   M 
  CAG CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC TAT 
   Q   L   S   S   L   T   S   E   D   S   A   V   Y   F   C   A   R   S   D   Y 
  ACT TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC 
   T   Y   S   F   Y   F   V   S   S   G   G   G   G   S   G   G   G   G   S   G 
  GGT GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT 
   G   G   G   S   T   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L 
                           |  SbfI  |    
  GGA ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC 
   G   T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I 
  ACT TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG 
   T   Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q 
  ATG TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT 
   M   S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D 
  TTC ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA 
   F   T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q 
    | XbaI |                  |  hexahistidine tag  |   
  AAT CTA GAA CTT CCG GCT AGA CAC CAT CAC CAC CAC CAT TGA GGGCCCTATTTCTATA   
   N   L   E   L   P   A   R   H   H   H   H   H   H   *    
  GTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTT 
CCTTGACCCTGGAAGGTGCCACTCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTTGTCTGATAGGTGTCATTCTATTCTGG
GGGGGTGGGGGTGGGGCAGACAA 3’ 
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Cy34.1.2 scFv-protamine-His6 nucleotide and amino acid sequences including the VH native signal 
sequence in pcDNA3 vector: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
……………ATAAGATGGAGCTGTATCATTCTCTTCTTGGTAGCAACAGCTACAAGTGTCGACTCCCAGGTCCAACTGCAGCACT  
 
GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT 
 G   A   E   I   V   R   P   G   T   S   V   K   L   S   C  
AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAG AGG CCT GGA 
 K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P   G  
                             | MfeI | 
CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA 
 Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N   Q  
GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG 
 E   F   K   G   K   A   T   L   T   V   D   T   S   S   T   T   A   Y   M   Q  
CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC CAT ACT 
 L   S   S   L   T   S   E   D   S   A   V   Y   F   C   A   R   S   D   H   T  
TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT 
 Y   S   F   Y   F   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G  
GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA 
 G   G   S   T   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G  
                     |  SbfI  | 
ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT 
 T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T  
TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG 
 Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M  
TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC 
 S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F  
ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA AAT 
 T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q   N  
                |EcoRI| |  …………   truncated protamine     ………………………….. 
CTA GAA CTT CCG GAA TTC CGA TCA CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA 
 L   E   L   P   E   F   R   S   Q   S   R   S   R   Y   Y   R   Q   R   Q   R  
         ………………………….              | |  hexahistidine tag  | 
TCA CGA CGA CGA CGA CGA CGA TCT AGA CAC CAT CAC CAC CAC CAT TGA GGGCCCTATTC   
 S   R   R   R   R   R   R   S   R   H   H   H   H   H   H   *      
 
TATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCC 
TTCCTTGACCCTGGAAGGTGCCACTCCACTGTCCTTTCCTAATAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTG
GGGGGTGGGGTGGGGCAGGACAGCAGGGGAGGATTGGGAAGCAATAGCAGCATGCTGGGATGCGCG 3’  
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Cy34.1.2 scFv-His6 nucleotide and amino acid sequences in pHEN1 vector containing pelB signal 
sequence: 
 
5’ AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGC 
AGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT
TGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAA
TGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTA 
 
      |Pel B signal peptide sequence|     |scFv 
  TTA CTC GCG GCC CAG CCG GCC ATG GCC CAG GTC CAA CTG CAG CAG CCT CAG 
   L   L   A   A   Q   P   A   M   A   Q   V   Q   L   Q   Q   P   Q 
  GTC CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC 
   V   Q   L   Q   Q   P   G   A   E   I   V   R   P   G   T   S   V   K   L   S 
  TGT AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAA AGG CCT 
   C   K   A   S   G   Y   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P 
                                   | MfeI | 
  GGA CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT 
   G   Q   G   L   E   W   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N 
  CAA GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG 
   Q   E   F   K   G   K   A   T   L   T   V   D   T   S   S   T   T   A   Y   M 
  CAG CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC TAT 
   Q   L   S   S   L   T   S   E   D   S   A   V   Y   F   C   A   R   S   D   Y 
  ACT TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC 
   T   Y   S   F   Y   F   V   S   S   G   G   G   G   S   G   G   G   G   S   G 
  GGT GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT 
   G   G   G   S   T   D   I   V   M   T   Q   A   A   F   S   N   P   V   T   L 
                           |  SbfI  | 
  GGA ACA TCA GCT TCC ATC TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC 
   G   T   S   A   S   I   S   C   R   S   S   K   S   L   L   H   S   N   G   I 
  ACT TAT TTG TAT TGG TAT CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG 
   T   Y   L   Y   W   Y   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q 
  ATG TCC AAC CTT GCC TCA GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT 
   M   S   N   L   A   S   G   V   P   D   R   F   S   S   S   G   S   G   T   D 
  TTC ACA CTG AGA ATC AGC AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA 
   F   T   L   R   I   S   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q 
    | XbaI |                  |  hexahistidine tag  |   
  AAT CTA GAA CTT CCG GCT AGA CAC CAT CAC CAC CAC CAT TGA   
   N   L   E   L   P   A   R   H   H   H   H   H   H   *    
 
GGCGGCCGCAGAACAAAAACTCATCTCAGAAGAGGATCTGAATGGGGCCGCATAGACTGTTGAAAGTTGTTTAGCAAAACCTCATACA 3’   
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Cy34.1.2 scFv-His6 nucleotide and amino acid sequences in pcDNA3 with hLAP signal sequence, hLAP 
and HRV3C sequences: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
 
                                       ……………….Human LAP……………………………… 
G GGG GAT TCT TGT GCG CAG GTA TAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC 
   G   D   S   C   A   Q   V   Y   T   L   Q   V   D   I   N   G   F   T   T   G  
  CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC 
   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A  
  ACC CCG CTG GAG AGG GCC CAT CAT CTG CAA AGC GAA TTC CGG GGA GGC GGA TCC  
   T   P   L   E   R   A   H   H   L   Q   S   E   F   R   G   G   G   S    
  |      HRV3C cleavage site    | 
  CTC GAG GTT CTC TTT CAG GGA CCC 
   L   E   V   L   F   Q   G   P 
  |……………………………Cy34.1.2 scFv………. 
  CAG GTC CAA CTG CAG CAG CCT CAG GTC CAA CTG CAG CAG CCT 
   Q   V   Q   L   Q   Q   P   Q   V   Q   L   Q   Q   P  
  GGG GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT AAG GCT TCA GGC TAC 
   G   A   E   I   V   R   P   G   T   S   V   K   L   S   C   K   A   S   G   Y  
  ACC TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAA AGG CCT GGA CAA GGC CTT GAG TGG 
   T   F   T   D   Y   W   M   N   W   V   K   Q   R   P   G   Q   G   L   E   W  
           | MfeI | 
  TTC GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA GAG TTC AAG GGC AAG 
   F   G   A   I   D   P   S   D   S   Y   T   R   Y   N   Q   E   F   K   G   K  
  GCC ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA 
   A   T   L   T   V   D   T   S   S   T   T   A   Y   M   Q   L   S   S   L   T  
  TCC GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC TAT ACT TAC TCA TTC TAC TTT 
   S   E   D   S   A   V   Y   F   C   A   R   S   D   Y   T   Y   S   F   Y   F  
  GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGG TCG ACG GAT 
   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   T   D  
  ATT GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA ACA TCA GCT TCC ATC 
   I   V   M   T   Q   A   A   F   S   N   P   V   T   L   G   T   S   A   S   I  
   |  SbfI  | 
  TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT TAT TTG TAT TGG TAT 
   S   C   R   S   S   K   S   L   L   H   S   N   G   I   T   Y   L   Y   W   Y  
  CTG CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG TCC AAC CTT GCC TCA 
   L   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M   S   N   L   A   S  
  GGA GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC ACA CTG AGA ATC AGC 
   G   V   P   D   R   F   S   S   S   G   S   G   T   D   F   T   L   R   I   S  
                                                            | XbaI | 
  AGA GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA AAT CTA GAA CTT CCG GCT 
   R   V   E   A   E   D   V   G   V   Y   Y   C   A   Q   N   L   E   L   P   A  
      |  hexahistidine tag  | 
  AGA CAC CAT CAC CAC CAC CAT TGA  
   R   H   H   H   H   H   H   *   
  
  GGGCCCGCTAGAGGGCCCTATTCTATAGGTCACTAAAGGCAGAATTTGT  3’ 
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Cy34.1.2 scFv-protamine-His6 nucleotide and amino acid sequences in pcDNA3 with hLAP signal 
sequence, hLAP and HRV3C sequences: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
 
………… hLAP …………………. 
GG GGC GTT TTT TGC GCA GCA TAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC 
    G   V   F   C   A   A   Y   T   L   Q   V   D   I   N   G   F   T   T   G   R 
  CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC 
   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A   T 
 
  CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC  
   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G   G   S   
|……… HRV3C cleavage site ………….| 
CTC GAG GTT CTC TTT CAG GGA CCC 
 L   E   V   L   F   Q   G   P 
  |……………………………Cy34.1.2 scFv………. 
  CAG GTC CAA CTG CAG CAG CCT CAG GTC CAA CTG CAG CAG CCT GGG 
   Q   V   Q   L   Q   Q   P   Q   V   Q   L   Q   Q   P   G 
  GCT GAA ATT GTG AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT AAG GCT TCA GGC TAC ACC 
   A   E   I   V   R   P   G   T   S   V   K   L   S   C   K   A   S   G   Y   T 
  TTT ACC GAC TAT TGG ATG AAC TGG GTG AAG CAA AGG CCT GGA CAA GGC CTT GAG TGG TTC 
   F   T   D   Y   W   M   N   W   V   K   Q   R   P   G   Q   G   L   E   W   F 
       | MfeI | 
  GGA GCA ATT GAT CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA GAG TTC AAG GGC AAG GCC 
   G   A   I   D   P   S   D   S   Y   T   R   Y   N   Q   E   F   K   G   K   A 
  ACA TTG ACT GTA GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCC 
   T   L   T   V   D   T   S   S   T   T   A   Y   M   Q   L   S   S   L   T   S 
  GAG GAC TCT GCG GTC TAT TTC TGT GCA AGA TCG GAC TAT ACT TAC TCA TTC TAC TTT GTC 
   E   D   S   A   V   Y   F   C   A   R   S   D   Y   T   Y   S   F   Y   F   V 
  TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGG TCG ACG GAT ATT 
   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   T   D   I 
  GTG ATG ACG CAG GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA ACA TCA GCT TCC ATC  
   V   M   T   Q   A   A   F   S   N   P   V   T   L   G   T   S   A   S   I    
  |  SbfI  | 
 TCC TGC AGG TCT AGT AAG AGT CTC CTA CAT AGT AAT GGC ATC ACT TAT TTG TAT TGG TAT CTG 
  S   C   R   S   S   K   S   L   L   H   S   N   G   I   T   Y   L   Y   W   Y   L 
  CAG AAG CCA GGC CAG TCT CCT CAG CTC CTG ATT TAT CAG ATG TCC AAC CTT GCC TCA GGA 
   Q   K   P   G   Q   S   P   Q   L   L   I   Y   Q   M   S   N   L   A   S   G 
  GTC CCA GAC AGG TTC AGT AGC AGT GGG TCA GGA ACT GAT TTC ACA CTG AGA ATC AGC AGA 
   V   P   D   R   F   S   S   S   G   S   G   T   D   F   T   L   R   I   S   R 
                                                                          |EcoRI| 
  GTG GAG GCT GAG GAT GTG GGT GTT TAT TAC TGT GCT CAA AAT CTA GAA CTT CCG GAA TTC 
   V   E   A   E   D   V   G   V   Y   Y   C   A   Q   N   L   E   L   P   E   F 
  | truncated protamine …………………………..  
  CGA TCA CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA TCA CGA CGA CGA CGA CGA  
   R   S   Q   S   R   S   R   Y   Y   R   Q   R   Q   R   S   R   R   R   R   R 
            | |  hexahistidine tag  | 
  CGA TCT AGA CAC CAT CAC CAC CAC CAT TGA  
   R   S   R   H   H   H   H   H   H   *  
   
  GGGCCCGCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC 
TGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTCCTAATAAATAGATGCC  3’ 
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Cy34.1.2 scFv-protamine-His6 nucelotdie and amino acid sequences in modified pDisplay vector with 
murine Ig kappa chain signal sequence: 
 
5’CC TGG TCG AGC TCG GAT CCA CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC GGC TTG GGG ATA 
      W   S   S   S   D   P   L   V   T   A   A   S   V   L   E   F   G   L   G   I 
          | …………………………………………………….   Ig kappa chain signal sequence 
  TCC ACC ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC 
   S   T   M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S 
  ……………………… |   |……………..SfiI……..| | Cy34.1.2 scFv …………. 
  ACT GGT GAC GGG GCC CAG CCG GCC CAG GTC CAA CTG CAG CAG CCT GGG GCT GAA ATT GTG 
   T   G   D   G   A   Q   P   A   Q   V   Q   L   Q   Q   P   G   A   E   I   V 
  AGG CCT GGG ACT TCA GTG AAG CTG TCC TGT AAG GCT TCA GGC TAC ACC TTT ACC GAC TAT 
   R   P   G   T   S   V   K   L   S   C   K   A   S   G   Y   T   F   T   D   Y 
                                                                       | MfeI | 
  TGG ATG AAC TGG GTG AAG CAG AGG CCT GGA CAA GGC CTT GAG TGG TTC GGA GCA ATT GAT 
   W   M   N   W   V   K   Q   R   P   G   Q   G   L   E   W   F   G   A   I   D 
  CCT TCT GAT AGT TAT ACT AGG TAC AAT CAA GAG TTC AAG GGC AAG GCC ACA TTG ACT GTA 
   P   S   D   S   Y   T   R   Y   N   Q   E   F   K   G   K   A   T   L   T   V 
  GAC ACA TCC TCC ACC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCC GAG GAC TCT GCG 
   D   T   S   S   T   T   A   Y   M   Q   L   S   S   L   T   S   E   D   S   A 
  GTC TAT TTC TGT GCA AGA TCG GAC CAT ACT TAC TCA TTC TAC TTT GTC TCG AGC GGT GGA 
   V   Y   F   C   A   R   S   D   H   T   Y   S   F   Y   F   V   S   S   G   G 
  GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGG TCG ACG GAT ATT GTG ATG ACG CAG 
   G   G   S   G   G   G   G   S   G   G   G   G   S   T   D   I   V   M   T   Q 
  GCT GCA TTC TCC AAT CCA GTC ACT CTT GGA ACA TCA GCT TCC ATC TCC TGC AGG TCT …… 
   A   A   F   S   N   P   V   T   L   G   T   S   A   S   I   S   C   R   S    
 
……..ATAAGAGTCTCCTACATAGTAATGGCATCACTTATTTGTATTGGTATCTGCAAAGCCAGCCAGTCTCCTCACTCCTGAATTATCAGAT
GCCAACCTTGCTCAGGATTCCC 3’ 
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HA22 scFv-protamine-His6 nucleotide and amino acid sequences in pDisplay vector with murine Ig kappa 
chain signal sequence: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
 
CCA GCA TGC TCG AGC TCG GAT CCA CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC GGC TTG   
 P   A   C   S   S   S   D   P   L   V   T   A   A   S   V   L   E   F   G   L    
                |   murine Ig kappa chain signal peptide sequence ……………… 
GGG ATA TCC ACC ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA   
 G   I   S   T   M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P  
 
       ……………………   | |haemaaglutinin A epitope sequence|   |………….SfiI…………..|  
GGT TCC ACT GGT GAC TAT CCA TAT GAT GTT CCA GAT TAT GCT GGG GCC CAG CCG GCC ATG   
 G   S   T   G   D   Y   P   Y   D   V   P   D   Y   A   G   A   Q   P   A   M    
|HA22 scFv…………………………………………. 
GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC   
 E   V   Q   L   V   E   S   G   G   G   L   V   K   P   G   G   S   L   K   L    
TCC TGT GCA GCC TCT GGA TTC GCT TTC AGT ATC TAT GAC ATG TCT TGG GTT CGC CAG ACT   
 S   C   A   A   S   G   F   A   F   S   I   Y   D   M   S   W   V   R   Q   T    
CCG GAG AAG AGG CTG GAG TGG GTC GCA TAC ATT AGT AGT GGT GGT GGT ACC ACC TAC TAT   
 P   E   K   R   L   E   W   V   A   Y   I   S   S   G   G   G   T   T   Y   Y    
CCA GAC ACT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC   
 P   D   T   V   K   G   R   F   T   I   S   R   D   N   A   K   N   T   L   Y    
CTG CAA ATG AGC AGT CTG AAG TCT GAG GAC ACA GCC ATG TAT TAC TGT GCA AGA CAT AGT   
 L   Q   M   S   S   L   K   S   E   D   T   A   M   Y   Y   C   A   R   H   S    
GGC TAC GGC ACG CAC TGG GGG GTT TTG TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT   
 G   Y   G   T   H   W   G   V   L   F   A   Y   W   G   Q   G   T   L   V   T    
                        |BamHI| 
GTC TCT GCA GGC GGA GGC GGA TCC GGT GGT GGC GGA TCT GGA GGT GGC GGA AGC GAT ATC   
 V   S   A   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   D   I    
CAG ATG ACC CAG ACT ACT TCC TCC CTG TCT GCC TCT CTG GGA GAC AGA GTC ACC ATT AGT   
 Q   M   T   Q   T   T   S   S   L   S   A   S   L   G   D   R   V   T   I   S    
TGC AGG GCA AGT CAG GAC ATT AGC AAT TAT TTA AAC TGG TAT CAG CAG AAA CCA GAT GGA   
 C   R   A   S   Q   D   I   S   N   Y   L   N   W   Y   Q   Q   K   P   D   G    
ACT GTT AAA CTC CTG ATC TAC TAC ACA TCA ATA TTA CAC TCA GGA GTC CCA TCA AGG TTC   
 T   V   K   L   L   I   Y   Y   T   S   I   L   H   S   G   V   P   S   R   F    
AGT GGC AGT GGG TCT GGA ACA GAT TAT TCT CTC ACC ATT AGC AAC CTG GAG CAA GAA GAT   
 S   G   S   G   S   G   T   D   Y   S   L   T   I   S   N   L   E   Q   E   D    
TTT GCC ACT TAC TTT TGC CAA CAG GGT AAT ACG CTT CCG TGG ACG TTC GGT GGA GGC ACC   
 F   A   T   Y   F   C   Q   Q   G   N   T   L   P   W   T   F   G   G   G   T    
                        | truncated protamine ………………………………………………. 
AAG CTG GAA AGC AGA TCT CGA TCA CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA   
 K   L   E   S   R   S   R   S   Q   S   R   S   R   Y   Y   R   Q   R   Q   R    
      ……………………….                  | |  hexahistidine tag  | 
TCA CGA CGA CGA CGA CGA CGA TCT AGA CAC CAT CAC CAC CAC CAT TAA   
 S   R   R   R   R   R   R   S   R   H   H   H   H   H   H   *    ……………………………. 
   
…………….CCGCGGCTGCAGGTCGACGAACAAAAACTCATCTCAGAAGAGGATCTGAATGCTGTGGGCCAGGACACGCAGGAGGTCATCGTGGT
GCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGC
TT GGCAGAAGAAGCCACGTAGCCCCGCCA  3’ 
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HA22 scFv-protamine-His6 nucleotide and amino acid sequences in modified pDisplay vector with murine 
Ig kappa chain signal sequence: 
                                                              5’end of hCMV 
                                                              | 
5’ GAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATT    
                                                 CMV enhancer region (5’end)                            
                                                 | 
   AATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC      
   TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA   
   ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG  
   ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC      
   GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC      
      CMV enhancer region (3’end)                                                    
                                |                                                     
   CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAA   
                                  TATA box     3'end hCMV promoter 
                                  ----         | 
   TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCT……………………………………..                                 
 
CGG CAG GCT TGG AAG GAG CTC GGA TCA CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC GGC   
 R   Q   A   W   K   E   L   G   S   L   V   T   A   A   S   V   L   E   F   G   
                    | murine Ig kappa chain signal peptide sequence ……….. 
TTG GGG ATA TCC ACC ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT   
 L   G   I   S   T   M   E   T   D   T   L   L   L   W   V   L   L   L   W   V    
  signal sequence ends|   |     SfiI      | | HA22 scFv …………………………… 
CCA GGT TCC ACT GGT GAC GGG GCC CAG CCG GCC ATG GAA GTG CAG CTG GTG GAG TCT GGG   
 P   G   S   T   G   D   G   A   Q   P   A   M   E   V   Q   L   V   E   S   G    
GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA TTC GCT   
 G   G   L   V   K   P   G   G   S   L   K   L   S   C   A   A   S   G   F   A    
TTC AGT ATC TAT GAC ATG TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC   
 F   S   I   Y   D   M   S   W   V   R   Q   T   P   E   K   R   L   E   W   V    
GCA TAC ATT AGT AGT GGT GGT GGT ACC ACC TAC TAT CCA GAC ACT GTG AAG GGC CGA TTC   
 A   Y   I   S   S   G   G   G   T   T   Y   Y   P   D   T   V   K   G   R   F    
ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AAG TCT   
 T   I   S   R   D   N   A   K   N   T   L   Y   L   Q   M   S   S   L   K   S    
GAG GAC ACA GCC ATG TAT TAC TGT GCA AGA CAT AGT GGC TAC GGC ACG CAC TGG GGG GTT   
 E   D   T   A   M   Y   Y   C   A   R   H   S   G   Y   G   T   H   W   G   V    
                                                                        |BamHI| 
TTG TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA GGC GGA GGC GGA TCC   
 L   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A   G   G   G   G   S    
GGT GGT GGC GGA TCT GGA GGT GGC GGA AGC GAT ATC CAG ATG ACC CAG ACT ACT TCC TCC   
 G   G   G   G   S   G   G   G   G   S   D   I   Q   M   T   Q   T   T   S   S    
CTG TCT GCC TCT CTG GGA GAC AGA GTC ACC ATT AGT TGC AGG GCA AGT CAG GAC ATT AGC   
 L   S   A   S   L   G   D   R   V   T   I   S   C   R   A   S   Q   D   I   S    
AAT TAT TTA AAC TGG TAT CAG CAG AAA CCA GAT GGA ACT GTT AAA CTC CTG ATC TAC TAC   
 N   Y   L   N   W   Y   Q   Q   K   P   D   G   T   V   K   L   L   I   Y   Y    
ACA TCA ATA TTA CAC TCA GGA GTC CCA TCA AGG TTC AGT GGC AGT GGG TCT GGA ACA GAT   
 T   S   I   L   H   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D    
TAT TCT CTC ACC ATT AGC AAC CTG GAG CAA GAA GAT TTT GCC ACT TAC TTT TGC CAA CAG   
 Y   S   L   T   I   S   N   L   E   Q   E   D   F   A   T   Y   F   C   Q   Q   
                                                                        | …….. 
GGT AAT ACG CTT CCG TGG ACG TTC GGT GGA GGC ACC AAG CTG GAA AGC AGA TCT CGA TCA   
 G   N   T   L   P   W   T   F   G   G   G   T   K   L   E   S   R   S   R   S 
         …………………………           truncated protamine ………………….    
CAA TCA CGA TCA CGA TAC TAC CGA CAA CGA CAA CGA TCA CGA CGA CGA CGA CGA CGA TCT   
 Q   S   R   S   R   Y   Y   R   Q   R   Q   R   S   R   R   R   R   R   R   S   
    |  hexahistidine tag  |  
AGA CAC CAT CAC CAC CAC CAT TAA  …………… CCGCGGCT 3’ 
 R   H   H   H   H   H   H   *     
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Appendix 3: Schematic illustrations of the constructs genetic maps with unique 
restriction sites.  
 
IFNβ-MMP-1-11E scFv in pFastBacTM1 
Cy34.1.2 scFv-His6 in pFastBacTM1 
Cy34.1.2 scFv-protamine-His6 in pFastBacTM1 
Cy34.1.2 scFv-His6 in pcDNA3 vector with VH native signal sequence 
Cy34.1.2 scFv-protamine-His6 in pcDNA3 vector with VH native signal sequence 
Cy34.1.2 scFv-His6 in pHEN1 vector with pelB signal sequence 
Cy34.1.2 scFv-His6 in pcDNA3 with hLAP signal sequence-hLAP-HRV3C 
Cy34.1.2 scFv-protamine-His6 in pcDNA3 with hLAP signal sequence-hLAP-HRV3C 
Cy34.1.2 scFv-protamine-His6 in pDisplay vector with murine Ig κ chain signal sequence 
HA22 scFv-protamine-His6 in modified pDisplay vector with murine Ig κ chain signal sequence 
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Genetic map for IFNβ-MMP-1-11E scFv in pFastBacTM1 vector showing unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
pFastBacTM1-IFNβ-MMP-1-11E 
6063 bp
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Genetic map for Cy34.1.2 scFv-His6 in pFastBacTM1 vector showing unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
pFastBacTM1-Cy34.1.2 scFv-His6 
5466 bp
sc
Fv
-H
is
6 
Appendices 
 
356 
 
Genetic map for Cy34.1.2 scFv-protamine-His6 in pFastBacTM1 vector showing unique 
restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
pFastBacTM1-Cy34.1.2 
scFv-protamine-His6 
5535 bpsc
Fv
-p
ro
ta
m
in
e-
H
is
6 
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Cy34.1.2 scFv-His6 in pcDNA3 vector with VH native signal sequence genetic map with unique 
restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
pcDNA3-Cy34.1.2 scFv-His6 
6114 bp
sc
Fv
-H
is
6 
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Cy34.1.2 scFv-protamine-His6 in pcDNA3 vector with VH native signal sequence genetic map 
with unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pcDNA3-Cy34.1.2 scFv-protamine-His6 
6183 bp
sc
Fv
-p
ro
ta
m
in
e-
H
is
6 
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Genetic map for Cy34.1.2 scFv-His6 in pHEN1 vector with pelB signal sequence showing unique 
restriction sites:  
 
 
 
 
 
 
 
 
 
 
 
 
pHEN1-Cy34.1.2 scFv-His6 
5215 bp
sc
Fv
-H
is
6 
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Genetic map for Cy34.1.2 scFv-His6 in pcDNA3 with hLAP and hLAP signal sequence showing 
unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
pcDNA3-hLAP-HRV3C-Cy34.1.2 
scFv-His6 
6948 bp
sc
Fv
-H
is
6 
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Genetic map for Cy34.1.2 scFv-protamine-His6 in pcDNA3 with hLAP and hLAP signal 
sequence showing unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pcDNA3-hLAP-HRV3C-Cy34.1.2 
scFv-protamine-His6 
7011 bp
sc
Fv
-p
ro
ta
m
in
e-
H
is
6 
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Genetic map for Cy34.1.2 scFv-protamine-His6 in modified pDisplay vector with murine Ig 
kappa-chain signal sequence showing unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pDisplay-Cy34.1.2 scFv-protamine-His6 
6085 bp
sc
Fv
-H
is
6 
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Genetic map for HA22 scFv-protamine-His6 in modified pDisplay vector with murine Ig kappa-
chain signal sequence showing unique restriction sites: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pDisplay-HA22 scFv-protamine-His6 
6142 bp
sc
Fv
-p
ro
ta
m
in
e-
H
is
6 
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Appendix 4: schematic illustration showing the genetic map of pMH112 construct 
containing anti-human BL22 (wild type) scFv with unique restriction sites 
 
 
 
 
pMH112
6047 bp
scFv BL22
Ava I (1787)
ClaI (4173)
EcoRI (714)
HindIII (665)
SfiI (837)
Sac II (1582)
ApaLI (2413)
ApaLI (5339) BamHI (683)
BamHI (1224)
Pst I (1214)
Pst I (1589)
Nco I (386)
Nco I (736)
Nco I (841)
Nco I (3585)
Nco I (4285)
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Appendix 5: schematic illustration showing the genetic map of pMH113 construct 
containing anti-human HA22 (mutant) scFv with unique restriction sites 
 
 
 
 
pMH113
6047 bp
scFv HA22
Ava I (1787)
ClaI (4173)
EcoRI (714)
HindIII (665)
SfiI (837)
Sac II (1582)
ApaLI (2413)
ApaLI (5339) BamHI (683)
BamHI (1224)
Pst I (1214)
Pst I (1589)
Nco I (386)
Nco I (736)
Nco I (841)
Nco I (3585)
Nco I (4285)
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Appendix 6: strategy for removal of haemagglutinin A epitope (HA tag) from the 
pDisplay vector: 
  
In the pDisplay mammalian expression vector, the nucleotide sequence which encodes 
haemagglutinin A epitope (YPYDVPDYA) precedes the multiple cloning site (MCS) in-frame with 
the signal peptide (Ig κ-chain signal sequence). In order to remove the HA tag (green), first a 
fragment of DNA that overlaps the signal peptide upstream of the HA tag between HindIII 
restriction site (red) and end of the leader signal sequence (blue) was PCR-amplified using 
pDisplay F HindIII forward primer: 5’GACCCAAGCTTGGTACCGAGCTCGGATCCA3’ pDisplay 
R SfiI reverse primer: 5’TGGATAGGCCGGCTGGGCCCCGTCACCAGTGGAACCTGG3’ to 
incorporate SfiI site at the start of MCS. Then the pDisplay vector backbone was digested with 
HindIII and SfiI enzymes and ligated with the PCR product that was digested with HindIII and SfiI 
enzymes. The ligation reaction was used to transform bacteria. Positive clones were identified 
and expanded by minipreparation.  
 
 
                                                 HindIII -----------------                       
………………………………………………………..pDisplay backbone……..     |      |                                         
CT TAT CGA AAT TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TTG GTA CCG AGC TCG   
    Y   R   N   *   Y   D   S   L   *   G   D   P   S   L   V   P   S   S       
GA ATA GCT TTA ATT ATG CTG AGT GAT ATC CCT CTG GGT TCG AAC CAT GGC TCG AGC  
 
---------------------------------------EcoRI--------------- 
                                        |     | 
GAT CCA CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC GGC TTG GGG 
 D   P   L   V   T   A   A   S   V   L   E   F   G   L   G 
CTA GGT GAT CAT TGC CGG CGG TCA CAC GAC CTT AAG CCG AAC CCC 
 
----------------|----------Ig kappa chain leader sequence 
ATA TCC ACC ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG   
 I   S   T   M   E   T   D   T   L   L   L   W   V   L   L       
TAT AGG TGG TAC CTC TGT CTG TGT GAG GAC GAT ACC CAT GAC GAC  
         
---------------------------------Æ| |    Haemagglutinin A epitope     | 
CTC TGG GTT CCA GGT TCC ACT GGT GAC TAT CCA TAT GAT GTT CCA GAT TAT GCT 
 L   W   V   P   G   S   T   G   D   Y   P   Y   D   V   P   D   Y   A 
GAG ACC CAA GGT CCA AGG TGA CCA CTG ATA GGT ATA CTA CAA GGT CTA ATA CGA 
 
   ………………SfiI……………… 
  |                ||Anti-CD22 scFv HA22 ………………………………………………………… 
GGG GCC CAG CCG GCC ATG GAA GTG CAG CTG GTG GAG TCT GGG AGG CTT G   
 G   A   Q   P   A   M   E   V   Q   L   V   E   S   G   R   L      
CCC CGG GTC GGC CGG TAC CTT CAC GTC GAC CAC CTC AGA CCC TCC GAA C 
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